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DELICATE BALANCE OF IMMuNE RESPONSES IN EARLY ChILDhOOD
The human body is continuously exposed to various pathogens. To protect itself from 
these potential harmful agents, an immune system is in place with mechanisms to inhibit 
the entrance of pathogens, and if this fails, to recognize, neutralize and quickly remove 
these pathogens. Aberrant immune protection, however, results in clinical disease, such 
as autoimmune diseases with an immune response directed against self-antigens, or al-
lergies/hypersensitivities with an excessive reaction to harmless foreign particles. Immune 
competence, therefore, reflects a delicate balance between ‘too little and too much’ toler-
ance, which develops in early childhood, or possibly even in utero.1, 2 This process may be 
prone to various external factors, especially during the first 5 years of life when antigens 
encounter the immature immune system for the first time. Immune mediated diseases 
such as celiac disease, diabetes mellitus type 1, allergic rhinitis, atopic dermatitis and 
allergic asthma are prevalent and have reached even epidemic proportions nowadays, 
resulting in a substantial global burden of disease in western countries.3-8 The incidence 
of these immune mediated disorders began to increase in the 1950s, and have doubled or 
tripled during the last 3 decades worldwide, particularly in young children in industrialized 
countries.4, 8 Concomitantly, an obvious decline in infectious diseases was observed, which 
together, led to the hypothesis that early exposure to potential pathogens may protect 
against the development of autoimmune and allergic diseases.8 The early childhood pe-
riod, therefore may reflect a window of vulnerability, during which various determinants 
‘shape’ the developing immune system and mediate the origin of immune mediated 
diseases.
ThE ShAPING OF ThE ADAPTIVE IMMuNE SYSTEM
The human immune system is formed during fetal development and “innate” responses 
can be generated after birth to protect the newborn against pathogens. However, at this 
stage the immune system is still immature. Following interactions with pathogens, the 
immune system “adapts” and memory is formed to quickly eliminate foreign substances 
without damaging the body’s own healthy tissue. However, when the delicately balanced 
regulation between self- and non-self-antigens is disturbed, autoimmunity might develop. 
Memory B and T cell populations
B and T cells are the key cells of adaptive immunity. Mature B and T cells circulate in the 
blood and in secondary lymphoid tissues after they have differentiated from precursor B 
and T cells in the bone marrow and thymus, respectively. These lymphocytes carry special-
ized receptors, i.e. a B-cell receptor (BCR) or T cell receptor (TCR). Each type of receptor is 
unique for each newly generated B and T cell. While B cells recognize complete antigens, T 
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cells only recognize an antigen when it is presented on specialized protein complexes, i.e. 
the human leukocyte antigens (HLA; also known as the major histocompatibility complex 
(MHC)). These antigens are presented by dendritic cells (DCs) in the lymph node, after these 
have migrated there from local tissue. Upon antigen recognition, a B or T cell becomes 
activated, resulting in extensive clonal proliferation and differentiation into effector cells. 
T cells comprise of 2 major lineages: cytotoxic (CD8+) and T-helper (CD4+) cells. The TCR 
of cytotoxic T cells recognizes antigens presented by HLA class I proteins that are expressed 
on all cells in the body, except on erythrocytes. Recognition of virus-infected cells by ac-
tivated T cells induces cytokine production, resulting in lysis of the infected cell.9 The TCR 
of T helper cells recognizes antigens presented by HLA class II proteins. Class II proteins 
present peptides taken up from the cells exterior, e.g. extracellular bacterial antigens. HLA 
class II proteins are only presented by immune cells, especially DCs and other antigen 
presenting cells (APCs). Therefore, helper T cell interactions are limited to the cells of the 
immune system. Activated helper T cells stimulate the activation of surrounding antigen 
specific B and cytotoxic T lymphocytes.9
Within the CD4+ and CD8+ T cell lineages, distinct T cell subsets can be distinguished 
depending on their function and differentiation pathway, reflected by differential expres-
sion of their cell-surface markers, such as costimulatory and adhesion molecules, and 
chemokines receptors (Figure 1). The term ‘differentiation’ relates to expression levels 
of genes that control cell cycle, survival, migration and effector functions of the cells,10, 11 
and is therefore generally accepted to describe lymphocyte maturation or development.12 
Although the exact differentiation pathways through which the various memory T cells 
populations are generated remain actively debated,10, 13 general agreement includes the 
characterization of naive, central memory (Tcm), and effector memory T cells (Tem) within 
both the CD4+ and CD8+ lineage.12, 13 Naive T cells (Tnaive) express CD45RA, CCR7 and the 
lymph node homing receptor L-selectin (CD62L), which together, enables migration to 
T-cell areas in secondary lymphoid organs to search for antigen presented by dendritic 
cells.12, 14 Upon antigen recognition, the cell will replace CD45RA with alternative splice 
variant CD45RO. The CD45-isotype-switch is associated with increased proliferation and T 
cell activation.15 Central memory T cells (Tcm) are part of the CD45RO+ memory cells, but 
express high levels of CCR7 and L-selection as well. 12, 14 Due to the maintained expression 
of these migration markers, these cells circulate through the blood, lymphoid system and 
secondary lymphoid tissues, but they lack potent effector functions.12 It has been pro-
posed that TCM cells are responsible for maintaining life-long memory: Upon re-exposure 
to antigens, TCM cells proliferate and differentiate into effector memory cells (Tem). Effector 
memory T (Tem) cells express either CD45RO+ (TemRO), or re-express CD45RA+ (TemRA) 
(the latter being considered as having more effector cell properties),16 but in contrast to 
Tcm, they lack expression of CCR7 and L-selectin. Instead, TEM express receptors (CCR4 and 
CCR5) for migration to inflamed tissues, such as the skin or intestine. Additionally, they 
express increased levels of effector functions, e.g. they carry perforin, and rapidly produce 
13
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IL-2, IL-4, IL5, IFN-γ and TNF-α following antigen encounter. The Tem are thus a mixture of 
TH1, as well as TH2, and cytotoxic T cells. 12 
Tcm
Tem
RO
Tnaive
Tem
RA
Tem
RO
Tem
RA
Lymph node
APC
Tcm
Tcm
Circulation
Tissue
Tnaive Tcm Tem
RO
Tem
RA
A
early interm late early interm late
CD45RA
CD45RO
CD27
CD28
CD127 (IL-7R)
CD57
KLRG1
PD-1
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IFNγ
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cytokine production           
and                           
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Figure 1. A, CD8+ T-cell responses Activated naive T cells differentiate into central memory T cells (TCM) or effec-
tor memory T cells (TEM), the latter being either CD45RO+ (TemRO) or CD45RO- (TemRA). TCM circulate between the 
blood and lymphatic system. TemRO and TemRA cells migrate into tissue and kill virus-infected cells. Figure adapted 
from van den Heuvel et al.146 B, T-cell subset expression levels of proteins involved in co-stimulation, cell survival 
and regulation of activation; cell migration and adhesion, cytokine production and cytotoxic function. White, not 
expressed, light blue, intermediate expression, dark-blue high expression. Adapted from van den Heuvel et al.146
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Based on the expression of the B cell surface markers IgD, CD27, and CD38, different 
stages of B-cell maturation can be identified (Figure 2). The majority of circulatory B cells 
comprise naive B cells (IgD+CD27-).17 Of these, ‘transitional B cells’ (IgD+ CD24+CD38hi) are 
new bone marrow emigrants and less mature than the naive mature B cells (IgD+ CD27-
IgM+CD24dimCD38dim).17, 18 Upon antigen recognition, naive mature B cells proliferate and 
differentiate either into memory B cells or plasma cells. Plasma cells directly produce 
antibodies to mediate protective memory, whereas memory B cells are necessary for reac-
tive memory, as reflected by the proliferation and differentiation into plasma cells upon 
secondary antigen encounters.12 The majority of memory B cells are T cell dependent (TD): 
They need a second signal from T-helper cells in the germinal center to become activated, 
resulting in extensive B cell proliferation and IgG class switch recombination.19 Hence, high 
affinity memory B cells and IgG producing plasma cells are formed.19 Five distinct memory 
B cell subsets are thought to develop via T cell dependent germinal center responses, 
naive
mature
transitional
germinal center
CD27+IgM+ 
CD27+IgG+
natural effector
CD27+IgA+
CD27-IgG+
CD27-IgE+
BCR maturation
Intestine
marginal zone
in spleen
proliferation
B TH
TI
TD
CD27-IgA+
CD27+IgE+
Figure 2. Memory B cell formation Naive B cells can undergo T cell dependent (TD) or T cell independent (TI) 
immune responses. TI responses occur locally in the mucosal tissue, inducing the formation of CD27-IgE+ and CD27-
IgA+ cells, or systematically in the splenic marginal zone, generating natural effector cells. TI responses are character-
ized by low proliferation and B-cell receptor (BCR) maturation levels as compared with TD responses. TD responses 
occur in germinal center structures. Primary germinal center responses induce the formation of CD27+IgM+, CD27-
IgG+, and CD27+IgE+ memory B cells with intermediate proliferation and BCR maturation. Secondary TD germinal 
center responses induce the formation of CD27+IgG+ and CD27+IgA+ memory B cells that underwent even stronger 
proliferation and BCR maturation. Adapted from Berkowska et al,19 and van den Heuvel et al.146
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and show subsequent increased proliferation: CD27+IgM+IgD- “IgM-only”, CD27-IgG+, 
CD27+IgE+, CD27+IgG+ and CD27+IgA+.19, 20 Additionally, B cells can respond to antigens in-
dependent of T cells (TI). These antigens are mostly blood-borne pathogens in the splenic 
marginal zone and non-protein antigens in mucosal tissues. CD27+IgM+ memory B cells 
that still co-express IgD+ (natural effectors) develop in the splenic marginal zone,21 and are 
thought to proliferate outside of the germinal centers of the spleen and lymph nodes. The 
other two TI B cell subsets (CD27-IgA+ and CD27-IgE+) originate from mucosal tissues.19, 20 
During childhood, the composition and numbers of immune cells considerably fluctuate 
as a consequence of ongoing antigen exposure, of whom the most obvious changes occur 
in the first 5 to 6 years of age.18, 22-24 Concurrent with an expansion of memory cells with 
increasing age, the repertoire of naive cells becomes smaller due to involution of the thy-
mus and decreased bone marrow output.18, 25 Immunity in adulthood, and subsequently 
protection against recurrence of disease in elderly, therefore, is largely depended on the 
memory pool that is built-up in the first years of life.25 Despite several cross-sectional studies 
presenting consistent observations of normal, i.e. age-dependent reference, values during 
childhood,18, 23, 24, 26-32 none of the previous studies assessed these kinetics longitudinally. 
Moreover, many external factors are thought to affect these patterns, but are previously 
largely unaddressed. Although differentiation pathways are still not fully elucidated, and 
the usefulness of various expression markers are still debated, the identification of various 
cell populations as described above is general accepted, which enables studying kinetics 
and determinants of these lymphocytes during early childhood. Understanding which fac-
tors contribute to the maturation of a delicately balanced and mature immune system will 
be of benefit for the assessment of normal and disturbed immune development. 
Immune shaping through external determinants 
Pre- and perinatal determinants
During pregnancy, the fetal immune system is largely immature, and predominantly com-
posed of innate leukocytes and naive lymphocytes.27, 32 Maternal IgG can be transferred 
through the placenta though, providing passive protection to the unborn child.33 Still, en-
vironmental factors, such as prenatal lifestyle, parity, fetal growth, and prematurity might 
affect programming of the fetal immune system in utero, and contribute to later develop-
ment of immune-mediated diseases.1, 2, 34 Maternal and fetal anti-inflammatory cytokines 
have been shown to strongly correlate,2 suggesting ‘transplacental immune regulation’, 
i.e. a significant alignment or crosstalk between maternal and fetal immunity, which may 
have long term effects for both mother and child.2 The prenatal period may therefore 
reflect a possible sensitive window of vulnerability during which intrauterine exposures 
can modulate the programming of the child’s immune system, and affect the course of im-
mune development and tolerance mechanisms.2, 34 Additionally, perinatal determinants, 
such as mode of delivery, duration of labor, and birth weight have been shown to affect 
innate leukocyte and memory lymphocyte populations, possibly partly through perinatal 
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stress and differences in microbial population of the gut.35-39 These immune alterations 
at birth have been associated with ‘TH2’-type immune mediated diseases, including food 
allergies and eczema.38-40 Still, it remains unclear whether a sensitive window of immune 
vulnerability exists, and whether innate and adaptive immune cell kinetics are predomi-
nantly influenced by pre-, peri- and/or postnatal determinants. Furthermore, none of the 
previous studies assessed the development of detailed innate leukocyte and memory lym-
phocyte populations longitudinally, covering intrapersonal correlations between repeated 
measures. 
Postnatal determinants 
Breastfeeding 
After birth, breastfeeding is known to protect the child from respiratory and gastro-
intestinal infections.41 Colostrum and breastmilk contain numerous beneficially factors, 
including maternal IgA, IgG and cytokines, providing the child passive protection during 
the period of breastfeeding, and possibly shortly after weaning.42 During this period in early 
life, the child has to build up its own active immunity, when the immune system is still 
functionally immature and encountering various, mainly viral antigens.43 Many previous 
studies have focused on the beneficial effects of breastfeeding on innate immunity and 
protection towards infectious diseases in childhood.41, 42, 44 However, studies focusing on 
adaptive immunity are scarce, and often not adjusted for potential confounding factors. 
Studying determinants of adaptive immunity is of particular importance, as adaptive 
immunity provides an extraordinary specific immune response against pathogens, and 
confers life-long immunity: principles that form the basis of vaccination. 
herpesviruses 
Most viruses that children encounter in the first few years of life are respiratory viruses, 
which are effectively cleared by the immune system, and memory B and T cells are formed. 
Several viruses, however, escape from this clearance. To date, 8 herpesviruses have been 
identified to infect humans, including Cytomegalovirus (CMV), Epstein-Barr virus (EBV), 
Herpes Simplex virus type 1 (HSV-1) and Varicella Zoster virus (VZV). Primary infection with 
these viruses predominantly occurs during childhood, and is often mild or asymptomatic.43 
Herpesviruses are effectively suppressed by the immune system, but establish lifelong la-
tency, with intermittent bouts of reactivation, causing for example scores or herpes zoster 
in cases of immune suppression. To prevent reactivation, the immune system, therefore, 
should constantly suppress these viruses, which may adversely affect the control of other 
encountering allergens or pathogens. Moreover, the constant viral pressure of latent infec-
tion might cause ‘immune exhaustion’ on the long run. It is not known, however, to what 
extent herpesviruses affect the balance and diversity between specific and preexisting 
memory B and T cells in early childhood. For example, newly formed CMV specific CD8+ T 
cells may expand the preexisting CD8+ repertoire, but may also ‘compete’ with the preexist-
17
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ing memory CD8+ T cells for ‘immune-space’, resulting in substantial depletion of preexist-
ing memory. In elderly, adverse effects have been described on the diversity of the B and 
T cell memory repertoire, resulting in overcrowding (accumulation of late differentiated 
CD8 memory, concurrent with reduced naive cells) and eventually loss of immunity against 
other pathogens.45-47 Still, these observations have not been persistently replicated.48-50 
Nevertheless, the flexibility of the immune system, viral pathogenesis and clinical outcome 
may be differentially affected by age. For example, beneficial protective effects of EBV have 
been observed in relation to atopic and allergic diseases in childhood,51-53 but seemingly 
depended on age, as early (<2y) and late (>2y) EBV infection resulted in opposite effects.52 
The seroprevalence of herpesviruses in adulthood reaches 30-100%,54-62 but these 
seroprevalences depend largely on geographic location, race/ethnic background, so-
cioeconomic disparities, population dynamics and various other factors that facilitate 
transmission.56-58, 61, 63 Cumulative population prevalence are difficult to estimate because 
of the asymptomatic course of primary infection in childhood. Thus, estimates had to be 
based on specific IgG antibodies against the virus.43 Most prevalence studies are from the 
1980s-1990’s,57 but social and demographic factors have changed over time, limiting up-to-
date conclusions on trends in childhood herpesvirus epidemiology nowadays. Moreover, 
most studies have not incorporated the relative distribution of all combined environmen-
tal factors. Insight into these infection dynamics and their determinants is important to 
understand herpesvirus associated disease epidemiology, and in the light of prevention, 
to advise on vaccination strategies on the long run. 
Conspicuously in industrialized countries, a shift towards an older age of primary in-
fections, concurrent with an increase in atopic and autoimmune diseases was observed, 
which led to the ‘hygiene’ or ‘old friends’ hypothesis.64 This hypothesis suggests a causal 
relationship between the decreasing incidence of infectious diseases in countries with a 
Western lifestyle and urbanization, and the increasing incidence and severity of atopic and 
autoimmune diseases.64-66 In this context, a diverse microenvironment in early life might 
protect against these diseases. In contrast, other studies observed that an increase in in-
fections, provokes autoimmunity.67 Herpesviruses primarily, have been suggested to initi-
ate and progress numerous autoimmune syndromes,68, 69 whereas others suggested rather 
protective effects.51-53, 70 Hence, evidence on this highly debated topic is conflicting, and 
simple mechanisms to describe pathways in autoimmunity do not capture the probably 
multifaceted and multiplicative signals/pathways involved in autoimmune development. 
Still, all autoimmune diseases have in common that tolerance mechanisms ‘fail’, resulting 
in an aberrant immune response against harmless food or allergens. 
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ThE EPIDEMIOLOGY, DETERMINANTS AND CONSEQuENCES OF uNRECOGNIZED 
CELIAC DISEASE
Celiac disease (CeD) is a common chronic multisystem immune-mediated disorder, 
characterized by an aberrant immune response against the body’s own cells and tissues 
in response to gluten ingestion in genetic susceptible individuals. Ingestion of gluten by 
persons with CeD causes immune-mediated inflammatory damage to the small intestine, 
which can cause gastrointestinal and nongastrointestinal illness. The local CD4+ T cell 
dependent immune reaction involves both TCR’s responses against gluten peptides, as 
well as B cell antibody formation (IgA or IgG) against the gliadin deaminating enzyme 
tissue transglutaminase type 2 (TG2), endomysium (EmA) or deamidated gliadin peptide 
(DGP).71 The presence of TG2-specific antibodies in serum is the most specific (98%) and 
sensitive (98%) diagnostic marker of active CeD.71-74 A cascade of inflammatory responses 
results in flattening of the small intestinal mucosa and a variable degree of small intes-
tinal mucosal atrophy. It is the most prevalent (1-3%) and chronic autoimmune disease 
in childhood, though severely underdiagnosed: Only 1:3 to 1:5 cases are recognized due 
to often atypical, mild or even asymptomatic modes of presentation in childhood.73, 75-77 
Classical clinical features include weight loss, abdominal pain, chronic or intermittent 
diarrhea or constipation.73, 77 However, CeD can also manifest with extra-intestinal mani-
festations, such as dermatitis herpetiformis or gluten ataxia, that are direct consequences 
of autoimmunity.78 Other extra-intestinal symptoms are indirectly related to inflammation 
and/or malabsorption, such as anemia, delayed or stunted growth, delayed puberty and 
osteoporosis.78 Several organs including the central nervous system, joints, liver and teeth 
can be affected,78, 79 reflecting its broad and variable clinical presentation. In most patients 
with CeD, strict adherence to a life-long gluten free diet (GFD), especially if started in early 
life, leads to a complete recovery of enteropathy and disappearance of CeD-associated 
symptoms and complications.80-82 
DEFINITIONS OF CELIAC DISEASE
The spectrum of CeD has broadened the past three decades, and also includes children 
with unrecognized forms of CeD, such as subclinical or potential forms of disease that are 
below the threshold of clinical detection (Figure 3, Table 1).80, 81 Children with subclinical 
and potential CeD, are per definition identified by serology screening. Depending on the 
presence or absence of villous atrophy, they are considered as having either subclinical or 
potential CeD. However, when the status of biopsy is not known, the term ‘CD autoimmu-
nity’ (CDA) or ‘TG2A positivity’ should be used. Although the definition of CD autoimmunity 
requires TG2A measurements on at least 2 occasions, we use the term “CD autoimmunity” 
(CDA) in the present thesis defined as single TG2A positive children, when the status of 
19
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biopsy is not known. Unrecognized CeD may include all forms of CeD, but as symptomatic 
and classical CeD are oft en diagnosed by routine clinical care, the majority concerns sub-
clinical or potential disease. 
Table 1. 
Definitions of Celiac Disease Equivalent 
discouraged 
term
Symptomatic Clinically evident gastrointestinal and/or extra-intestinal symptoms attributable 
to gluten intake in accordance with enteropathy (defined as Marsh-Oberhuber 
grade >2).
Overt
Classical Signs and symptoms of malabsorption. Diarrhoea, steatorrhoea, weight loss or 
growth failure is required in accordance with enteropathy (defined as Marsh-
Oberhuber grade >2). 
Typical
Subclinical‡ Positive serology (TG2A, EmA, DGPA (IgA/IgG)) and mucosal atrophy, without 
signs or symptoms suff icient to trigger CeD testing in clinical practice. 
Silent/ 
asymptomatic† 
Potential‡ Positive CeD serology, but without symptoms and mucosal atrophy. At increased 
risk for CeD. If the biopsy is positive, then this is CeD, if the biopsy is negative 
than it is potential CeD. 
Latent
Refractory Persistent or recurrent malabsorptive symptoms and signs with villous atrophy 
despite a strict GFD for more than 12 months.
Celiac disease 
autoimmunity
Positive TG2A or EmA, on at least 2 occasions when the status of biopsy is not 
known. 
TG2A positivity* When TG2A has only been measured on one occasion
According to the Oslo definitions 80 
‡ Only identified by serology screening. 
*In the present thesis TG2A positivity was defined by using the cutoff  for clinical practice of 7 U/mL. 
†Asymptomatic CeD is not accompanied by symptoms even in response to direct questioning at initial diagnosis. 
Many of these patients suff er from decreased quality of life. Sometimes minor symptoms (eg, fatigue) are only rec-
ognized aft er the introduction of a GFD; such patients do not suff er from true asymptomatic CeD and should be 
reclassified as having subclinical CeD.
Healthy children
The Iceberg of celiac disease
Subclinical /poten�al celiac disease
Celiac disease autoimmunity
IgA-TG2 7 U/ml
Diagnosed
Undiagnosed
Symptoma�c
Delayed growth, 
Reduced bone mineral density, 
Gastrointes�nal symptoms 
Consequences
?
Normal 
development
Fig.3
Figure 3. The iceberg of celiac disease The tip of the iceberg reflects symptomatic and diagnosed celiac disease 
(above the red line). However, subclinical and potential forms of the disease are oft en not recognized (below the red 
line). Children with a positive serology (indicated by positive IgA-TG2) are at increased risk of developing symptom-
atic CeD. The consequences of these unrecognized forms of CeD remain largely unknown.
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Multifactorial etiology
Carriership of either the HLA-DQ 2.2, HLA-DQ 2.5 or HLA-DQ8 haplotypes is a prerequisite 
for CeD.71 However, >25% of the general population carries one of the necessary risk alleles 
of CeD, whereas only a small fraction (1-3%) develops CeD.83-85 Hence, >90% of genetically 
predisposed individuals do not develop CeD. It remains unknown why only a minority of 
genetic susceptible individuals develop CeD. Besides gluten and a genetic prerequisite, 
other determinants must contribute to disease initiation.71, 75 Though, the search for 
environmental factors that contribute to the development of CeD has reached limited suc-
cess.71 Swedish birth cohort studies observed a difference in CeD incidence after a change 
in feeding recommendations in the 1980s and 1990s,86-88 which gave rise to the concept 
that breastfeeding and the timing of gluten introduction may affect CeD development in 
predisposed persons. Introducing gluten between 4-6 months of age while breastfeeding 
was thought to prevent, or to delay, onset of CeD by inducing desensitization, or ‘oral 
tolerance’.88-92 I.e. if gradually small amounts of food substances are administered during 
a critical time period, the small intestinal barrier is more mature, and the local immature 
immune system ‘learns’ not to respond to this substance. Following the Scandinavian 
observations,86, 87, 90, 91 some observational studies, however, could not confirm these find-
ings.93-95 The lack of consistency between these observational studies may be partly due 
to the majority of studies being retrospective or ecological. Hence, selection or recall bias 
of feeding habits may be an important concern. Because of the ongoing discussion on 
the possible role of gluten introduction and breastfeeding in the pathogenesis of CeD in 
2013-2014, we studied these associations in a population of children screened for CeD. We 
conducted and published our study prior to the publication of 2 randomized clinical trials 
in 2014, including one from the ‘PreventCD’ Study,84 that convincingly showed that neither 
early introduction (4 months of age) nor late (1 year of age) of gluten while breastfeeding 
affects the development of CeD.84, 96 Several other determinants including a variety of (viral) 
infections and epigenetic factors could affect the intestinal microbiome, disrupt toler-
ance mechanisms in the intestine, affect the developing immune system and contribute 
to CeD development.75, 97, 98 Substantial geographical differences in CeD prevalence have 
been observed between European countries, ranging from 0.3% in Germany to 2.4% in 
Finland, despite using common criteria for CeD diagnosis.76 Therefore, environmental 
factors need further investigation.97 CeD has been reported to be particularly on the rise 
in Western countries,99-102 where a simultaneous decrease in herpesvirus infections over 
time was observed.103, 104 Additionally, ethnic/racial disparities in CeD prevalence have 
been observed within single regions: CeD is more prevalent in non-Hispanic whites than in 
blacks, 105 which is in line with the delayed age of primary infection in non-Hispanic whites 
relative to blacks.103 Hence, on top of differences in genetic predisposition, a link between 
herpesviruses and CeD may exist. Although previous studies have addressed associations 
between ‘infections’ and CeD in early life,94, 98, 106, 107 these studies are inconclusive and dif-
ficult to compare due to often retrospective designs, various differences in pathogens and 
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port d’entrée’s, differences in timing of infection, data acquisition (questionnaire-derived 
or serology proven) and limited statistical power. On top of this, determinants of symptom-
atic diagnosed CeD may be different than for subclinical or potential CeD. 
Consequences of Celiac Disease Autoimmunity
CeD has been associated with a wide range of adverse effects on health and development. 
One of the most common complications of CeD are changes in bone mineralization, osteo-
penia and osteoporosis, which affect up to 75% of adult patients.108, 109 Both osteoporosis 
and osteopenia increase osteoporotic fracture risk (i.e fracture risk is 2-7 times higher in 
CeD patients), leading to lower quality of life.108, 110, 111 Other severe adverse consequences 
include cognitive impairment, infertility (although evidence is not consistent),112 intestinal 
lymphomas, adenocarcinomas, and other malignancies including non-Hodgkin lympho-
mas.81, 82, 113-122 Considerable evidence shows that a GFD can reverse the increased risk for 
associated malignancies,116, 123-125 but the increased risk for non-Hodgkin lymphomas seems 
to persist.116 Overall mortality of CeD patients has not been found increased in the majority 
of studies,121, 126 neither in symptomatic CeD, nor in subclinical CeD.113, 127 The strength of 
this association is, however, conflicting and varies widely among different studies, ranging 
from no associations to a 3,9 fold increased risk.101, 113, 121, 125, 127-131 Nevertheless, it should 
be noted that several factors might dilute mortality rates and complication risks, such as 
differences in age at diagnosis and definitions of seropositivity, the adherence to a GFD, 
follow-up time, and type of clinical presentation.132-134 Importantly, complications may 
be different for symptomatic than for subclinical CeD.131 However, data on consequences 
of unrecognized CeD in children are scarce, complicating conclusions on whether these 
children should be identified and treated earlier. 
In newly diagnosed children with both symptomatic and asymptomatic CeD, delayed 
growth and decreased BMD have been observed, which completely recover upon gluten 
avoidance.135-137 Reduced bone mineralization have been shown to be present even 
before the appearance of any other symptom.137, 138 Once the GFD starts, most of these 
children catch up their height and weight growth and bone mineralization rate within 1-2 
years.108, 136, 139 The younger the children start, especially before puberty, the better the bone 
mineral density (BMD).108, 137, 138 In contrast, by the time CeD is diagnosed in adulthood, 
complete bone recovery is not always achieved.140 In fact, delayed diagnosis or lack of treat-
ment in childhood, induces severe osteoporosis in up to one third of adult patients.137, 141 It 
is estimated that by the time childhood CeD is diagnosed, one third of patients have osteo-
porosis, one third have osteopenia and only the remaining one third have a normal BMD.131 
Consequently, part of the idiopathic adult osteoporosis may be explained by unrecognized 
CeD in childhood.109 Importantly, adverse effects on bone health have also been observed 
in adult patients with subclinical and potential CeD, which improved upon introduction of 
a GFD,108, 109, 138, 142, 143 indicating that merely the presence of positive serology is sufficient to 
have adverse effects. This highlights the importance of CeD diagnosis as early as possible, 
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and it suggests that these patients would benefit from early treatment. Still, it is currently 
unknown whether adverse effects on growth and development are present in screening 
identified, TG2A positive children, prior to the onset of other complications, and irrespec-
tive of the presence of villous atrophy (Figure 3). 
AIMS
The first aim of this thesis was to identify determinants of the developing immune system 
in childhood, focusing predominantly on the adaptive immune compartment. The second 
aim was to study determinants and the consequences of celiac disease autoimmunity 
(CDA) within a population based prospective cohort. 
ThE GENERATION R STuDY
The studies in this thesis were embedded within the Generation R Study, a population 
based prospective multi-ethnic birth cohort, following pregnant mothers and their chil-
dren from fetal life until young adulthood, in Rotterdam, The Netherlands.144, 145 In total, 
9,778 pregnant women were included in the cohort, all residing in Rotterdam at their 
delivery date. All children were born between April 2002 and January 2006. During the two 
postnatal phases of the study (0-4 years and 6 years), information was obtained from 7,893 
and 8,305 children, respectively. In the pre-school period, information was collected by 
parental reported questionnaires at the ages of 2,6,12,14,24, 36 and 48 months, and regular 
routine visits to the child health centers. At 6 years of age, blood samples were drawn from 
4,593 children. The overall blood sample response rate at 6 years of age was 69%. The 31% 
missing were due to lack of consent by the parents or non-successful vena punctures.144 
The majority of studies presented in Part I “Shaping of adaptive immunity”, were performed 
in a subgroup of 1,232 Dutch pregnant women and their children born between Febru-
ary 2003 and August 2005, and include more detailed measurements.144 This subgroup is 
ethnically homogeneous to exclude confounding or effect modification by ethnicity. From 
a total of 1,247 children, 1,079 children were available for postnatal analyses. After birth, 
the children were invited to visit the research center at 1.5, 6, 14, 24 and 48 months of 
age. Measurements during these visits included, among others, collection of venous blood 
samples (both serum and plasma). Detailed immune phenotyping was available from cord 
blood (n=230), 6 months (n=377), 14 months (n=243), and 24 months (n=259). At 6 years 
of age, n=1,121 Dutch and non-Dutch children of the cohort provided data on detailed 
immune phenotyping. Data on total T, B and NK cell numbers (TruCounts) at 6 years of 
age were available in n=3,465 children. Information on determinants such as breastfeed-
ing, and many other environmental determinants (e.g. socioeconomic status, maternal 
23
Chapter 1  |  General introduction, aims and outline
Ch
ap
te
r 1
smoking habits, number of siblings, daycare attendance and so on) was obtained from 
a combination of parental reported pre- and postnatal questionnaires at the ages of 1.5 
and 6 months, 1,2,3,4, and 6 years of age. Celiac testing at 6 years of age was performed in 
4,442 children. 
OuTLINE
The objectives are addressed in several studies presented in this thesis. Part I is devoted 
to the shaping of the adaptive immune system. In Chapter 2, we aim to identify develop-
mental age-related patterns of blood innate leukocyte, naive and memory B and T cells 
numbers, and to study external determinants which may influence these patterns. Next, 
we describe to what extent breastfeeding (Chapter 3), and persistent herpesvirus infec-
tions (Chapter 4) influence the build-up of adaptive immune cell numbers, and whether 
the effects of cytomegalovirus (CMV) on the immune system are differentially affected by 
sex (Chapter 5). Additionally, we study whether CDA is associated with abnormalities in 
blood T cell numbers (Chapter 6). Part II focuses on determinants of CDA. We study the 
associations between infant feeding and anti-tissue transglutaminase positivity (Chapter 
7), and between herpesvirus infections and CDA (Chapter 8). Additionally, we describe 
whether ethnic differences are present in CDA and to what extent these can be explained 
by environmental factors (Chapter 9). Chapter 10 describes to what extent ethnic differ-
ences in herpesvirus infections can be explained by social and environmental factors. Part 
III covers the consequences of CDA. First, we study consequences of CDA on childhood 
growth and bone development (Chapter 11). Second, we describe the identification of 
subclinical CeD by screening in asymptomatic children (Chapter 12). Finally, Chapter 13 
provides an overall discussion, including a description of the main findings of this thesis. 
The results are described in a broader context, including methodological considerations, 
and directions for future research. A summary of this thesis is presented in Chapter 14.
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ABSTRACT
Background
Numbers of blood leukocyte subsets are highly dynamic in childhood, and differ greatly 
between subjects. Interindividual variation is only partly accounted for by genetic factors.
Objective
We sought to determine which nongenetic factors affect the dynamics of innate leukocytes 
and naive and memory lymphocyte subsets.
Methods
We performed 6-color flow cytometry and linear mixed-effects modeling to define the 
dynamics of 62 leukocyte subsets from birth to 6 years of age in 1182 children, with 1 to 
5 measurements per subject. Subsequently, we defined the effect of prenatal maternal 
lifestyle-related or immunemediated determinants, birth characteristics, and bacterial/ 
viral exposure–related determinants on leukocyte subset dynamics.
Results
Functionally similar leukocyte populations were grouped by using unbiased hierarchical 
clustering of patterns of age-related leukocyte dynamics. Innate leukocyte numbers were 
high at birth and predominantly affected by maternal low education level. Naive lympho-
cyte counts peaked around 1 year, whereas most memory lymphocyte subsets more gradu-
ally increased during the first 4 years of life. Dynamics of CD4+ T cells were predominantly 
associated with sex, birth characteristics, and persistent infections with cytomegalovirus 
(CMV) or EBV. CD8+ T cells were predominantly associated with CMV and EBV infections, 
and T-cell receptor γδ+ T cells were predominantly associated with premature rupture of 
membranes and CMV infection. B-cell subsets were predominantly associated with sex, 
breast-feeding, and Helicobacter pylori carriership.
Conclusions
Our study identifies specific dynamic patterns of leukocyte subset numbers, as well as 
nongenetic determinants that affect these patterns, thereby providing new insights into 
the shaping of the childhood immune system.
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INTRODuCTION
The human immune system shows high diversity in cellular composition and functional 
responses between subjects. Blood leukocytes in young children are highly dynamic in 
number and composition.1-6 Numbers of innate cells, such as neutrophils and natural 
killer (NK) cells, are higher in neonates than in children or adults1,5,7 and already display 
dynamic changes within the first few days after birth.1,5,6 B and T cells are mostly naive 
in infants, whereas protective immunity is gradually built up in the form of increasing 
numbers of memory B (Bmem) and memory T (Tmem) cells during the first 5 years of life, 
after which these numbers stabilize.2-4,8-11 Recent studies have found that 25% to 50% of 
interindividual variation in cellular composition and functional responses were accounted 
for by genetic factors,12,13 indicating that nongenetic determinants underlie a large part of 
immune trait variance,14 which will potentially have long-term effects and underlie part 
of the immune trait variation in adults. To date, correlations of patterns between differ-
ent immune cells are incompletely studied because of either the restricted numbers of 
analyzed subsets, the short-term follow-up, or the lack of longitudinal analyses correcting 
for intrapersonal correlations between repeated measures. Furthermore, the nongenetic 
determinants that drive the kinetics of each type of immune cell remain less well studied. 
It is likely that these involve various environmental determinants, such as maternal life-
style, maternal immune-mediated diseases, birth characteristics, and bacterial and viral 
exposure in childhood.15-24 Studying the effect of these nongenetic factors on the dynamics 
of childhood immune development requires large cohorts of healthy young children, with 
multiple measurements per subject. We investigated which nongenetic factors related to 
the prenatal maternal lifestyle, prenatal maternal immune-mediated diseases, and birth 
characteristics or bacterial/viral exposure- related characteristics influence the dynamics 
of blood leukocyte populations from birth until 6 years of age. This concerned a total of 
62 leukocyte populations, including innate leukocyte subsets and naive T- and B-cell and 
Bmem and Tmem subsets.
PATIENTS AND METhODS
Study subjects
This study was embedded in the Generation R Study, a prospective population-based 
cohort study from fetal life until young adulthood.25,26 The current study focused on a 
subgroup of 1182 two-generation Dutch children born between August 2003 and August 
2006. Peripheral blood was obtained at birth and a median age of 6, 14, 25, and 72 months. 
Detailed immunophenotyping was performed at 1 to 5 time points per child, resulting in a 
total of 2010 data points (details are provided in supplemental material). Written informed 
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consent was obtained from parents according to the Medical Ethics Committee guidelines 
of Erasmus MC.
Immunophenotyping
Absolute numbers of leukocytes, NK cells, T cells and B cells were obtained with a diagnostic 
lyse-no-wash protocol, using a BD FACSCalibur (BD Biosciences, San Jose, Calif). Six-color 
flow cytometry was performed to quantify 62 well-defined leukocyte populations (Table 
1), which included NK-cell, monocyte, granulocyte, naive and memory B-cell, naive and 
memory TCRαβ+ T-cell and TCRγδ+ T-cell subsets (Supplemental Table 1). Flowcytometric 
analyses were performed on an LSRII (BD Biosciences) by using standardized measure-
ment settings (details in supplemental material).27
Table 1. Definition of leukocyte subsets
n=62 n=31 Name population Phenotype definition
Innate leukocytes
1 Granulocytes SSChighCD45+
2 CD15+ granulocytes SSChighCD45+CD15+
3 + Neutrophils SSChighCD45+CD16+
4 + Eosinophils SSChighCD45+CD16-
5 Monocytes FSCinterSSCinterCD45+
6 + Classical monocytes FSCinterSSCinterCD45+CD14+CD16-
7 + Intermediate monocytes FSCinterSSCinterCD45+CD14+CD16+
8 + Non-classical monocytes FSCinterSSCinterCD45+CD14-CD16+
9 + NK cells SSClowCD45+CD3-CD16+or CD56+
Lymphocytes
10 T cells SSClowCD45+CD3+
11 TCRαβ+ T cells SSClowCD3+TCRγδ-TCRαβ+
12 CD4+ TCRαβ+ T cells SSClowCD3+TCRγδ-TCRαβ+CD8-CD4+
13 CD8+ TCRαβ+ T cells SSClowCD3+TCRγδ-TCRαβ+CD8+CD4-
14 TCRγδ+ T cells SSClowCD3+TCRγδ+TCRαβ-
15 CD4+ TCRγδ+ T cells SSClowCD3+TCRγδ+TCRαβ-CD8-CD4+
16 CD8+ TCRγδ+ T cells SSClowCD3+TCRγδ+TCRαβ-CD8+CD4-
17 Vδ1-Vδ2- TCRαβ- T cells SSClowCD3+TCRαβ-Vδ1-Vδ2-
18 Vδ2+ T cells SSClowCD3+TCRαβ-Vδ1-Vδ2+
19 + Vδ1+ T cells SSClowCD3+TCRαβ-Vδ1+Vδ2-
20 Vγ9+ T cells FSClowSSClowCD3+TCRαβ-Vγ9+
21 +  Vδ2+Vγ9+ T cells FSClowSSClowCD3+TCRαβ-Vδ2+Vγ9+
22 CD4+ T cells SSClowCD45+CD3+CD4+CD8-
23 + CD4+ Tnaive FSClowSSClowCD3+CD8-CD197+CD45RO-CD27+CD28+
24 CD4+ Tmem FSClowSSClowCD3+CD8- CD197- and CD197+CD45RO+
39
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Table 1. Definition of leukocyte subsets (continued)
n=62 n=31 Name population Phenotype definition
25 +  CD4+ Tcm FSClowSSClowCD3+CD8-CD197+CD45RO+CD27+CD28+
26  CD4+ TemRO FSClowSSClowCD3+CD8-CD197-CD45RO+
27 +   CD4+ early TemRO FSClowSSClowCD3+CD8-CD197-CD45RO+CD27+CD28+
28 +   CD4+ interm TemRO FSClowSSClowCD3+CD8-CD197-CD45RO+CD27-CD28+
29 +   CD4+ late TemRO FSClowSSClowCD3+CD8-CD197-CD45RO+CD27-CD28-
30  CD4+ TemRA FSClowSSClowCD3+CD8-CD197-CD45RO-
31 +   CD4+ early TemRA FSClowSSClowCD3+CD8-CD197-CD45RO-CD27+CD28+
32 +   CD4+ interm TemRA FSClowSSClowCD3+CD8-CD197-CD45RO-CD27-CD28+
33 +   CD4+ late TemRA FSClowSSClowCD3+CD8-CD197-CD45RO-CD27-CD28-
34 CD8+ T cells SSClowCD45+CD3+CD4-CD8+
35 + CD8+ Tnaive FSClowSSClowCD3+CD8+CD197+CD45RO-CD27+CD28+
36 CD8+ Tmem FSClowSSClowCD3+CD8+CD197- and CD197+CD45RO+
37 +  CD8+ Tcm FSClowSSClowCD3+CD8+CD197+CD45RO+CD27+CD28+
38  CD8+ TemRO FSClowSSClowCD3+CD8+CD197-CD45RO+
39 +   CD8+ early TemRO FSClowSSClowCD3+CD8+CD197-CD45RO+CD27+CD28+
40 +   CD8+ interm TemRO FSClowSSClowCD3+CD8+CD197-CD45RO+CD27+CD28-
41 +   CD8+ late TemRO FSClowSSClowCD3+CD8+CD197-CD45RO+CD27-CD28-
42  CD8+ TemRA FSClowSSClowCD3+CD8+CD197-CD45RO-
43 +   CD8+ early TemRA FSClowSSClowCD3+CD8+CD197-CD45RO-CD27+CD28+
44 +   CD8+ interm TemRA FSClowSSClowCD3+CD8+CD197-CD45RO-CD27+CD28-
45 +   CD8+ late TemRA FSClowSSClowCD3+CD8+CD197-CD45RO-CD27-CD28-
46 B cells SSClowCD45+CD19+
47 + Bnaive SSClowCD19+CD27-IgD+
48 Bmem SSClowCD19+ IgD- and CD27+IgD+ 
49 CD27- Bmem SSClowCD19+CD27-IgD-
50 CD27+ Bmem SSClowCD19+CD27+IgD-
51 IgM+ Bmem SSClowCD19+CD27+IgM+
52 +  Natural effector SSClowCD19+CD27+IgM+IgD+
53 +  IgMonly SSClowCD19+CD27+IgM+IgD-
54 IgA+ Bmem SSClowCD19+IgA+
55 +  CD27-IgA+ SSClowCD19+CD27-IgA+
56 +  CD27+IgA+ SSClowCD19+CD27+IgA+
57 IgG+ Bmem SSClowCD19+IgG+
58 +  CD27-IgG+ SSClowCD19+CD27-IgG+
59 +  CD27+IgG+ SSClowCD19+CD27+IgG+
60 CD21low B cells SSClowCD19+CD38lowCD21low
61 Igλ+ B cells SSClowCD19+Igκ-Igλ+
62 Igκ+ B cells SSClowCD19+Igκ+Igλ-
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Determinants
Information on 22 dichotomized and 4 continuous determinants was obtained (Table 
II).25,26 Six determinants were related to prenatal maternal lifestyle and evaluated by us-
ing questionnaires in the first, second, and third trimesters of pregnancy26: maternal age 
and body mass index before pregnancy, education, net household income, and smoking 
or alcohol use during pregnancy. Three determinants were related to prenatal maternal 
immunemediated diseases: data on maternal atopy were obtained by means of maternal 
reported questionnaires during pregnancy,26 and serum anti–thyroid peroxidase IgG (anti-
TPO) and anti–tissue transglutaminase IgA antibody levels were measured in the second 
trimester of pregnancy (mean 6 SD: 13.4 ± 2.0 and 20.6 ± 1.2 weeks, respectively).28,29 Infor-
mation on 6 birthrelated determinants (ie, sex, gestational age [preterm birth, <37 weeks], 
birth weight [low birth weight, <2500 g], premature ruptures of the membranes, mode 
of delivery, and birth season) was obtained from obstetric records assessed in midwife 
practices and hospitals.25,26 Eleven bacterial or viral infection- related determinants were 
included: breast-feeding and breast-feeding duration, having siblings, antibiotics use, and 
presence of upper or lower respiratory tract infections in the first year of life (obtained by 
using questionnaires at child’s age of 2, 3, 6, and 12 months),26 Helicobacter pylori car-
riership at 6 years of age, and seropositivity (IgG) for cytomegalovirus (CMV), EBV, herpes 
simplex virus 1 (HSV-1), and varicella zoster virus at the age of 6 years.22,30,31
Statistical modeling
Linear mixed-effects analyses were performed to model leukocyte dynamics between 
birth and age 6 years. By including random effects in the model, this approach enabled 
modeling of cross-sectional data, with further improvement in accuracy by incorporating 
longitudinal follow-up data from individual children. To capture the trend in the data more 
precisely, the age of the children was included as a natural spline with different knots (0-3 
knots) into the models. Basically, the number of knots is inversely related to the smooth-
ness of the curve. Positions of the knots were defined as the 50th percentile (25.5 months) 
in the 1-knot model and the 33rd and 66th percentiles (14.1 and 70 months) in the 2-knot 
model. The knots in the 3-knot model were defined manually at 6, 14, and 24 months, 
focusing around the time points of data measurement. Model selection was performed 
by using the likelihood ratio test. Next, for each leukocyte population, the effect of all 26 
determinants on the models was assessed by first adding each determinant univariably 
into the model and analyzing fixed-effects estimates. To correct for potential multiple test-
ing errors, a correction for the 4 groups of determinants was performed, and consequently, 
only determinants with an effect P value of less than .0125 were defined as significant. 
Subsequently, for each leukocyte population, the determinants with a significant effect 
(<3 determinants were significant per model) were combined in a multivariable model 
to correct for possible confounding effects. Finally, to test whether changes in leukocyte 
dynamics over time (from birth until 6 years) induced by the determinant of interest was 
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most noticeable at a specific age interval, the individual determinants were tested in rela-
tion to the age of the children in a multivariable model. The P value for significance for 
the multivariable analyses was less than .05. Statistical analyses were performed with R 
software (version R-3.2.1; details are provided in Supplemental Material and Methods.32
Clustering analyses
The modeled data of each population were normalized into zero means and unit SDs (z-
score) to cluster patterns of leukocyte subset kinetics by using the following calculation:
 
The normalized leukocyte models were subsequently clustered using agglomerative 
(bottom-up) Ward hierarchical clustering at each step, clustering two clusters with mini-
mum between-cluster distance by using the Euclidean distance measure. 
RESuLTS
Linear mixed effect modeling of leukocyte-subset cell numbers versus child’s 
age
To study the dynamics of blood immune cells in young children, we quantified cell 
numbers of 11 leukocyte subsets in 1,182 children between birth and 76 months (6y) of 
age. Statistical modeling showed that the numbers of four innate leukocyte subsets, i.e. 
monocytes, neutrophils, eosinophils and NK cells were high at birth, quickly declined 
within the first 6 months of age and subsequently remained stable (Figure 1A). Naive B-cell 
and T-cell numbers strongly increased after birth, peaked between 6 and 14 months of age 
and subsequently decreased to stable levels around the age of 2 to 6 years (Figure 1B). 
Memory B and memory T cell numbers slowly increased within the first 6 to 14 months of 
life, after which numbers decreased marginally and stabilized from approximately 3 years 
onward (Figure 1B). Total TCRγδ+ T-cell numbers increased until 6 months and remained 
quite stable at these levels (Figure 1C). 
Distinct dynamics of innate leukocyte, and naive and memory B and T cells
To evaluate whether functionally related immune populations would follow similar dy-
namics with increasing age, we extended our analysis in the same children to 62 leukocyte 
subsetsbased on recent insights into naive and memory B-cell and T-cell subsets (Table 1 
and Supplemental Figures 1-5; reference values per age category are presented in Supple-
mental Table 2).24, 33 
Hierarchical clustering of all 62 leukocyte populations resulted in 4 distinct clusters of 
leukocyte dynamics (Figure 2A). Cell numbers of all populations in the first cluster were 
high at birth, followed by a sharp decrease within the first 6 months of life, after which 
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Figure 2. Hierarchical clustering of leukocyte subset dynamics in early childhood. 
A) Ward’s hierarchical clustering of the cellularity of the 62 populations derived from the linear mixed models. Cel-
lularity between 0-76 months of age was converted to zero mean and unit standard deviation (z score). B) Average 
patterns +/- 1 standard deviation of the subsets in each of the 4 major clusters. Populations are numbered according 
to their order in Table 1.
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they stabilized (Figure 2B). This cluster exclusively contained innate leukocyte subsets. All 
defined innate leukocyte subsets clustered within cluster 1, except for the intermediate 
monocytes. 
The populations in cluster 2 strongly increased shortly after birth and peaked before 14 
months of age, followed by a long-term gradual decrease. Cluster 2 included the 3 major 
naive lymphocyte subsets (CD4+ Tnaive, CD8+ Tnaive and Bnaive), as well as 5 memory 
populations (CD4+ central memory T cells (Tcm), CD8+ Tcm cells, early differentiated CD8+ 
CD45RO- effector memory T cells (CD8+ early TemRA), CD27-IgA+ memory B cells and natural 
effector memory B cells). Also the total B-cell, CD8+ T-cells, CD4+ T-cells and total T-cell sub-
sets clustered in cluster 2, as did the intermediate monocytes and the Vδ1+ T cells.
The populations in clusters 3 and 4 gradually increased in cell number and peaked 
either at 14 months (cluster 3) or after approximately 4 years (cluster 4). Clusters 3 and 4 
contained only memory B-cell and T-cell subsets and the TCRγδ+ T-cell subsets. Cluster 3 
contained the total memory lymphocyte populations Bmem, CD4+ Tmem and CD8+ Tmem. 
In particular, these memory populations included the early, intermediate and late CD8+ 
TemRO subpopulations, late CD8+ TemRA cells, early CD4+ TemRA cells, and the IgMonly, 
CD27+IgA+ and CD27-IgG+ memory B-cell subsets. Cluster 4 contained total TCRγδ+ T cells 
and the Vδ2+ and the Vγ9+ T-cell subsets, as well as the early, intermediate and late CD4+ 
TemRO subpopulations, late CD4+ TemRA cells, intermediate CD8+ TemRA cells, and 
CD27+IgG+ memory B cells. 
An additional clustering was performed on a selection of 31 non-overlapping popula-
tions (Table 1) to test the effect of including populations with overlapping population 
definitions on clustering. The resulting clusters showed similar dynamics (Figure 2B and 
Supplemental Figure 6B) with only 3 populations (non-classical monocytes, CD8+ late 
TemRO and CD8+ late TemRA) assigned to a different cluster, indicating that the overlap-
ping populations did not overtly skew our clustering approach. Thus, functionally related 
populations, as well as populations with phenotypic overlapping definitions, displayed 
similar dynamics in early childhood.
Associations between nongenetic factors and leukocyte subset dynamics in the 
4 clusters
The memory B- and T-cell subset showed large interindividual variation in dynamics of 
cell numbers (Figure 1). To study the effects of external factors, we analyzed 6 maternal 
life style- and 3 maternal immune-related determinants, 6 birth characteristics, and 11 
bacterial/viral exposure-related determinants (Table 2). Twelve of these 26 determinants 
showed a significant association with the dynamics of one or more of the 62 leukocyte 
populations after multivariable correction (Table 2). Bacterial/viral exposure-related de-
terminants were more frequently found to affect cell numbers in clusters 2, 3 and 4 than in 
cluster 1 (Figure 3A-B).
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In cluster 1, a low maternal education level was associated with a reduction in the pat-
terns of eosinophils and classical monocytes (Figure 4). Female sex was associated with a 
significant increase in the pattern of neutrophils and the phenotypically overlapping CD15+ 
Table 2. Characteristics of nongenetic factors
 
 
negative 
individuals 
(%)
positive 
individuals 
(%)
missing 
(%)
significant 
effect on 
cluster a
Prenatal maternal life style
Maternal age (years) (continuous determinant) 0 (0) -
Low maternal educational level 400 (33.8) 760 (64.3) 22 (1.9) 1,2,3,4
Net household income per month >€ 2200 242 (20.5) 847 (71.7) 93 (7.9) -
Smoking during pregnancy 815 (69) 256 (21.7) 111 (9.4) -
Alcohol use continued during pregnancy 299 (25.3) 750 (63.5) 133 (11.3) -
Body Mass Index before pregnancy (kg/m2) (continuous determinant) 181 (15.3) -
Prenatal maternal immune-mediated diseases
Maternal atopy (eczema, allergy HDM, hay-fever 683 (57.8) 383 (32.4) 116 (9.8) -
Anti-TPO (before 18 weeks of pregnancy) (mU/ml) (continuous determinant) 278 (23.5) 2
Maternal TG2A during pregnancy U/ml (continuous determinant) 208 (17.6) -
Birth characteristics
Gender (girl yes/no) 600 (50.8) 582 (49.2) 0 (0) 1,2,3,4
Preterm birth <37 weeks 76 (6.4) 1106 (93.6) 0 (0) -
Low birth weight <2500g 1119 (94.7) 63 (5.3) 0 (0) -
Premature rupture of membranes 1089 (92.1) 53 (4.5) 40 (3.4) 4
Caesarian section versus vaginal/ forceps/vacuum assisted 903 (76.4) 154 (13) 125 (10.6) 3,4
Birth season (born in Fall/Winter) 682 (57.7) 500 (42.3) 0 (0) -
Bacterial/viral exposure-related characteristics 
Breastfeeding ever 109 (9.2) 969 (82) 104 (8.8) -
Breastfeeding at 6 months of age 754 (63.8) 299 (25.3) 129 (10.9) 2,4
Siblings >1 687 (58.1) 480 (40.6) 15 (1.3) 1
Antibiotics/Penicillin use in 1st y 636 (53.8) 342 (28.9) 204 (17.3) 1,3
Upper respiratory tract infections in 1st y 547 (46.3) 475 (40.2) 160 (13.5) -
Lower respiratory tract infections in 1st y (doctor attended) 819 (69.3) 131 (11.1) 232 (19.6) -
Carrier of Helicobacter pylori within 6yrs 887 (75) 49 (4.1) 246 (20.8) 2,3
Seropositivity for Cytomegalovirus (CMV) at 6y 665 (56.3) 269 (22.8) 248 (21) 1,2,3,4
Seropositivity for Epstein Barr virus (EBV) at 6y 534 (45.2) 400 (33.8) 248 (21) 2,3,4
Seropositivity for Herpes simplex virus-1 (HSV-1) at 6y 810 (68.5) 124 (10.5) 248 (21) 2
Seropositivity for Varicella zoster virus (VZV) at 6y 73 (6.2) 861 (72.8) 248 (21) -
a First, each determinant was added to the linear mixed effect model univariately to test for a significant effect (Sig-
nificance was defined as p<0.0125); Subsequently, per leukocyte population, all determinants with a significant in-
dividual effect were added in a multivariable model to correct for confounding effects. Up to 3 determinants were 
added per multivariable model. Significance was defined as p<0.05. IU, international units. No confounding effect 
was observed
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granulocyte population. Having more than 1 sibling was associated with a reduction in 
NK cell numbers, and CMV infection with an increase in NK cell numbers. Antibiotic use in 
the first year of life was associated with an increase in non-classical monocytes. Overall 
effect estimates and associations of effects with specific age-intervals are presented in 
Supplemental Table 3.
In cluster 2, none of the determinants included in our study affected the patterns of more 
than 25% of the populations (Figure 3C-D). However, female sex was associated with an in-
crease in the patterns of CD4+ naive and Tcm cells and, consequently, in the phenotypically 
overlapping CD4+TCRαβ+ and total CD4+ T cells. Although breastfeeding for more than 6 
months was associated with a reduction in the pattern of total IgA+ and CD27-IgA+ memory 
B cells, H. pylori carriership was associated with an increase in these populations. Further-
more, H. pylori carriership was associated with an increase in total Igκ+ B cells and TCRαβ+ T 
cell counts. CMV and EBV were both associated with an increase in the strongly related 
total and TCRαβ+ CD8+ T cell numbers, and CMV was associated with an increase in Vδ1+ T 
cell numbers. HSV-1 seropositivity was associated with a decrease in the large population 
of naive B cells and, consequently, with total B cells and Igκ+ and Igλ+ B-cell subsets. 
In cluster 3 CMV and EBV seropositivity were significantly associated with changes in 
dynamics of greater than 40% of subsets (Figure 3C; Suppl Table 3). Both viruses were 
associated with an increase in CD8+ intermediate and late TemRO cell numbers, and the 
phenotypically-related total CD8+ TemRO and total CD8+ Tmem populations. In addition, 
CMV was associated with an increase in CD8+TCRγδ+ T cells and CD8+ late TemRA cells and 
the phenotypically-related total CD8+ TemRA population. EBV was associated with an 
increase in CD8+ early TemRO cells and a decrease in numbers of total Bmem cells and the 
CD27- and CD27+ Bmem subsets. The effects on CD8+ late TemRO and TemRA cells were still 
present in the analysis of 31 non-overlapping population, even though these were now 
included in cluster 4 (Figure 3D).
In cluster 4 sex, premature rupture of membranes, CMV and EBV were significantly as-
sociated with changes in dynamics of 40% of subsets (Figure 3C and D; Suppl Table 3). 
Female sex was associated with an increase in the patterns of CD27+IgG+ memory B cells, 
and CD4+ early TemRO cells and with a reduction in total TCRγδ+ T cells and CD4+ interme-
diate and late TemRA populations. Premature rupture of membranes was associated with 
an increase in numbers of CD4+ late TemRO cells, CD4+ intermediate TemRA cells and Vδ2+ 
and Vγ9+ T-cell subsets. CMV and EBV seropositivity were both associated with an increase 
in numbers of total CD4+ TemRO and CD4+ late TemRO and TemRA cells, as well as CD8+ in-
termediate TemRA cells. In addition, CMV was associated with increased numbers of CD4+ 
intermediate TemRO cells, and EBV with an increase in CD4+ early TemRO cell numbers. 
Altogether, we identified multiple determinants that had a significant effect on the dy-
namics of leukocyte subset numbers within 1 or more of the 4 distinct age-related patterns. 
Still, considerable variation of effects could be observed within individual clusters.
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Effects of nongenetic factors on leukocyte dynamics within distinct leukocyte 
lineages
Because clusters 2, 3 and 4 each contained various B-cell and T-cell populations, each with 
distinct humoral or cellular functions, we next studied the effects of the 26 determinants 
distribution of determinants with a significant effect (%)
B
0 10 20 30 40 50 60 70 80 90 100
cluster 1
(n=5 effects)
cluster 2
(n=8 effects)
cluster 3 
(n=6 effects)
cluster 4
(n=20 effects)
life style maternal immune-mediated birth characteristics bacterial/viral exposure
Cluster 1
4  leukocyte pop.
Cluster 2
11  leukocyte pop.
Cluster 3 
6  leukocyte pop.
Cluster 4 
10  leukocyte pop.fre
qu
en
cy
 o
f p
op
ul
at
io
ns
 a
ffe
ct
ed
 w
ith
in
 e
ac
h 
cl
us
te
r (
%
)
D
E
B
V
C
M
V
H
S
V-
1
H
.p
yl
or
i
si
bl
in
gs
br
ea
st
fe
ed
in
g 
>6
m
an
tib
io
tic
s 
1y
se
ct
io
P
R
O
M
M
ge
nd
er
ed
uc
at
io
n
fre
qu
en
cy
 o
f p
op
ul
at
io
ns
 a
ffe
ct
ed
 w
ith
in
 e
ac
h 
cl
us
te
r (
%
)
cluster 1
(n=8 effects)
cluster 2
(n= 21 effects)
cluster 3
(n= 24 effects)
cluster 4
(n= 23 effects)
distribution of determinants with a significant effect (%)
0 10 20 30 40 50 60 70 80 90 100
31 non-overlapping populationsTotal 62 populationsA
C 31 non-overlapping populationsTotal 62 populations
bacterial/viral
exposure-related
characteristics
prenatal
maternal
life style
immune-
mediated 
diseases
birth
charact.
TP
O
0
10
20
30
40
50
0
10
20
30
40
50
0
10
20
30
40
50
0
10
20
30
40
50
Cluster 1
8 leukocyte pop.
Cluster 2
24 leukocyte pop.
Cluster 3 
18 leukocyte pop.
Cluster 4 
12 leukocyte pop.
0
10
20
30
40
50
60
0
10
20
30
40
50
60
0
10
20
30
40
50
60
0
10
20
30
40
50
60
E
B
V
C
M
V
H
S
V-
1
H
.p
yl
or
i
si
bl
in
gs
br
ea
st
fe
ed
in
g 
>6
m
an
tib
io
tic
s 
1y
se
ct
io
P
R
O
M
M
ge
nd
er
ed
uc
at
io
n
V
ZV
lo
w
er
 R
TI
 1
y
up
pe
r R
TI
 1
y
br
ea
st
fe
ed
in
g 
ev
er
pr
et
er
m
 b
irt
h
lo
w
 b
irt
h 
w
ei
gh
t
tT
G
TP
O
at
op
y
B
M
I
al
co
ho
l
sm
ok
in
g
ag
e
bi
rth
 s
ea
so
n
ho
us
eh
ol
d 
in
co
m
e
4
5
6 2
3
9 8
12
22
23
25
9
60
13
19
34
54
55
11
54
55
62
13
34
46
47
61
62
58
16
48
49
42
45
56 16
16
36
38
40
41
42
4556
36
38
39
40
41
48
49
50
18
20
21
29
32 27
14
27
32
33
5918 18
26
28
29
33
44
26
27
29
33
44
37
3
4
6
99
37
23
25 855 55 19 47
56 5658
39
4040
28
29
33
41
44
45
21
29
32 27
27
32
33
45
59
27
29
33
41
44.
Figure 3. Nongenetic factors associated with leukocyte dynamics in the four clusters. 
Significant associations of the 26 determinants with leukocyte subsets in clusters 1-4 based on the clustering of 62 
leukocyte populations as in Figure 2 (A and C) or of the 31 non-overlapping subsets as in Suppl Figure 6 (B and D) 
corrected for confounding effects. A and B) Relative distribution of types of determinants that significantly affect 
leukocyte kinetics. C and D) Frequencies of populations within a cluster that were affected by individual determi-
nants. Abbreviations: PROMM, premature rupture of membranes; RTI, respiratory tract infection. Numbers in each 
bar refer to the populations as defined in Table 1. 
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on the patterns of individual leukocyte lineages.
Within the B-cell lineage, low maternal educational level was associated with a reduc-
tion in the patterns of total memory B cells (Figure 4). Female sex was associated with an 
increase in the patterns of CD27+IgA+ and CD27+IgG+ memory B cells, although these effects 
were not reflected in the total memory B-cell populations. Breastfeeding for more than 
6 months was associated with a selective reduction in the pattern of CD27-IgA+ memory 
B cells, antibiotics use in the first year of life was associated with a selective increase in 
the pattern of CD27-IgG+ memory B cells, and H. pylori carriership was associated with an 
increase in the patterns of both CD27-IgA+ and CD27+IgA+ memory B cells. EBV infection was 
associated with a reduction in the pattern of total memory B cells, although not with a 
specific memory B-cell subset, and HSV-1 infection was associated with a selective reduc-
tion in the pattern of naive B cells.
Within the CD4+ and CD8+ T-cell lineages, increased serum anti-TPO levels were associ-
ated with an increase in CD8+ Tcm cells. Female sex was associated with an increase in 
the patterns of CD4+ naive, Tcm and early TemRO cells, although these effects were not 
reflected in the total CD4+ memory T-cell populations. In contrast, female sex was associ-
ated with a decrease in the patterns of CD4+ intermediate and late TemRA and CD8+ late 
TemRA cells. Whereas premature rupture of membranes was associated with an increase in 
CD4+ late TemRO and CD4+ intermediate TemRA cells, child birth through caesarian section 
was associated with a reduction in the pattern of CD4+ early TemRO cells. Persistent viral 
infection with CMV and EBV significantly affected CD4+ and CD8+ T-cell dynamics in contrast 
to breastfeeding, antibiotics usage, H. pylori, HSV-1 and VZV carriership. CMV infection as-
sociated exclusively with an increase in the patterns of intermediate and late differentiated 
CD4+ and CD8+ TemRO and TemRA cells. Associations with EBV were slightly more variable, 
also including early differentiated CD4+ and CD8+ TemRO cells. 
Within the TCRγδ+ T-cell lineage, premature rupture of membranes was associated with 
an increase in Vδ2+Vγ9+ T cell counts and CMV infection associated with an increase in the 
pattern of Vδ1+ T cells. 
DISCuSSION 
Here we modeled the kinetics of 62 leukocyte subsets and identified distinct patterns of cell 
numbers in the first 6 years of life for innate leukocytes, naive B and T cells, and memory B 
and T cells. Unsupervised clustering revealed that leukocyte dynamics between birth and 
age 6 years could be summarized into 4 major profiles, with either (1) early predominance 
and fast decrease to stable numbers, (2) gradual increased in first year followed by a gradual 
decline, or (3 and 4) a slow increase in the first 1 to 2 years, followed by stabilization. 
Consistent with their early predominance, innate leukocyte kinetics were affected by 
maternal education level, which might already influence the fetus prenatally. Low mater-
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nal education level is strongly related to a less healthy life.34 These observations suggest 
that maternal life style is especially important for shaping of innate leukocyte populations, 
although the exact mediator remains to be determined.
The non-classical and intermediate monocytes did not consistently cluster with the 
innate leukocyte subsets because of a later peak in numbers or a slower decrease. This 
altered kinetics could be the result of these being derived from classical monocytes, and 
not directly from precursors in bone marrow.35 Still, the various subsets of monocytes 
express distinct levels of proteins involved in HLA-class II-dependent antigen presentation 
and CD40-CD40L co-stimulation,35 and differ in parasite pattern recognition.35-38 Thus our 
data support the need to discriminate intermediate and non-classical monocytes from the 
dominant population of classical monocytes in kinetics studies. 
All naive B- and T-cell populations followed profile 2, with a gradual increase in the 
first 14 months followed by a more gradual decrease. After the first 1 to 2 years of life, B-
lymphocyte production in bone marrow decreases,39, 40 and the thymus starts to involute.41 
These processes are likely causes of the decrease we observed. 
Memory B-cell populations showed different patterns. Natural effector and CD27-IgA+ 
memory B-cell kinetics were similar to naive B cells. Both memory B-cell populations 
are suggested to derive, at least in part, from germinal center-independent responses 
without T-cell help in the splenic marginal zone and the intestinal lamina propria.33, 42, 43 
The relatively fast increase in these cell numbers within the first 6 months of life contrasts 
with the kinetics of the other T-cell dependent memory B-cell subsets. IgM-only, CD27-IgG+ 
and CD27+IgA+ memory B cells followed profile 3, representing gradual memory formation. 
The CD27+IgG+ population followed profile 4 and developed slightly slower than the other 
memory B-cell populations. These observations supports the concept of rapid generation 
of T-cell independent memory B cells in the absence of the extensive proliferation and 
selection processes of the germinal center,33 whereas CD27+IgG+ memory B cells might 
represent the most mature memory B-cell population. In adults, this subset shows a 
higher level of affinity maturation, a more extensive replication history, and more frequent 
development through consecutive class-switching than CD27-IgG+ memory B cells.33, 44 It 
is perceivable that many of these CD27+IgG+ cells are generated from CD27-IgG+ memory B 
cells in secondary responses, which could explain the gradual decrease in CD27-IgG+ B cell 
numbers after 14 months of age. Together, the different clustering of the memory B-cell 
populations thereby follows their increasing functional maturity (Supplemental Figure 5 I).
Several external determinants significantly affected the B-cell kinetics. First, we con-
firmed our previous observations regarding lower numbers of memory B cells in breastfed 
children.20, 22 However, in the current analysis we could not reproduce the previously 
reported association between breastfeeding duration and germinal center-dependent 
memory B-cell numbers at 6 months of age.22 The difference is likely due to our current 
analysis in which duration of breastfeeding was not included and the overall pattern be-
tween birth and 6 years of age was studied. 
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Numbers of IgA+ memory B cells were significantly increased in H. pylori positive children. 
The colonization of the gastric mucus by H. pylori was found to correlate with an increase 
in total blood B-cell counts,45 on top of the local expansion of antibody-secreting IgA+ 
cells,46 which are important for the protection against H. pylori infection.47 Our observed 
expansion of circulating IgA+ memory B cells included both the CD27+IgA+ and mucosa-
derived CD27-IgA+ subsets. This would suggest that the presence of H. pylori does not only 
result in a local expansion of plasma cells, but also a systemic expansion of memory B cells 
in otherwise asymptomatic carriers. It remains to be determined whether this expansion is 
beneficial for the host as the bacterial protein CagA inhibits B-cell apoptosis and thereby 
increases the risk for mucosa-associated B-cell malignancies.48, 49 
Memory T-cell subsets were found in clusters 2, 3 and 4. CD4+ and CD8+ Tcm (cluster 2) 
express lymph node homing markers and are the presumed precursors of effector memory 
T cells.24, 50, 51 The early peak in Tcm numbers prior to those of effector memory T cells in 
young children would fit with this function. Similarly, CD8+ early TemRA cells might be 
precursors for further differentiated TemRA subsets. Vδ1+ T-cell numbers (cluster 2) peaked 
prior to the Vδ2+ and Vγ9+ subsets (cluster 4), thereby confirming the previously observed 
early shift from Vδ1+ to Vδ2+Vγ9+ predominance in children.52, 53 
In line with previous observations in both children and elderly,22, 54-58 both CD4+ and CD8+ 
memory T-cell dynamics were predominantly affected by CMV and/or EBV seropositivity. 
This concerned mostly late effector memory T-cell numbers for CMV and early effector 
memory T-cell subsets for EBV.24, 59 HSV-1 seropositivity did not affect CD4+ and CD8+ T-cell 
populations,22, 58 but was associated with a loss of naive B cells. This association has not 
been described before. EBV infection was associated with a reduction in memory B cells, 
likely because of the selective EBV persistence in these cells.60, 61 Our large-scale analysis 
allowed us to separate the herpesvirus-associated effects, with CMV and EBV being associ-
ated with memory T-cell expansions, and HSV-1 and EBV being associated with a decrease 
in naive or memory B-cell numbers, respectively. 
Sex had a widespread effect on 14 subsets within multiple leukocyte lineages. Interest-
ingly, girls showed a skewing of humoral and early differentiated CD4+ T-cell responses 
over cellular cytotoxic responses in contrast to boys. These effects might be associated 
with differences in sex-hormone levels (testosterone, estradiol) which are already detect-
able during early infancy, as well as with genetic differences between females and males.62 
These insights can especially be important for dissection of auto-immune diseases, which 
are much more prevalent in females than in males, although predisposition for allergic 
diseases seems to be opposite in infancy.62, 63 
Methodological considerations 
The strength of this study is its prospective longitudinal population-based design with more 
than 1000 children and the possibility to study 26 external determinants in 4 subgroups 
with adjustments for major confounders. The linear mixed model approach enabled mod-
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eling of cross-sectional data, with further improvement of the accuracy by incorporating 
additionally available longitudinal follow-up data. Furthermore, we included only children 
with a two-generation Dutch ancestry, which prevented interference of our analyses by 
strong ethnic and cultural influences. However, extrapolation of our findings to different 
ethnic and cultural populations might be limited, and would require additional analysis of 
ethnically-different population cohorts. 
The inclusion of 62 leukocyte populations allowed for the large-scale analysis of the effect 
of external determinants on both total cell lineages and small subsets defined by extensive 
and detailed phenotypic definition. The overlap in some populations could have skewed 
the hierarchical clustering. However, our selection of 31 phenotypically non-overlapping 
populations resulted in clusters with similar patterns, indicating the robustness of the 4 
major patterns of leukocyte dynamics and the observed effects of external determinants. 
Our study was primarily explorative with a focus on the identification of determinants 
that affected leukocyte dynamics between birth and 6 years of age. Although we defined 
whether determinants had a positive or negative association with leukocyte numbers, we 
were unable to identify the exact nature of the effect (i.e. exactly when these effects pre-
sented and whether these effects will be transient, persistent or potentially even increasing 
over time). Consequently, more research into individual determinants will be needed to 
extend our observations by specifying these effects. 
Finally, special consideration needs to be taken for serology of infectious agents that 
were measured at the age of 6 years. We cannot determine the exact timing of primary 
infections, and this can consequently be in the whole period preceding the age of 6 years. 
Still, most H. pylori infections already occur in early childhood, and IgG seropositivity to 
herpesviruses only appears several weeks to 3 months after infection. Thus, these determi-
nants were present already during or before the sixth year of life. 
Conclusions
With our unbiased approach, for the first time, we classified leukocyte populations accord-
ing to their dynamics between birth and 6 years of age. Moreover, we identified nongenetic 
factors that are associated with the dynamics of cell lineages or specific leukocyte subsets 
and that underlie, at least in part, human immunological diversity. These newly identified 
determinants can provide new targets for studies on the molecular processes that regulate 
leukocyte development and immune responses and that together underlie formation 
of long-lasting immunity without inducing destructive, excessive or insufficient immune 
responses.
53
Chapter 2  |  Determinants of leukocyte subset kinetics in children
Ch
ap
te
r 2
REFERENCES
 1. Comans-Bitter WM, de Groot R, van den Beemd R, Neijens HJ, Hop WC, Groeneveld K, et al. Immunophe-
notyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. J Pediatr 
1997; 130:388-93.
 2. van Gent R, van Tilburg CM, Nibbelke EE, Otto SA, Gaiser JF, Janssens-Korpela PL, et al. Refined character-
ization and reference values of the pediatric T- and B-cell compartments. Clin Immunol 2009; 133:95-107.
 3. Tosato F, Bucciol G, Pantano G, Putti MC, Sanzari MC, Basso G, et al. Lymphocytes subsets reference values 
in childhood. Cytometry A 2015; 87:81-5.
 4. Duchamp M, Sterlin D, Diabate A, Uring-Lambert B, Guerin-El Khourouj V, Le Mauff B, et al. B-cell subpopu-
lations in children: National reference values. Immun Inflamm Dis 2014; 2:131-40.
 5. Xanthou M. Leucocyte blood picture in healthy full-term and premature babies during neonatal period. 
Arch Dis Child 1970; 45:242-9.
 6. Manroe BL, Weinberg AG, Rosenfeld CR, Browne R. The neonatal blood count in health and disease. I. 
Reference values for neutrophilic cells. J Pediatr 1979; 95:89-98.
 7. Sagnia B, Ateba Ndongo F, Ndiang Moyo Tetang S, Ndongo Torimiro J, Cairo C, Domkam I, et al. Reference 
values of lymphocyte subsets in healthy, HIV-negative children in Cameroon. Clin Vaccine Immunol 2011; 
18:790-5.
 8. Huck K, Feyen O, Ghosh S, Beltz K, Bellert S, Niehues T. Memory B-cells in healthy and antibody-deficient 
children. Clin Immunol 2009; 131:50-9.
 9. Morbach H, Eichhorn EM, Liese JG, Girschick HJ. Reference values for B cell subpopulations from infancy 
to adulthood. Clin Exp Immunol 2010; 162:271-9.
 10. Piatosa B, Wolska-Kusnierz B, Pac M, Siewiera K, Galkowska E, Bernatowska E. B cell subsets in healthy 
children: reference values for evaluation of B cell maturation process in peripheral blood. Cytometry B 
Clin Cytom 2010; 78:372-81.
 11. Driessen GJ, Dalm VA, van Hagen PM, Grashoff HA, Hartwig NG, van Rossum AM, et al. Common variable 
immunodeficiency and idiopathic primary hypogammaglobulinemia: two different conditions within the 
same disease spectrum. Haematologica 2013; 98:1617-23.
 12. Brodin P, Jojic V, Gao T, Bhattacharya S, Angel CJ, Furman D, et al. Variation in the human immune system 
is largely driven by non-heritable influences. Cell 2015; 160:37-47.
 13. Orru V, Steri M, Sole G, Sidore C, Virdis F, Dei M, et al. Genetic variants regulating immune cell levels in 
health and disease. Cell 2013; 155:242-56.
 14. Carr EJ, Dooley J, Garcia-Perez JE, Lagou V, Lee JC, Wouters C, et al. The cellular composition of the hu-
man immune system is shaped by age and cohabitation. Nat Immunol 2016; 17:461-8.
 15. Pabst HF, Spady DW, Pilarski LM, Carson MM, Beeler JA, Krezolek MP. Differential modulation of the im-
mune response by breast- or formula-feeding of infants. Acta Paediatr 1997; 86:1291-7.
 16. Winkler B, Aulenbach J, Meyer T, Wiegering A, Eyrich M, Schlegel PG, et al. Formula-feeding is associated 
with shift towards Th1 cytokines. Eur J Nutr 2015; 54:129-38.
 17. Hanson L, Silfverdal SA, Stromback L, Erling V, Zaman S, Olcen P, et al. The immunological role of breast 
feeding. Pediatr Allergy Immunol 2001; 12 Suppl 14:15-9.
 18. Hanson LA, Korotkova M, Lundin S, Haversen L, Silfverdal SA, Mattsby-Baltzer I, et al. The transfer of im-
munity from mother to child. Ann N Y Acad Sci 2003; 987:199-206.
 19. Duijts L, Ramadhani MK, Moll HA. Breastfeeding protects against infectious diseases during infancy in 
industrialized countries. A systematic review. Matern Child Nutr 2009; 5:199-210.
 20. Hawkes JS, Neumann MA, Gibson RA. The effect of breast feeding on lymphocyte subpopulations in 
healthy term infants at 6 months of age. Pediatr Res 1999; 45:648-51.
Chapter 2  |  Determinants of leukocyte subset kinetics in children
54
 21. M’Rabet L, Vos AP, Boehm G, Garssen J. Breast-feeding and its role in early development of the immune 
system in infants: consequences for health later in life. J Nutr 2008; 138:1782S-90S.
 22. Jansen MA, van den Heuvel D, van Zelm MC, Jaddoe VW, Hofman A, de Jongste JC, et al. Decreased 
memory B cells and increased CD8 memory T cells in blood of breastfed children: the generation R study. 
PLoS One 2015; 10:e0126019.
 23. Bekker V, Scherpbier H, Pajkrt D, Jurriaans S, Zaaijer H, Kuijpers TW. Persistent humoral immune defect 
in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies 
against attenuated vaccine strains and natural viral infection. Pediatrics 2006; 118:e315-22.
 24. Appay V, van Lier RA, Sallusto F, Roederer M. Phenotype and function of human T lymphocyte subsets: 
consensus and issues. Cytometry A 2008; 73:975-83.
 25. Jaddoe VW, van Duijn CM, Franco OH, van der Heijden AJ, van Iizendoorn MH, de Jongste JC, et al. The 
Generation R Study: design and cohort update 2012. Eur J Epidemiol 2012; 27:739-56.
 26. Kruithof CJ, Kooijman MN, van Duijn CM, Franco OH, de Jongste JC, Klaver CC, et al. The Generation R 
Study: Biobank update 2015. Eur J Epidemiol 2014; 29:911-27.
 27. Kalina T, Flores-Montero J, van der Velden VH, Martin-Ayuso M, Bottcher S, Ritgen M, et al. EuroFlow stan-
dardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 2012; 
26:1986-2010.
 28. Korevaar TI, Medici M, de Rijke YB, Visser W, de Muinck Keizer-Schrama SM, Jaddoe VW, et al. Ethnic differ-
ences in maternal thyroid parameters during pregnancy: the Generation R study. J Clin Endocrinol Metab 
2013; 98:3678-86.
 29. Kiefte-de Jong JC, Jaddoe VW, Uitterlinden AG, Steegers EA, Willemsen SP, Hofman A, et al. Levels of 
antibodies against tissue transglutaminase during pregnancy are associated with reduced fetal weight 
and birth weight. Gastroenterology 2013; 144:726-35 e2.
 30. Jansen MA, Tromp, II, Kiefte-de Jong JC, Jaddoe VW, Hofman A, Escher JC, et al. Infant feeding and 
anti-tissue transglutaminase antibody concentrations in the Generation R Study. Am J Clin Nutr 2014; 
100:1095-101.
 31. den Hollander WJ, Holster IL, van Gilst B, van Vuuren AJ, Jaddoe VW, Hofman A, et al. Intergenerational 
reduction in Helicobacter pylori prevalence is similar between different ethnic groups living in a Western 
city. Gut 2014.
 32. R Core Team; R Foundation for Statistical Computing V, Austria. R: A language and environment for statis-
tical computing. . 2015.
 33. Berkowska MA, Driessen GJ, Bikos V, Grosserichter-Wagener C, Stamatopoulos K, Cerutti A, et al. Human 
memory B cells originate from three distinct germinal center-dependent and -independent maturation 
pathways. Blood 2011; 118:2150-8.
 34. Bouthoorn SH, Silva LM, Murray SE, Steegers EA, Jaddoe VW, Moll H, et al. Low-educated women have an 
increased risk of gestational diabetes mellitus: the Generation R Study. Acta Diabetol 2015; 52:445-52.
 35. Wong KL, Tai JJ, Wong WC, Han H, Sem X, Yeap WH, et al. Gene expression profiling reveals the defining 
features of the classical, intermediate, and nonclassical human monocyte subsets. Blood 2011; 118:e16-
31.
 36. Turner JD, Bourke CD, Meurs L, Mbow M, Dieye TN, Mboup S, et al. Circulating CD14brightCD16+ ‘interme-
diate’ monocytes exhibit enhanced parasite pattern recognition in human helminth infection. PLoS Negl 
Trop Dis 2014; 8:e2817.
 37. Hijdra D, Vorselaars AD, Grutters JC, Claessen AM, Rijkers GT. Phenotypic characterization of human 
intermediate monocytes. Front Immunol 2013; 4:339.
 38. Ziegler-Heitbrock L, Hofer TP. Toward a refined definition of monocyte subsets. Front Immunol 2013; 4:23.
 39. Kogut I, Scholz JL, Cancro MP, Cambier JC. B cell maintenance and function in aging. Semin Immunol 
2012; 24:342-9.
55
Chapter 2  |  Determinants of leukocyte subset kinetics in children
Ch
ap
te
r 2
 40. Jensen K, Schaffer L, Olstad OK, Bechensteen AG, Hellebostad M, Tjonnfjord GE, et al. Striking decrease in 
the total precursor B-cell compartment during early childhood as evidenced by flow cytometry and gene 
expression changes. Pediatr Hematol Oncol 2010; 27:31-45.
 41. Flores KG, Li J, Sempowski GD, Haynes BF, Hale LP. Analysis of the human thymic perivascular space dur-
ing aging. J Clin Invest 1999; 104:1031-9.
 42. Weller S, Braun MC, Tan BK, Rosenwald A, Cordier C, Conley ME, et al. Human blood IgM “memory” B cells 
are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood 
2004; 104:3647-54.
 43. Weller S, Faili A, Garcia C, Braun MC, Le Deist FF, de Saint Basile GG, et al. CD40-CD40L independent Ig gene 
hypermutation suggests a second B cell diversification pathway in humans. Proc Natl Acad Sci U S A 2001; 
98:1166-70.
 44. Jackson KJ, Wang Y, Collins AM. Human immunoglobulin classes and subclasses show variability in VDJ 
gene mutation levels. Immunol Cell Biol 2014; 92:729-33.
 45. Helmin-Basa A, Michalkiewicz J, Gackowska L, Kubiszewska I, Eljaszewicz A, Mierzwa G, et al. Pediatric 
Helicobacter pylori infection and circulating T-lymphocyte activation and differentiation. Helicobacter 
2011; 16:27-35.
 46. Mattsson A, Quiding-Jarbrink M, Lonroth H, Hamlet A, Ahlstedt I, Svennerholm A. Antibody-secreting cells 
in the stomachs of symptomatic and asymptomatic Helicobacter pylori-infected subjects. Infect Immun 
1998; 66:2705-12.
 47. Lee CK, Weltzin R, Thomas WD, Jr., Kleanthous H, Ermak TH, Soman G, et al. Oral immunization with 
recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from chal-
lenge with Helicobacter felis. J Infect Dis 1995; 172:161-72.
 48. Umehara S, Higashi H, Ohnishi N, Asaka M, Hatakeyama M. Effects of Helicobacter pylori CagA protein on 
the growth and survival of B lymphocytes, the origin of MALT lymphoma. Oncogene 2003; 22:8337-42.
 49. Lin WC, Tsai HF, Kuo SH, Wu MS, Lin CW, Hsu PI, et al. Translocation of Helicobacter pylori CagA into 
Human B lymphocytes, the origin of mucosa-associated lymphoid tissue lymphoma. Cancer Res 2010; 
70:5740-8.
 50. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, 
generation, and maintenance. Annu Rev Immunol 2004; 22:745-63.
 51. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct 
homing potentials and effector functions. Nature 1999; 401:708-12.
 52. Sandberg Y, Almeida J, Gonzalez M, Lima M, Barcena P, Szczepanski T, et al. TCRgammadelta+ large granu-
lar lymphocyte leukemias reflect the spectrum of normal antigen-selected TCRgammadelta+ T-cells. 
Leukemia 2006; 20:505-13.
 53. Breit TM, Wolvers-Tettero IL, van Dongen JJ. Unique selection determinant in polyclonal V delta 2-J delta 
1 junctional regions of human peripheral gamma delta T lymphocytes. J Immunol 1994; 152:2860-4.
 54. Bekker V, Bronke C, Scherpbier HJ, Weel JF, Jurriaans S, Wertheim-van Dillen PM, et al. Cytomegalovirus 
rather than HIV triggers the outgrowth of effector CD8+CD45RA+CD27- T cells in HIV-1-infected children. 
Aids 2005; 19:1025-34.
 55. Weinberger B, Lazuardi L, Weiskirchner I, Keller M, Neuner C, Fischer KH, et al. Healthy aging and latent 
infection with CMV lead to distinct changes in CD8+ and CD4+ T-cell subsets in the elderly. Hum Immunol 
2007; 68:86-90.
 56. van Leeuwen EM, Remmerswaal EB, Vossen MT, Rowshani AT, Wertheim-van Dillen PM, van Lier RA, et al. 
Emergence of a CD4+CD28- granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary 
cytomegalovirus infection. J Immunol 2004; 173:1834-41.
Chapter 2  |  Determinants of leukocyte subset kinetics in children
56
 57. Chidrawar S, Khan N, Wei W, McLarnon A, Smith N, Nayak L, et al. Cytomegalovirus-seropositivity has 
a profound influence on the magnitude of major lymphoid subsets within healthy individuals. Clin Exp 
Immunol 2009; 155:423-32.
 58. Derhovanessian E, Maier AB, Hahnel K, Beck R, de Craen AJ, Slagboom EP, et al. Infection with cytomegalo-
virus but not herpes simplex virus induces the accumulation of late-differentiated CD4+ and CD8+ T-cells 
in humans. J Gen Virol 2011; 92:2746-56.
 59. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, et al. Memory CD8+ T cells vary in 
differentiation phenotype in different persistent virus infections. Nat Med 2002; 8:379-85.
 60. Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA. EBV persistence in memory B cells in vivo. Immunity 
1998; 9:395-404.
 61. Chaganti S, Heath EM, Bergler W, Kuo M, Buettner M, Niedobitek G, et al. Epstein-Barr virus colonization of 
tonsillar and peripheral blood B-cell subsets in primary infection and persistence. Blood 2009; 113:6372-
81.
 62. Ober C, Loisel DA, Gilad Y. Sex-specific genetic architecture of human disease. Nat Rev Genet 2008; 9:911-
22.
 63. Whitacre CC, Reingold SC, O’Looney PA. A gender gap in autoimmunity. Science 1999; 283:1277-8.
57
Chapter 2  |  Determinants of leukocyte subset kinetics in children
Ch
ap
te
r 2
SuPPLEMENTAL MATERIALS AND METhODS
Study subjects
Included in our study are 1182 two-generation Dutch children. Peripheral blood was ob-
tained from 220 children at birth, from 376 children at the age of 5-9 months, from 241 
children at the age of 13-17 months, from 257 children at the age of 22-30 months and from 
916 children at the age of 61-95 months. Of 237 children, detailed immunophenotyping 
data was available at 3 or more follow-up time points, of 90 children at 4 or more time 
points. The complete follow-up at 5 time points was available for 12 children. 
Sample preparation
Approximately 4ml of blood was collected in EDTA-anticoagulant tubes by venous punc-
ture. Blood was kept at room temperature and processed within 24 hours after sampling. 
50µl Full blood was mixed with BD Trucount beads (BD Biosciences; San Jose, CA) and 
stained for CD3, CD16, CD56, CD19 and CD45 in a diagnostic lyse-no-wash approach to 
obtain absolute cell counts. Subsequently, red blood cells were lysed by adding NH4Cl. 
Absolute numbers of leukocytes, NK cells, T cells and B cells were obtained without a wash 
step on a BD FACSCalibur (BD Biosciences; San Jose, CA). 
2ml Full blood was subjected to bulk lysis of red blood cells by 10 min incubation with 
NH4Cl. Following wash steps, the remaining white blood cells were divided over 10 tubes 
for 6-color flowcytometric analyses with the antibodies listed in Supplemental Table 1. 
Following 10 min incubation at room temperature, cells were washed and immunopheno-
typic measurements were performed on a 3-laser BD LSRII (BD Biosciences; San Jose, CA). 
The 488nm laser was used to excite the FITC (530/30nm filter), PE (575/26nm), PerCP-Cy5.5 
(695/40nm) and PE-Cy7 (780/60nm) fluorophores, and the 633nm laser for APC (660/20nm) 
and APC-Cy7 (780/60nm). PMT voltages were set using 8-peak rainbow beads based on 
target values for the 7th peak as established within the EuroFlow consortium.27 Absolute 
cells per µl blood of leukocyte subpopulations were recalculated using the total leukocyte, 
NK-cell, T-cell and B-cell numbers obtained from the Trucount analysis.
Statistical modeling
Our dataset included 62 leukocyte populations and 26 determinants for 1182 children, 
with for each leukocyte population (defined as population “i”), a total of 2010 data points. 
Linear mixed effect modeling of leukocyte kinetics
For each leukocyte population “i” in our dataset, the following 4 linear mixed effect models 
were tested:
lmR_0knots<-
lmer(dataset[,i] ~ ns(Age,1)+(1|Id),REML=FALSE,data=data)
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lmR_1knots<-
lmer(dataset[,i] ~ ns(Age,2, knots = c(25.5))+(1|Id),REML=FALSE,data=dataset)
lmR_2knots<-
lmer(dataset[,i] ~ ns(Age,3, knots = c(14.1 , 70))+(1|Id),REML=FALSE,data=dataset)
lmR_3knots<-
lmer(dataset[,i] ~ ns(Age,4, knots = c(6, 14, 24))+(1|Id),REML=FALSE,data=dataset)
# ns(Age,...) defines the natural spline of the age of the children, with indicated knots; 
# (1|Id) defines the child’s Id-number as a random effect in the model, to include longi-
tudinal measurements.
The optimal model was selected by likelyhood ratio test:
 anov[1]<-ifelse(anova(lmR_0knots,lmR_1knots)[[8]][2]<0.05,2,0)
 anov[2]<-ifelse(anova(lmR_1knots,lmR_2knots)[[8]][2]<0.05,3,0)
 anov[3]<-ifelse(anova(lmR_2knots,lmR_3knots)[[8]][2]<0.05,4,0)
 selected.lmR<-max(anov)
univariate analyses of the effect of nongenetic determinants on leukocyte kinetics
Each determinant “j” in our dataset was included independently as a fixed effect to the 
optimal linear mixed effect model of individual leukocyte populations (below an example 
for a leukocyte population modelled by model lmR_3knots)
lmer(dataset[,i] ~ ns(Age,4, knots = 
c(6,14,24))+determinant[,j]+(1|Id),REML=FALSE,data=dataset)
Determinants with an effect of p<0.0125 were defined as significant.
Multivariable analyses of the effect of nongenetic determinants on leukocyte kinetics
All determinants with a significant univariate effect on a leukocyte population (up to three 
determinants per leukocyte population), were combined and included as fixed effects to 
the optimal linear mixed effect model of individual leukocyte populations to correct for 
confounding effects (below an example for a leukocyte population modelled by model 
lmR_3knots)
lmer(dataset[,i] ~ ns(Age,4, knots = c(6,14,24))+significant determinant 1+ significant 
determinant 2+ etc +(1|Id),REML=FALSE,data=dataset)
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Determinants with an effect of p<0.05 were defined as significant after multivariable cor-
rection.
Define whether a determinant has an age-associated affect on a leukocyte population
For determinants that still affected leukocyte kinetics after multivariable correction, we 
subsequently defined whether this effect was significantly stronger within a selective age-
period (either between the age of 0months – knot1, knot1 – knot2 , knot2 – knot3 or knot3 
– 76 months). To test this, the models for multivariable analyses were adjusted, testing 
individual determinants in relation to the age in the children:
e.g. Test the age-associated effect of determinant 1: lmer(dataset[,i] ~ ns(Age,4, knots 
= c(6,14,24))* significant determinant 1 + significant determinant 2+ etc +(1|Id),RE
ML=FALSE,data=dataset)
# “*” indicates a test of the natural spline of the age of the children in relation to de-
terminant 1
# the other determinants significantly affecting this leukocyte population were still 
included as fixed effects to correct for potential confounding effects
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SuPPLEMENTAL TABLES
Supplemental Table 1. Antibody details
Tube
  Fluorochrome
FITC PE PerCP-Cy5.5 PE-Cy7 APC APC-Cy7
1
Antibody CD3 CD16+CD56 CD45 CD4 CD19 CD8
Clone SK7 B73.1 + C5.9 2D1 SK3 SJ25C1 SK1
Manufacturer BD BD+Dako BD BD BD BD
2
Antibody CD15 - CD45 CD16 - CD14
Clone MMA - 2D1 3G8 - MO-P9
Manufacturer BD - BD BD - BD
3
Antibody Igκ Igλ CD19 CD21 - -
Clone polyclonal polyclonal SJ25C1 B-ly-4 - -
Manufacturer Dako Southern Biotech BD BD - -
4
Antibody CD38 - CD19 CD21 - -
Clone HB7 - SJ25C1 B-ly-4 - -
Manufacturer BD - BD BD - -
5
Antibody IgD - CD19 - IgM CD27
Clone polyclonal - SJ25C1 - polyclonal L128
Manufacturer Southern Biotech - BD - BD BD
6
Antibody IgA IgG CD19 - IgM CD27
Clone polyclonal polyclonal SJ25C1 - polyclonal L128
Manufacturer Kallestad Southern Biotech BD - BD BD
7
Antibody TCRαβ TCRγδ CD3 CD4 CD8 -
Clone WT31 11F2 SK7 SK3 SK1 -
Manufacturer BD BD BD BD BD -
8
Antibody Vδ2 Vδ1 * CD3 CD4 TCRαβ CD8
Clone B6.1 R9.12 SK7 SK3 IP26 SK1
Manufacturer BD Beckman Coulter BD BD eBiosciences BD
9
Antibody CD28 CD197 CD3 CD8 CD45RO CD27
Clone CD28.2 3D13 SK7 SK1 UCHL-1 L128
Manufacturer BD eBiosciences BD BD BD BD
10
Antibody Vδ2 Vγ9 CD3 CD4 TCRαβ CD8
Clone B6.1 B3.1 SK7 SK3 IP26 SK1
Manufacturer BD BD BD BD eBiosciences BD
Manufactures listed are BD Biosciences, San Jose, Calif; DakoCytomation, Glostrup, Denmark; Southern Biotech, 
Birmingham, Ala; Kallestad Diagnostics, Chaska, Minn; Beckman Coulter, Indianapolis, Ind; and eBioscience, San 
Diego, Calif. 
APC, Allophycocyanin; FITC, fluorescin isothiocyanate; PE, phycoerythrin; PerCP, peridin-chlorophyll-protein com-
plex. 
* Unconjugated antibody detected with Goat anti-Mouse IgG PE (polyclonal; Invitrogen, Waltham, Mass).
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Supplemental Table 2. Age-associated reference values of leukocyte populations
percentile
Age category (months)
0 6 14 25 72
 Number of children - 220 376 241 257 916
Age (months)
5th 0.0 5.5 13.6 23.6 69.3
25th 0.0 6.0 14.1 24.4 70.6
50th 0.0 6.2 14.4 25.1 72.4
75th 0.0 6.7 14.8 25.8 75.0
95th 0.0 7.7 16.1 27.3 79.0
 
Innate Leukocytes
Granulocytes
5th 4884.2 1026.1 1196.3 1352.5 1562.4
25th 8263.0 2055.0 2250.4 1990.9 2840.2
50th 10572.7 2850.0 3074.1 2822.9 3715.0
75th 13727.9 4167.8 4143.0 3832.6 5041.0
95th 18784.8 6519.8 6056.8 6467.5 7597.8
CD15+ granulocytes
5th 5161.2 871.6 1138.2 1310.8 1521.0
25th 8010.4 1735.8 2072.7 1931.9 2736.1
50th 10397.8 2617.3 2973.2 2690.5 3608.8
75th 13564.7 3789.1 4066.6 3746.3 4896.7
95th 17933.3 5913.7 5633.9 6194.1 7527.4
Neutrophils
5th 4433.3 824.4 1026.1 1116.3 1321.7
25th 7064.5 1668.6 1926.4 1840.5 2414.2
50th 9091.8 2497.6 2750.9 2533.5 3274.0
75th 11634.0 3671.1 3795.5 3665.9 4451.2
95th 16483.1 5653.1 5506.1 5983.6 6810.9
Eosinophils
5th 489.5 155.2 84.5 83.9 109.4
25th 891.3 253.1 178.1 142.2 199.1
50th 1340.0 351.6 248.0 203.8 356.4
75th 1999.2 486.7 373.2 315.6 598.1
95th 3721.9 856.0 763.6 617.5 1261.5
Monocytes
5th 496.1 360.1 320.6 272.8 233.9
25th 1002.2 582.8 504.0 433.1 370.4
50th 1346.5 789.6 691.6 577.4 490.9
75th 1749.6 1065.8 962.7 729.6 623.7
95th 2429.0 1755.0 1510.6 1066.6 924.1
Classical monocytes
5th 378.1 220.4 192.7 190.0 168.8
25th 829.5 338.6 301.7 304.0 267.4
50th 1114.3 461.1 425.3 402.6 349.6
75th 1425.4 623.9 572.6 522.9 455.9
95th 2125.5 992.3 849.1 714.1 676.4
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Supplemental Table 2. Age-associated reference values of leukocyte populations (continued)
percentile
Age category (months)
0 6 14 25 72
Intermediate monocytes
5th 20.6 19.4 26.1 11.6 10.1
25th 46.6 36.0 42.4 27.9 21.0
50th 72.3 55.1 70.3 43.7 31.0
75th 112.1 87.0 116.7 72.0 44.8
95th 170.0 202.7 243.3 124.3 89.8
Non-classical monocytes
5th 24.0 16.2 13.4 4.2 4.8
25th 50.6 39.3 24.3 12.6 11.7
50th 77.3 60.8 41.3 26.8 22.0
75th 116.0 92.6 66.1 48.9 41.2
95th 207.5 162.2 139.2 93.4 80.3
NK cells
5th 229.5 160.0 130.0 120.0 90.0
25th 460.0 250.0 210.0 180.0 140.0
50th 840.0 330.0 280.0 240.0 190.0
75th 1350.0 450.0 400.0 320.0 250.3
95th 2100.5 752.5 690.0 536.0 420.0
Lymphocytes
T cells
5th 1478.5 2587.5 2180.0 1586.0 1329.0
25th 2187.5 3740.0 3080.0 2220.0 1770.0
50th 2695.0 4620.0 3700.0 2830.0 2102.0
75th 3457.5 5690.0 4610.0 3650.0 2571.8
95th 4745.5 7722.5 6010.0 4956.0 3560.0
TCRαβ+ T cells
5th 1403.3 2509.1 2063.6 1461.9 1170.2
25th 2130.3 3680.3 2934.0 2064.0 1593.1
50th 2607.5 4477.9 3534.7 2691.3 1916.9
75th 3318.6 5426.5 4401.4 3345.1 2328.9
95th 4598.5 7552.0 5697.5 4565.6 3295.1
CD4+TCRαβ+ T cells
5th 957.5 1788.3 1388.1 896.6 685.2
25th 1446.6 2679.3 1926.2 1338.0 949.5
50th 1848.8 3295.1 2401.3 1739.1 1177.0
75th 2338.7 3994.7 3023.6 2233.5 1450.3
95th 3085.2 5597.1 4019.3 3167.0 2067.5
CD8+TCRαβ+ T cells
5th 351.4 575.1 503.3 411.9 364.1
25th 542.7 856.5 796.1 630.5 537.4
50th 736.4 1101.7 1013.3 813.2 669.9
75th 957.6 1427.4 1291.6 1053.7 857.0
95th 1454.5 2112.0 1894.5 1582.7 1227.1
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Supplemental Table 2. Age-associated reference values of leukocyte populations (continued)
percentile
Age category (months)
0 6 14 25 72
TCRγδ+ T cells
5th 31.5 69.1 68.8 63.7 82.3
25th 63.1 123.3 106.5 109.3 132.2
50th 87.7 164.0 162.8 163.1 178.2
75th 126.0 226.5 213.2 219.8 248.2
95th 225.1 333.2 332.6 352.8 377.7
CD4+ TCRγδ+ T cells
5th 5.4 6.6 4.8 3.4 2.1
25th 11.5 13.7 9.1 6.6 4.4
50th 17.6 20.4 13.3 10.4 6.9
75th 26.0 31.6 19.3 14.7 10.4
95th 43.5 50.8 36.0 25.2 18.5
CD8+ TCRγδ+ T cells
5th 3.2 8.5 7.2 6.7 6.9
25th 7.6 18.2 15.7 14.3 14.3
50th 12.6 27.7 28.3 25.7 22.3
75th 19.4 44.4 42.6 41.2 33.7
95th 39.8 81.0 92.5 75.4 62.2
Vδ1-Vδ2- TCRαβ- T cells
5th 22.9 69.1 28.0 30.6 23.6
25th 43.1 113.5 53.6 49.0 43.9
50th 62.5 173.8 89.9 70.7 65.9
75th 89.7 274.8 130.6 95.9 93.6
95th 164.1 448.2 288.3 151.5 164.7
Vδ2+ T cells
5th 4.0 13.1 11.4 12.9 22.8
25th 8.1 30.4 28.8 30.8 50.9
50th 12.2 43.5 47.5 53.5 77.1
75th 19.7 65.5 74.1 90.9 118.4
95th 35.0 124.4 127.8 177.5 212.9
Vδ1+ T cells
5th 7.6 29.0 23.4 18.5 13.6
25th 18.6 48.2 42.2 33.2 25.4
50th 30.7 65.1 62.8 49.7 37.7
75th 43.8 96.4 87.4 67.8 54.3
95th 69.2 163.8 135.5 134.4 94.4
Vγ9+ T cells
5th 15.1 25.0 28.0 24.7 25.5
25th 20.1 39.9 43.5 45.1 46.8
50th 29.7 56.7 62.8 67.1 69.5
75th 38.7 80.8 100.3 99.2 104.0
95th 53.6 119.0 181.9 174.8 187.0
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Supplemental Table 2. Age-associated reference values of leukocyte populations (continued)
percentile
Age category (months)
0 6 14 25 72
Vδ2+Vγ9+ T cells
5th 1.5 5.2 9.0 8.7 13.3
25th 3.6 11.8 18.3 20.9 31.0
50th 5.7 22.9 31.7 39.2 49.9
75th 12.5 38.4 58.0 66.0 83.9
95th 24.3 71.0 116.5 135.7 163.1
CD4+ T cells
5th 1060.7 1820.5 1430.2 922.3 737.1
25th 1552.3 2706.7 1991.4 1362.5 988.2
50th 1972.5 3366.2 2457.8 1782.7 1240.0
75th 2498.9 4101.9 3062.0 2288.7 1525.3
95th 3266.2 5553.1 4123.0 3217.7 2134.0
CD4+ Tnaive
5th 848.7 1519.9 941.0 575.3 392.9
25th 1321.1 2233.6 1469.5 916.6 621.4
50th 1695.9 2849.1 1972.0 1256.0 821.9
75th 2159.7 3460.9 2461.5 1662.9 1069.7
95th 2898.2 4841.4 3373.4 2336.6 1538.0
CD4+ Tmem
5th 161.0 354.1 331.6 325.1 344.5
25th 259.6 470.8 526.9 504.6 461.7
50th 355.9 580.2 669.0 651.4 559.2
75th 465.1 713.2 834.9 850.9 679.5
95th 754.6 953.0 1227.9 1274.9 878.5
CD4+ Tcm
5th 39.5 134.9 111.0 86.7 74.2
25th 81.4 202.7 176.0 129.5 112.5
50th 121.3 261.9 242.8 173.1 149.0
75th 198.3 322.1 313.2 223.6 198.9
95th 395.6 449.3 427.4 349.3 285.0
CD4+ TemRO
5th 23.4 61.2 31.8 76.9 118.3
25th 51.5 93.0 123.7 152.4 181.5
50th 73.8 138.3 184.3 205.4 235.2
75th 107.0 177.5 254.7 260.3 295.5
95th 172.6 260.8 387.9 387.4 408.5
CD4+ early TemRO
5th 21.0 50.8 20.6 54.6 82.5
25th 47.6 79.0 95.6 116.7 127.1
50th 65.0 110.3 148.8 154.8 168.0
75th 98.9 144.8 199.8 197.5 210.1
95th 155.8 211.9 301.6 276.4 292.4
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Supplemental Table 2. Age-associated reference values of leukocyte populations (continued)
percentile
Age category (months)
0 6 14 25 72
CD4+ intermediate TemRO
5th 0.0 2.7 2.6 9.7 18.2
25th 1.8 10.2 14.0 17.7 29.7
50th 3.8 17.3 23.0 26.2 43.9
75th 7.0 24.7 33.2 36.4 61.5
95th 19.6 38.5 53.4 64.0 105.2
CD4+ late TemRO
5th 0.0 0.0 0.0 1.4 1.1
25th 0.0 0.0 2.5 3.8 3.0
50th 0.0 0.0 5.1 7.7 6.3
75th 0.0 3.8 11.2 17.6 12.9
95th 3.3 14.3 29.0 43.4 30.1
CD4+ TemRA
5th 35.9 79.9 50.3 58.1 55.8
25th 89.2 122.0 115.1 144.0 102.4
50th 126.8 178.0 221.2 245.8 153.6
75th 181.1 241.2 343.4 415.3 227.8
95th 312.1 376.8 570.5 812.5 371.7
CD4+ early TemRA
5th 27.9 66.7 33.1 40.3 36.3
25th 74.2 104.3 91.1 114.3 67.6
50th 113.7 149.9 189.8 213.6 110.7
75th 162.7 204.6 304.4 356.7 168.4
95th 287.3 357.8 542.8 782.6 317.4
CD4+ intermediate TemRA
5th 0.0 0.0 0.0 0.0 0.8
25th 0.0 0.0 0.0 1.4 1.8
50th 2.7 3.6 2.7 2.7 3.6
75th 5.1 5.7 4.6 4.7 6.9
95th 13.5 11.0 9.0 7.8 18.2
CD4+ late TemRA
5th 0.0 0.0 0.0 1.7 1.7
25th 0.0 0.0 3.3 4.4 4.7
50th 1.5 3.6 6.9 8.8 9.4
75th 2.9 6.6 15.2 16.0 17.4
95th 10.4 17.8 44.5 42.0 42.6
CD8+ T cells
5th 316.6 527.3 447.2 389.3 335.8
25th 493.3 836.6 776.2 619.4 509.0
50th 655.5 1093.1 998.8 805.1 649.7
75th 886.4 1389.5 1277.1 1038.8 841.6
95th 1319.3 2060.9 1831.8 1571.6 1197.8
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Supplemental Table 2. Age-associated reference values of leukocyte populations (continued)
percentile
Age category (months)
0 6 14 25 72
CD8+ Tnaive
5th 182.4 380.4 269.6 205.6 166.1
25th 351.1 591.2 453.9 363.8 287.2
50th 487.2 835.1 610.3 465.1 383.6
75th 695.2 1081.6 809.5 640.3 513.2
95th 1037.3 1632.3 1238.7 1033.7 768.1
CD8+ Tmem
5th 57.2 98.1 102.0 71.6 122.4
25th 102.8 171.4 181.4 152.3 199.0
50th 149.1 236.3 268.9 224.3 261.0
75th 214.9 343.6 432.3 331.4 365.3
95th 351.2 674.6 888.7 550.0 597.5
CD8+ Tcm
5th 10.2 16.7 13.5 9.5 5.1
25th 27.7 32.1 26.1 18.6 9.3
50th 47.7 49.2 39.8 31.0 14.4
75th 71.7 72.6 68.8 56.3 21.7
95th 147.6 128.0 140.4 109.2 43.8
CD8+ TemRO
5th 7.9 16.7 17.8 14.0 40.5
25th 17.3 39.3 43.5 36.0 75.5
50th 29.6 62.6 74.9 67.5 114.9
75th 48.4 106.4 151.2 108.1 166.3
95th 98.7 284.8 362.8 244.3 281.8
CD8+ early TemRO
5th 5.5 10.7 7.4 6.4 19.4
25th 12.2 22.7 22.7 19.6 38.1
50th 22.2 36.5 38.3 30.5 56.6
75th 32.9 55.4 68.0 48.7 79.9
95th 64.3 106.8 145.0 88.0 132.0
CD8+ intermediate TemRO
5th 0.3 0.9 0.1 0.5 3.1
25th 2.1 4.7 4.7 3.4 8.5
50th 5.8 10.2 11.6 8.2 17.1
75th 11.3 21.5 29.9 18.1 30.2
95th 27.7 64.9 98.6 56.1 64.0
CD8+ late TemRO
5th 0.0 0.0 0.0 0.8 2.2
25th 0.0 1.2 3.2 3.7 6.5
50th 0.0 3.1 8.3 9.2 14.0
75th 0.0 9.4 22.0 24.5 30.4
95th 0.7 85.0 94.8 73.9 72.6
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Supplemental Table 2. Age-associated reference values of leukocyte populations (continued)
percentile
Age category (months)
0 6 14 25 72
CD8+ TemRA
5th 18.9 34.4 33.0 14.8 44.5
25th 43.1 76.8 69.9 53.0 86.0
50th 62.5 109.4 122.2 102.8 129.4
75th 96.3 168.9 224.6 180.9 194.2
95th 165.1 345.1 467.4 367.6 346.9
CD8+ early TemRA
5th 11.7 22.3 13.7 5.5 17.9
25th 29.2 44.5 36.4 28.8 33.5
50th 48.0 68.3 62.1 54.1 52.1
75th 75.7 106.0 101.0 89.9 76.4
95th 123.8 167.0 211.4 169.2 139.8
CD8+ intermediate TemRA
5th 1.4 2.6 2.9 1.1 8.9
25th 6.7 9.8 11.0 6.8 20.4
50th 11.5 20.8 22.8 17.5 33.8
75th 18.8 38.9 46.8 34.7 53.4
95th 40.9 91.3 114.4 79.7 108.0
CD8+ late TemRA
5th 0.0 0.0 1.2 1.2 4.4
25th 0.0 2.8 5.5 5.4 11.9
50th 0.4 6.3 11.8 12.9 24.6
75th 1.0 15.6 36.6 33.0 52.2
95th 2.1 90.4 187.3 151.6 162.6
B cells
5th 240.0 810.0 710.0 520.0 321.5
25th 467.5 1310.0 1150.0 860.0 480.0
50th 675.0 1720.0 1490.0 1130.0 630.0
75th 930.0 2260.0 1950.0 1440.0 765.3
95th 1663.5 3277.5 2590.0 1890.0 1110.0
Bnaive
5th 260.8 733.9 621.0 466.0 250.2
25th 425.6 1190.7 1001.1 772.7 389.5
50th 616.3 1609.4 1339.5 1019.3 513.6
75th 854.8 2104.3 1757.7 1292.0 639.9
95th 1500.9 3030.8 2310.1 1731.0 933.7
Bmem
5th 16.2 47.2 59.1 48.8 46.0
25th 31.4 79.3 98.4 78.3 74.1
50th 48.0 118.1 142.1 108.2 98.3
75th 81.2 171.6 191.7 151.5 131.2
95th 168.4 291.3 305.1 212.6 200.0
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Supplemental Table 2. Age-associated reference values of leukocyte populations (continued)
percentile
Age category (months)
0 6 14 25 72
CD27- Bmem
5th 7.7 20.7 27.4 29.4 20.8
25th 19.3 38.7 52.6 44.2 35.8
50th 29.6 62.1 72.2 62.8 48.8
75th 51.7 88.6 98.6 90.5 65.9
95th 116.2 153.7 157.5 130.0 103.8
CD27+ Bmem
5th 0.0 4.1 6.2 6.3 9.8
25th 1.2 10.0 18.4 12.0 17.0
50th 1.7 16.3 28.1 21.1 25.2
75th 3.7 27.7 42.5 30.9 37.2
95th 7.0 65.2 75.3 57.1 65.9
IgM+ Bmem
5th 3.1 11.4 12.2 8.9 8.7
25th 6.8 24.5 26.0 15.5 16.2
50th 13.0 41.8 41.2 24.7 25.0
75th 24.7 65.9 68.0 38.1 36.8
95th 67.3 131.2 133.8 70.2 61.7
Natural effector
5th 2.7 8.8 9.6 6.9 6.9
25th 6.3 19.3 20.1 12.3 13.0
50th 12.5 33.7 33.3 20.4 19.7
75th 22.3 53.3 55.8 31.3 30.2
95th 65.2 107.4 113.5 58.3 52.1
IgMonly
5th 0.0 1.0 0.8 0.9 1.0
25th 0.0 2.8 3.6 2.4 2.4
50th 0.6 5.7 6.0 4.0 4.1
75th 1.3 10.8 10.1 6.5 7.1
95th 3.6 27.2 25.2 15.6 15.7
IgA+ Bmem
5th 5.8 16.9 16.4 15.0 11.6
25th 11.8 41.3 38.0 30.7 20.4
50th 21.6 70.2 60.8 47.5 28.9
75th 36.3 117.1 90.9 75.2 40.0
95th 67.9 225.2 151.6 131.3 68.1
CD27-IgA+
5th 4.7 11.3 10.4 10.1 5.0
25th 10.3 31.2 25.3 20.3 10.2
50th 19.0 55.8 43.4 32.4 16.0
75th 31.9 94.5 67.3 55.6 23.8
95th 62.9 196.7 119.1 101.9 42.6
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Supplemental Table 2. Age-associated reference values of leukocyte populations (continued)
percentile
Age category (months)
0 6 14 25 72
CD27+IgA+
5th 0.0 3.0 3.3 3.5 4.5
25th 0.9 7.4 9.8 8.1 8.4
50th 1.7 12.0 16.3 13.2 12.2
75th 3.1 20.1 26.7 21.6 17.3
95th 7.9 42.2 44.2 37.1 27.9
IgG+ Bmem
5th 4.2 30.9 33.1 29.7 31.3
25th 8.5 61.0 74.3 61.6 55.7
50th 13.3 87.5 116.8 94.0 77.0
75th 22.4 143.4 187.6 160.8 102.3
95th 47.9 229.2 318.2 280.1 158.2
CD27-IgG+
5th 3.6 23.3 25.9 23.8 19.2
25th 7.1 48.7 52.6 45.6 36.8
50th 11.2 76.6 87.7 75.4 53.8
75th 19.2 124.2 151.0 129.2 74.1
95th 42.2 200.3 274.1 224.0 119.3
CD27+IgG+
5th 0.0 3.4 4.4 5.2 7.7
25th 0.8 8.1 14.7 12.6 14.7
50th 1.6 12.3 23.0 19.6 21.1
75th 3.3 19.2 37.9 33.4 30.1
95th 7.2 35.3 60.8 58.8 51.0
CD21low B cells
5th 22.0 66.2 60.4 43.1 22.0
25th 38.8 113.7 98.2 74.5 38.4
50th 57.8 157.2 142.8 100.3 55.2
75th 91.1 222.4 193.7 134.8 78.1
95th 166.2 351.1 282.9 220.0 124.0
Igλ+ B cells
5th 115.0 323.7 290.3 203.9 127.0
25th 220.7 545.5 500.0 351.5 188.8
50th 313.6 757.4 638.0 476.5 251.3
75th 417.7 975.7 840.0 636.2 317.4
95th 798.4 1486.1 1186.2 847.7 477.2
Igκ+ B cells
5th 126.1 456.6 404.8 293.4 179.0
25th 248.8 718.2 635.8 490.5 272.3
50th 352.2 967.0 813.6 634.5 357.0
75th 493.0 1263.5 1101.9 821.5 439.7
95th 841.4 1857.9 1429.7 1057.4 621.4
The presented reference values (in cells per microliter of blood) were obtained by using cross-sectional analyses of 
all 2010 data points on the indicated time points.
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Supplemental Figure 1. Dynamics of innate leukocyte subsets in children between birth and 6 years of age. 
A) Gating strategy used to identify innate leukocyte subsets. Plots depict data of a representative 61- to 95 months-old child. SSC, Side scatter. B-D) Absolute numbers and modeled 
dynamics of granulocytes, monocytes and NK cells (B), CD15+, neutrophilic and eosinophilic granulocytes (C), and classical, intermediate and non-classical monocyte subsets (D), from birth 
until 6 years of age. Linear mixed effect models were generated for each population (solid black line) and represented with the 90% confidence interval (CI) of the model (dashed black 
lines). For clarity of the graphs, gray lines connect only consecutive time points within one individual; i.e. 0-6 months, 6-14 months, 14-25 months or 25-76 months.   
  
Supplemental Figure 1. Dynamics of innate leukocyte subsets in children between birth and 6 years of 
age.
A) Gating strategy used t  identify innate l ukocyte subsets. Plots depict data of a representative 61- to 95 months-
old child. SSC, Side scatter. B-D) Absolute numbers and modeled dynamics of granulocytes, monocytes and NK cells 
(B), CD15+, neutrophilic and eosinophilic granulocytes (C), and classical, intermediate and non-classical monocyte 
subsets (D), from birth until 6 years of age. Linear mixed effect models were generated for each population (solid 
black line) and represented with the 90% confidence interval (CI) of the model (dashed black lines). For clarity of the 
graphs, gray lines connect only consecutive time points within one individual; i.e. 0-6 months, 6-14 months, 14-25 
months or 25-76 months. 
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Supplemental Figure 2. Dynamics of TCRαβ+ T-cell and TCRγδ+ T-cell subsets in children between birth and 6 years of age.  
A) Gating strategy used to identify TCRαβ+ T-cell and TCRγδ+ T-cell subsets. Plots depict data of a representative 61- to 95 months-old child. B-D) Absolute numbers and modeled dynamics of T cells (B), TCRαβ+ T-cell populations (C), and TCRγδ+ T-cell populations (D), from birth until 6 years 
of age. Linear mixed effect models were generated for each population (solid black line) and represented with the 90% confidence interval (CI) of the model (dashed black lines). For clarity of the graphs, gray lines connect only consecutive time points within one individual; i.e. 0-6 months, 
6-14 months, 14-25 months or 25-76 months.   
Supplemental Figur  2. Dynamics f TCRαβ+ T-cell and TCRγδ+ T-cell subsets in children between birth and 
6 years of age. 
A) Gating strategy used to identify TCRαβ+ T-cell and TCRγδ+ T-cell subsets. Plots depict data of a representative 
61- to 95 months-old child. B-D) Absolute numbers and modeled dynamics of T cells (B), TCRαβ+ T-cell populations 
(C), and TCRγδ+ T-cell populations (D), from birth until 6 years of age. Linear mixed effect models were generated 
for each population (solid black line) and represented with the 90% confidence interval (CI) of the model (dashed 
black lines). For clarity of the graphs, gray lines connect only consecutive time points within one individual; i.e. 0-6 
months, 6-14 months, 14-25 months or 25-76 months. 
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Supplemental Figure 3. Dynamics of CD4+ T-cell subsets in children between birth and 6 years of age. 
A) Gating strategy used to identify CD4+ T-cell subsets. Plots depict data of a representative 61- to 95 months-old child. B-E) Absolute numbers and modeled dynamics of total, naive and 
memory CD4+ T cells (B); CD4+ central memory T cells (Tcm), CD45RO+ effector memory (TemRO) and CD45RO- effector memory (TemRA) T-cell subsets (C); early, intermediate or late 
differentiated TemRO subsets (D); or early, intermediate or late differentiated TemRA subsets (E), between birth and 6 years of age. Linear mixed effect models were generated for each 
population (solid black line) and represented with the 90% confidence interval (CI) of the model (dashed black lines). For clarity of the graphs, gray lines connect only consecutive time 
points within one individual; i.e. 0-6 months, 6-14 months, 14-25 months or 25-76 months.   
  
Supplemental Figure 3. Dynamics of CD4+ T-cell subsets in children between birth and 6 years of age.
A) Gating strategy used to identify CD4+ T-cell subsets. Plots depict data of a representative 61- to 95 months-old 
child. B-E) Absolute numbers and modeled dynamics of total, naive and memory CD4+ T cells (B); CD4+ central 
memory T cells (Tcm), CD45RO+ effector memory (TemRO) and CD45RO- effector memory (TemRA) T-cell subsets 
(C); early, intermediate or late differentiated TemRO subsets (D); or early, intermediate or late differentiated TemRA 
subsets (E), between birth and 6 years of age. Linear mixed effect models were generated for each population (solid 
black line) and represented with the 90% confidence interval (CI) of the model (dashed black lines). For clarity of the 
graphs, gray lines connect only consecutive time points within one individual; i.e. 0-6 months, 6-14 months, 14-25 
months or 25-76 months. 
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Supplemental Figure 4. Dynamics of CD8+ T-cell subsets in children between birth and 6 years of age. 
A) Gating strategy used to identify CD8+ T-cell subsets. Plots depict data of a representative 61- to 95 months-old child. B-E) Absolute numbers and modeled dynamics of total, naive and 
memory CD8+ T cells (B); CD8+ central memory T cells (Tcm), CD45RO+ effector memory (TemRO) and CD45RO- effector memory (TemRA) T cell subsets (C); early, intermediate or late 
differentiated TemRO subsets (D); or early, intermediate or late differentiated TemRA subsets (E), between birth and 6 years of age. Linear mixed effect models were generated for each 
population (solid black line) and represented with the 90% confidence interval (CI) of the model (dashed black lines). For clarity of the graphs, gray lines connect only consecutive time 
points within one individual; i.e. 0-6 months, 6-14 months, 14-25 months or 25-76 months.    
  
Supplemental Figure 4. Dynamics of CD8+ T-cell subsets in children between birth and 6 years of age.
A) Gating strategy used to identify CD8+ T-cell subsets. Plots epict data of a representative 61- to 95 onths-old 
child. B-E) Absolut  numbers and modeled dynamics f total, naiv  and memory CD8+ T cells (B); CD8+ c ntral 
memory T cells (Tcm), CD45RO+ effector memory (TemRO) and CD45RO- effector memory (TemRA) T cell subsets 
(C); early, intermediate or late differentiated TemRO subsets (D); or early, intermediate or late differentiated TemRA 
subsets (E), between birth and 6 years of age. Linear mixed effect models were generated for each population (solid 
black line) and represented with the 90% confidence interval (CI) of the model (dashed black lines). For clarity of the 
graphs, gray lines connect only consecutive time points within one individual; i.e. 0-6 months, 6-14 months, 14-25 
months or 25-76 months. 
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Supplemental Figure 5. Dynamics of B-cell subsets in children between birth and 6 years of age. 
A) Gating strategy used to identify B-cell subsets. Plots depict data of a representative 61-95 months-old child. B-I) Absolute numbers and modeled dynamics of total B cells (B); naive and total memory B cells (C); total Igκ+ and Igλ+ B-cells populations (D); and CD21low B cells (E); CD27- and 
CD27+ memory B cells (F); total IgM+, IgA+ or IgG+ memory B cells (G); IgM+, IgA+ or IgG+ memory B-cell subsets (H) between birth and 6 years of age. Linear mixed effect models were generated for each population (solid black line) and represented with the 90% confidence interval (CI) of 
the model (dashed black lines). For clarity of the graphs, gray lines connect only consecutive time points within one individual; i.e. 0-6 months, 6-14 months, 14-25 months or 25-76 months. I) Overlay of the normalized (zero mean; unit SD) linear mixed effects models of the memory B-cell 
populations as in panel H.    
Supplemental Figure 5. Dynamics of B-cell subsets in children between birth and 6 years of age.
A) Gat g strategy used to identify B-cell subsets. Plots depict data of a representative 61-95 months-old child. B-I) 
Absolute numbers and modeled dynamics of total B cells (B); naive and total memory B cells (C); total Igκ+ and 
Igλ+ B-cells populations (D); and CD21low B cells (E); CD27- and CD27+ memory B cells (F); total IgM+, IgA+ or IgG+ 
memory B cells (G); IgM+, IgA+ or IgG+ memory B-cell subsets (H) between birth and 6 years of age. Linear mixed effect 
models were generated for each population (solid black line) and represented with the 90% confidence interval (CI) 
of the model (dashed black lines). For clarity of the graphs, gray lines connect only consecutive time points within 
one individual; i.e. 0-6 months, 6-14 months, 14-25 months or 25-76 months. I) Overlay of the normalized (zero 
mean; unit SD) linear mixed effects models of the memory B-cell populations as in panel H. 
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Supplemental Figure 6. Hierarchical clustering of the dynamics of 31 non-overlapping leuko-
cyte subsets in early childhood.  
A) Ward hierarchical clustering was performed as in Figure 2, including only the 31 non-overlapping leukocyte subsets. Indicated in gray squares in front 
of the heat map is the cluster to which each population was assigned in the analysis of the total 62 leukocyte subsets in Figure 2.  B) Average patterns  
± 1 SD of the subsets in each of the 4 major clusters. Indicated in black squares are 3 subsets that were assigned to different clusters than in Figure 2. 
Supplemental Figure 6. Hierarchical clustering of the dynamics of 31 non-overlapping leukocyte subsets 
in early childhood. 
A) Ward hierarchical clusterin  was performed s in Figure 2, including only the 31 non-overlapping leukocyte sub-
sets. Indicated in gray squares in front of the heat map is the cluster to which each population was assigned in the 
analysis of the total 62 leukocyte subsets in Figure 2. B) Average patterns 
± 1 SD of the subsets in each of the 4 major clusters. Indicated in black squares are 3 subsets that were assigned to 
different clusters than in Figure 2.
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ABSTRACT
Background
Breastfeeding provides a protective effect against infectious diseases in infancy. Still, 
immunological evidence for enhanced adaptive immunity in breastfed children remains 
inconclusive. 
Objective
To determine whether breastfeeding affects B- and T- cell memory in the first years of life. 
Methods
We performed immunophenotypic analysis on blood samples within a population-based 
prospective cohort study. Participants included children at 6 months (n=258), 14 months 
(n=166), 25 months (n=112) and 6 years of age (n=332) with both data on breastfeeding and 
blood lymphocytes. Total B- and T-cell numbers and their memory subsets were deter-
mined with 6-color flow cytometry. Mothers completed questionnaires on breastfeeding 
when their children were aged 2, 6, and 12 months. Multiple linear regression models with 
adjustments for potential confounders were performed. 
Results
Per month continuation of breastfeeding, a 3% (95% CI -6,-1) decrease in CD27+IgM+, a 
2% (95 CI % -5,-1) decrease in CD27+IgA+ and a 2% (95% CI -4,-1) decrease in CD27-IgG+ 
memory B cell numbers were observed at 6 months of age. CD8 T-cell numbers at 6 months 
of age were 20% (95% CI 3,37) higher in breastfed than in non-breastfed infants. This was 
mainly found for central memory CD8 T cells and associated with exposure to breast milk, 
rather than duration. The same trend was observed at 14 months, but associations disap-
peared at older ages. 
Conclusions
Longer breastfeeding is associated with increased CD8 T-cell memory, but not B-cell 
memory numbers in the first 6 months of life. This transient skewing towards T cell memory 
might contribute to the protective effect against infectious diseases in infancy.
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INTRODuCTION
Breast milk contains factors that enhance nutrient absorption, stimulate growth and en-
hance the defense against pathogens.1 Consequently, breastfeeding provides protection 
against infectious diseases during infancy.2,3,4 The protective effect persists during child-
hood 5,6, and modulates vaccination responses.7,8,9 Thus, it is likely that breastfeeding not 
only provides passive immunization, but also enhances adaptive immunity.10 
B and T lymphocytes comprise the cellular components of adaptive immunity, and are 
generated throughout life. B cells contribute to humoral immunity through the produc-
tion of immunoglobulins (Ig), whereas CD8+ cytotoxic T cells provide cellular immune re-
sponses. CD4+ helper T cells support both humoral and cellular immune responses. Each 
B and T cell generates a unique antigen receptor during precursor differentiation in bone 
marrow or thymus, respectively. Only those cells that specifically recognize antigen with 
their receptor will undergo clonal proliferation and are involved in the antigen response. 
Cells generated from the clonal expansion will remain present in the body as long-lived 
memory cells and will initiate a fast and quantitatively stronger response upon secondary 
antigen encounter. In addition to CD27- naive B cells, six memory B-cell subsets can be 
identified.11 Four of these express CD27 and are either positive for IgM, IgM and IgD, IgA or 
IgG. In addition, CD27-IgA+ and CD27-IgG+ memory B cells can be identified. Within both 
the CD4 and CD8 T-cell lineages, central memory (CD45RO+CCR7+), CD45RO+CCR7- effec-
tor memory (TemRO) and CD45RO-CCR7- (TemRA) can be distinguished from naive T cells 
(CD45RO-CCR7+).12 Central memory T cells are most efficient in generating a new immune 
response by proliferating extensively in response to an antigen upon secondary antigen 
encounter.13,14,15 The diversity and composition of the B- and T-cell compartments are 
highly dynamic in the first years of life; blood cell counts are especially high up to 2 years of 
age, following which they slowly decline to reach adult levels between 6 and 10 years.16-20 
At birth, nearly all B and T cells are naive, and memory cells are gradually built up in the 
first 6 years of life.19 
Several studies have addressed the effects of breastfeeding on adaptive immunity. 
Breastfeeding was found to be associated with decreased frequencies of blood CD4+ T 
cells.21 This was mostly due to lower frequencies of naïve (CD45RA+) T cells in breastfed 
children. Still, these observations were not consistently reproduced with some studies 
showing increased, and some decreased numbers of CD4+ T cells.21-24 Furthermore, long 
term breastfeeding was found to be associated with increasing numbers of CD4+ and CD8+ 
T cells.24 Thus, although previous studies have addressed the influence of breastfeeding on 
blood lymphocyte populations,21-24 the results remained inconclusive, mainly due to small 
samples sizes and limitations in the detection of memory cells.21-24 
In the present study we used 6-color flow cytometric analysis of lymphocyte subsets in 
a population-based prospective cohort study to assess the impact of breastfeeding on 
build-up of memory B and T cells in infants and young children.
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MATERIALS AND METhODS
Design and study population
This study was embedded in the Generation R Study, a prospective population-based 
cohort study that follows pregnant women and their children from fetal life onwards in 
the Netherlands.25 The study has been approved by the Medical Ethics Committee of the 
Erasmus MC, University Medical Centre Rotterdam. Written informed consent was obtained 
from all parents of participants. We included 1,079 Dutch pregnant women and their chil-
dren participating in a detailed subgroup study.25 All children were born between February 
2002 and August 2006. We excluded twins (n=27) in the present analysis to prevent bias 
due to correlation. Of these, data on both breastfeeding and immunophenotyping were 
available from 258 children at 6 months, 166 at 14 months, 112 at 25 months and 332 at 6 
years of age. The main reasons for missing samples were due to non-consent of the parents 
(approximately 55% per visit) and technical or logistical failure (approximately 10% per 
visit). 
Breastfeeding
Information regarding breastfeeding was obtained in postnatal questionnaires at the ages 
of 2, 6 and 12 months.25 Mothers were asked whether they had ever breastfed their child 
(yes or no) and, if yes, at what age (months) they had stopped.26,27 Breastfeeding dura-
tion was then categorized into four groups: never, <3 months, between 3 and 6 months 
and >6 months. An approximation of exclusive breastfeeding was performed according to 
whether the child received breastfeeding without any other bottle feeding, milk or solids.27 
Partial breastfeeding indicates infants receiving both breast-feeding, bottle feeding and/or 
solids in this period. Subsequently, the information on exclusiveness of breastfeeding was 
combined and categorized into the following breastfeeding categories: never; partial until 
4 months and exclusive until 4 months. 
Immunophenotyping of lymphocyte subsets
Flow cytometry was performed within 24 hours following sampling on fresh whole blood at 
the ages of 6 months (median 6.2; range 5.2; 8.2), 14 months (median 14.4; range 13.1-17.4), 
25 months (median 25.2; range 23.3-29.8) and 6 years (median 5.9; range 5.1-7.2). Absolute 
counts of blood CD3+ T cells, CD16/56+ NK cells, and CD19+ B cells were obtained with a 
diagnostic lyse-no-wash protocol. Lymphocytes were gated on the basis of CD45, FSC and 
SSC characteristics. Gates were set based on cells that are known to lack expression of 
the indicated marker. Additionally, 6-color flow cytometry was performed on an LSRII (BD 
Biosciences) to distinguish naive and memory B- and T- lymphocyte subsets as defined 
previously (S3 Table).11,12 All flow cytometry acquisition was performed on whole blood 
after red blood cell lysis with ammonium chloride.
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Covariates 
The covariates that were assessed in this study were obtained from midwife and hospital 
registries at birth (birth weight, gestational age and gender) or through measurements at 
the research center (child anthropometrics). Additionally, information on smoking and al-
cohol use during pregnancy and socioeconomic status was obtained by prenatal question-
naires sent during the first, second and third trimesters of pregnancy [28 29]. Information 
on day-care attendance was obtained from parent-reported questionnaires at the ages of 
6 and 12 months. 
Statistical methods
Because the distribution of lymphocyte numbers in different age groups was skewed, 
these values were normalized by transformation to a natural log-scale. Differences in ma-
ternal and infant characteristics between breastfed versus never breastfed children were 
tested using independent samples t-tests and Chi-Square tests. Differences in baseline 
characteristics among the groups with different duration of breastfeeding were assessed 
using ANOVA tests and Chi-Square tests. Additionally, the associations of breastfeeding, 
breastfeeding duration (measured in groups, and measured continuously per month con-
tinuation of breastfeeding) and breastfeeding exclusivity with the change in lymphocyte 
numbers were assessed using multiple linear regression models with adjustment for poten-
tial confounders. For all ages, the category with no breastfeeding was the reference. First, 
associations between breastfeeding and total B, T, CD4 and CD8 counts were assessed. 
Subsequently, associations for B, CD4 and CD8 subpopulations were studied to assess the 
effect of breastfeeding on memory cells specifically. Multivariable regression models were 
created with stepwise adjustment for potential confounders, which were selected based 
on previous literature. Potential confounders included: maternal age, socioeconomic 
status (SES), marital status, maternal BMI, maternal smoking and alcohol consumption 
during pregnancy, maternal reported autoimmune disease (including thyroid disease, 
multiple sclerosis, systemic lupus erythematosus, diabetes mellitus and arthritis), elevated 
anti-tTG level during pregnancy, maternal fever in the last trimester of pregnancy, family 
history of asthma or atopy (hay-fever, allergy, eczema), multiple parities, mode of delivery 
(caesarean section), gender, birth weight, gestational age, preterm birth, APGAR score, 
birth season, weight and age at focus visit, fever in the first 6 months (yes/no), frequency 
of upper and lower respiratory tract infections, and day-care attendance in the first year 
of life. Covariates were kept in the final multivariate model if the covariate resulted in an 
alteration in effect estimate of > 10%,30 or if the variables were associated with breastfeed-
ing (determinant) and lymphocyte numbers (outcome) in our study. Because of the small 
numbers in the never breastfed group, final adjustment for potential confounders was 
restricted to those who attained the strongest alteration (%) in effect estimates. Because 
of the strong correlation between our outcomes (e.g. Pearson’s correlation between total 
CD8 T cells and naive CD8 T cells r =0.82, and between total B cells and IgA r=0.57), and 
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unweighted calculations only hold if the tests are independent,31,32 we did not perform 
adjustments for multiple testing. All measures of associations are presented with their 95% 
confidence interval. All statistical analyses were performed using the Statistical Package 
for the Social Sciences version 20.0 for Windows (SPSS Inc, Chicago, IL, USA). P values <0.05 
were considered to be statistically significant. 
RESuLTS
Population characteristics
No major differences in characteristics between children included at 6, 14, 25 months and 
6 years of age were observed (Table 1, Supplemental Table 1) Overall, more than 86% of 
mothers started breastfeeding. Mother’s educational level was significantly associated 
with the start of breastfeeding at 6 and 25 months, and 6 years of age. Moreover, mother’s 
educational level was significantly associated with both the duration of breastfeeding and 
with B cell memory subsets at 6 months of age [data not shown]. In addition, maternal 
alcohol use was related to both breastfeeding duration and total T, B, CD4 and CD8 cell 
numbers at 6 months [data not shown]. 
Both maternal educational level and alcohol use influenced the regression coefficients 
by more than 10%. Therefore, all subsequent analysis on breastfeeding duration and cell 
numbers were adjusted for both maternal education and maternal alcohol use during 
pregnancy.
Decrease in B-cell memory
Breastfeeding exposure (Fig. 1b) and duration (Fig. 1c) were not associated with total B cell 
numbers at 6, 14, 25 months and 6 years of age (Table 2, S2 Table). Furthermore, no associa-
tions were observed between breastfeeding exposure and duration and naive B cells, which 
constitute the majority of total B-cell numbers (Table 3, Figs. 1b and 1c) However, a longer 
duration of breastfeeding, was associated with changes in the memory B-cell compartment. 
Per month longer breastfeeding, a 3% decrease in absolute numbers of CD27+IgM+, and a 
2% decrease in both CD27+IgA+ and CD27-IgG+ memory B cells at 6 months of age were 
observed (Table 3, Fig. 1c). CD27+IgG+ and CD27-IgA+ memory B cells at 6 months of age did 
not change with differences in breastfeeding duration. Stronger negative trends were ob-
served for the associations between breastfeeding duration and frequencies of CD27+IgM+, 
CD27+IgA+ and CD27-IgG+ memory B cells within total B cells at 6 months of age, resp. -4% 
(95% CI -7,-1), -4% (95% CI -7, -1), and -3% (95% CI -5,-1) (data not shown). 
At 14 months of age, similar trends for breastfeeding duration and total B-cell numbers 
were observed, although not significant (Table 2). At older ages the effects disappeared. (S2 
Table). Thus, a longer breastfeeding duration seems to negatively impact B-cell numbers in 
infants at least until the age of 6 months, at older ages these effects disappeared.
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Table 1. Maternal and infant characteristics of the study population at 6 months 
Not breastfed (n=35) Breastfed (n=223)
Maternal characteristics (n=258)
Age (Mean + SD; years) 32 (3.6) 32 (3.8)
Educational level (n; %)
Lower 24 (69%) 71 (32%)
Higher 11 (31%) 152 (68%)*
Net household income per month (n; %)
< € 2400 2 (7%) 23 (11%)
> € 2400 29 (93%) 178 (89%)
Smoking continued during pregnancy (n; %) 4 (14%) 21 (13%)
Alcohol use continued during pregnancy (n; %) 8 (29%) 55 (35%)
Body Mass Index before pregnancy (Mean + SD; kg/m2) 23 (3) 23 (4)
Fever in third trimester of pregnancy (n; %) 3 (9) 14 (6%)
Maternal atopy (eczema, allergy HDM, hay-fever)(n; %) 8 (25%) 72 (35%)
Paternal atopy (eczema, allergy HDM, hay-fever) (n; %) 8 (28%) 55 (28%)
Family history of asthma / atopy (n; %) 13 (37%) 107 (49%)
Any reported autoimmune disease (diabetes mellitus, SLE, arthritis, MS, 
thyroid disorder, or celiac disease) (n; %) 
0 (0%) 5 (0.02%)
Mode of delivery (n; %)
Vaginal 21 (64%) 129 (61%)
Forceps or vacuum assisted 5 (15%) 44 (20%)
Caesarian section 7 (21%) 40 (19%)
Premature rupture of membranes (n; %) 3 (9%) 6 (3%)
Infant characteristics (n=258)
Males (n; %) 19 (54%) 113 (51%)
Gestational age ( Mean + SD; weeks) 39.4 (2.4) 40.0 (1.7)
Preterm birth (<37 weeks) (n; %) 2 (6%) 11 (5%)
Birth weight ( Mean + SD; grams) 3439 (632) 3504 (524)
Apgar score at 5 min <7 (n; %) 0 (0%) 3 (1%)
Birth season (n; %)
Winter (dec-jan-feb) 5 (14%) 36 (16%)
Spring (mar-apr-may) 10 (29%) 81 (36%)
Summer (jun-jul-aug) 11 (31%) 62 (28%)
Autumn (sept-oct-nov) 9 (26%) 44 (20%)
Siblings >1 (n; %) 4 (11%) 26 (12%)
Day-care >16 hours /week (n; %) 5 (33%) 77 (46%)
Fever in first 6 months (n; %) 12 (60%) 121 (62%)
Age at focus visit (Median + range; months) 6.6 (6.2-8.2) 6.2 (5.2-7.9)*
Values are means (SD), absolute numbers (percentages) or #medians (90% range). *Significantly different between 
groups. 
Data were missing on: Household income (n=26) Smoking during pregnancy (n=72), Alcohol during pregnancy 
(n=72) BMI before pregnancy (n=37), Fever in third trimester (n=9) Mode of delivery (n=12) Maternal atopy (n=22) Pa-
ternal atopy (n=29), Family history of asthma or atopy (n=3) Mode of delivery (n=12), maternal reported autoimmune 
disease (n=29), maternal reported any other chronic condition (n=31), premature rupture of membranes (n=5), Apgar 
(n=4), Day-care (n=42), weight at focus visit (n=1), fever in first 6 months (n=42). Any reported autoimmune disease 
included thyroid disease (n=4) and elevated anti-tTG level during pregnancy (n=1).
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Increase in T-cell memory 
Breastfeeding exposure and duration were not associated with total T-cell and CD4+ T-cell 
numbers at 6, 14, 25 months and 6 years of age (Table 2, Figs. 2b and 2c, and S2Table). 
However, the exposure to breastfeeding was associated with CD8+T cell numbers. CD8+ T-
cell numbers were 19% (95% CI 3, 35) higher in 6-month old infants who were breastfed for 
less than 3 months and remained 20% (95% CI 3, 37) higher in children who were breastfed 
until 6 months (Table 2, Fig. 2b), than in children who were never breastfed. Comparable ef-
fect sizes were observed for exclusiveness of breastfeeding in relation to CD8 T cells (Table 
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4 and 5). Partial breastfeeding until 4 months was associated with a 20% increase in total 
CD8 T cells, and remained 21% higher in infants who were exclusively breastfed (Table 5). 
At 14 and 25 months of age, similar tendencies for breastfeeding exposure and CD8+ T cell 
numbers were observed, however the associations were not significant. (Table 2, S2 Table). 
Within the CD8 T-cell compartment at 6 months of age, central memory cell numbers 
(CD45RO+CCR7+) were 30% (95% CI 4, 57) higher in children who were breastfed until 3 
months than in non-breastfed children (Table 3, Fig. 2b). This effect was irrespective of 
Table 3. Adjusted associations between breastfeeding and memory B-cell and T-cell subsets at 6 months
Regression coefficients for logtransformed cell numbers (*10e9/L)
B (n=258) T CD4+ (n=258) T CD8+ (n=258)
Naive B 
CD27- IgD+
CD27+
IgM+
CD27+
IgA+
CD27-
IgA+
CD27+
IgG+
CD27-
IgG+
CD4+ 
 naive
CD4+
 cm
CD4+
TemRO
CD4+
TemRA
CD8+
T naive
CD8+
T cm
CD8+
TemRO
CD8+
emRA
DURATION
Breastfeeding (n=223) increase 
per month
-1(-3,1) -3(-6,-1)* -2 (-5,-1)* -2 (-5,1) 1 (-3,2) -2 (-4,-1)* -2 (-3,0) -1(-2,1) -1(-3,2) 0(-3,2) -2 (-4,1) 0(-2,3) 0(-3,3) 2 (-1,5)
EXPOSURE
Never (n= 35) REF REF REF REF REF REF REF REF REF REF REF REF REF REF
< 3 months (n= 86) 12 (-6,31) 9(-19,36) 1 (-28,30) 15 (-14,43) -9 (-34,16) -1 (-22,22) 7(-10,24) -3(-20,14) 17(-4,38) 14(-8,37) 23 (0,46) 30 (4,57)* 15(-18,47) 20(-8,47)
> 3 < 6 months (n= 64) 18 (-1,38) 18(-11,48) 1 (-30,32) 14 (-17,44) 0 (-26,27) 1 (-22,25) 4(-14,22) -5(-23,13) 9(-14,31) 8(-16,32) 23 (-2,448) 17 (-11,45) -4(-38,31) 9 (-20,39)
> 6 months (n= 73) 6 (-13,26) -4(-34,25) -11 (-40,19) -2 (-31,28) -7 (-33,19) -13 (-36,10) -5(-23,14) -3(-21,15) 13(-10,35) 10(-14,34) 10(-15,34) 29 (1,57)* -5(-39,30) 21(-9,51)
Values are log transformed regression coefficients (95% confidence interval of cell numbers (*10e9/L)) derived from 
linear regression models and reflect the increase or decrease (%) in log transformed cell numbers per month con-
tinuation of breastfeeding.(duration), and the increase or decrease (%) in log transformed cell numbers of groups 
Table 4. Unadjusted associations between breastfeeding exclusivity and CD8+ T cell numbers at 6 months 
Regression coefficients for logtransformed cell numbers (*10e9/L)
6 months (n=258)
CD8 Total CD8 Tnaive CD8 Tcm CD8 TemRA CD8 TemRO
EXCLUSIVENESS
Never (n= 35) REF REF REF REF REF
Partial until 4 months (n=157) 13 (-3,29) 9 (-11,29) 17 (-7,41) -5 (-30,21) 3 (-27,32)
Exclusive until 4 months(n=80 14 (-3,31) 3 (-19,25) 33 (7,59)* 12 (-16,40) 28 (-3,59)
Unadjusted values are log transformed regression coefficients (95% confidence interval of cell numbers (*10e9/L)) 
derived from linear regression models and reflect the increase or decrease (%) in 
log transformed cell numbers of partial and exclusive breastfed groups relative to the reference group (never breast-
feeding). Partial breastfeeding indicates infants receiving both breast-feeding, 
bottle feeding and/or solids in this period.*P-value <0.05.
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duration; central memory cell numbers were still 29% (95% CI 1, 57) higher in infants who 
were breastfed for 6 months or longer than in infants who were never breastfed (Table 3, 
Fig 2b). In line with this, no significant associations were found between the duration of 
breastfeeding and CD8 central memory numbers (Table 3, Fig. 2c).
Thus, CD8 central memory T cells were associated with breastfeeding exposure, but not 
with the duration of breastfeeding. 
Table 3. Adjusted associations between breastfeeding and memory B-cell and T-cell subsets at 6 months
Regression coefficients for logtransformed cell numbers (*10e9/L)
B (n=258) T CD4+ (n=258) T CD8+ (n=258)
Naive B 
CD27- IgD+
CD27+
IgM+
CD27+
IgA+
CD27-
IgA+
CD27+
IgG+
CD27-
IgG+
CD4+ 
 naive
CD4+
 cm
CD4+
TemRO
CD4+
TemRA
CD8+
T naive
CD8+
T cm
CD8+
TemRO
CD8+
emRA
DURATION
Breastfeeding (n=223) increase 
per month
-1(-3,1) -3(-6,-1)* -2 (-5,-1)* -2 (-5,1) 1 (-3,2) -2 (-4,-1)* -2 (-3,0) -1(-2,1) -1(-3,2) 0(-3,2) -2 (-4,1) 0(-2,3) 0(-3,3) 2 (-1,5)
EXPOSURE
Never (n= 35) REF REF REF REF REF REF REF REF REF REF REF REF REF REF
< 3 months (n= 86) 12 (-6,31) 9(-19,36) 1 (-28,30) 15 (-14,43) -9 (-34,16) -1 (-22,22) 7(-10,24) -3(-20,14) 17(-4,38) 14(-8,37) 23 (0,46) 30 (4,57)* 15(-18,47) 20(-8,47)
> 3 < 6 months (n= 64) 18 (-1,38) 18(-11,48) 1 (-30,32) 14 (-17,44) 0 (-26,27) 1 (-22,25) 4(-14,22) -5(-23,13) 9(-14,31) 8(-16,32) 23 (-2,448) 17 (-11,45) -4(-38,31) 9 (-20,39)
> 6 months (n= 73) 6 (-13,26) -4(-34,25) -11 (-40,19) -2 (-31,28) -7 (-33,19) -13 (-36,10) -5(-23,14) -3(-21,15) 13(-10,35) 10(-14,34) 10(-15,34) 29 (1,57)* -5(-39,30) 21(-9,51)
Values are log transformed regression coefficients (95% confidence interval of cell numbers (*10e9/L)) derived from 
linear regression models and reflect the increase or decrease (%) in log transformed cell numbers per month con-
tinuation of breastfeeding.(duration), and the increase or decrease (%) in log transformed cell numbers of groups 
exposed to breastfeeding relative to the reference group (never breastfeeding). Breastfed groups include both par-
tially and exclusively breastfed children. *P-value <0.05.Adjusted for maternal education and maternal alcohol use 
during pregnancy.
Table 5. Adjusted associations between breastfeeding exclusivity and CD8+ T cell numbers at 6 months
Regression coefficients for logtransformed cell numbers (*10e9/L)
6 months (n=258)
CD8 Total CD8 Tnaive CD8 Tcm CD8 TemRA CD8 TemRO
EXCLUSIVENESS
Never (n= 35) REF REF REF REF REF
Partial until 4 months (n=143) 20 (3, 38)* 20 (-5, 44) 12 (-17,40) 18 (-11, 47) 4 (-31, 39)
Exclusive until 4 months (80) 21 (2, 40)* 14 (-14, 41) 16 (-15, 48) 27 (-5, 59) 12 (-28, 51)
Values are log transformed regression coefficients (95% confidence interval of cell numbers (*10e9/L)) derived from 
linear regression models and reflect the increase or decrease (%) in 
log transformed cell numbers of partial and exclusive breastfed groups relative to the reference group (never breast-
feeding). Partial breastfeeding indicates infants receiving both breast-feeding, 
bottle feeding and/or solids in this period.*P-value <0.05. Adjusted for maternal education and maternal alcohol use 
during pregnancy. 
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DISCuSSION
Overall we found that breastfeeding was associated with a decrease in B-cell memory and 
an increase in CD8 T-cell memory at 6 months of age. The same trend was observed at 14 
months of age, and disappeared at older ages. The decrease in B-cell memory was associ-
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Figure 2. Impact of breastfeeding duration on T-lymphocyte subsets at 6 months of age.
A) Gating strategy for T-cell subset delineation. CD4+ and CD8+ T-cell subsets were defined within total CD3+ T cells, 
and subsequently dissected using CD45RO and CCR7 into naive, central memory, CD45RO+ effector memory (Tem-
RO) and CD45RO- effector memory (TemRA) T cells. The reference depict density plots of total lymphocytes and were 
used to set the gates accordingly. B) Backtransformed CD4 and CD8 cell counts (cells/µL) at 6 months of age ac-
cording to different breastfeeding duration categories (reference category is never). Categories of breastfed children 
contain both partial and exclusively breasted children. C) The estimated backtransformed regression line reflects 
CD4 and CD8 cell counts (cells/µL) at 6 months of age, per month increase in breastfeeding duration. *, P<0.05.
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ated with the duration of breastfeeding, while the increase in total CD8 T cells and central 
memory CD8 T cells did not depend on the duration of breastfeeding. This suggests that 
breastfeeding enhances T-cell maturation, but not B-cell maturation. 
Total B-cell numbers nor frequencies were significantly related with breastfeeding. This 
is in line with previous studies.21,23 Only one study reported higher frequencies of total 
B cells in breastfed children at 6 months of age, however sample sizes were small (n=7 
breastfed infants).22 We found that the duration of breastfeeding was associated with 
decreased numbers of CD27+IgA+, CD27+IgM+ and CD27-IgG+ memory B cells, which are 
mostly derived from systemic T-cell dependent responses.11 This suggests that continuous 
breastfeeding inhibits memory B-cell development. One of the candidate factors in breast 
milk that is likely to mediate this, is secretory IgA (sIgA).33,34 Continuous breastfeeding 
will provide a constant supply of maternal sIgA onto the epithelial surface of the infant’s 
gastrointestinal tract. This sIgA might prevent exposure of microorganisms to the infant’s 
humoral immune system, and translocation of gut bacteria.34,35 Thus, fewer naive B cells 
might be activated to differentiate into memory B cells (Supplemental Fig 1). Indeed, in 
suckling mice it has been suggested that maternal sIgA blocks mucosal B cell responses in 
the offspring.36,37 Alternatively, the unchanged numbers of T-cell independent CD27-IgA+ B 
cells suggest that breastfeeding does not affect local IgA responses. It is therefore possible 
that maternal IgA helps to block translocation of intestinal bacteria, thereby only prevent-
ing systemic T-cell dependent B-cell memory formation. Other growth factors in breast 
milk that can reduce exposure of microbiota to B cells are epidermal growth factor, IGF-1, 
TGF-β, leptin and prolactin. These factors enhance maturation of the epithelial barrier,33,38 
and decrease uptake of foreign protein antigens. Factors such as lactoferrin, oligosaccha-
rides and lipids may directly prevent attachment of the bacterial outer membrane to the 
mucosal surface.33 Finally, the passive transfer of functional Ig-secreting plasma cells in 
breast milk may prevent bacterial or viral transmission.39,40 
Total T-cell numbers nor CD4 T-cell numbers were associated with breastfeeding ex-
posure or breastfeeding duration. However, infants who were breastfed until 3 months 
had higher CD8 T-cell numbers than infants who were never breastfed, and this change 
persisted when breastfeeding was prolonged until 6 months, suggesting an ongoing ac-
tivation of CD8 T cells by exposure to breast milk, but no accumulation over time. These 
results extend previous observations in small studies (n<40) of increased frequencies of 
CD8 T cells or decreased CD4/CD8 ratios.21,22,24 In addition, an increase in CD8 T cells from 8 
to 10 months of age was observed before,24 suggesting a longer-lasting effect of breastfeed-
ing. However, the children received breastfeeding until 8 months of age.24 In addition, the 
number of children in the breastfeeding group was small (n=35), and no detailed analysis 
of CD8 subsets was performed. Therefore, future studies will be needed to validate these 
findings.
Within total CD8 T cells, the central memory subset was most significantly increased 
in breastfed children. This expansion will be the result of stimulation of mature T cells. 
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Candidate immune stimulatory factors in breast milk are lactoferrin and exosomes. Lac-
toferrin has direct microbicidal properties, including binding of the bacterial cell wall and 
the concomitant release of lipopolysaccharide (LPS, endotoxin). Moreover, lactoferrin is 
known to enhance T-cell proliferation.21,33 Exosomes are carrier vesicles of 50-100 nm that 
can bud from the membrane of eukaryotic cells.41 Exosomes formed by B cells or dendritic 
cells contain MHC class I and class II, and have the potential to stimulate T cells.42,43 Human 
breast milk has been found to contain immune modulatory exosomes that express MHC 
molecules, IL-2, IFNγ and TNFα. In line with our findings that breastfeeding did not affect 
memory CD4 T cells, these vesicles did not appear to stimulate CD4 T cells.44 It is, however, 
likely that immunostimulatory compounds such as exosomes, do have CD8 T-cell stimulat-
ing capacities and contribute to the increase in central memory T cells in breastfed infants 
(S1 Fig.). In addition, it has been described that the infants take up live and functional 
maternal immune cells from the breast milk.45-47 This might result in stimulation of CD8 T 
cells. Thus, it remains unclear whether the increase in central memory CD8 T cells can be 
attributed to immunostimulatory factors in breast milk, such as lactoferrin and exosomes, 
or reflects a role for maternal immune cells. Nevertheless, central memory T cells might 
mediate reactive immunity,48 because they circulate between the spleen, blood and lymph 
nodes and proliferate extensively in response to a second encounter of an antigen.13,14,15 
Therefore, it could be hypothesized that an increase in central memory T cells is associated 
with increased reactive immunity. 
Beneficial effects of breastfeeding on adaptive immune responses have previously been 
demonstrated in vaccination studies.7,8,9 Breasted children showed increased interferon-γ 
production, and increased frequencies of CD8+ T cells after vaccination with measles, 
mumps and rubella.9 Furthermore, breastfeeding had beneficial effects on virus-specific 
immune responses to poliovirus, diphtheria toxoid and tetanus toxoid,49 whereas the 
responses to rotavirus are not clearly enhanced.50,51 These studies included relatively 
few children, and confounding factors could not be taken into account. Thus, our results 
extend these previous observations from vaccination studies. Unfortunately, we were not 
able to study virus-specific memory cells and studies determining associations between 
central memory cell numbers and functional immunity are lacking. Thus, interpretations 
regarding cell-mediated immunity should be made with caution. 
We did not observe associations between breastfeeding and naive T cells or effector 
memory T cells. In contrast, a previous study reported lower frequencies of naive CD4 T 
cells [21], but no differences in memory T-cell frequencies. Therefore, it was suggested that 
the adaptive immune system develops slower in breastfed infants.21 However, the study 
reported on a relatively small number of children in the breastfeeding group (n=34), and 
lacked data on absolute B- and T-cell counts.21 
Our study was conducted in a large population-based prospective birth cohort. Previous 
studies that addressed the effects of breastfeeding on adaptive immunity, had smaller 
sample size and/or lacked follow-up.21,22,23,24 Most of these retrospective studies were 
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based on recall of infant feeding after several years, making recall bias of feeding habits an 
important concern.52 Because of the prospective design of our study, detailed information 
on the duration of breastfeeding was collected at multiple time points shortly after breast-
feeding was finished, thereby limiting potential recall bias.52 Still, data on breastfeeding 
was collected retrospectively, and due to the use of questionnaires, misclassification may 
occur.52 Because any misclassification would be independent of laboratory determined T 
and B cell numbers, it is unlikely that these affected the outcome. In addition, our study 
design provided information on a large number of potential confounders. We used an 
unbiased approach, investigating a broad panel of determinants on lymphocyte numbers 
and frequencies. Moreover, we performed measurements of lymphocytes at different ages, 
enabling us to study the effect of breastfeeding on adaptive immunity over a longer period 
of time. Finally, using detailed 6-color flow cytometry, we were able to discriminate mul-
tiple, functionally distinct B- and T-cell subsets.11,12,53 Thus, we could evaluate the effects of 
breastfeeding on specific aspects of adaptive immunity. 
At 14 months or age, we observed the same trends of decreasing B-cell numbers with 
longer breastfeeding duration, and higher CD8 T-cell numbers with breastfeeding expo-
sure, as we did for 6 months, although effects were not significant. The sample size at 14 
months was smaller than the sample size at 6 months. Hence, we cannot exclude that 
non-significant effects at 14 months are due to loss of statistical power, and some effects 
of breastfeeding remain at this age. 
Our measurements were limited to peripheral blood. Thus, it is not possible to deduce 
whether B- and T-cell numbers in lymphoid tissue were affected. Theoretically, preferential 
homing to or away from tissue could result in changes in blood lymphocyte counts [54]. If 
breastfeeding affects this preferential homing, the effects will be lost once breastfeeding 
is discontinued. Nearly all children were no longer receiving breast milk and still showed 
lower memory B cell numbers and higher CD8 T-cell numbers. Thus, we conclude that the 
effects of breastfeeding on preferential tissue homing was limited.
In conclusion, this prospective population-based cohort study among a large number 
of healthy children showed that CD27+IgA+, CD27+IgM+ and CD27-IgG+ memory B-cell 
numbers decreased with a longer breastfeeding duration. CD8 T cells, and especially CD8 
central memory T-cell numbers, were higher in breastfed children up to 6 months of age. 
This suggests that breastfeeding enhances T-cell maturation in the first 6 months of life. 
On top of the protective effects of maternal IgA in breast milk, this might contribute to the 
protective effect against infectious diseases in infancy. 
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Supplemental Table 1. Maternal and infant characteristics of the study population at 14, 25 months and 
6 years. 
14 months (n=166) 25 months (n=112) 6 years (n=332)
No 
breastfed 
(n=16)
Breastfed
(n=150)
No 
breastfed 
(n=16)
Breastfed
(n=96)
No 
breastfed
(n=37)
Breastfed
(n=295)
Maternal characteristics
Age (Mean + SD; years) 31 (4.2) 32 (3.9) 31 (4.1) 32 (3.8) 31 (3.6) 32 (3.6)
Educational level (n; %) 
Lower 7 (44%) 59 (40%) 12 (75%) 31 (33%) 22 (59%) 96 (33%)
Higher 9 (56%) 90 (60%) 4 (25%) 64 (67%)* 15 (41%) 196 (67%)*
Net household income per month (n; %)
< € 2400 0 (0%) 21 (15%) 1 (8%) 13 (15%) 4 (12%) 33 (13%)
> € 2400 13 (100%) 112 (84%) 12 (92%) 73 (85%) 30 (88%) 227 (87%)
Smoking continued during 
pregnancy (n; %)
2 (14%) 16 (15%) 1 (7%) 8 (11%) 6 (20%) 32 (15%)
Alcohol use continued during 
pregnancy (n; %)
6 (43%) 41 (38%) 4 (29%) 29 (39%) 11 (37%) 83 (37%)
Body Mass Index before pregnancy 
(Mean + SD; kg/m2)
25 (5) 24 (5) 25 (5) 23 (4) 24 (5) 24 (4)
Fever in third trimester of 
pregnancy (n; %)
1(6%) 9 (6%) 2 (13%) 5 (6%) 2 (6%) 19 (7%)
Maternal atopy (eczema, allergy 
HDM, hay-fever)(n; %)
3 (21%) 51 (36%) 6 (40%) 41 (46%) 9 (27%) 109 (40%)
Paternal atopy (eczema, allergy 
HDM, hay-fever) (n; %)
3 (23%) 41 (29%) 5 (39%) 24 (28%) 13 (39%) 77 (29%)
Family history of asthma / atopy 
(n; %)
5 (31%) 77 (52%) 9 (56%) 56 (59%) 20 (54%) 156 (54%)
Any reported autoimmune disease 
(diabetes mellitus, SLE, arthritis, 
MS, thyroid disorder, or celiac 
disease) (n; %)
0 (0%) 3 (2%) 0 (0%) 2 (2%) 2 (5%) 8 (3%)
Mode of delivery (n; %) 
Vaginal 9 (56%) 19 (64%) 7 (47%) 48 (55%) 20 (59%) 182 (65%)
Forceps or vacuum assisted 2 (13%) 30 (21%) 2 (13%) 21 (24%) 5 (15%) 59 (21%)
Caesarian section 5( 31%) 21 (15%) 6 (40%) 19 (22%) 9 (26%) 40 (14%)
Premature rupture of membranes 
(n; %)
1 (6%) 2 (1%) 1 (6%) 2 (2%) 3 (8%) 4 (2%)
Infant characteristics (n=258)
Males (n; %) 9 (56%) 77 (51%) 7 (44%) 47 (49%) 20 (54%) 144 (49%)
Gestational age ( Mean + SD; weeks) 39.2 (2.2) 40.1 (1.9) 39.7 (1.9) 39.9(1.5) 39.7 (1.7) 40.1 (1.6)
Preterm birth (<37 weeks) (n; %) 1 (6% 3 (2%) 1 (6%) 4 (4%) 2 (5%) 8 (3%)
Birth weight ( Mean + SD; grams) 3,455 (738) 3,505 (513) 3,516 (614) 3,542 (480) 3,543 (554) 3,531 (508)
Apgar score at 5 min <7 (n; %) 0 (0%) 3 (2%) 0 (0%) 0 (0%) 0 (0%) 3 (1%)
Birth season (n; %)
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Supplemental Table 1. Maternal and infant characteristics of the study population at 14, 25 months and 
6 years. (continued)
14 months (n=166) 25 months (n=112) 6 years (n=332)
No 
breastfed 
(n=16)
Breastfed
(n=150)
No 
breastfed 
(n=16)
Breastfed
(n=96)
No 
breastfed
(n=37)
Breastfed
(n=295)
Winter (Dec-Jan-Feb) 2 (13%) 38 (25%) 3 (19%) 28 (29%) 6 (16%) 73 (25%)
Spring (Mar-Apr-May) 5 (31%) 41 (27%) 3 (19%) 26 (27%) 6 (16%) 93 (31%)
Summer (Jun-Jul-Aug) 3 (18%) 32 (21%) 4 (25%) 21 (22%) 11 (30%) 65 (22%)
Autumn (Sept-Oct-Nov) 6 (38%) 39 (26) 6 (37%) 21 (22%) 14 (38%) 64 (22%)
Siblings >1 (n; %)  2 (12%) 17 (11%) 1 (6%) 8 (8%) 2 (5%) 26 (9%)
Day-care >16 hours /week (n; %) 3 (33%) 51 (47%) 4 (25%) 33 (34%) 5 (33%) 99 (47%)
Fever in first 6 months (n; %) 7 (78%) 80 (63%) 3 (60%) 51 (62%) 13 (57%) 175 (67%)
Age at focus visit (Median + range; 
months/years)
14.4 
(13.2-16.3)
14.4
(13.1-17.4)
25.3 
(23.4-27.5)
25.2 
(23.3-29.8)
6.0 
(5.8-6.6)
5.8 
(5.1-7.2)
Values are means (SD), absolute numbers (percentages) or #medians (90% range). * Significantly different between 
breastfeeding and no breastfeeding groups.
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Supplemental Table 3. Antibody panel used for 6-color flow cytometry. 
Labeling Conjugated monoclonal antibodies (clone)
FITC PE PerCP-Cy5.5 PE-Cy7 APC APC-Cy7
1 CD3 CD16.56 CD45 CD4 CD19 CD8
(SK7) (B73.1C5.9) (2D1) (SK3) (SJ25C1) (SK1)
2 IgD CD23 CD19 CD21 IgM CD27
(poly) (EBVCS5) (SJ25C1) (B-ly-4) (G20-127) (M-T271)
3 IgA IgG CD19 CD40 IgM CD27
(poly) (poly) (SJ25C1) (5C3) (G20-127) (M-T271)
4 CD28 CD197 CD3 CD8 CD45RO CD27
(CD28.2) (3D13) (SK7) (SK1) (UCHL-1) (M-T271)
FITC= fluorescein isothiocyanate, PE=phycoerythrin, PerCPCy5.5= peridin chlorophyll protein, PE-Cy7= phycoery-
thrin-cyanin dye, APC=allophycocyanin and APC-Cy7= allophycocyanin-cyanin dye, poly = polyclonal antibody.
DC
No breastfeeding Breastfeeding
DC
bloodblood
BTcm
B Tn
B Tn cmT
 Bn
intestineintestine
B Tn
B Tn
BTcm
BTcm BTcm
BTcm
B Bn
 Bn
B Bn
pc
pc
pc
pc
B Bm B Bm B Bm B Bm
bacteriumvirus
sIgA
maternal sIgA
maternal
exosome
BTcm
BTcm
Supplemental Figure 1. Summarizing mechanism of how breastfeeding might affect adaptive memory. In 
absence of breast milk, the infant’s B and T cells respond to microorganisms in the intestine and generate long-lived 
memory cells and IgA (blue) that circulate through the body (left). Breast milk contains immune modulating com-
ponents (right). Of these, maternal sIgA (green) is able to catch microorganisms and prevent recognition of these by 
B-cells. This might inhibit B-cell responses and B-cell memory formation. Other immunostimulatory components, 
such as exosomes, might stimulate naive T cells and increase T-cell memory formation. Abbreviations: Bn, naïve B 
cell; Bm, memory B cell; DC, dendritic cell; pc,plasma cell; Tn, naive T cell; Tm, memory T cell. 
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ABSTRACT
Background
Cytomegalovirus (CMV) and Epstein Barr virus (EBV) induce effector memory T-cell expan-
sions, which are variable and potentially depend on the age at primary exposure and co-
infections. We evaluated the T-cell compartment and herpesvirus infections in 6-year-old 
children.
Methods
T-cell subsets and immunoglobulin G (IgG) seropositivity for CMV, EBV, herpes simplex 
virus-1 (HSV-1) and varicella zoster virus (VZV) were studied in 1079 6-year-old children. A 
random subgroup of 225 children was evaluated for CMV and EBV seropositivity before 2 
years of age and for vaccination responses against measles and tetanus.
Results
CMV and EBV infections were associated with significant expansions of CD27- and CD27+ 
effector memory T cells, respectively. These expansions were enhanced in CMV+EBV+ chil-
dren and were independent of VZV or HSV-1 co-infection. Naive and central memory T-cell 
numbers were not affected, nor were anti-tetanus and anti-measles IgG levels. Children 
infected before 2 years of age showed smaller effector memory T-cell expansions than 
children infected between 2 and 6 years of age. 
Conclusions
CMV- and EBV-related T-cell expansions do not impair naive T-cell numbers or mainte-
nance of protective responses against non-related pathogens. Duration of infection was 
not directly related to larger expansions of effector memory T cells in children, suggesting 
that other mechanisms affect these expansions at later age. 
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INTRODuCTION
Cytomegalovirus (CMV) and Epstein Barr Virus (EBV) are ubiquitous in the human popula-
tion and persist with presumed viral latency.1,2 Infection occurs mainly in childhood, reach-
ing approximately 50% seropositivity at around the age of 6 years and in 80-90% in adults 
within the Western world.3,4 CMV and EBV are associated with changes in immunological 
memory. Infected adults display persistent expansions of virus-specific effector memory T 
cells in both the CD8+ and the CD4+ lineages.5,6 CMV-specific CD8+ T cells are predominantly 
CCR7-CD45RO+CD27+/- in young adults, and more clonal CCR7-CD45RA+CD27- populations 
are found in elderly.5,7-14 EBV-specific T cells are mainly CCR7-CD45RO+CD27+.5,8,15,16 The 
majorities of these populations have an extended lifespan, but a poor response to T-cell 
mitogens.7-9,16-18
Co-infection with CMV and EBV can have both synergistic and antagonistic effects: CMV 
co-infection can restore defective vaccination responses in EBV-infected children, and 
EBV co-infection can boost CMV-induced NK-cell differentiation; together they affect the 
chance for developing allergic complications.19-21 In contrast, infections with herpes sim-
plex virus 1 (HSV-1) do not result in persistent effector T-cell expansions.15 Less is known 
for co-infection with varicella zoster virus (VZV), because this already reaches 90-100% 
seropositivity in young adulthood in the Western world. 
Accumulations of CMV- and EBV-induced effector memory T-cells have been suggested 
to overcrowd T cells with other specificities,5,22 and to negatively affect immune responses 
to other infections and/or vaccinations.9,17,23-25 Moreover, CMV and EBV persistence are as-
sociated with cardiovascular disease, infectious complications and with increased mortal-
ity rates, especially in immunosuppressed individuals or the very elderly.23,26-31 Still, these 
effects are not consistently observed,32-35 and despite high CMV and EBV seropositivity 
rates in elderly persons, clinical complications develop in only a minority. An explanation 
could be the variation in T-cell responses: virus-specific T-cell numbers vary from barely 
detectable to >30% of total memory T-cells in peripheral blood. This diversity might be 
affected by the infectious dose,36 and long-term infection, and may thus especially develop 
in individuals who had been infected early in life. However, in contrast to infection after 
puberty, primary infections with CMV or EBV in early childhood are mostly asymptomatic 
and might even be protective against the development of celiac disease and allergies.37,38 
To study whether the developing immune system in childhood provides more effective 
control of persistent viruses,39 we studied 1079 6-year old children in the Generation R 
cohort. The combined analysis of CMV, EBV, HSV-1 and VZV infection in this large cohort 
allowed us to study virus-specific and modifying effects on the T-cell compartment and 
their relation with vaccination responses to tetanus and measles. 
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MATERIALS AND METhODS 
Study subjects
This study was conducted in the context of the Generation R Study, a prospective 
population-based cohort study from fetal life until young adulthood.40 We included 1079 
6-year-old children (range 5.0-7.9 years) in whom CMV, EBV, HSV-1 and VZV IgG serology and 
detailed immunophenotyping of blood T cells was performed. From a random selection of 
225 of these children, additional virus serology and immunophenotyping was performed 
on blood samples obtained in the second year of life (age range 13.1-29.9 months). Written 
informed consent was obtained from all parents of participating children. Ethical approval 
for the study was obtained from the Medical Ethical Committee of the Erasmus MC.
Serology
Blood plasma samples were subjected to enzyme-linked immunoassays for IgG antibodies 
against CMV, EBV capsid antigen, HSV-1 glycoprotein C1, VZV, tetanus toxoid or measles 
antigen (Euroimmun). Results were evaluated relative to a manufacturer-provided refer-
ence threshold sample. Seropositivity, and assumed virus persistence, was defined by a 
sample/threshold ratio above 0.6 (CMV), 0.8 (EBV capsid antigen), 1.6 (HSV-1) and 1.0 (VZV). 
Anti-measles and anti-tetanus IgG levels were analyzed in international units/mL (IU/mL) 
as a continuous variable and with plasma levels above 275 IU/mL (measles) or 0.5 IU/mL 
(tetanus) being defined as protective vaccination responses. 
Immunophenotyping
Absolute numbers of CD3+ T cells were obtained with a routine diagnostic lyse-no-wash 
protocol. Detailed analysis of T-cell subsets was performed with 6-color flowcytometry 
(Supplemental Table 1 and Supplemental Figure 1).22,41 
Antigen-specific T-cells were detected in thawed post-Ficoll peripheral blood mono-
nuclear cells of 15 CMV+ and 14 EBV+ children who carried the HLA-A*0201 allele, defined 
by single-nucleotide polymorphism tags rs2844821(G) and rs762324(C) in previously 
generated single-nucleotide polymorphism arrays.40,42 Virus-specific CD8+ T cells were 
detected with HLA-A*0201 tetramers loaded with CMV peptides NLVPMVATV (from pp65; 
allophycocyanin (APC)-labeled) or VLEETSVML (from IE-1; phycoerythrin (PE)-labeled) 
proteins and EBV peptides GLCTLVAML (from BMLF-1; APC-labeled) or YVLDHLIVV (BRLF-1; 
PE-labeled). Flow cytometric data were acquired on a FACSCalibur or LSRII (BD Biosci-
ences) and analyzed using FACSDiva (BD Biosciences; version 6.2) and Infinicyte (Cytognos; 
version 1.7) analysis software.43 
Statistical analyses
Differences in infection prevalence were assessed using Chi-square tests. Differences in 
lymphocyte counts (or frequencies) between uninfected controls and virus-infected groups 
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were assessed with Kruskal-Wallis tests, followed by post-hoc Dunn tests. Differences in 
longitudinal frequencies of lymphocyte populations were assessed using paired t-tests. 
Differences were considered statistically significant at P <0.05. 
RESuLTS
herpesvirus seropositivity
Among the 1079 children included in the study, 36.2% were IgG-seropositive for CMV, 47.1% 
for EBV, 14.0% for HSV-1 and 92.1% for VZV. Because mainly CMV and EBV are reported to 
result in chronic T-cell expansions, we divided the 1079 children into 4 groups: no CMV or 
EBV infection (uninfected; n=399); CMV but no EBV infection (CMV infected; n=172); EBV but 
no CMV infection (EBV infection; n=289) and CMV and EBV coinfection (n=219) (Table 1). 
Table 1. HSV-1 or VZV co-infection in correlation to CMV and EBV IgG seropositivity at 6 years of age.
  n %
HSV
n (% of group)
VZV
n (% of group)
HSV and VZV
n (% of group)
None 399 37.0 39 (9.8%)refa 367 (92%)refa 35 (8.8%)refa
CMV only 172 15.9 18 (10.5%) 165 (95.9%) 18 (10.5%)
EBV only 289 26.8 46 (15.9%)* 260 (90%) 42 (14.5%)*
CMV and EBV 219 20.3 48 (21.9%)**** 202 (92.2%) 40 (18.3%)***
Total 1079 100 151 (14%) 994 (92.1%) 135 (12.5%)
Abbreviations: CMV, cytomegalovirus; EBV Epstein-Barr virus, HSV-1, herpes simplex virus type 1, IgG immunoglobu-
lin G, VZV varicella-zoster virus. a The significance of co-infection in the CMV infected, EBV infected and CMV+EBV+ 
coinfected group was tested relative to the CMV-EBV- uninfected controls, using Chi-square tests. * P<0.05. *** 
P<0.001.**** P<0.0001. 
The rate of coinfection with VZV was >90% in all groups. HSV-1 infection was significantly 
more frequent in EBV-infected (p=0.02) or CMV+EBV+ coinfected (p<0.001) children (Table 
1). Therefore, HSV-1 infection in particular needs to be considered for possible confound-
ing effects in our analyses on EBV. 
CMV- and EBV-specific effector memory T-cells 
To analyze whether 6-year-old children carried virus-specific T-cell expansions, we phe-
notyped virus-specific CD8+ T cells in 15 CMV+ and 14 EBV+ infected children using CD27 
and CD45RA and HLA-A*0201 tetramers loaded with CMV-specific peptides of pp65 and IE-1 
and EBV-specific peptides of BMLF-1 and BRLF-1 (Figure 1). Virus-specific CD8+ T cells were 
detected in blood at frequencies of 0.01-0.52% (pp65-NLV) and 0.01-2.32% (IE-1-VLE) for 
CMV peptides and 0.02-0.64% (BMLF-1-GLC) and 0.02-2.6% (BRLF-1-YVL) for EBV peptides. 
The CMV- and EBV-specific CD8+ T-cells were phenotypically diverse and predominantly 
consisted of CD45RA-CD27+/- and CD45RA+CD27- memory T-cells (Figure 1). Thus, 6-year old 
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children already display expansions of effector memory T cells directed against CMV and 
EBV antigens. 
CMV and EBV associated memory T-cell expansions
To study the effects of CMV and EBV on the T-cell compartment, we immunophenotyped 
CD8+ and CD8- (CD4+) T cells in 18-20 randomly-selected children who were either unin-
fected, CMV ifected, EBV infected or CMV and EBV coinfected. T-cell data from each group 
of children were merged and subjected to automatic population separation with Infinicyte 
software,43 based on the expression of CD3, CD8, CCR7, CD45RO, CD27 and CD28. Within 
both CD8+ and CD4+ T cells, four populations were distinguished in 2 dimensional plots 
of principle component 1 vs principal component 2 (Figure 2). CMV was associated with a 
relative increase of two CD8+ populations: population 2 (CCR7-CD45RO-; 9.2% uninfected 
and 15.1% CMV infected) and population 3 (CCR7-CD45RO+; 2.8% uninfected and 5.9% CMV 
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Figure 1. Frequencies and phenotypes of cytomegalovirus (CMV)- and Epstein-Barr virus (EBV) -specific 
CD8+ T cells in 6-year-old children. 
CD8+ T cells recognizing CMV-specific (A,B) or EBV-specific (C,D) peptides were detected with multicolor flowcytom-
etry and further analyzed for CD27 and CD45RA expression. Flowcytometry plots consist of merged data files of 14 
representative CMV infected (A,B) or EBV infected (C,D) children who carried the HLA A*0201 allele. Bottom graphs 
depict for each individual the relative distributions of tetramer-positive cells as fold increase compared with the 
relative distribution of total CD8+ T cells.
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infected). EBV-infected children showed an increase in CCR7-CD45RO+ populations, both 
CD27- (population 3; 2.8% uninfected and 4.1% EBV infected) and CD27+ (population 4; and 
10.5% uninfected vs 14.1% EBV infected). CMV and EBV infections were also associated with 
CD4+ T-cell memory expansions: CCR7-CD45RO+ (population 3; 14.2% uninfected, 20.6% 
CMV infected, and 16.6% EBV infected) and CCR7-CD45RO- (population 4; 6.7% uninfected, 
10.9% CMV infected, and 8.6% EBV infected) (Figure 2B/D). Thus, CMV and EBV infection in 
young children are associated with relative expansions of memory T cells.
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Figure 2. Relative change in the T-cell phenotype in cytomegalovirus (CMV)- or Epstein-Barr virus (EBV)-
infected children.
Unbiased flowcytometric analyses of CD8+ T cells (A) and CD8- T cells (B) in uninfected, CMV infected, EBV infected 
and CMV+EBV+ coinfected children. Data from 18-20 children in each group were merged into a single file, and sub-
jected to automatic population separation based on the expression of CD3, CD8, CCR7, CD45RO, CD27 and CD28. 
2D projections of principle component (PC)1 versus PC2 revealed 4 populations. The relative contributions of CCR7, 
CD45RO, CD27 and CD28 to PC1 or PC2 are indicated. C,D, CD45RO versus CCR7 expression of the populations de-
fined by automatic population separation. Populations 3 and 4 in C were both CCR7-CD45RO+ but differed in CD27 
and CD28 expression (small inset). 
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Normal numbers of naive and central memory T cells in CMV- or EBV-infected 
children 
To determine whether the relative memory T-cell expansions in CMV and/or EBV carriers 
also affected absolute T-cell numbers, we next evaluated the CD4+ and CD8+ T-cell lineages 
in 1079 6-year-old children. CCR7+CD45RO-CD27+CD28+ naive T cells were distinguished 
from CCR7+CD45RO+CD27+CD28+ central memory T cells (Tcm), CCR7-CD45RO+ effector 
memory (TemRO) and CCR7-CD45RO- effector memory (TemRA) (Supplemental Figure 
1A).22,41 TemRO and TemRA CD8+ T cells were significantly increased in children with CMV 
or EBV infection compared to uninfected controls (Figure 3B). For CMV, these specifically 
concerned a 4.4 fold increase of CD27-CD28- late differentiated TemRA cells and 1.3-3.3 fold 
increase of CD27-/+CD28- intermediate to late-differentiated TemRO cells compared with 
uninfected controls (Figure 3C-D). EBV-infected children showed a 1.2-1.3 fold increase in 
CD27-/+CD28- intermediate to late-differentiated TemRA cells compared with uninfected 
controls and a 1.4-1.8 fold increase in all TemRO cell subsets (Figure 3C-D). Naive CD8+ 
T cells and CD8+ Tcm cells were present in normal numbers. Thus, the expansions of ef-
fector memory cells resulted in a significant 1.1 fold increase in the total number of CD8+ 
T cells (Figure 3A). Combined, CMV and EBV infections resulted in a further increase in 
total CD8+ T-cell numbers (Figure 3A), with seemingly additive effects of the two viruses in 
doubly infected children compared with singly infected children (Figure 3). Thus, in these 
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Figure 3. Absolute numbers of CD8+ T-cell subsets in cytomegalovirus (CMV)- or Epstein-Barr virus (EBV)-
infected children. 
A, Absolute numbers of total CD8+ T-cells in children uninfected with CMV or EBV, infected with only CMV, only EBV 
or both CMV and EBV. B, Similar findings as in A, for 4 main CD8+ T-cell subsets: CCR7+CD45RO-CD27+CD28+ Naive, 
CCR7+CD45RO+CD27+CD28+ Central memory (Tcm), CCR7-CD45RO+ Effector memory (TemRO) and CCR7-CD45RO- Ef-
fector memory (TemRA) cells 41. C,D, Similar findings as in A, for CD27+CD28+ early, CD27+CD28- intermediate and 
CD27-CD28- late TemRO (C) and TemRA (D) populations 22. Bars represent stacked median values per T-cell popula-
tion. The number of individuals per category is indicated underneath each plot. Significance was tested first with a 
Kruskal-Wallis test per T-cell population relative to the uninfected controls, if results were significant (P<0.05) Dunn 
tests were performed to compare individual patient groups. Significance for the Dunn’s test is indicated in the plots: 
* P<0.05; **P<0.01; *** P <0.001; **** P <0.0001. 
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6-year-old children, infections with CMV and EBV were both associated with T-cell memory 
expansions. The phenotypes of the expanded populations differed for each of the viruses, 
did not affect each other in CMV+EBV+ double infection, and did not result in loss of naive 
CD8+ T cells. 
Total CD4+ T-cell numbers were not affected by CMV and/or EBV infection (Supplemental 
Figure 1B). Still, EBV-infected children had 1.5 fold more CD27-CD28- late-differentiated 
TemRO cells than uninfected controls. Furthermore, CMV-infected children showed a 1.3-
2 fold increase in CD27- intermediate and late-differentiated TemRO cells, and a 1.9 fold 
increase in CD27-CD28- late-differentiated TemRA cells compared with uninfected controls 
(Supplemental Figure 1B). Similar to CD8+ T cells, CMV and EBV infection independently 
resulted in effector memory CD4+ T-cell expansions, which did not affect naive T-cell num-
bers.
Effect of hSV-1 and VZV on T-cell subset numbers
Through combined analysis of children with single CMV, or single EBV, and double CMV/
EBV infection, we could distinguish distinct effects of these viruses on the T-cell compart-
ment in young children. Still, the observed effects could be influenced by infection with 
other viruses, such as HSV-1 or VZV, especially considering the increased HSV-1 positivity 
in EBV+ children (Table 1). Therefore, we separated the groups of uninfected controls, CMV 
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Figure 4. Effect of HSV-1 and VZV on blood CD8+ TemRO and TemRA cell numbers.
Uninfected, CMV infected, EBV infected and CMV+EBV+ coinfected children were further subdivided in children with-
out HSV-1 or VZV (white), co-infected with only VZV (light gray) or with both HSV-1 and VZV (dark gray). Absolute 
numbers of CD8+ TemRO (A) and TemRA (B) cells in all population groups depicted as 10-90% box-whisker-plots; 
the number of individuals per category is indicated underneath each plot. Significance was tested with Kruskal-
Wallis test per T-cell population, if results were significant (P<0.05) Dunn tests of individual patient groups were 
performed to compare HSV-1 and/or VZV subgroups within each category of uninfected, CMV infected, EBV infected 
or CMV+EBV+ coinfected children.
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infected, EBV infected and CMV+EBV+ coinfected children further into 3groups: VZV and 
HSV-1 uninfected, VZV infected but HSV-1 uninfected, and VZV+ and HSV-1+ coinfected. 
Because VZV prevalence was >90% in our cohort, the effect of HSV-1, without VZV, could not 
be determined. Although the TemRO and TemRA populations differed significantly between 
all virus-infected groups (Kruskal Wallis; p<0.0001), these effects were only caused by CMV- 
or EBV-associated expansions. The presence of VZV and HSV-1 within the CMV infected or 
CMV+EBV+ coinfected group was associated only with a slight but not significant increase 
in TemRA cells (Figure 4). Thus, co-infection with VZV and HSV-1 did not significantly affect 
CMV- or EBV-associated effector memory T-cell expansion. 
Normal vaccination responses in CMV- or EBV-infected children
The effector memory T-cell expansions in CMV- or EBV-infected children did not result in 
reduced naive and Tcm numbers (Figures 2 and 3). To determine whether immunological 
memory to other pathogens was normally present in these 6-year-old children, we tested 
their responses to previous vaccinations with tetanus at 2, 3, 4, 11 months and 4 years, 
and to measles at 14 months, according to the Dutch national vaccination protocol.44 We 
defined vaccination responses in a randomly selected subgroup of 225 6-year-old children 
who showed similar seroprevalence for CMV and EBV (Supplemental Table 2), and similar 
effector memory T-cell expansions (data not shown) as the total cohort of 1079 children. 
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Figure 5. Vaccination responses in 6-year-old CMV or EBV infected children.
Anti-measles (A) and anti-tetanus (B) immunoglobulin G (IgG) levels in uninfected, CMV infected, EBV infected, or 
CMV+EBV+ coinfected children. Specific IgG levels did not differ significantly between the virus-positive groups and 
uninfected controls, as determined with the Kruskal-Wallis test. Percentages at the top represent the number of 
children with a protective anti-measles IgG response >275 international units/mL (IU/mL) (A) or anti-tetanus IgG 
response >0.5 IU/ml (B). Percentages were not significantly different (Chi-square test). 
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Furthermore, the seroprevalence of coinfection with HSV-1 and VZV was not significantly 
different between the CMV+ or EBV+ infected groups in this selected cohort (Supplemental 
Table 3). In total, 81.2% of the children had IgG antibodies against measles, and 63.2% 
against tetanus. These frequencies did not differ significantly in children with CMV and/or 
EBV infection (Figure 5). Furthermore, median titers of anti-measles and anti-tetanus IgG 
did not differ between the four groups. Thus, EBV and CMV seropositivity did not impair 
immunity to measles and tetanus vaccination in 6-year-old children. 
No association between T-cell expansions and duration of CMV or EBV infection
Our results indicate that the EBV- and CMV-specific T-cell expansions do not affect naive 
T-cell numbers or vaccination responses to tetanus and measles in 6-year old children. 
To determine whether infection early in childhood has different immunological conse-
quences than infection later in childhood, we assessed CMV and EBV seropositivity around 
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Figure 6. Limited effector memory T-cell expansions in children infected with EBV and CMV at age <2 years. 
Six-year old CMV+EBV+ coinfected children were divided into subgroups based on age at infection: <2 years (early; 
n=11) (light gray) or >2 years (late; n=10) (dark gray), and compared with CMV-EBV- uninfected controls (n=397) 
(white). A,B, Absolute number of CD8+ TemRO (A) and TemRA (B) cell subsets, shown as 10-90% box-whisker plots. 
Significance was tested first with Kruskal-Wallis tests per T-cell population; if results were significant (P<0.05), Dunn 
tests of individual patient groups were performed. Significance for the Dunn’s test is indicated in the plots: * P<0.05; 
** P <0.01; *** P <0.001; **** P <0.0001. C,D) Longitudinal follow-up of frequencies of CD8+ TemRO (C) and TemRA 
(D) subsets at age 2 and 6 years in early-infected children. No significant differences between these ages were seen 
with paired T-test (P>0.12).
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2 years of age in a subgroup of 225 children. We observed that of the CMV+EBV+ coinfected 
children, 80% already carried anti-CMV IgG before 2 years of age, and 46.8% anti-EBV IgG.
We subdivided the EBV+ and CMV+ infected children into early-infected (before 2 years) 
and late-infected subgroups (2-6 years), and compared their T-cell compartments at 6 
years of age. Neither early nor late infection affected naive and Tcm cell numbers (not 
shown), but CD4+ and CD8+ effector memory T cells were significantly increased (Figure 6 
and Supplemental Figure 1C). CMV+EBV+ coinfected children with early infection had sig-
nificantly smaller CD8+ TemRO and TemRA T-cell populations than late-infected children, 
with numbers in early-infected children similar to those in uninfected controls (Figure 6A). 
Moreover, retrospective longitudinal analysis of early-infected children indicated that CD8+ 
effector memory T-cell numbers were stable between the ages of 2 and 6 years (Figure 6B). 
CD4+ effector memory T-cell numbers did not differ significantly between early-infected 
and late-infected children. Still, some subsets in late-infected children were significantly 
higher than in uninfected controls, and these were not increased in early-infected children 
(Supplemental Figure 1C). Furthermore, CD4+ effector memory T-cell numbers increased 
between the ages of 2 and 6 years in early-infected children (Supplemental Figure 1D). 
Together, these results suggest that CD8+ effector memory T-cell numbers are not directly 
related to the time after infection. Rather, early infections were associated with smaller 
expansions of effector memory T cells at age 6 years.
DISCuSSION
We studied the effects of single or combined infection with CMV, EBV, HSV-1 and/or VZV 
on naive and memory T cells in a large cohort of >1000 6-year-old children. CMV and EBV 
infections each resulted in distinct effector memory T-cell expansions, which were additive 
in co-infection. HSV-1 and VZV infections did not significantly affect the T-cell compart-
ment, but might slightly enhance CMV- and EBV-associated T-cell expansions. In contrast 
to adults, CD8+ Tem (either TemRO or TemRA) cell expansions in CMV- or EBV-infected 
children did neither result in overcrowding of naive and Tcm compartments, nor in loss of 
vaccination responses to tetanus or measles. Notably, children infected <2 years showed 
fewer Tem cells at age 6 years than children infected between age 2 and 6 years. Thus, de-
pending on the age at the time of infection, CMV and EBV infections seem to be controlled 
differently. 
In our current study, we detected sizeable CMV- and EBV-specific CD8+ memory T-cell ex-
pansions in 6-year-old children. Unfortunately, the real extent of virus-specific T-cell expan-
sions is difficult to assess owing to the large number of viral epitopes and the diverse HLA 
backgrounds of the children. However, because 1) the phenotype of the antigen-specific 
T cells is largely similar to that of the expanded effector memory T-cell populations, both 
relatively and absolute, within the total CD8+ T-cell pool in our cohort of children, and 2) 
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the antigen-specific phenotypes are in accordance with previous literature on CMV and 
EBV infections in adults,45 we are convinced that phenotyping the total CD8+ T-cell com-
partment generates an reliable representation of virus-associated changes in the immune 
compartment. 
Our observation that CMV and EBV were associated with an increase of distinct CD8+ Tem 
subsets is consistent with previous literature in adults and children.5,7-12,15,46,47 Importantly, 
our large cohort allowed us to further analyze the possible antagonistic, synergistic or 
independent impact of CMV and EBV on the immune compartment. Importantly, in the 
group children coinfected with CMV and EBV, an additive effect was seen for the Tem cell 
expansions compared with that seen in singly infected patients. Furthermore, the size of 
the CMV-associated TemRA late cell population was not (negatively) affected by the size of 
the EBV-associated TemRO cell populations in individual patients (data not shown). Thus, 
the distinct effects of CMV and EBV on CD8+ Tem cell expansions seem to be independent 
of each other.
In addition to CD8+ Tem cell expansions, we found that CD4+ Tem cell numbers were 
increased in both CMV and EBV infections, which is similar to observations in adults.6 
Although these expansions were smaller and did not significantly increase in total CD4+ 
T-cell numbers, they were distinct between both viruses. Furthermore, the phenotypes of 
the CD4+ Tem cell expansions were remarkably similar to those of their CD8+ counterparts 
and were additive in CMV and EBV doubly infected children. Despite these seemingly minor 
expansions, CD4+ T cells have an important role in controlling primary CMV infection.48 The 
formation of sizeable Tem populations is apparently necessary to successfully suppress 
the virus. Importantly, these expansions did not result in overcrowding of more immature 
T-cell subsets, something that for CMV infection in elderly has been associated with poor 
CD4+ memory T-cell responses to influenza proteins.24 
Our large cohort allowed us to study the effects of HSV-1 and VZV in EBV and CMV unin-
fected children, as well as any modifying effects on CMV and/or EBV infections. Because 
virtually all adults are infected with VZV, little is known on the effects on T-cell memory15 
and we could for the first time conclude that VZV does not modify T-cell memory alone 
or in combination with CMV and/or EBV. Co-infection with HSV-1 was more frequent in 
EBV-infected and CMV+EBV+ coinfected children and might therefore be an important 
contributor to the immune modulation that is currently assumed to be EBV-associated. 
Still, HSV-1 did not affect Tem in EBV infected children, suggesting that these expansions 
are EBV specific and not due to HSV-1. The difference in T-cell modulation between CMV 
and EBV on the one hand and VZV and HSV-1 on the other is most likely due to tropism and 
anatomical localization of the viruses. In fact, it is well-possible that HSV-1 and VZV induce 
T-cell expansions, but these cells are thought to reside mostly in the human skin or locally 
around virus-infected cells.49
Despite the expansions of CD8+ and CD4+ Tem in children infected with CMV and/or EBV, 
these did not result in decreased naive or Tcm cell numbers. In fact, infected children had 
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significantly more total CD8+ T cells. Especially in immunosuppressed individuals, but also 
in CMV-infected elderly persons, effector memory T-cell expansions with a subsequent 
loss of naive T cells and loss of vaccination responses have been described as hallmarks 
of CMV-associated immunosenescence.9,17,24,25 However, fimdings in the literature are 
inconsistent,32-35 and the loss of vaccination responsiveness in children is not consistently 
observed.19 In our cohort, IgG titers to previous measles and tetanus vaccinations were 
similar in uninfected and infected children. Combined, our data suggest that 6-year-old 
CMV- and/or EBV-infected children do not lose their immune responsiveness owing to 
virus-related effects. 
An important explanation for the discrepancy in the literature on the loss of naive T cells 
could be differences in analysis strategies. In fact, owing to the Tem cell expansions, the 
relative proportions of naive and Tcm were decreased in infected children in our study. 
Moreover, the expansion of total CD8+ T-cell numbers cause a shift in the ratio of CD4 to 
CD8 T-cells. These relative shifts, however, are the results of data analysis, rather than real 
defects, because the absolute naive CD8+ and total CD4+ T-cell numbers were normal. This 
is why we have long advocated for consistent analysis of absolute cell numbers with age-
matched controls.50
Although 90% of elderly persons are infected with CMV and EBV, only a minority of them 
shows loss of naive T-cell numbers, impaired vaccination responses and clinical complica-
tions. The reason for this is still unclear. Our findings in children at age 6 years indicate 
that early infection before age 2 years results in smaller Tem expansions than infection 
between 2 and 6 years. Because the size of the expanded virus-specific Tem pool has been 
directly correlated with the extent of CMV-induced endothelial damage, the children who 
were infected before 2 years might have a reduced risk of cardiovascular complications.31 
CMV-related clinical complications might occur only in individuals infected later in life, who 
show the strongest CMV-associated T-cell expansions. An important factor influencing the 
variability in the response might be the infectious dose.36 It would therefore be interesting 
to correlate the age at infection and the subsequent size of the Tem-cell expansions with 
the infectious dose and the development of clinical complications in children and adults, 
in a separate cohort or in longitudinal follow-up of the uninfected children in our cohort. 
In conclusion, we here provide evidence that in young children, CMV and EBV infections 
lead to sizeable Tem expansions but not to the associated immunosenescence. In fact, the 
Tem expansion result in increased total T-cell numbers, whereas naive and Tcm remain 
normally present, as do responses to previous vaccinations. Moreover, in 6-year old chil-
dren infected before age 2 years, stable control of these persistent viruses was maintained 
with only limited Tem expansions. These new insights into the immunomodulatory effects 
of herpesviruses in young children are important in our understanding of herpesvirus-
associated immunosenescence in the elderly.
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Supplemental Table 1. Antibody details
Antibody clone manufacturer
CD45-PerCP 2D1 BD Biosciences
CD3-FITC SK7 BD Biosciences
CD3-PerCP SK7 BD Biosciences
CD4-PE-Cy7 SK3 BD Biosciences
CD8-APC-H7 SK1 BD Biosciences
CD8-PE-Cy7 SK1 BD Biosciences
CD45RO-APC UCHL-1 BD Biosciences
CD28-FITC CD28.2 BD Biosciences
CD27-APC-H7 M-T271 BD Biosciences
CD197(CCR7)-PE 3D13 e-Bioscience
Supplemental Table 2. CMV- and EBV- IgG seropositivities in the total and selected cohorts 
Total cohort n(%) Selected cohort n(%)
Uninfected 399 (37.0) 90 (40.0)
CMV+ 172 (15.9) 41 (18.2)
EBV+ 289 (26.8) 52 (23.1)
CMV+EBV+ 219 (20.3) 42 (18.7)
total 1079 225
No significant differences were observed in IgG seropositivity between the two cohorts using the Chi-square test.
Supplemental Table 3. HSV-1 or VZV co-infection in relation to CMV- and EBV-carriership.
  n %
HSV+ 
n(% of group)
VZV+
n(% of group)
HSV+VZV+
n(% of group)
Uninfected 90 40.0 9 (10%)refa 83 (92.2%)refa 8 (8.9%)refa
CMV+ 41 18.2 5 (12.2%) 41 (100%) 5 (12.2%)
EBV+ 52 23.1 10 (19.2%) 48 (92.3%) 9 (17.3%)
CMV+EBV+ 42 18.7 6 (14.3%) 39 (92.9%) 6 (14.3%)
total 225 100.0 30 (13.3%) 211 (93.8%) 28 (12.4%)
a No significant differences were observed of co-infection in the CMV infected, EBV infected or CMV+EBV+ coinfected 
groups relative to the CMV-EBV- 
uninfected controls using the Chi-square test.
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Supplemental Figure 1. CD4+ T cell subset analyses 
A, Gating strategy for delineating T-cell subsets. Total CD3+ T cells were subdivided into CD8+ (blue) and CD8- (CD4+) (green) T cells. Both CD4+ and CD8+ T 
cells were further subdivided into CCR7+CD45RO- Naive, CCR7+CD45RO+ central memory (TCM), CCR7-CD45RO+ effector memory (TEMRO) and CCR7-
CD45RO- effector memory (TEMRA) cells.41 TEMRO and TEMRA subsets were further subdivided into CD27+CD28+ early, CD27+CD28- (CD8+) or CD27-CD28+ 
(CD4+) intermediate and CD27-CD28- late populations.22 B, Absolute numbers of total CD4+ T-cells and CD4+ T-cell subsets in children uninfected with 
CMV or EBV (uninf), infected with only CMV (CMV), only EBV (EBV) or both CMV and EBV (CMV EBV). Bars depict stacked median values per T-cell 
population. The number of individuals per category is indicated underneath each plot. C, Absolute numbers of CD8+ TEMRO (left) and TEMRA (right) cell 
subsets in 6-year-old children who were either CMV-EBV-, became CMV+EBV+ before the age of 2 years (early) or CMV+EBV+ between 2 and 6 years of 
age (late). Plots depict 10-90% box-whisker plots. B,C, Significance was tested first with a Kruskal-Wallis test per lymphocyte population, if results were 
significant (P<0.05) Dunn tests of individual patient groups were performed. Significance for Dunn tests is indicated in the plots: *P<0.05; ** P <0.01; *** 
P <0.001. D, Longitudinal follow-up of frequencies of CD8- (CD4+) TEMRO (left) and TEMRA (right) subsets at the age of 2 and 6 years in 9 early infected 
children. Significance between 2 and 6 years was tested with paired T-tests: *P<0.05.  
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ABSTRACT 
Persistent infections with cytomegalovirus (CMV) differentially affect the host immune 
phenotype in middle-aged males and females. As CMV already impacts on T-cell memory 
at a young age, we here studied whether these effects were modified by sex in 1,079 chil-
dren with an average age of 6-years. Sex and CMV independently impacted on multiple 
B-cell and T-cell subsets. However, there was no significant effect of their interaction. 
Importantly, the effects of sex and CMV were in part explained by age and infection with 
other herpesviruses. Thus, immune aging is likely to be more complex, with involvement 
of hormonal changes with age, socioeconomic status, birth characteristics, and pathogen 
exposure
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INTRODuCTION
Cytomegalovirus (CMV) is a β-herpesvirus that persists following primary infection, and is 
actively suppressed by the host’s immune system.1 Primary infections are usually mild, 
but complications can arise for the fetus in pregnant women or as a result of viral reac-
tivation in immunocompromised individuals.2 Furthermore, CMV infection is associated 
with impaired immune responses and increased mortality in elderly persons,3 a process 
referred to as immunosenescence.4 These effects were initially ascribed to CMV-associated 
expansions of effector memory T (Tem) cells within the CD4 and CD8 lineages5,6 and the 
resulting relative decline in naive T (Tn) cells.7 However, absolute naive T-cell numbers are 
normal in most CMV+ individuals,8 CMV-specific effector Tem cells do not accumulate in 
lymph nodes,9 and CMV-positive elderly can mount responses to influenza vaccination [10]. 
Moreover, CMV-driven T-cell expansions are already present in young children and are not 
associated with age of infection, decreased naive Tn-cell numbers or impaired protective 
immune responses.11 Thus, the effects of CMV on early immunosenescence are still incon-
clusive and are likely impacted on by other determinants. 
We recently identified differential effects of CMV carriage on the immune phenotype in 
pre-elderly males and females.12 Middle-aged, CMV-infected males had lower numbers of 
Tn and central memory T (Tcm) cells within the CD4 and CD8 lineages, as well as lower fol-
licular helper T (Tfh) cells, regulatory T cells, and memory B-cells than CMV-infected female 
subjects.12 However, it remains unclear if the observed sex-specific differences are related 
to older age and whether these are impacted on by confounding factors. 
Therefore, we here analyzed the combined effects of CMV infection and sex in our previ-
ously published cohort of 1,079 children with an average age of 6 years from the Genera-
tion R Study.11 All effects on B- and T-cell subsets were adjusted for socioeconomic factors, 
ethnicity, breastfeeding and co-infection with Epstein-Barr virus (EBV) and herpes simplex 
virus type 1 (HSV-1).
METhODS
Study subjects
This study was conducted in the context of the Generation R Study, a prospective popula-
tion-based cohort study from fetal life until young adulthood.13 We included 1,079 children 
(mean = 6.1 y; range = 5.0-7.9 y) from whom CMV Immunoglobulin G (IgG) serology and 
detailed immunophenotyping of blood B- and T-cells was performed.11 Data on sex, gesta-
tional age, birth weight, parity and mode of delivery were obtained from obstetric records 
from hospitals and mid-wife practices. Age-adjusted standard deviation scores (SDSs) for 
weight and body mass index (BMI) were obtained by using Dutch reference growth curves 
(Growth Analyzer 3.0; Dutch Growth Research Foundation, Rotterdam, Netherlands), and 
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data on sociodemographic and lifestyle factors from prenatal and postnatal questionnaires 
completed by both parents, as described before.14 Written informed consent was obtained 
from all parents of participating children. Ethical approval for the study was obtained from 
the Medical Ethical Committee of the Erasmus MC.
herpesvirus serology
Blood plasma samples were subjected to enzyme-linked immunoassays for IgG antibodies 
against CMV, EBV (viral capsid antigen [VCA]) and HSV-1 (EUROIMMUN, Lübeck, Germany).11 
Immunophenotyping
Absolute numbers of CD3+ T cells and CD19+ B cells were obtained with a routine diagnos-
tic lyse-no-wash protocol. Detailed analysis of B- and T-cell subsets was performed with 
6-color flowcytometry.15 
Statistical analyses
Leukocyte subset numbers were natural log-transformed to normalize the data. To test 
whether maternal and child characteristics were different between the 4 groups, chi-
square tests, independent t tests and non-parametric Mann-Whitney U tests were applied. 
Independent associations of CMV seropositivity with each leukocyte subset number were 
examined using multivariable linear regression model, wherein the P value indicates sig-
nificance for association with the natural log-transformed absolute numbers of immune 
cells. The ratio (antilog of β coefficient) indicates the strength of the association; the higher 
the value of β, the larger the difference in mean between either female vs male, CMV+ vs 
CMV-, male CMV+ vs male CMV-, or female CMV+ vs female CMV-. A positive value indicates 
a higher number of cells, and a negative value a lower number. Effect modification by sex 
was evaluated by adding the interaction term (ie, product term of the independent vari-
able (CMV) and subgroup [sex]; CMVxsex, as covariate in the model. The interaction term 
compares the logs of the 2 ratios, and reflects whether CMV-induced immune responses 
are differentially affected by sex. The age-adjusted model included only CMV status (0=se-
ronegative, 1=seropositive), sex (0=male, 1=female), age (years) and the interaction term 
CMVxsex. Because of previously identified significant effects,11,14 the model was additionally 
adjusted for ethnic background (Western vs non-Western), EBV seropositivity, HSV-1 sero-
positivity, breastfeeding at 6 months (yes/no), daycare in first year of life (yes/no), maternal 
educational level (low/high), and antibiotic use in first year of life (yes/no). The results 
were reported as β, ratios (antilog of β) and 95% confidence intervals (CIs); P≤0.05 were 
considered statistically significant. Additional adjustment for multiple comparisons in the 
regression analyses (n=27 tests) was performed by the Bonferroni method; only values with 
P<0.0019 (p=0.05/27) were considered significant. Statistical analyses were performed in 
SPSS 24.0 for Windows. 
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RESuLTS AND DISCuSSION
Characteristics of study participants
A total of 1,079 children with mean age 6.1 years (range 5.0-7.9 years) participated in the 
study. Of these, 553 were boys (51.3%), and 391 (36.2%) were IgG+ for CMV (Supplemental 
Table 1).11 Median age and mean BMI were similar between boys and girls, as well as be-
tween CMV+ and CMV- children. However, CMV+ children were more often of non-Western 
origin, were more frequently coinfected with EBV and HSV-1, were breastfed longer, went 
to daycare more often, more frequently needed antibiotics during their first year of life, and 
their mothers were lower educated than CMV- children (Supplemental Table 1).14 
Effects of sex on circulating leukocyte subsets 
Numbers of multiple B- and T-cell subsets were significantly different between girls and 
boys. The largest effect of sex was observed for CD27- memory B cells: girls had 1.16-fold 
(95% CI 1.07-1.26) more CD27- memory B cells than boys, followed by 1.12-fold (95% CI 
1.02-1.24) more CD8 Tem cells expressing CD45RO+ (TemRO) cells. Additionally, girls had 
1.11-fold (95% CI 1.04-1.19) more CD4 Tn cells, 1.09-fold (95% CI 1.02-1.17) more CD4 Tcm 
cells, 1.08-fold (95% CI 1.02-1.13) more CD4 T cells, and 1.06-fold (95% CI 1.00-1.11) more 
total T cells. The smallest effect of sex was observed for total lymphocyte numbers: girls 
had 1.05-fold (95% CI 1.00-1.11) more total lymphocyte numbers than boys (Table 2, fully 
adjusted model 2). Similar differences have been reported for pre-elderly persons, although 
middle-aged males lack expansions of memory T cells, and have additional decreases in 
CD8 Tn cells and all CD4 T-cell subsets 12.
Effects of Cytomegalovirus status on circulating leukocyte subsets
We previously reported expansions of Tem cells in the CD8 and CD4 lineages (all P<0.001) in 
CMV+ children using unadjusted comparisons [11]. Following adjustment, we here observed 
the largest effects of CMV for the CD8 Tem CD45RO- (TemRA) late and CD8 TemRO late cells: 
CMV+ children had 4.04-fold (95% CI 3.47-4.71) and 2.83-fold (95% CI 2.40-3.35) more CD8 
TemRA late and CD8 TemRO late cell numbers, respectively, than CMV- children, followed 
by 1.84-fold (95% CI 1.58-2.14) more CD4 TemRA late cells, and 1.77-fold (95% CI 1.51-2.08) 
more CD4 TemRO late cells (Table 2, model 2). In addition, CD27- memory B cells were 
increased in CMV+ children (ratio of 1.14; 95% CI 1.04-1.23) (Table 2). 
Effects of Cytomegalovirus status on circulating leukocyte subsets in boys and girls
To determine whether CMV infection was associated with differential effects on the immune 
phenotype between males and females, the study cohort was divided into 4 groups: CMV− 
boys, CMV+ boys, CMV− girls, and CMV+ girls (Table 1). In both girls and boys, CMV positivity 
was associated with significantly increased numbers of γδT cells, CD8 T lymphocytes, and 
CD4 and CD8 Tem cell populations, and a significantly lower CD4/CD8 ratio. 
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Table 1. Absolute numbers of leukocyte subsets in blood of boys and girls with and without Cytomegalo-
virus
n=1079 Male CMV-
n=348
Male CMV+
n=205
Ratio #
(95% CI)
Female CMV-
n=340
Female CMV+
 n=186
Ratio ¶
(95% CI)
β Interaction
(95% CI)
age adjusted
P value, 
model 1
P value, 
model 2
Leukocyte subsets, cells/µl blood
granulocyte 3545 (3372 – 3728) 3396 (3194 – 3611) 0.96 (0.88;1.04) 3769 (3567 – 3983) 3663 (3410 - 3935) 0.97 (0.87;1.07) 1.02 (0.91;1.17) 0.67 0.53
monocyte 648 (623 – 674) 601 (572 – 631) 0.93 (0.87;0.99)* 647 (621 – 675) 611 (583 - 640) 0.94 (0.88;1.01) 1.03 (0.94;1.13) 0.51 0.15
lymphocyte 2924 (2836 – 3016) 3033 (2907 – 3163) 1.04 (0.99;1.09) 3027 (2934 – 3123) 3185 (3068 - 3306) 1.05 (1.00;1.11) 1.02 (0.94;1.10) 0.66 0.98
NK cell 176 (168 - 185) 210 (196 - 225) 1.19 (1.10;1.29)*** 191 (183 - 200) 204 (191 - 218) 1.07 (0.99;1.16)
T cell 2037 (1971 – 2105) 2111 (2021 – 2204) 1.04 (0.98;1.09) 2122 (2052 – 2195) 2264 (2174 - 2358) 1.07 (1.01;1.13)* 1.03 (0.95;1.11) 0.52 0.88
 γδ T cell 182 (173 – 191) 199 (185 – 213) 1.09 (1.01;1.19)* 171 (163 – 180) 191 (180 - 204 1.12 (1.03;1.21)** 1.01 (0.90;1.14) 0.81 0.86
 CD4 T cell 1353 (1309 – 1399) 1347 (1289 – 1409) 1.00 (0.94;1.05) 1449 (1400 – 1500) 1478 (1416 - 1543) 1.02 (0.96;1.08) 1.02 (0.94;1.11) 0.69 0.98
 CD8 T cell 667 (640 – 694) 745 (708 – 784) 1.12 (1.05;1.19)*** 658 (632 – 684) 780 (745 - 818) 1.19 (1.11;1.26)*** 1.05 (0.95;1.15) 0.32 0.63
 CD4/CD8 ratio 2.03 (1.97 – 2.09) 1.81 (1.74 – 1.88) 0.89 (0.85;0.94)*** 2.20 (2.14 – 2.27) 1.89 (1.82 - 1.97) 0.86 (0.45;2.27)*** 0.97 (0.90;1.04) 0.39 0.54
 CD4 T naive 766 (731 – 802) 716 (673 – 762) 0.94 (0.87;0.99) 851 (813 – 891) 817 (768 - 870) 0.96 (0.89;1.04) 1.01 (0.90;1.13) 0.83 0.71
 CD4 Tcm 143 (137 – 150) 140 (132 – 149) 0.98 (0.91;1.06) 155 (148 – 162) 157 (147 - 167) 1.01(0.94;1.09) 1.02 (0.91;1.14) 0.72 0.92
 CD4 TemRO 216 (207 – 225) 251 (237 – 265) 1.16 (1.08;1.25)*** 226 (217 – 235) 257 (242 - 272) 1.14 (1.06;1.22) 0.97 (0.88;1.07) 0.54 0.43
 CD4 TemRO late 5.65 (5.11 – 6.26) 9.83 (8.69 – 11.1) 1.74 (1.48;2.04)*** 5.20 (4.69 – 5.76) 10.17 (8.95 - 11.55) 1.96 (1.66;2.31)*** 1.13 (0.89;1.43) 0.32 0.46
 CD4 TemRA 147 (138 – 156) 164 (152 - 177) 1.12 (1.01;1.23)* 143 (134 – 153) 156 (143 – 171) 1.09 (0.98;1.22) 0.99 (0.85;1.15) 0.90 0.81
 CD4 TemRA late 7.91 (7.20 – 8.70) 14.57 (12.74-16.67) 1.84 (1.57;2.16)*** 6.92 (6.28 – 7.62) 12.70 (11.39-14.17) 1.84 (1.57;2.14)*** 1.03 (0.82;1.29) 0.80 0.64
 CD8 T naive 378 (359-398) 357 (333-382) 0.94 (0.87;1.03) 373 (355-392.) 368 (347-391) 0.99 (0.91;1.07) 1.02 (0.90;1.15) 0.75 0.88
 CD8 Tcm cells 14.5 (13.6-15.6) 14.0 (12.8-15.3) 0.97 (0.86; 1.08) 14.7 (13.7-15.7) 15.1 (13.6-16.7) 1.03 (0.91;1.15) 1.06 (0.90;1.26) 0.49 0.90
 CD8 TemRO 98.2 (92.3-104.5) 129.4 (118.8-141.0) 1.32 (1.19;1.46)*** 105.0 (98.7-111.7) 144.2 (131.2-158.5) 1.37 (1.23;1.53)*** 1.01 (0.87;1.18) 0.90 0.43
 CD8 TemRO late 9.70 (8.79-10.70) 28.73 (25.19-32.78) 2.96 (2.52;3.49)*** 9.38 (8.47-10.38) 30.71 (26.79-35.20) 3.27 (2.76;3.88)*** 1.06 (0.83;1.35) 0.63 0.54
 CD8 TemRA 114 (108-121) 168.8 (156.0-182.7) 1.48 (1.34;1.63)*** 105.7 (99.0-112.9) 172.8 (158.3-188.6) 1.63 (1.46;1.82)*** 1.10 (0.95;1.28) 0.21 0.28
 CD8 TemRA late 17.8 (16.3-19.6) 66.9 (59.4-75.3) 3.75 (3.23;4.35)*** 14.47 (13.16-15.91) 58.20 (50.81-66.67) 4.02 (3.42;4.73)*** 1.08 (0.86;1.35) 0.51 0.71
B cell 601 (577-626) 597 (564-633) 0.99 (0.93;1.07) 613 (588-639) 622 (594-651) 1.01 (0.94;1.08) 1.02 (0.93;1.13) 0.64 0.82
 transitional 60.5 (56.9-64.3) 61.7 (57.6-66.2) 1.02 (0.93;1.12) 58.8 (55.2-62.7) 59.9 (55.8-64.4) 1.02 (0.92;1.13) 0.98 (0.85;1.13) 0.80 0.66
 naive mature 390.6 (370.8-411.4) 388.0 (364.0-413.6) 0.99 (0.91;1.08) 400.4 (382.3-419.3) 405.4 (384.9-426.9) 1.01 (0.94;1.09) 1.02 (0.91;1.14) 0.73 0.93
 natural effector 18.9 (17.6-20.3) 18.7 (17.0-20.4) 0.99 (0.88;1.11) 19.8 (18.5-21.1) 19.1 (17.6-20.7) 0.96 (0.87;1.07) 0.99 (0.84;1.16) 0.87 0.71
 CD27- memory 44.6 (42.2-47.1) 49.3 (45.7-53.1) 1.11 (1.01;1.21)* 50.3 (47.9-52.8) 54.4 (50.7-58.3) 1.08 (0.99; 1.17) 0.98 (0.87;1.12) 0.80 0.45
 CD27+ memory 23.5 (22.0-25.0) 25.1 (23.0-27.5) 1.07 (0.96;1.19) 25.2 (23.8-26.8) 26.2 (24.0-28.6) 1.04 (0.94; 1.15) 0.97 (0.83;1.13) 0.68 0.35
The interaction term compares the logs of the 2 ratios, and reflects whether cytomegalovirus (CMV)-induced im-
mune responses are differentially affected by sex. The P values indicate whether the interaction effect of sex is sig-
nificant for model 1 and model 2. Model 1 includes the predicting variables sex, CMV and age. Model 2 additionally 
includes the variables: ethnicity, EBV and HSV-1 serostatus, breastfeeding at 6 months, daycare attendance, mater-
nal educational level and antibiotic use in the first year of life.
Values represent geometric mean cells per microliter of blood [95% CI]. Differences in geometric means between 
the groups were calculated by unadjusted linear regression analysis.Bolding indicates significant differences (P < 
0.05). Abbreviations: CI, confidence interval; Tcm, central memory T cells; TemRO, CD45RO+ effector memory T cells; 
TemRA, CD45RO- effector memory T cells. 
#Ratio of geometric means (95% CI) comparing CMV+ and CMV- males; ¶ Ratio of geometric means (95% CI) compar-
ing CMV+ and CMV- females. *p<0.05 **p<0.01 ***p<0.001. 
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Table 1. Absolute numbers of leukocyte subsets in blood of boys and girls with and without Cytomegalo-
virus
n=1079 Male CMV-
n=348
Male CMV+
n=205
Ratio #
(95% CI)
Female CMV-
n=340
Female CMV+
 n=186
Ratio ¶
(95% CI)
β Interaction
(95% CI)
age adjusted
P value, 
model 1
P value, 
model 2
Leukocyte subsets, cells/µl blood
granulocyte 3545 (3372 – 3728) 3396 (3194 – 3611) 0.96 (0.88;1.04) 3769 (3567 – 3983) 3663 (3410 - 3935) 0.97 (0.87;1.07) 1.02 (0.91;1.17) 0.67 0.53
monocyte 648 (623 – 674) 601 (572 – 631) 0.93 (0.87;0.99)* 647 (621 – 675) 611 (583 - 640) 0.94 (0.88;1.01) 1.03 (0.94;1.13) 0.51 0.15
lymphocyte 2924 (2836 – 3016) 3033 (2907 – 3163) 1.04 (0.99;1.09) 3027 (2934 – 3123) 3185 (3068 - 3306) 1.05 (1.00;1.11) 1.02 (0.94;1.10) 0.66 0.98
NK cell 176 (168 - 185) 210 (196 - 225) 1.19 (1.10;1.29)*** 191 (183 - 200) 204 (191 - 218) 1.07 (0.99;1.16)
T cell 2037 (1971 – 2105) 2111 (2021 – 2204) 1.04 (0.98;1.09) 2122 (2052 – 2195) 2264 (2174 - 2358) 1.07 (1.01;1.13)* 1.03 (0.95;1.11) 0.52 0.88
 γδ T cell 182 (173 – 191) 199 (185 – 213) 1.09 (1.01;1.19)* 171 (163 – 180) 191 (180 - 204 1.12 (1.03;1.21)** 1.01 (0.90;1.14) 0.81 0.86
 CD4 T cell 1353 (1309 – 1399) 1347 (1289 – 1409) 1.00 (0.94;1.05) 1449 (1400 – 1500) 1478 (1416 - 1543) 1.02 (0.96;1.08) 1.02 (0.94;1.11) 0.69 0.98
 CD8 T cell 667 (640 – 694) 745 (708 – 784) 1.12 (1.05;1.19)*** 658 (632 – 684) 780 (745 - 818) 1.19 (1.11;1.26)*** 1.05 (0.95;1.15) 0.32 0.63
 CD4/CD8 ratio 2.03 (1.97 – 2.09) 1.81 (1.74 – 1.88) 0.89 (0.85;0.94)*** 2.20 (2.14 – 2.27) 1.89 (1.82 - 1.97) 0.86 (0.45;2.27)*** 0.97 (0.90;1.04) 0.39 0.54
 CD4 T naive 766 (731 – 802) 716 (673 – 762) 0.94 (0.87;0.99) 851 (813 – 891) 817 (768 - 870) 0.96 (0.89;1.04) 1.01 (0.90;1.13) 0.83 0.71
 CD4 Tcm 143 (137 – 150) 140 (132 – 149) 0.98 (0.91;1.06) 155 (148 – 162) 157 (147 - 167) 1.01(0.94;1.09) 1.02 (0.91;1.14) 0.72 0.92
 CD4 TemRO 216 (207 – 225) 251 (237 – 265) 1.16 (1.08;1.25)*** 226 (217 – 235) 257 (242 - 272) 1.14 (1.06;1.22) 0.97 (0.88;1.07) 0.54 0.43
 CD4 TemRO late 5.65 (5.11 – 6.26) 9.83 (8.69 – 11.1) 1.74 (1.48;2.04)*** 5.20 (4.69 – 5.76) 10.17 (8.95 - 11.55) 1.96 (1.66;2.31)*** 1.13 (0.89;1.43) 0.32 0.46
 CD4 TemRA 147 (138 – 156) 164 (152 - 177) 1.12 (1.01;1.23)* 143 (134 – 153) 156 (143 – 171) 1.09 (0.98;1.22) 0.99 (0.85;1.15) 0.90 0.81
 CD4 TemRA late 7.91 (7.20 – 8.70) 14.57 (12.74-16.67) 1.84 (1.57;2.16)*** 6.92 (6.28 – 7.62) 12.70 (11.39-14.17) 1.84 (1.57;2.14)*** 1.03 (0.82;1.29) 0.80 0.64
 CD8 T naive 378 (359-398) 357 (333-382) 0.94 (0.87;1.03) 373 (355-392.) 368 (347-391) 0.99 (0.91;1.07) 1.02 (0.90;1.15) 0.75 0.88
 CD8 Tcm cells 14.5 (13.6-15.6) 14.0 (12.8-15.3) 0.97 (0.86; 1.08) 14.7 (13.7-15.7) 15.1 (13.6-16.7) 1.03 (0.91;1.15) 1.06 (0.90;1.26) 0.49 0.90
 CD8 TemRO 98.2 (92.3-104.5) 129.4 (118.8-141.0) 1.32 (1.19;1.46)*** 105.0 (98.7-111.7) 144.2 (131.2-158.5) 1.37 (1.23;1.53)*** 1.01 (0.87;1.18) 0.90 0.43
 CD8 TemRO late 9.70 (8.79-10.70) 28.73 (25.19-32.78) 2.96 (2.52;3.49)*** 9.38 (8.47-10.38) 30.71 (26.79-35.20) 3.27 (2.76;3.88)*** 1.06 (0.83;1.35) 0.63 0.54
 CD8 TemRA 114 (108-121) 168.8 (156.0-182.7) 1.48 (1.34;1.63)*** 105.7 (99.0-112.9) 172.8 (158.3-188.6) 1.63 (1.46;1.82)*** 1.10 (0.95;1.28) 0.21 0.28
 CD8 TemRA late 17.8 (16.3-19.6) 66.9 (59.4-75.3) 3.75 (3.23;4.35)*** 14.47 (13.16-15.91) 58.20 (50.81-66.67) 4.02 (3.42;4.73)*** 1.08 (0.86;1.35) 0.51 0.71
B cell 601 (577-626) 597 (564-633) 0.99 (0.93;1.07) 613 (588-639) 622 (594-651) 1.01 (0.94;1.08) 1.02 (0.93;1.13) 0.64 0.82
 transitional 60.5 (56.9-64.3) 61.7 (57.6-66.2) 1.02 (0.93;1.12) 58.8 (55.2-62.7) 59.9 (55.8-64.4) 1.02 (0.92;1.13) 0.98 (0.85;1.13) 0.80 0.66
 naive mature 390.6 (370.8-411.4) 388.0 (364.0-413.6) 0.99 (0.91;1.08) 400.4 (382.3-419.3) 405.4 (384.9-426.9) 1.01 (0.94;1.09) 1.02 (0.91;1.14) 0.73 0.93
 natural effector 18.9 (17.6-20.3) 18.7 (17.0-20.4) 0.99 (0.88;1.11) 19.8 (18.5-21.1) 19.1 (17.6-20.7) 0.96 (0.87;1.07) 0.99 (0.84;1.16) 0.87 0.71
 CD27- memory 44.6 (42.2-47.1) 49.3 (45.7-53.1) 1.11 (1.01;1.21)* 50.3 (47.9-52.8) 54.4 (50.7-58.3) 1.08 (0.99; 1.17) 0.98 (0.87;1.12) 0.80 0.45
 CD27+ memory 23.5 (22.0-25.0) 25.1 (23.0-27.5) 1.07 (0.96;1.19) 25.2 (23.8-26.8) 26.2 (24.0-28.6) 1.04 (0.94; 1.15) 0.97 (0.83;1.13) 0.68 0.35
The interaction term compares the logs of the 2 ratios, and reflects whether cytomegalovirus (CMV)-induced im-
mune responses are differentially affected by sex. The P values indicate whether the interaction effect of sex is sig-
nificant for model 1 and model 2. Model 1 includes the predicting variables sex, CMV and age. Model 2 additionally 
includes the variables: ethnicity, EBV and HSV-1 serostatus, breastfeeding at 6 months, daycare attendance, mater-
nal educational level and antibiotic use in the first year of life.
Values represent geometric mean cells per microliter of blood [95% CI]. Differences in geometric means between 
the groups were calculated by unadjusted linear regression analysis.Bolding indicates significant differences (P < 
0.05). Abbreviations: CI, confidence interval; Tcm, central memory T cells; TemRO, CD45RO+ effector memory T cells; 
TemRA, CD45RO- effector memory T cells. 
#Ratio of geometric means (95% CI) comparing CMV+ and CMV- males; ¶ Ratio of geometric means (95% CI) compar-
ing CMV+ and CMV- females. *p<0.05 **p<0.01 ***p<0.001. 
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Table 2. Linear regression analysis for the absolute cell numbers per leukocyte subset
Cell subset Predicting 
variable 
Ratio (95% CI)
Age adjusted 
model1
p-value1 Ratio (95% CI)
Fully adjusted 
model2
P value2
lymphocyte CMV status
sex
1.05 (1.01; 1.09)
1.04 (1.01; 1.08)
0.007
0.02
1.06 (1.01; 1.11)
1.05 (1.00; 1.11)
0.02
0.03
T cell CMV status
sex
1.06 (1.02; 1.11)
1.06 (1.01; 1.10)
0.003
0.006
1.07 (1.01; 1.12)
1.06 (1.00; 1.11)
0.014
0.033
CD4 T cell CMV status
sex 
1.02 (0.97; 1.06)
1.08 (1.04; 1.12)
0.47
0.00
1.02 (0.96; 1.07)
1.08 (1.02; 1.13)
0.56
0.004
CD4 Tnaive CMV status
sex
0.96 (0.91; 1.02)
1.12 (1.06; 1.18)
0.17
0.000
0.99 (0.92; 1.06)
1.11 (1.04; 1.19)
0.67
0.003
CD4 Tcm CMV status
sex
1.01 (0.95; 1.06)
1.10 (1.04; 1.16)
0.85
0.00
1.02 (0.96; 1.11)
1.09 (1.02; 1.17)
0.34
0.009
CD4 TemRO CMV status
sex
1.13 (1.08; 1.19)
1.04 (0.99; 1.09)
0.00
0.11
1.09 (1.03; 1.17)
1.03 (0.96; 1.10)
0.007
0.39
CD4 TemRO late CMV status
sex
1.82 (1.62; 2.05)
0.96 (0.86; 1.08)
0.00
0.49
1.77 (1.51; 2.08)
0.98 (0.84; 1.15)
0.00
0.79
CD4 TemRA CMV status
sex
1.10 (1.03; 1.19)
0.96 (0.89; 1.03)
0.009
0.23
1.07 (0.97; 1.18)
0.96 (0.87; 1.05)
0.16
0.36
CD4 TemRA late CMV status
sex
1.82 (1.63; 2.03)
0.87 (0.78; 0.97)
0.00
0.01
1.84 (1.58; 2.14)
0.94 (0.81; 1.09)
0.00
0.38
CD8 T cell CMV status
sex
1.16 (1.11; 1.22)
1.01 (0.97; 1.06)
0.00
0.62
1.18 (1.11; 1.25)
1.02 (0.95; 1.08)
0.00
0.64
CD8 Tnaive CMV status
sex
0.98 (0.93; 1.04)
1.00 (0.95; 1.06)
0.59
0.90
1.03 (0.95; 1.11)
0.99 (0.92; 1.07)
0.50
0.84
CD8 Tcm CMV status
sex
1.01 (0.93; 1.10)
1.03 (0.95; 1.12)
0.85
0.45
1.06 (0.95; 1.19)
1.05 (0.93; 1.17)
0.30
0.44
CD8 TemRO CMV status
sex
1.33 (1.23; 1.43)
1.10 (1.02; 1.18)
0.00
0.01
1.28 (1.15; 1.41)
1.12 (1.02; 1.24)
0.00
0.02
CD8 TemRO late CMV status
sex 
3.05 (2.70; 3.44)
1.01 (0.90; 1.14)
0.00
0.82
2.83 (2.40; 3.35)
1.05 (0.89; 1.23)
0.00
0.56
CD8 TemRA CMV status 
sex
1.55 (1.44; 1.67)
0.97 (0.90; 1.04)
0.00
0.34
1.52 (1.37; 1.69)
0.98 (0.88; 1.09)
0.00
0.69
CD8 TemRA late CMV status
sex
3.88 (3.47; 4.33)
0.84 (0.76; 0.94)
0.00
0.001
4.04 (3.47; 4.71)
0.84 (0.73; 0.98)
0.00
0.03
B cell CMV status
sex
1.01 (0.96; 1.06)
1.03 (0.98; 1.08)
0.71
0.19
1.02 (0.95; 1.09)
1.07 (1.00; 1.14)
0.60
0.04
transitional CMV status
sex
1.02 (0.94; 1.09)
0.98 (0.92; 1.05)
0.65
0.58
1.01 (0.92; 1.12)
1.02 (0.92; 1.12)
0.80
0.75
naive mature CMV status
sex
1.01 (0.95; 1.07)
1.04 (0.98; 1.10)
0.78
0.20
1.00 (0.93; 1.08)
1.08 (1.00; 1.15)
0.92
0.04
natural effector CMV status
sex
0.97 (0.90; 1.05)
1.04 (0.96; 1.12)
0.46
0.30
1.00 (0.90; 1.12)
1.06 (0.95; 1.18)
0.94
0.31
CD27- memory CMV status
sex
1.09 (1.03; 1.17)
1.12 (1.05; 1.19)
0.005
0.00
1.14 (1.04; 1.23)
1.16 (1.07; 1.26)
0.003
0.00
CD27+ memory CMV status
sex
1.05 (0.98; 1.14)
1.07 (1.00; 1.15)
0.18
0.07
1.11 (1.00; 1.24)
1.10 (0.99; 1.23)
0.05
0.06
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To study whether associations between CMV status and leukocyte subsets were differen-
tially affected by sex, we performed linear regression analyses that included the following 
variables: sex, age, CMV status, and the interaction term CMVx sex (Table 2). In contrast with 
pre-elderly persons [12], sex did not significantly modify the associations between CMV and 
total CD4 T cells (β-interaction=1.02, P=0.69), CD4+ Tcm cells (β-interaction=1.02, P=0.72), 
CD4 TemRO (β-interaction=0.97, P=0.54), and CD8+ Tcm cells (β-interaction=1.06, P=0.49). 
Confounding factors in the association between sex, Cytomegalovirus and 
leukocyte subsets
CMV seropositivity in children is associated with socioeconomic factors, crowding and eth-
nic backgrounds (Supplemental Table 1).14 Because these differences between CMV+ and 
CMV- children can potentially mask the presence of effect modification by sex, multivari-
able linear regression analyses were performed with additional inclusion of the following 
potential confounding factors: ethnicity, breastfeeding, daycare attendance, education 
level of the mother, antibiotics usage, and EBV- and HSV-1 seropositivity (Table 1). Follow-
ing correction for these confounders, the CMVxsex interaction remained nonsignificant for 
total CD4 (P=0.98), CD4 Tcm cells (P=0.92), CD4 TemRO cells (p=0.43) and CD8 Tcm cells 
(P=0.90); Table 1, model 2). Thus, the effects of CMV on the immune phenotypes were not 
sex-specific in both the unadjusted and adjusted models. 
Furthermore, following correction for confounders, the initially observed positive effect 
estimates of CMV seropositivity reduced markedly. Hence, the effect of CMV can be partly 
attributed to the combination of variables included in the multivariable model, especially 
to EBV and HSV-1. Specifically, EBV carriership was an independent predictor for CD8+ 
TemRO and TemRO late cells,11 with ratios of 1.32 (95% CI 1.19-1.46, P<0.001) and 1.49 
(95% CI 1.26-1.75, P<0.001), respectively. In addition, EBV affected the association between 
CMV and B cell populations (esp. CD27- memory B cells), and HSV-1 affected associations 
between CMV and T cells. In contrast, the effect sizes of sex did not materially change after 
inclusion of the potential confounders in the fully adjusted model (Table 2). Notably, after 
inclusion of the confounding variables, girls were found to have 1.08-fold (P=0.04) more 
naive mature B cells than boys (without adjustment 1.04-fold, P=0.20). Thus, to enable 
Linear regression was performed on natural log-transformed data by using the variables cytomegalovirus (CMV) 
status (0=seronegative, 1=seropositive), sex (0=male, 1= female), and Age (years). Because the CMV*sex interaction 
term was not significant in the crude, age-adjusted and fully adjusted model, the interaction-term was omitted. Bold 
text indicates significant differences within 1 subset. Italicized text indicates differences that remained significant 
after multiple testing correction (n=27 tests; p< 0.0019). The ratios (antilog of the β) compare the adjusted geometric 
means between sexes and between CMV+ and CMV- children. The P value indicates the association between the 
predicting variable and the absolute number of immune cells.1 Abbreviations: CI, confidence interval; Tcm, central 
memory T cells; TemRO, CD45RO+ effector memory T cells; TemRA, CD45RO- effector memory T cells; Tn, naieve T 
cells. The age adjusted model includes the predicting variables sex, CMV, and age.2 The fully adjusted model ad-
ditionally includes the variables: ethnicity, EBV and HSV-1 serostatus, breastfeeding duration, daycare attendance, 
maternal educational level, and antibiotic use in the first year.
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delineation of specific determinants such as sex and CMV (and their possibly interaction) 
in relation to immune cells, various confounders, such as other herpesviruses, but also 
breastfeeding and lifestyle characteristics should be taken into account. Arguably, some of 
the effects observed in pre-elderly persons could have been impacted upon by confound-
ing factors such as coinfections. However, as nearly all pre-elderly persons in the study of 
Van der Heiden et al were EBV seropositive, the EBV serostatus is not likely to explain the 
observed sex-specific effects of CMV on CD8 Tcm cells.12
Technical considerations
In our study we were not able to analyze Tfh cells. However, because these are CD45RA-
CCR7+, their definition mostly overlaps with CD4 Tcm cells. Therefore, it is unlikely that in 
young children these numbers are differentially affected by an interaction of sex and CMV.
A major strength of the present study is that we used a multivariable approach to assess 
the relative contributions of CMV seropositivity, age, sex and their possible interactions on 
immune subsets in a large prospective population-based cohort study of healthy children. 
In contrast with the previous study in pre-elderly persons,12 we could adjust in our child-
hood cohort for a broad range of potential confounders, including socioeconomic status, 
ethnicity, breastfeeding, daycare, herpesvirus co-infections, and antibiotic use. These 
analyses limit the possibility of bias introduced by confounding. However, the observed 
associations might still be related to unmeasured variables, such as lifestyle, other viral 
infections and microbial burden. Hence, residual confounding cannot be fully excluded. 
Conclusion
We here found that both CMV carriage and sex affect blood immune cell numbers. However, 
in contrast to pre-elderly persons, there is no combined effect of the two. The potential 
difference between these populations could be age-related and further affected by hor-
mone balances. This would need further analysis in additional study cohorts, especially 
in teenagers and in young adults, with longitudinal follow-up data. This would ensure that 
not only CMV serostatus, but also other important characteristics of socioeconomic status, 
birth and pathogen exposure are taken into account and delineate the main determinants 
of immune aging.
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ABSTRACT
Celiac disease (CeD) is a digestive and autoimmune disorder driven by an immune re-
sponse to modified gluten peptides. Affected intestines show infiltrates of various T-cell 
and NK-cell subsets. It is currently unclear if individuals with subclinical CeD have systemic 
abnormalities in immune cells. We here studied whether subclinical CeD is associated 
with changes in blood CD57-expressing and Vδ1-expressing lymphocytes in children, and 
whether cytomegalovirus (CMV) infection modifies this association. Included were 1,068 
children from the Generation R Study. Serum Immunoglobulin G (IgG) levels against CMV 
were measured by ELISA; Tissue transglutaminase type 2 antibody (TG2A) levels with fluo-
rescence enzyme immunoassay (FEIA). Duodenal biopsies, additional Human Leukocyte 
Antigen (HLA) DQ 2.2, 2.5 and 8 and endomysial antibody (EMA) typing were performed in 
TG2A positive children. Subclinical CeD cases (n=12) had 1.8 fold (95% CI 1.06; 3.1) fewer 
Vδ1+ T cells which was predominantly observed in CMV seronegative children (p-interac-
tion 0.02), and 2.7 fold (95% CI 1.25; 5.99) more CD57+ T cells than HLA DQ2/-DQ8 positive 
controls (n=339). Hence, children with subclinical CeD have alterations in specific blood 
T cell subsets that are linked to viral pathology. The observed interaction effect between 
subclinical CeD and CMV may contribute to the understanding of disease pathogenesis. 
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INTRODuCTION
Celiac disease is a chronic T-cell mediated systemic condition, driven by an immune re-
sponse to modified gluten peptides. The interaction between gluten-specific CD4+ T cells 
and IL-15 in the intestinal epithelium activates CD8+ intraepithelial T lymphocytes (IELs), 
causing a cascade of inflammatory responses leading to small intestinal enteropathy.1, 2 
As modified gluten peptides can only be presented by HLA DQ2.2, HLA DQ2.5 or HLA DQ8 
molecules, carriership of these alleles is a prerequisite for CeD.2, 3 Still, 40% of the general 
population carries one of these alleles, and only a minority develops celiac disease.[3, 4] 
Pathogenesis is therefore considered multifactorial, including a role for environmental 
factors, such as infections.2 
Infiltration of both αβ and γδ T cells into the small intestinal epithelium marks one of 
the earliest stages in celiac disease pathogenesis.5, 6 Although the majority of intestinal 
γδ T cells express a Vδ1 chain, Vδ1+ T cells are relatively rare in blood.5 Still, they possess 
powerful cytotoxic, immune suppressive, tumoricidal and regulatory properties.7-10 The 
majority of previous studies reported expansions of total γδ T and Vδ1+T cells in the gut of 
celiac disease patients.5, 9, 11, 12 Based on a concurrent decrease in blood Vδ1+ T cell num-
bers,5, 13 this is potentially due to recruitment to the intestinal epithelium in response to 
stressed epithelium or to repair tissue damage.9, 14, 15 In patients with latent celiac disease, 
intraepithelial γδ T cells can already be prominent several years before appearance of mu-
cosal atrophy.16 This early recruitment of Vδ1+ T cells from blood to the intestinal mucosa 
potentially occurs even prior to the onset of intestinal inflammation, making blood Vδ1+ 
T-cell numbers a promising marker for subclinical celiac disease. Not all studies reported 
changes in blood cell numbers.5, 11 However, the study of Kutlu et al included a hetero-
geneous study population consisting of both children and adults, with varying degrees 
of mucosal atrophy and differences in gluten intake.11 Decreased blood Vδ1+ T cells have 
been found in adults with celiac disease, but were not affected in children.5 Nonetheless, 
evidence in children is scarce: Only one study reported on these associations in children.5
In contrast to expanded γδ T-cell populations, decreased numbers of NK and NKT 
cells have been observed within IELs of patients with celiac disease.5, 12 NK and NKT cell 
numbers were affected by gluten intake and degree of enteropathy, and were also found 
to be decreased in blood.5, 12 Still, these associations have been found in adults, but not 
in children,5 suggesting that associations may be different between children and adults. 
Chronic stimulation of T cells, as observed in autoimmunity or chronic infection, can result 
in development of CD8+ T cells that are capable of cytokine production, yet incapable 
of cell proliferation.17 CD57 is a marker of such proliferative inability or T cell exhaustion. 
CD57-expressing T- and NK-cell numbers are reported to be increased in cytomegalovirus 
(CMV) carriers, as well as in patients with autoimmune diseases, including type 1 diabetes 
mellitus, rheumatoid arthritis and dermatomyositis.17-19 Moreover, it is thought to predict 
the course of autoimmunity.18-20 However, it is not known whether blood CD57+ expressing 
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lymphocytes are abnormal in celiac disease. Because CD57 is a marker of large granular 
leukemia of T-cell origin, one of the complications of refractory celiac disease,21 it could be 
hypothesized that in subclinical celiac disease, chronic inflammation already drives the 
expansion of these cells. Although CMV can drive expansions of CD57+ T cells, NK cells 
and NKT cells, as well as Vδ1+ T cells,22, 23 it has been inversely related to celiac disease.24, 25 
Thus, it remains unclear if CMV infection confounds or modifies associations between ce-
liac disease and these blood cells. 
We studied blood lymphocytes in children with subclinical celiac disease with the aim to 
identify associations with blood Vδ1+ γδT-cell, CD57+ T-cell and CD57+ NK-cell numbers, 
and to assess whether these associations are modified by CMV seropositivity. 
METhODS
Study design
This study was embedded within the Generation R study, a prospective population based 
cohort study from fetal life until young adulthood, described in detail previously.26 Ethics 
approval was obtained from the Medical Ethical Committee of Erasmus MC, University 
Medical Center Rotterdam, The Netherlands. Written informed consent was obtained from 
all participants. Children were born between April 2002 and January 2006. At the age of 
6 years, 6,690 children visited the research center.26, 27 During this visit, blood samples 
were collected from 4,593 children. Data on Tissue Transglutaminase Type 2 Antibody 
(TG2A) levels and CMV seropositivity was available in 4,442 children. Of these, HLA-DQ2 or 
HLA-DQ8 carriership was measured in 2,915 children (42% carried one of the alleles), and 
detailed immune phenotyping was available in 1,068 children. Combined, from a total of 
352 HLA-DQ2 or HLA-DQ8 positive children, detailed immunophenotyping of leukocytes, 
serum TG2A levels and CMV seropositivity could be determined [Supplemental Figure 1].
Tissue Transglutaminase Type 2 Antibodies, hLA risk alleles and Celiac Disease 
diagnosis
Tissue Transglutaminase type 2 Antibody (TG2A) serum levels (IgA) were measured at 
the median age of 6.0 years using a fluorescence enzyme immunoassay (Elia Celikey IgA, 
Phadia ImmunoCAP 250, Phadia AB, Uppsala, Sweden).27 Sera with a TG2A level of 7 U/
ml or higher were considered to be positive per manufacturer’s instructions. HLA-DQ2 
or HLA-DQ8 carriership in the total cohort was assessed based on DNA from cord blood 
cells, using a tag single nucleotide polymorphism (SNP) approach,28 as described in detail 
previously.29 Of 13 TG2A positive children who carried one of the genetic risk alleles and 
anti-endomysial antibodies (EMA), 12 children were diagnosed with celiac disease accord-
ing to the ESPGHAN guideline.30 All 12 subclinical celiac disease cases were identified in a 
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screening-based setting, and did not report more frequent or more severe gastrointestinal 
symptoms than controls (own unpublished results) [Supplemental Methods]. 
Immunophenotyping of CD57+ T cell and Vδ1+ T-cell subsets
Detailed 6-color flow cytometry was performed within 24 hours following sampling on 
fresh whole blood at the median age of 6.0 years.31 Absolute cell numbers and relative 
frequencies of blood CD3+ T cells, and CD3-CD16/56+ NK cells were obtained with a lyse-
no-wash- protocol. 6-color flow cytometry was performed on an LSRII (BD Biosciences) to 
distinguish CD57-expressing T (CD3+), NK (CD3-CD16/56+) and NKT (CD3+CD16/56+) cells, 
as well as total, Vδ1+ and Vδ2+ γδT cells [Supplemental Tables 1 and 2]. 
Cytomegalovirus serology
Venous blood samples, taken at the median age of 6.0 years, were analysed using enzyme 
immunoassays for IgG antibodies against CMV (EUROIMMUN®, Lübeck, Germany).[31] Re-
sults were evaluated semiquantitatively. Per manufacturer’s instructions, a ratio of the test 
sample over a manufacturer-provided threshold sample >1.1 was defined as positive. 
Covariates
Data on potential confounders, such as gender and mode of delivery were obtained from 
obstetric records from hospitals and mid-wife practices.32 Data on sociodemographic and 
lifestyle factors were obtained by a combination of pre- and postnatal questionnaires 
completed by both parents. Prenatal questionnaires included information on ethnicity 
(Western/non-Western),33 maternal smoking during pregnancy, maternal educational level 
(low/high),34 and household income per month (<€2,200 and >€2,200).35 Postnatal ques-
tionnaires included information on breastfeeding, day-care attendance, gastro-intestinal 
and respiratory tract infections and antibiotic use during the first year of life. 
Statistical analysis
First, Chi-square tests and non-parametric Mann-Whitney U tests were applied to test 
whether maternal and child characteristics were different between children with and 
without subclinical celiac disease. Mann-Whitney U tests were applied to test for differ-
ences in median blood cell numbers between children with and without subclinical celiac 
disease. Because cell numbers were not normally distributed, these were subsequently 
natural log transformed. Multivariable linear regression models with adjustment for po-
tential confounders were created with celiac disease diagnosis as independent variable, 
and natural log transformed blood cell numbers as dependent variable. Effect estimates 
(beta, β) and their 95% confidence intervals (CI) on the natural logarithm scale were back 
transformed (exponent β) for interpretation purposes. To assess whether the association 
between celiac disease and blood CD57+ T-cell numbers were modified by CMV seroposi-
tivity, statistical interaction was evaluated by adding the product term of the independent 
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variable and subgroup (independent variable x subgroup) as covariate in the model. If the 
interaction term was significant (p<0.10), we stratified our analyses. Second, to examine 
whether CMV seropositivity was associated with natural log transformed blood CD57+ T 
cell and Vδ1+ T- cell numbers, multivariable linear regression models were created. The 
results were reported in this paper as beta’s (β’s) and 95% confidence intervals (CIs). A 
p-value ≤0.05 was considered statistically significant. Statistical analyses were performed 
in SPSS 20.0 for Windows (SPSS Inc., Chicago, IL). 
RESuLTS
Subject characteristics
Maternal and child characteristics are shown in [Table 1]. Of n=352 children, 13 had increased 
serum TG2A levels, of whom 12 children were classified as having subclinical celiac disease 
[Supplemental Figure 1, Table 1]. Children with subclinical celiac disease were slightly 
younger (5.9 vs 6.0 years) than HLA DQ2/DQ8 positive controls (n=339), but no significant 
differences were observed in socioeconomic position, child’s gender, body mass index, 
ethnicity, gastrointestinal or respiratory tract infections in the first year of life [Table 1]. 
CeD is associated with increased CD57+ T-cell and decreased Vδ1+ T-cell numbers
Children with subclinical celiac disease had higher blood CD57+ T-cell numbers (median 
110.9 cells/µL; range 20.3-365.8) than controls (median 53.1 cells/µL; range 1.8-613.5). 
This was due to higher CD8+CD57+ T cell numbers (77.3 cells/µL; range 14.3-297.7 versus 
35.9 cells/µL range 1.3-540.7), and higher CD4+CD57+ T cell numbers (28.7 cells/µL; range 
6.2-94.6 versus 15.2 cells/µL range 1.4-145.2). No significant differences were observed for 
CD57+ NKT cell nor CD57+ NK-cell numbers [Figures 1 and 2A]. Similar differences were 
found when frequencies of CD57-expressing cells within their parent populations were 
compared between subclinical celiac disease cases and controls [Supplemental Table 3]. 
Absolute numbers of total, Vδ1+ and Vδ2+ γδT cells were not significantly different between 
subclinical celiac disease cases and controls [Figure 1B]. Still, as a result of a slightly lower 
Vδ1+ cells and slightly higher Vδ2+ cells, Vδ1+T-cell frequencies were significantly lower 
(median 12.2%; range 9.6-30.5) in subclinical celiac disease cases than in controls (median 
19.2%; range 3.4-60.9) [Supplemental Table 3]. 
Adjustment for potential confounding factors led to an increase in the differences for 
CD57+ T-cell numbers: subclinical celiac disease cases had 2.4-fold (95% CI 1.36; 4.31) more 
CD57+ T cells, 2.6-fold more (95% CI 1.35; 4.86) CD57+CD8+ T cells, and 2.0-fold more (95% 
CI 1.14; 3.68) CD57+ CD4+ T cells than controls (p=0.003, 0.004, 0.017 resp.) [Figure 2]. The 
adjustment did not improve fold changes nor p-values for total, Vδ1+ and Vδ2+ γδT cell 
numbers. The results for the observed associations persisted after including HLA-DQ2/-
DQ8 negative controls [Supplemental Figure 2].
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Cytomegalovirus modifies the association between celiac disease, CD57+ T cells, 
and Vδ1+ T cells. 
We further studied associations between CMV infection, CD57+ T cells, and Vδ1+ T cells 
[Figure 3]. CMV seropositivity was associated with a 3.52 fold increase (95% CI 2.64; 4.71) 
in CD57+ T-cell numbers (p<0.0001), and a 1.3 fold increase (95% CI 1.01; 1.68) in Vδ1+ T-
cell numbers (p=0.039) in the HLA DQ2/DQ8 positive children. Associations were similar 
between children with and without subclinical celiac disease (p-interaction>0.14), and did 
not change after inclusion of the HLA DQ2/DQ8 negative controls [data not shown]. 
CMV seropositivity did not significantly modify the association between CeD diagnosis 
and CD57+ T cells (p-interaction=0.17). Still, associations between CD57+ T-cell numbers 
and subclinical celiac disease were stronger and merely present in CMV seronegative 
children. Children with subclinical celiac disease who were CMV seronegative had 2.54 fold 
(95% CI 1.17; 5.53) more CD57+ T-cell numbers than children who were CMV seronegative 
without celiac disease, mainly because they had more blood CD8+CD57+ T cells [Figure 4]. 
Table 1. Characteristics of study population 
HLA DQ2/DQ8 carriers only (n=351)
Characteristics
No Celiac Disease
n=339 (96.6%)
Subclinical Celiac Disease
n=12 (3.4%)
Maternal characteristics
High educational level (n;%) 228 (69.1%) 6 (50%)
Household income per month (>2200 euro) (n;%) 232 (74.6%) 8 (66.7%)
Smoking during pregnancy (n;%) 85 (27.6%) 4 (40%)
Caesarian section (n;%) 34 (10.8%) 3 (27.3%)
Multiparity (n;%) 143 (42.3%) 3 (25%)
Child characteristics
Female (n;%) 165 (48.7%) 8 (66.7%)
Western ethnicity (n;%) 308 (90.9%) 11 (91.7%)
Age (years; median; range) 6.04 (5.5-7.9) 5.88 (5.8-6.2)
SDS BMI for age 0.17 (-2.3 ; 3.0) -0.29 (-2.0 - 1.7)
Gluten free/low diet (n;%) 1 (0.3%) 0 (0%)
Breastfeeding ever (n;%) 265 (89.2%) 12 (100%)
Day care attendance first year (n;%) 183 (91.5%) 7 (78%)
Gastro intestinal tract infections first year (n;%) 82 (47.7%) 5 (55.6%)
Respiratory tract infections first year (n;%) 135 (50.9%) 7 (70%)
Use of antibiotics / penicillin first year (n;%) 84 (32.1%) 4 (40%)
Herpesvirus seropositivity at 6 years (n;%)
CMV 107 (32%) 3 (25%)
EBV 148 (44%) 5 (42%)
HSV-1 56 (17%) 1 (8%)
Values are medians (range). Bold values indicate significant differences (p<0.05). Differences in maternal and child char-
acteristics between groups with and without subclinical celiac disease were calculated with the non-parametric Mann-
Whitney U test for non-normally distributed continuous variables), and the chi-square test for categorical variables. 
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Figure 1. Diff erence in blood median lymphocyte cell numbers (cell/µL) between 6-year old children with 
and without subclinical celiac disease. A, Flowcytometric gating strategy. B, Children with subclinical CD (n=12), 
HLA DQ2 or DQ8 positive controls (n=339). Mann-Whitney U tests were performed to test for diff erences between 
continuous non-normally distributed variables. 
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Figure 2. Relative diff erences in blood lymphocyte numbers between children with and without subclini-
cal celiac disease. A, Mean lymphocyte numbers (cell/µL) in blood of children with subclinical CD (n=12), stan-
dardized to the same cell numbers in HLA DQ2/DQ8 positive controls (n=339) (unadjusted). B, Mean lymphocyte 
numbers (cell/µL) in blood of children with subclinical CD, standardized to the same cell numbers in HLA DQ2/DQ8 
positive controls (adjusted for child’s age, SDS BMI for age, gender, CMV, EBV and HSV-1 seropositivity, ethnicity 
(western/non-western), socioeconomic position (maternal educational level), respiratory and gastrointestinal tract 
infections, daycare attendance (yes/no), and breastfeeding (ever/never). The estimated back-transformed (a)β and 
95% CI (exp Ln β + exp Ln (95% CI) are derived from univariable (A) and multivariable (B) linear regression models, 
and indicate the relative diff erence in mean cell numbers between children with and without subclinical CD. *p<0.05, 
**p<0.01. 
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Figure 3. Associations between CMV seropositivity and blood CD57+ T cells, and Vδ1+ TCRγδ cells. Mean 
lymphocyte numbers (cell/µL) in peripheral blood of CMV seropositive children (n=110), standardized to the same 
cell numbers in CMV seronegative controls (n=241) within a HLA DQ2/DQ8 positive population. The estimated back-
transformed (a)β and 95% CI (exp Ln β + exp Ln (95% CI) are derived from univariable and multivariable linear re-
gression models, and indicate the relative difference in mean cell numbers between children with and without CMV 
*<0.01, ¶p<0.0001. Multivariable models are adjusted for child’s age, SDS BMI for age, gender, CMV, EBV and HSV-1 
seropositivity, ethnicity (western/non-western), socioeconomic position (maternal educational level), respiratory 
and gastrointestinal tract infections, daycare attendance (yes/no), and breastfeeding (ever/never). 
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Figure 4. Associations between CD, blood CD57+ T cells, and Vδ1+ TCRγδ cells, stratified on CMV seroposi-
tivity.
A, Mean lymphocyte numbers (cell/µL) in peripheral blood of children with subclinical celiac disease, standard-
ized to HLA DQ2/DQ8 positive controls in CMV seropositive children (n=110). B, Mean lymphocyte numbers (cell/
µL) in peripheral blood of children with subclinical celiac disease, standardized to HLA DQ2/DQ8 positive controls 
in CMV seronegative children (n=241). The estimated back-transformed aβ and 95% CI (exp Ln β + exp Ln (95% CI) 
are derived from multivariable linear regression models, and indicate the relative difference in mean cell numbers 
between children with and without subclinical celiac disease. *p<0.05, **p<0.01. Models are adjusted for child’s age, 
SDS BMI for age, gender, CMV, EBV and HSV-1 seropositivity, ethnicity (western/non-western), socioeconomic posi-
tion (maternal educational level), respiratory and gastrointestinal tract infections, daycare attendance (yes/no), and 
breastfeeding (ever/never). 
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The inverse association between Vδ1+ T cells and subclinical celiac disease was only 
observed in CMV seronegative children (p-interaction=0.02). Children with subclinical 
celiac disease who were CMV seronegative had 2.22 fold (95% CI 1.22; 4.0) lower Vδ1+T-cell 
numbers than children who were CMV seronegative without celiac disease [Figure 4]. The 
results for the observed stratified associations persisted after including HLA-DQ2/-DQ8 
negative controls [Supplemental Figure 3]. Thus, children with subclinical celiac disease 
had more blood CD57+ expressing T cells, and fewer blood Vδ1+ expressing T cells than 
controls, particularly in CMV seronegative children. 
EBV and HSV-1 seropositivity did not significantly modify the associations between CeD 
diagnosis and Vδ1+ cells (p-interaction 0.19, and 0.75 resp.), nor between CeD diagnosis 
and CD57+ T cells (p-interaction 0.95 and 0.62 resp.) in the HLA DQ2/DQ8 positive group. 
Additionally, no statistical interactions were observed after inclusion of the HLA DQ2/DQ8 
negative children.
DISCuSSION
We showed in a population-based cohort study that 6-year-old children with subclinical 
celiac disease had higher numbers of CD57+ CD8+ T-cells, and lower numbers of Vδ1+ T 
cells in blood than healthy controls of the same age who carried the genetic risk type for 
celiac disease. The inverse association between blood Vδ1+ T cells and subclinical celiac 
disease was most prominent in CMV seronegative children. 
To the best of our knowledge, this is the first study examining blood immune cell num-
bers in children with subclinical celiac disease. Most studies have been performed in adult 
patients with symptomatic celiac disease,5, 13 whereas studies including patients with sub-
clinical disease are scarce.36 In addition, our observation that CMV infection modifies the 
association between celiac disease and blood Vδ1+ T-cell numbers is novel, and extends 
the few previous studies that showed similar abnormalities in innate-like lymphocyte 
populations in celiac disease, specifically Vδ1+ T cells.5, 13 However, most studies merely 
studied total γδ T cells,11, 36 or total NK and T cells,5, 12 but lacked detailed measurements 
of Vδ1+ or CD57+ expression. Moreover, only one study addressed these associations 
in children with celiac disease;5 the majority of studies have been performed in adults. 
Besides, results on total NK and T cell-numbers have been contradictive.5, 12 Conflicting 
results might be due to differences in age, stage of disease, variability in the quality of 
duodenal biopsies, genetic background, geographical region, and environmental fac-
tors, such as viral infections. The latter two factors are known to affect the composition 
of circulating T cells,22, 36 but have not been included in previous studies. Moreover, we 
show that differences in blood cell numbers between cases and controls persisted after 
including HLA-DQ2/-DQ8 negative individuals from the control group. Thus, carriership 
of the HLA risk alleles does not affect the observed differences in cell numbers between 
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subclinical celiac disease cases and controls. Our observations are in line with a previous 
study that suggested that the altered distribution of γδ T-cell subsets in celiac patients is 
a consequence of an ongoing immunological process, rather than a phenomenon directly 
caused by the genetic risk allele.13 Our observations do not provide direct insights into 
causality between abnormal cell numbers and celiac disease. Still, the cell types that were 
studied could be directly involved in disease pathogenesis. 
First, we observed a positive association between celiac disease and blood CD57+ T-cell 
numbers, suggesting that celiac disease is associated with proliferative inability or T cell 
exhaustion.17 Increased numbers of CD57+ T cells are reported in patients with frequent or 
chronic infections, such as CMV, or in patients with chronic stimulation of T cells.17 Hence, 
the observed increased CD57 expression in subclinical celiac disease patients is likely to be 
a result of chronic inflammation, rather than a specific marker for celiac disease. Despite 
previous reports of increased CD57+ T-cell numbers in CMV carriers, our associations were 
still present, and even more pronounced, in the seronegative children. Hence, both CMV 
and celiac disease were independently associated with increased CD57+ T-cell numbers. 
Alternatively, this increase might reflect chronic immune activation induced by other 
chronic viruses, or chronic stimulation of T cells induced by celiac disease itself. Path-
ways involved in the proliferation of T cells, include signaling via IL-15 or IL-21.37, 38 These 
pleiotropic cytokines are also greatly upregulated in the gut of celiac disease patients.39 
Moreover, IL-21 levels are increased in children with potential celiac disease, although to 
a lesser extent than in active disease.40 Still, it is likely that on top of IL-15 and IL-21, other 
factors are involved, because CD57+ T cells are a heterogeneous mixture of cytotoxic and 
immunosuppressive subsets.19 
Second, we identified an inverse association between blood Vδ1+ T cells and the pres-
ence of subclinical celiac disease. This is in line with previous observations in celiac disease 
patients of increased Vδ1+ T-cell numbers in gut epithelium,5, 9, 11, 12 with a decrease in blood. 
As previous studies reported blood Vδ1+ T-cell numbers to be associated with the degree 
of small intestinal enteropathy,12 and to depend on the amount of gluten exposure,41 this 
association may be causal. The first stage of celiac disease is reflected by an increased 
number of IELs in the villi,6 which are predominantly of the Vδ1 subtype.5 These cells have 
a distinct and limited T cell receptor diversity, and play an important role in intestinal 
homeostasis and oral mucosal tolerance.42-44 Although relatively little is known about the 
biological function of blood Vδ1+ T cells,7 they have been shown to secret inflammatory, 
as well as immunosuppressive and regulatory cytokines,8 including IFN-γ, TNF-α, IL-10 and 
IL-17, suggesting a role in autoimmune and allergic diseases.42 In addition, Vδ1+ T cells may 
have a pivotal role in cancer surveillance based on their IL-2 and IL-15 mediated anti-tumor 
cytolytic function.45 Our observed decrease in blood Vδ1+ T-cell numbers in celiac disease 
directly contrasts findings from inflammatory bowel disorders, where an increase in blood 
Vδ1+ T cells is noted.5 This might directly reflect a difference in disease pathology. Still, the 
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functional significance of these changes in relation to subclinical celiac disease remains 
unclear. 
Third, our results are in line with previous studies suggesting that CMV infection induces 
expansion of peripheral Vδ1+ T cells.22 Combined with the suggested regulatory properties 
of Vδ1+ T cells, and the inverse association between celiac disease and CMV,24 it is tempt-
ing to speculate that decreased blood Vδ1+ T-cell numbers reflect celiac disease activity, 
whereas early CMV infection might prevent celiac disease by increasing blood Vδ1+ T cells. 
On the other hand, it could be speculated that decreased peripheral Vδ1+ T cells in celiac 
disease patients reflect the absence of CMV infection, rather than a celiac disease specific 
pathway. 
Methodological considerations
To our knowledge, this is the first population-based cohort study that examined associa-
tions between subclinical celiac disease, CD57+ T cells and Vδ1+ T cells in combination 
with CMV seropositivity in children. A major strength of the present study is that we used 
a multivariable approach to assess the relative contributions of both CMV seropositivity 
and subclinical celiac disease on immune subsets. Second, we examined children with 
an early presentation of celiac disease confirmed by biopsy, without clinical signs and 
symptoms, instead of symptomatic children. Furthermore, we performed our analyses in 
a large sample, and information on a broad range of potential confounders was available, 
including socioeconomic status, ethnicity, breastfeeding, daycare, gastrointestinal and 
respiratory tract infections and antibiotic use. However, some limitations should be taken 
into account. First, despite a large number of healthy controls, the number of subclinical 
CeD cases was limited to only 12 children. Therefore, the results of our analyses should 
be interpreted with caution. Second, causality remains uncertain, since detailed immune 
phenotyping and antibodies against CMV were measured at the same time as TG2A levels. 
Therefore, reverse causation cannot be excluded. Third, although we adjusted for a broad 
range of potential confounders, the observed associations might still be related to unmea-
sured variables, such as lifestyle, other viral infections and microbial burden. Moreover, 
CMV carriership may be associated with other T-cell subsets that we did not include in our 
analyses, thereby possibly influencing the observed associations between celiac disease 
and CD57+ T cells. Hence, residual confounding cannot be fully excluded. Last, we did not 
have data on effector functions of studied lymphocytes, such as the expression of effector 
markers (e.g. FOXP3), or cytokines such as IL-10 and TGF-β, precluding conclusions on ef-
fector or regulatory mechanisms of CD57+ T cells and Vδ1 cells. 
Conclusion 
This population-based cohort study showed that alterations in Vδ1 and CD57 expressing T-
cell numbers were already present in children with subclinical CeD, prior to the occurrence 
of overt clinical symptoms. Associations were dependent on cytomegalovirus seropositiv-
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ity. Hence, alterations in blood T cells in subclinical CeD are linked to viral pathology, which 
may contribute to the understanding of CeD pathogenesis. 
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Supplemental Figure 1. Flowchart of participants included in the study
The population for analyses included 12 children with subclinical celiac disease, and n=339 HLA DQ2/DQ8 positive 
controls. 
SuPPLEMENTAL METhODS 
Of 13 TG2A positive children who carried one of the genetic risk alleles and anti-endomysial 
antibodies (EMA), 12 children were diagnosed with celiac disease according to the ESP-
GHAN guideline. Of these, nine had intestinal biopsy confirmed enteropathy (Marsh 2 n=1; 
Marsh 3a n=7, Marsh 3b n=1), and in one child biopsy was omitted because of high levels 
of TG2A and EMA. Two children did not provide consent for intestinal biopsies. Still, these 
children were considered celiac disease cases, as their serum TG2A levels were high at two 
time points, and they carried the genetic HLA risk allele (HLADQ 2.2 and HLA DQ8). One 
child had Marsh grade 1 and was therefore considered as having potential celiac disease 
(excluded from analysis). 
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Supplemental Figure 2. Relative diff erences in blood lymphocyte numbers between children with sub-
clinical celiac disease and HLA DQ2/DQ8 positive and negative controls (n=1,065). Figure Legend: A, Mean 
lymphocyte numbers (cell/µL) in blood of children with subclinical CeD (n=12), standardized to the same cell num-
bers in to HLA DQ2/DQ8 positive and negative controls (n=1,053) (unadjusted). B, Mean lymphocyte numbers (cell/
µL) in blood of children with subclinical CeD, standardized to the same cell numbers in to HLA DQ2/DQ8 positive 
and negative controls (adjusted for child’s age, SDS BMI for age, gender, CMV, EBV and HSV-1 seropositivity, ethnicity 
(western/non-western), socioeconomic position (maternal educational level), respiratory and gastrointestinal tract 
infections, daycare attendance (yes/no), and breastfeeding (ever/never). The estimated back-transformed (a)β and 
95% CI (exp Ln β + exp Ln (95% CI) are derived from univariable (A) and multivariable (B) linear regression models, 
and indicate the relative diff erence in mean cell numbers between children with and without subclinical CD. *p<0.05, 
**p<0.01. 
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Supplemental Figure 3. Associations between celiac disease, blood CD57+ expressing T cells, and Vδ1+ 
expressing T cells in HLA DQ2/DQ8 positive and negative children, stratified on CMV seropositivity. Figure 
legend: A, Mean lymphocyte numbers (cell/µL) in peripheral blood of children with subclinical celiac disease, stan-
dardized to HLA DQ2/DQ8 positive and negative controls in CMV seropositive children (n=728). B, Mean lymphocyte 
numbers (cell/µL) in peripheral blood of children with subclinical celiac disease, standardized to HLA DQ2/DQ8 posi-
tive and negative controls in CMV seronegative children (n=336). The estimated back-transformed aβ and 95% CI 
(exp Ln β + exp Ln (95% CI) are derived from multivariable linear regression models, and indicate the relative diff er-
ence in mean cell counts between children with and without subclinical celiac disease. *p<0.05, **p<0.01.
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Supplemental Table 1. Definition of lymphocyte subsets
Cell type Phenotype definition
CD57+ T cells SSClowCD45+CD3+CD56-CD57+ 
CD8+CD57+ T cells SSClowCD45+CD3+CD8+CD56-CD57+ 
CD4+CD57+ T cells SSClowCD45+CD3+CD8-CD56-CD57+
CD57+ NKT cells SSClowCD45+CD3+CD56+CD57+ 
CD57+ NK cells SSClowCD45+CD3-CD56+CD57+ 
TCR γδ+ T cells (% within CD3+) SSClowCD3+TCRαβ-TCRγδ+
Vδ1+ T cells (% within γδ+ T cells) SSClowCD3+TCRαβ- Vδ1+ Vδ2-
Vδ2+ T cells (% within γδ+ T cells) SSClowCD3+TCRαβ- Vδ1- Vδ2+
Supplemental Table 2. Antibody details
Tube
Fluorochrome
  FITC PE PerCP-Cy5.5 PE-Cy7 APC APC-Cy7
1
Antibody CD3 CD16+CD56 CD45 CD4 - CD8
Clone SK7 B73.1+C5.9 2D1 SK3 - SK1
Manufacturer
BD 
Biosciences
BD Biosciences 
+ Dako
BD 
Biosciences
BD 
Biosciences -
BD 
Biosciences
2
Antibody TCRαβ TCRγδ CD3 CD4 CD8 -
Clone WT31 11F2 SK7 SK3 SK1 -
Manufacturer
BD 
Biosciences BD Biosciences
BD 
Biosciences
BD 
Biosciences
BD 
Biosciences -
3
Antibody Vδ2 Vδ1 * CD3 CD4 TCRαβ CD8
Clone B6.1 R9.12 SK7 SK3 IP26 SK1
Manufacturer
BD 
Biosciences Beckman Coulter
BD 
Biosciences
BD 
Biosciences eBiosciences
BD 
Biosciences
4
Antibody CD57 CD38 CD3 CD56 HLA-DR CD8
Clone HNK-1 HB7 SK7 B159 L243 SK1
Manufacturer
BD 
Biosciences BD Biosciences
BD 
Biosciences
BD 
Biosciences
BD 
Biosciences
BD 
Biosciences
*, unconjugated antibody, detected with Goat anti-Mouse IgG PE (polyclonal; Invitrogen)
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Supplemental Table 3. Blood T and NK cell subset frequencies in HLA DQ2/DQ8 positive children with and 
without celiac disease
HLA DQ2/DQ8 carriers only 
(n=351)
Cell frequencies within their parent populations (%) (median, range)
Cell type No Celiac Disease
n=339 (96.6%)
Subclinical Celiac Disease
n=12 (3.4%)
P-value
CD57+ T cells (% of CD3+) 2.8 (0.1-46.6) 5.8 (1.6-13.5) 0.059
CD8+CD57+ (% of CD8+) 5.8 (0.2-53.5) 11.5 (3.6-34.6) 0.05
CD4+CD57+ (% of CD4+) 1.1 (0.1-13.0) 2.2 (0.5-4.8) 0.04
CD57+ NK cells (% of CD3-CD56+) 25.1 (1.5-72.6) 23.3 (6.5-49.1) 0.96
CD57+ NKT cells (% of CD3+CD56+) 9.9 (0.8-103.1) 13.2 (2.5-32.7) 0.44
γδ+ T cells (% of CD3+) 8.8 (2.2-21.5) 7.0 (3.3-16.0) 0.20
Vδ1 (% of γδ+ T cells) 19.2 (3.4-60.9) 12.2 (9.6-30.5) 0.018
Vδ2 (% of γδ+ T cells) 42.4 (8.7-82.7) 44.1 (30.8-64.0) 0.26
Values are medians (range), p value reflects differences in median cell frequencies within their parent populations 
(%) between children with and without subclinical celiac disease in the HLA DQ2/DQ8 positive population, as calcu-
lated with the non-parametric Mann-Whitney U test. 
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ABSTRACT
Background
Celiac disease (CeD) has emerged as a common, but largely undiagnosed health problem. 
Numerous studies examined the influence of infant nutrition on the development of diag-
nosed CeD. However, results are still inconsistent. In addition, the effect of infant feeding 
practices on the development of potential forms of CeD might be different.
Objective
To examine whether the timing of gluten introduction and breastfeeding duration are as-
sociated with Celiac Disease Autoimmunity (CDA) in children at the age of 6 y.
Design
This study was embedded in the Generation R study, a population-based prospective co-
hort study. Participants included 1679 Dutch children positive for (HLA) DQ2/DQ8. Data on 
the timing of gluten introduction (<6 mo compared to ≥6 mo) and duration of breastfeeding 
(<6 months vs. ≥6 months) were obtained by questionnaire. Serum samples were analyzed 
for anti-tissue transglutaminase (tTG) levels at age 6 y. Anti-tTG levels were categorized 
into negative (<7 U/ml) and positive (>7 U/ml) values. Positive anti-tTG levels were further 
categorized based on the >10 times upper limit of normal (ULN) values of the test kit (>7-70 
U/ml and >70 U/ml). Multivariable logistic regression analyses were performed. 
Results
Positive anti-tTG concentrations were found in 43 children, 26 of whomn had concentra-
tions ≥10 times the ULN (≥70 IU/ml). The introduction of gluten from the age of 6 mo on-
ward and breastfeeding for ≥6 mo were not significantly associated with positive anti-tTG 
levels. In addition, the timing of gluten introduction and duration of breastfeeding were 
not significantly associated with positive anti-tTG concentrations below or above the 10 
times ULN. 
Conclusions
Delayed introduction of gluten beyond the age of 6 mo does not increase the risk of CDA. 
Also, breastfeeding for ≥6 mo does not decrease the risk of CDA in children at 6 y of age.
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INTRODuCTION
Celiac disease (CeD) has emerged as a common, but largely undiagnosed health prob-
lem.1, 2 Untreated CeD is associated with excess morbidity in children and adults.3 CeD is 
characterized by an adaptive T-cell mediated response against gluten, classically resulting 
in chronic inflammation of the small intestinal mucosa and gastrointestinal complaints.4, 5 
However, the clinical presentation of CeD has changed over the past few decades to include 
milder, non-classic forms.6, 7 Therefore, diagnosed CeD only represents the more visible tip 
of the iceberg, ie children having clinical symptoms, whereas asymptomatic or atypical 
cases are often missed.6
Both human leucocyte antigen (HLA) DQ2/DQ8 carrier status and gluten exposure are 
prerequisites to develop CeD. Breastfeeding and timing of gluten exposure might influence 
the risk of CeD. Underlying mechanisms remain uncertain, but might involve a complex 
interplay between innate and adaptive immune responses, gut colonization, intestinal 
membrane permeability, genetic predisposition and environmental factors such as infec-
tions and infant feeding habits.8-10 
Numerous studies examined the influence of infant nutrition, including breastfeeding 
and the timing of gluten introduction, on the development of diagnosed CeD. On the basis 
of current literature, the European Society for Pediatric Gastroenterology, Hepatology , and 
Nutrition (ESPGHAN) Committee on Nutrition recommends to avoid both early (< 4 mo) 
and late (> 7 mo) introduction of gluten, and to introduce gluten gradually while the child 
is still being breastfed.11 However, results are still inconsistent in this respect.7, 9, 12-19 The 
lack of consistency between studies may be due to the majority of these studies being 
retrospective (ie comparing history of infant feeding practices in CeD cases compared with 
controls)13, 17, 18, 20 or ecological (ie, linking incidence rates of diagnosed CeD to national 
infant feeding practices).1 These latter studies were mainly based on clinical CeD. However, 
because subclinical, silent or latent forms of CeD might exist,4 it could be speculated that 
these forms have different etiologies but these are not fully understood. Therefore, the 
effect of infant feeding practices on the development of subclinical, silent or latent forms 
of CeD might be different.17, 21 For example, a Swedish study found a decreased prevalence 
of symptomatic CeD after new infant feeding recommendations were introduced but did 
not find any difference in prevalence of undiagnosed (screening detected) CeD.21 However, 
a later replication within the same cohort study did not support these findings.19 The aim of 
the current study, was to examine whether breastfeeding duration and the timing of gluten 
introduction was associated with celiac disease autoimmunity (CDA) in a population-
based prospective cohort study of 6-y-old children. 
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SuBJECTS AND METhODS
Participants and study design
This study was embedded in the Generation R study, a prospective population based 
cohort study from fetal life onward, and has been described in detail previously.22 A total of 
8305 mothers with a delivery date from April 2002 through January 2006 provided consent 
for school age follow-up. Ethical approval for the study was obtained from the Medical 
Ethical Committee of the Erasmus MC, University Medical Center Rotterdam.
Duration of breastfeeding 
Information regarding breastfeeding was obtained by a combination of delivery reports 
and postnatal questionnaires at the ages of 2, 6 and 12 mo.22 Mothers were asked by ques-
tionnaire whether they had ever breastfed their child and, if yes, at what age (in mo) they 
had stopped breastfeeding. Breastfeeding duration was categorized as reported by Stordal 
et al(14) but later dichotomized as <6 mo and >6 mo because only 1 infant still received 
breast milk at the age of 13 mo. Questionnaire response rates were 82%, 73% and 72% at 
age 2, 6 and 12 mo, respectively.
Introduction of gluten in the first year of life
At the child’s age of 6 and 12 mo parents were asked by questionnaire the age of first-time 
introduction of gluten in their infant’s diet. In addition, parents were asked to complete a 
short food-frequency questionnaire consisting of food products frequently consumed ac-
cording to a Dutch food consumption survey in infants.23 The timing of gluten introduction 
was cross checked with the consumption of bread and biscuits and type of porridge (based 
on wheat or oats instead of rice) at the age of 6 and 12 mo as described previously.24 The 
timing of introduction of gluten was categorized as <6 mo and ≥6 mo. 
Anti-Tissue Transglutaminase concentrations
Anti-tissue transglutaminase (anti-tTG) concentrations were assessed in venous blood serum 
samples by using a fluorescence enzyme immunoassay (ELiA Celikey IgA, PhadiaImmunocap 
250, Phadia AB, Upsala Sweden) at the Department of Immunology, Erasmus MC-University 
Medical Center Rotterdam, the Netherlands. The intra and inter-assay CVs were below 10% 
and 15%, respectively. Of 8305 children participating at the age of 6 y, serum anti-tTG was 
available in 53% of children. We excluded 20 children in whom IgA concentrations were low, 
possibly indicating IgA deficiency. None of the participants were aware of tTG-IgA determi-
nation. Median anti-tTG concentration of the study population was 0.25 U/ml, varying from 
0.10 U/ml to 125 U/ml. Anti-tTG concentrations were categorized into negative and positive, 
using the cutoff for clinical practice of 7 U/ml [Figure 1]. Positive anti-tTG concentrations were 
further categorized into 2 categories based on the >10 times the upper limit of normal (ULN) 
values of the test kit (cutoffs for positive anti-tTG: >7-70 U/ml and >70 U/ml) [Figure 1].25
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Figure 1: Flowchart of the participants within the Generation R Study 
 
Visit to research centre age 6 years  
(n=6690) 
 
Serum collection  
(n=4593) 
 
Serum anti-tTG concentrations available 
(n=4442) 
 
HLA-DQ2/DQ8 carrier 
(n=1679) 
 
Excluded: random sample within 
siblings (n=373), children with 
diagnosed celiac disease (n=8) and no 
HLA-DQ2/DQ8 carrier (n=2382) 
 
Negative anti-tTG 
(n=1636) 
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Figure 1. Flowchart of the participants within the Generation R Study
Detection of human Leukocyte Antigen Risk Alleles
To capture whether the children carried the HLA-DQ risk type DQ2 or DQ8, a tag nucleo-
tide polymorphisms (single nucleotide polymorphism) approach was used as has been 
described in detail previously.26, 27 Children were genotyped for these single nucleotide 
polymorphisms for HLA-DQ2 (rs2187668, rs2395182, rs4713586 and rs7775228) and DQ8 
(rs7454108)26 by using genome-wide Illumina 610 Quad Array. Genotype and allele frequen-
cies were in Hardy-Weinberg equilibrium (rs2187668, p=0.71; rs2395182, p=0.85; rs4713586, 
p=0.57; rs7775228, p=0.92; rs7454108, p=0.76).
Covariates
Data on potential confounders as fetal sex, gestational age, birth weight and caesarian 
section (no differentiation was made between planned and unplanned) were obtained 
from obstetric records assessed in mid-wife practices and hospitals.22 Maternal anti-tTG 
concentrations were measured during pregnancy. Data on other sociodemographic and 
lifestyle factors were obtained by a combination of pre-and postnatal questionnaires com-
pleted by both parents. This included information on ethnicity (Western or non-Western),28 
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parity, maternal smoking during pregnancy, maternal educational level (low or high),29 and 
household income per month (≤ € 2200 and > € 2200).30 Postnatal questionnaires included 
information on vitamin D supplementation, gastrointestinal and respiratory tract infec-
tions and day-care attendance in the first year.
Population for analyses
Of all children with anti-tTG data available (n=4442), we excluded from the analysis those 
with diagnosed celiac disease (n=8) at the age of 6 years, and children who were HLA-DQ2/
DQ8 negative (n=2382) from the analysis. To prevent clustering, only one child per family 
within the Generation R cohort was included by random selection (n=373). In total, 1679 
children were available for statistical analyses [Figure 1]. 
Statistical analysis
First, independent Student’s t-test and Chi-Square tests were performed to test for differ-
ences in characteristics between groups of anti-tTG concentrations. Second, logistic regression 
analysis was performed with anti-tTG concentrations at the age of 6 y as dependent variable. 
Breastfeeding and the timing of gluten introduction were analyzed separately as independent 
variables and adjusted for major confounders. Due to small numbers in the positive anti-tTG 
group, the selection of potential confounders in the multivariate model was restricted to those 
with an alteration of ≥10% in ORs.31 To assess whether the association between breastfeeding 
or the timing of gluten introduction and anti-tTG concentrations differed by ethnicity and chil-
dren with and without gastrointestinal infections during infancy, statistical interactions were 
evaluated by adding the product term of independent variable and subgroup (independent 
variable ˟ subgroup) as covariate to the univariate model. To reduce attrition bias, multiple 
imputation of the exposures (i.e. breastfeeding and timing of gluten introduction) and covari-
ates was performed (n=5 imputations). The multiple imputation procedure was based on the 
correlation between each variable with missing values with other subject characteristics.32 The 
pooled results of the 5 imputed datasets are reported in this paper as ORs and 95% confidence 
intervals (95% CIs). A p-value <0.05 was considered as statistically significant. The Statistical 
analyses were performed in SPSS 20.0 for Windows (SPSS Inc).
RESuLTS
Maternal and child characteristics of the study population are shown in table 1. In all 1679 
HLA- DQ2/DQ8 positive children, 2.6% had positive anti-tTG concentrations and 97.4% 
had negative anti-tTG concentrations [Table 1 and figure 1]. Of children with positive anti-
tTG concentrations (n=43), 60% of children (n=26) had values >10 times the ULN (>70 IU/
ml) [Table 1 and figure 1]. Breastfeeding for >6 mo was reported in 47% of children with 
positive and negative anti-tTG levels [Figure 2]. The introduction of gluten from the age of 
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6 mo onward was reported in 56% and 64% of children with positive and negative anti-tTG 
concentrations, respectively [Figure 2]. 
Table 1: Maternal and child characteristics according to anti-tTG concentrations. 
N=1679
Negative anti-tTG Positive anti-tTG
n= 1636 (97.4%)
7-70 IU/ml >70 IU/ml
n=17 (1%) n=26 (1.6%)
N (%) N (%) N (%)
Maternal characteristics
Educational level
Low 369 23 6 35 2 8
Mid 854 52 7 41 15 58
High 413 25 4 24 9 34
Household income per month 
≤ 2200 euro 732 45 9 53 5 19 
> 2200 euro 904 55 8 47 21 81*
Smoking during pregnancy
Never 1203 74 13 76 20 77
Smoked during pregnancy 433 26 4 24 6 23
Caesarean section 213 13 2 12 2 8
Parity 711 43 7 41 10 38
Maternal anti-tTG during pregnancy 1
Negative 1242 99 12 100 20 100
Positive 6 1 0 0 0 0
Child characteristics
Male 843 52 4 24 * 8 31 *
Ethnicity
Western 1107 68 11 65 25 96 *
Non-Western 529 32 6 35 1 4
Birth weight z-score mean (SD) -0.04 0.99 0.16 1.13 -0.28 1.14
Breastfeeding
0 to <3 mo 461 28 3 18 9 35
3 to <6 mo 402 25 3 18 8 30
≥ 6 mo 773 47 11 64 9 35
Introduction of gluten
< 6 mo 586 36 5 29 14 54 *
≥ 6 mo 1050 64 12 71 12 46
Gastro intestinal tract infections first year 1072 66 11 65 18 69
Respiratory tract infections first year 893 55 10 59 18 69
Vitamin D supplementation age 6-12 months 874 53 10 59 12 46
Day care attendance first year 1099 67 12 71 24 92 *
*Significantly different from negative anti-tTG levels
1 Was not multiple imputed
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Figure 2. Duration of breastfeeding and timing of gluten introduction according to anti-tTG level
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Figure 2. Duration of breastfeeding and timing of gluten introduction according to anti-tTG concentration. 
A, Proportion of children breastfed ≥6 mo according to anti-tTG concentration (<7 U/ml n=1636, or >7U/ml n=43). 
B, Proportion of children introduced to gluten from the age of 6 mo onward according to anti-tTG concentration (<7 
U/ml n=1636, or >7 U/ml n=43).
Breastfeeding and anti-tTG levels
Relative to breastfeeding for ≤6 mo, breastfeeding for >6 mo was not significantly associat-
ed with positive anti-tTG concentrations [Table 2]. In addition, breastfeeding for >6 mo was 
not significantly associated with positive anti-tTG concentrations below or above 10 times 
the ULN (>70 IU/ml) [Table 3]. In comparison with breastfeeding for ≤3 mo, breastfeeding 
between 3 and 6 mo and for >6 mo was not significantly associated with anti-tTG concen-
trations [data not shown]. No significant interaction was found between breastfeeding and 
ethnicity or gastrointestinal infections during infancy (p-interaction>0.50).
Table 2. Association between breastfeeding duration and positive anti-tTG concentrations.
N=1679
Breastfeeding N (%)
Crude model
OR, 95% CI
Multivariate model
aOR, 95% CIa
< 6 mo 885 (53%) Reference Reference
≥ 6 mo 794 (47%) 1.07 (0.52,2.22) 1.20 (0.56,2.59)
OR: Odds ratio; 95% CI: 95% confidence interval. 
a Adjusted for smoking during pregnancy, caesarean section, parity, day-care attendance first year, respiratory tract in-
fections first year, vitamin D supplementation age 6-12 mo, household income per month, maternal educational level.
Additional adjustment for sex, ethnicity, birth weight z-score, timing of gluten introduction, gastrointestinal tract 
infections in the first year and maternal anti-tTG concentration did not provide an alteration of ≥ 10% in ORs. 
Timing of gluten introduction and anti-tTG levels
In comparison with the introduction of gluten before the age of 6 mo, the introduction of 
gluten from the age of 6 mo onward was not significantly associated with positive anti-
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tTG concentrations [Table 4]. In addition, the introduction of gluten from the age of 6 mo 
onward was not significantly associated with positive anti-tTG concentrations below or 
above 10 times the ULN (>70 IU/ml) [Table 5]. No significant interaction was found between 
the timing of gluten introduction and ethnicity or gastrointestinal infections during infancy 
(p-interaction >0.69).
Table 3. Association between breastfeeding duration and positive anti-tTG concentrations below and 
above 10 times the ULN.
N=1679
Breastfeeding N (%)
7-70 IU/ml
N=17
>70 IU/ml
N=26
Crude model
OR, 95% CI
Multivariate model
aOR, 95% CI a
Crude model
OR, 95% CI
Multivariate model
aOR, 95% CI a
< 6 mo 885 (53%) Reference Reference Reference Reference
≥ 6 mo 794 (47%) 2.57 (0.56,11.75) 2.52 (0.59,10.84) 0.64 (0.24,1.73) 0.78 (0.27,2.27)
OR: Odds ratio; 95% CI: 95% confidence interval. 
a Adjusted for smoking during pregnancy, caesarean section, parity, day-care attendance first year, respiratory tract 
infections first year, vitamin D supplementation age 6-12 mo, household income per month, maternal educational 
level.
Additional adjustment for sex, ethnicity, birth weight z-score, timing of gluten introduction, gastrointestinal tract 
infections in the first year and maternal anti-tTG concentration did not provide an alteration of ≥ 10% in ORs. 
Table 4. Association between the introduction of gluten and positive anti-tTG concentrations.
N=1679
Gluten introduction N (%)
Crude model
OR, 95% CI
Multivariate model
aOR, 95% CIa
< 6 mo 605 (36%) Reference Reference
≥ 6 mo 1074 (64%) 0.68 (0.34,1.35) 0.64 (0.31,1.31)
OR: Odds ratio; 95% CI: 95% confidence interval. 
a Adjusted for ethnicity and household income per month.
Adjustment for sex, birth weight z-score, smoking during pregnancy, breastfeeding, parity, caesarean section, day-
care attendance, vitamin D supplementation, gastrointestinal and respiratory tract infections in the first year, mater-
nal educational level and maternal anti-tTG concentration did not provide an alteration of ≥ 10% in ORs.
Table 5. Association between the introduction of gluten and positive anti-tTG levels below and above 10 
times the ULN.
N=1679
Gluten 
introduction
N (%)
7-70 IU/ml
N=17
>70 IU/ml
N=26
Crude model
OR, 95% CI
Multivariate model
aOR, 95% CI a
Crude model
OR, 95% CI
Multivariate model
aOR, 95% CI a
< 6 mo 605 (36%) Reference Reference Reference Reference
≥ 6 mo 1074 (64%) 1.27 (0.37,4.37) 1.30 (0.38,4.41) 0.47 (0.19,1.13) 0.42 (0.17,1.02)
OR: Odds ratio; 95% CI: 95% confidence interval. 
a Adjusted for ethnicity and household income per month. 
Additional adjustment for sex, birth weight z-score, smoking during pregnancy, breastfeeding, parity, caesarean sec-
tion, day-care attendance, vitamin D supplementation, gastrointestinal and respiratory tract infections in the first 
year, maternal educational level and maternal anti-tTG concentration did not provide an alteration of ≥ 10% in ORs. 
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DISCuSSION
In this population-based prospective birth cohort, we did not find an association with 
breastfeeding duration and the timing of gluten introduction and positive anti-tTG con-
centrations in children with CDA at the age of 6 y. 
The ESPGHAN Committee on Nutrition recommends that both early and late introduc-
tion of gluten should be avoided. In addition, it is recommended to introduce gluten in 
small amounts into the diet when the infant is still being breastfed.11 However, evidence 
for avoiding very early and late introduction of gluten for the prevention of CeD is inconsis-
tent. We did not find a relationship between timing of gluten introduction and the risk of 
CeD in childhood, which is in accordance with other studies.13, 15, 17 In contrast, findings of 2 
other prospective studies support a role for the timing of gluten introduction.9, 14 Norris et 
al9 found an increased risk of biopsy-confirmed CeD in CDA positive children for both early 
(≤3 mo) and late (≥7 mo) introduction of gluten.9 Strikingly, before restricting their analyses 
to biopsy-confirmed CeD, Norris et al did not find late introduction to increase the risk of 
CDA. This suggests that timing of gluten introduction may be differentially associated with 
biopsy-confirmed and non biopsy-confirmed CeD. However, diagnosed CeD is subjected to 
bias, depending on the awareness of the pediatricians to make the diagnosis. In addition, 
Norris et al focused on high risk children defined as having a first degree relative with type 1 
diabetes or having HLA genotypes associated with CeD and type 1 diabetes. Therefore, the 
results cannot be directly extrapolated to our study. Very recently, the Norwegian Mother 
and Child Cohort Study14 found late (≥7 mo), but not early (≤4 mo) introduction, to be 
borderline associated with an increased risk for CeD (adjusted OR: 1.27 95% CI 1.01, 1.65). 
We could not confirm these results in our study, nor did we find the effect estimates in the 
same direction (adjusted OR: 0.64, 95% CI 0.31, 1.3). However, the Norwegian Mother and 
Child Cohort Study included children with clinical CeD instead of CDA which may explain 
the different results.
The results of our study on breastfeeding and the development of CDA are in line with the 
findings of other prospective studies.9, 15, 33 Stordal et al 14 also did not find breastfeeding 
for ≥6 mo (6-12 mo) to be associated with CeD, but found breastfeeding beyond 12 mo to 
be associated with an increased risk of CeD. The majority of children in our cohort did not 
breastfeed after the age of 12 mo; therefore we were unable to replicate this analysis.14 
Several studies did find breastfeeding to reduce the risk of CeD,12, 17 especially breastfeed-
ing at the time of (13, 34, 35) and beyond12, 13, 19, 35 the introduction of gluten, as well as with 
gradual introduction of gluten while breastfeeding.12, 13, 19 However, most of these studies 
were based on retrospective collected data which may lead to recall bias (ie, differential 
reporting on infant feeding practices in those with and without CeD diagnosis).13, 17, 18, 20, 35 
In addition, it remains unclear whether the protective effect of breastfeeding is persistent 
or only delays the onset of symptoms, and therefore CeD diagnosis.12, 20, 34, 35 For example, 
previous studies found longer breastfeeding35 and breastfeeding exclusivity18 only to delay 
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the onset of CeD in infancy. This may explain why we did not find any association between 
breastfeeding duration and CDA. Although we did not find breastfeeding duration and the 
timing of gluten introduction to be associated with CDA, we do not exclude the role of 
infant feeding in the development of CeD. Breastfeeding and the timing of gluten introduc-
tion might not be protective for the development of subclinical, silent or latent forms of 
CeD, but could protect against developing symptomatic CeD. Also, gluten introduction 
while breastfeeding and the amount of gluten, could be more important than the duration 
of breastfeeding and the timing of gluten introduction, as suggested by Ivarsson et al.13
An important strength of this study is first, the assessment of serum anti-tTG concen-
trations and HLA testing in the general pediatric population, which are good methods to 
detect clinical silent CeD.6 Previous studies selected children with diagnosed CeD,17 or with 
symptomatic CeD leading to CeD diagnosis,13, 15 or focused on high-risk children.9 Second, 
we subdivided positive anti-tTG concentrations (>7 U/ml) into 2 groups based on 10 times 
the ULN level (>70 IU/ml), because positive anti-tTG concentrations >10 times the ULN 
show high diagnostic accuracies.25 Of all anti-tTG positive children in our study popula-
tion, > 60% had anti-tTG concentrations >10 times the ULN, suggesting that these children 
likely have CeD. Third, our study design provided information on a broad range of potential 
confounders, including ethnicity, socioeconomic status, smoking during pregnancy, and 
infections.
Some limitations should be taken into account in the interpretation of the results. Infor-
mation on breastfeeding duration and the timing of gluten introduction was obtained by 
parental self-report. Nevertheless, only if misclassification of infant feeding practices were 
related to CeD diagnosis would it have influenced our results, which is unlikely because 
questionnaires on feeding practices were completed prior to anti-tTG measurement at 6 
y of age. In addition, participants in our study were unaware of tTG-IgA determination, so 
a response bias is therefore highly unlikely. Also, it may be questioned whether our study 
had sufficient power to detect small differences in gluten introduction practices between 
children with and without CDA development. Our study had a power of 80% (at an α of 0.05) 
to detect at least a 22% difference in gluten >6 mo to be statistically significant between 
children with and without CDA. A recent study19 (n=13,279) found a difference of 2.5% in 
gluten >6 mo to be statistically significant, whereas Norris et al9 found a difference of 12% 
to be significant (n=1,560). Although the sensitivity and specificity of anti-tTG are high,25, 36 
only when anti-tTG concentrations are >10 times the ULN in combination with symptoms 
and positive anti-endomysial antibody can (clinical) CeD be diagnosed without duodenal 
biopsy.25 According to the ESPGHAN, clinically diagnosed CeD concerns children who visit 
the pediatrician because of symptoms, whereas subclinical CeD is found by screening and 
must be verified by biopsy specimens. However, because our study did not have biopsy 
specimens, we examined the development of CDA. Therefore, final conclusions concerning 
(subclinical) CeD diagnosis should be made with caution. Furthermore, we adjusted for 
potential confounders in our analysis, but residual confounding cannot be fully excluded. 
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Another limitation of this study is that our study cannot examine the effect of gluten in-
troduction before the age of 4 mo, as well as the amount of gluten introduced in relation 
to anti-tTG concentrations. Although a previous study in Dutch infants showed that the 
majority of children receive gluten between 3 and 6 mo of age and not before that time,37 
a window of opportunity in which gluten introduction might prevent CDA cannot be fully 
ruled out. In relation to breastfeeding, this study cannot examine the effect of breastfeed-
ing at the time of and beyond gluten introduction. Hence, our study precludes conclusions 
on the effect of very early introduction of gluten, gradual introduction of gluten, and the 
introduction while breastfeeding.
In conclusion, the results suggest that a delayed introduction of gluten beyond the age 
of 6 mo does not increase the risk of CDA. In addition, breastfeeding for >6 mo does not 
decrease the risk of CDA in children at 6 y of age. Our study precludes conclusions on the 
timing of gluten introduction while breastfeeding. 
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ABSTRACT
Objectives
Persistent viral infections have been implicated in the etiology of autoimmune diseases 
in adulthood, but it is not known whether herpesviruses are associated with the develop-
ment of celiac disease autoimmunity (CDA) in childhood. We assessed whether herpesvirus 
infections are associated with transglutaminase type 2 antibody (TG2A) concentrations in 
children at 6 years of age. 
Methods
This study was embedded within a population-based prospective cohort study. Serum 
immunoglobulin G levels against Epstein-Barr virus, cytomegalovirus (CMV), and herpes 
simplex virus type 1 were measured by enzyme-linked immunosorbent assay, and TG2A 
concentrations with fluorescence enzyme immunoassay in 4420 children at 6 years of age. 
Children were categorized based on TG2A concentrations into negative (<7 U/ml), positive 
(>7-70 U/ml) and strongly positive (>70 U/ml), that is 10 times upper limit normal (ULN). 
Results
Fifty-nine children (1.3%) were TG2A positive, and of these 31 (53%) had concentrations 
70 U/ml or more. Children with TG2A concentrations 70 U/ml or more were less often 
infected with CMV (adjusted odds ratio (aOR) 0.38; 95% CI 0.14, 0.98; p=0.04) and with any 
of the three viruses (aOR 0.38; 95% CI 0.18, 0.78; p<0.01) than children with TG2A negative 
concentrations. In addition, children with TG2A concentrations 70 U/ml or more were less 
often infected with 2 or more viruses than children with TG2A negative concentrations (aOR 
0.15; 95 % CI 0.03, 0.65; p=0.01). 
Conclusions
Both CMV single infection and combined CMV, Epstein-Barr virus and/or herpes simplex 
virus type 1 infections are inversely associated with strongly TG2A positivity. This may 
indicate a protective effect of herpesvirus infections in the pathogenesis of celiac disease 
autoimmunity. 
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INTRODuCTION
Species of the human herpesvirus family have been implicated in the pathogenesis of 
autoimmune diseases in adulthood,1 but their role in childhood autoimmunity remains 
poorly studied.2 Celiac disease (CeD) is one of the most prevalent, immune-mediated sys-
temic disorders in childhood, and is characterised by villous atrophy causing enteropathy 
and a wide variety of clinical manifestations.3 Carriership of either the HLA-DQ2 or HLA-DQ8 
haplotype is a prerequisite for CeD.3-5 Furthermore, the presence of IgA antibodies against 
the enzyme transglutaminase type 2 (TG2A) is a specific disease marker. CeD diagnosis is 
based on biopsy specimens, but these are omitted in HLA DQ2-DQ8 positive children hav-
ing TG2A concentrations >10 times upper limit normal (ULN; 70 U/ml), in accordance with 
both clinical complaints and positive anti-endomysial antibody levels.6, 7 The disease may 
present at any age. Still, the majority of patients initially lack typical clinical symptoms,8 
resulting in delayed diagnosis or even under diagnosis. Screening for TG2A positivity is, 
thereforem considered an effective method to detect potential and subclinical CeD.9, 10 
Similar to many autoimmune diseases, the prevalence of CeD has been increasing rap-
idly with up to a 4-fold increase in the last 50-years. This is considered a true rise, rather 
than a result of improved detection.11-14 Given its rapidity, this cannot be merely attributed 
to genetic factors. Environmental factors early in life, such as the amount of infections, 
might be involved.4 Herpesviruses, including Epstein-Barr virus (EBV), Cytomegalovirus 
(CMV) and Herpes Simplex virus type 1 (HSV-1) are ubiquitous and highly contagious, but 
the age at primary infection is delayed in Western countries,15-17 which together with the 
increase in CeD prevalence may suggest that infections early in life might have a protective 
role in the etiology of CeD. In addition, seroprevalences of herpesviruses depend on ethnic 
/geographic background and socioeconomic position,18, 19 which may further explain 
some of the ethnic/geographic variation in CeD incidence.20 In the present study, we used 
herpesviruses as a proxy for the amount of infections in early life. To our knowledge, as-
sociations between herpesvirus infections and TG2A concentrations in childhood have 
never been studied in a population based cohort. The objective of this study, therefore, 
was to examine whether EBV, CMV and/or HSV-1 infections were inversely associated with 
the presence of TG2A positivity as marker for celiac disease autoimmunity in children at 6 
years of age. 
METhODS
Study design
This present study was embedded within the Generation R study, a prospective popula-
tion based cohort study from fetal life until young adulthood. The background, design and 
aims have been described in detail previously.21 Ethics approval for the study design, the 
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research aims and all the specific measurements were obtained from the Medical Ethical 
Committee of Erasmus MC, University Medical Centre Rotterdam, The Netherlands. Writ-
ten informed consent was obtained from all participants. A total of 9778 mothers with a 
delivery data between April 2002 and January 2006 were enrolled in the study. At the age of 
6 years, n=8305 children (85% of the original cohort) still participated in the study, of whom 
81% (n=6690) visited the research centre.21 During this visit, blood samples were collected 
from 4593 children. From a total of 4436 children both serological viral tests and TG2A con-
centrations could be determined at the median age of 6.0 years. We excluded children with 
a questionnaire reported low or gluten free diet (GFD) (n=10), because TG2A concentra-
tions drop as a results of the GFD, and we excluded children with a questionnaire-reported 
CeD diagnosis, but negative TG2A concentrations (n=6). Of 9,778 children participating in 
the original cohort, the resulting population for analysis consisted of 4,420 children (45%). 
[Supplementary Figure 1]. 
herpes virus serology
Venous blood plasma samples were analysed using enzyme immunoassays for IgG anti-
bodies against EBV (native mixture of several viral capsid antigens), CMV (purified native 
antigens from strain “AD169”), and HSV-1 (glycoprotein C1; all from EUROIMMUN, Lübeck, 
Germany).22 Results were evaluated semiquantitatively relative to a manufacturer-provided 
reference threshold sample. Per manufacturer’s instructions, an optical density in the 
patient sample >10% above the provided threshold sample was defined as positive. The 
inter-assay and intraassay coefficients of variation (CV) as provided by the manufacturer 
were <10%, based on 20 measurements performed on 3 sera for the intraassay CV, and 4 
measurements for the interassay CV. In our study, we used 53 kits, and the interassay CV 
of the positive controls that were provided with the kits were 6% (CMV), 5% (EBV) and 11% 
(HSV-1).
Detection of transglutaminase type 2 antibodies 
Serum IgA antibody concentrations against transglutaminase type 2 were measured using 
a fluorescence enzyme immunoassay (Elia Celikey IgA, Phadia ImmunoCAP 250, Phadia 
AB, Uppsala, Sweden). The intra- and interassay CV was <10% and 15% respectively. Sera 
with a TG2A concentration of 7 U/ml or higher were considered to be positive per manufac-
turer’s instructions. In addition, TG2A positive concentrations were further categorized into 
2 categories based on the 10 times or more upper limit normal (ULN) of the test kit (>7-70 
U/ml, and >70 U/ml) [Supplemental Figure 1].6, 23 
Detection of hLA Risk Alleles
A genome-wide association scan (Illumia 610K) of child DNA was taken from n=5908 cord 
blood samples. Missing cord blood samples were mainly due to logistical constraints 
during delivery.21 To identify the children carrying HLA-DQ2 or –DQ8 alleles, a tag single 
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nucleotide polymorphism approach was used as described in detail previously.24, 25 Chil-
dren were genotyped for single nucleotide polymorphisms linked to HLA-DQ2 (rs2187668, 
rs2395182, rs4713586 and rs7775228) and DQ8 (rs7454108) by using genome-wide Illu-
mina 610 Quad Array (San Diego, CA, USA). Genotype and allele frequencies were in Hardy 
Weinberg Equilibrium (rs218677, p=0.88; rs2395182, p=0.78; rs4713586, p=0.96; rs7775228, 
p=0.86; rs7454108, p=0.90). 
Covariates
Data on potential confounders, such as foetal sex, gestational age, birth weight, birth 
season, and mode of delivery were obtained from obstetric records from hospitals and 
mid-wife practices. Data on sociodemographic and lifestyle factors were obtained by a 
combination of pre- and postnatal questionnaires completed by both parents. Prenatal 
questionnaires included information on ethnicity,26 parity, maternal smoking during 
pregnancy, maternal educational level27 and family net household income per month.28 
Child’s ethnic background was dichotomized into ‘Western’ and ‘non-Western’ ethnicity 
according to the Dutch agency for statistics. In addition, information on Caucasian versus 
non-Caucasian background was derived from GWAS data from cord blood.21 The cut-off of 
2200 euro/month was used based on the average income per household in the study area. 
Information on the highest level of achieved maternal education was subsequently dichot-
omized into ‘low’ and ‘high’ (university or PhD degree). Postnatal questionnaires included 
information on breastfeeding, timing of gluten introduction, vitamin D supplementation, 
day-care attendance, gastrointestinal and respiratory tract infections, and antibiotic use 
during the first 6 years of life. Information on the duration and exclusiveness of breastfeed-
ing was asked by parental reported questionnaires at the ages of 2, 6 and 12 months and 
crosschecked. Because breastfeeding duration was stronger related to CMV seropositivity 
than breastfeeding exclusiveness, we included breastfeeding duration in the multivariable 
model. Information on gastrointestinal, upper and lower respiratory tract infections, and 
antibiotic use was assessed by parental reported questionnaires which were administered 
yearly from birth until 6 years of age. 
Statistical analysis
First, independent student’s t tests and Chi-square tests were used to test whether mater-
nal and child characteristics were different between TG2A positive and negative groups. 
Second, logistic regression analyses was performed with TG2A positivity at the age of 6 
years as dependent variable. Viral seropositivity (IgG against either EBV, CMV or HSV-1) was 
analyzed separately as independent dichotomous variable. The variable ‘frequency of viral 
infection’ was calculated by taking the sum of EBV, CMV and/or HSV-1 IgG seropositivity, 
resulting in 3 categories: 0, 1 or >2 seropositive results. Multivariable models were cre-
ated, with stepwise adjustment for potential confounders. Because of small numbers in 
the TG2A positive group (n=59), the selection of potential confounders was restricted to 
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those who attained a 10% or more change in odds ratio (OR).29 To assess whether the as-
sociation between viral antibody levels and TG2A concentrations was different by ethnicity 
and children with and without prior gastrointestinal infections during infancy, statistical 
interaction was evaluated by adding the product term of the independent variable and 
subgroup (independent variable x subgroup) as covariate in the model. If the test was 
significant (p<0.05), we also stratified the analysis by the variables. To reduce attrition bias, 
multiple imputation of the covariates was performed (n=10 imputations). The multiple 
imputation procedure was based on the correlation of the variable with missing values 
with other subject characteristics.30 Regression coefficients were pooled by taking the 
average of the coefficients of the 10 imputed datasets. The pooled standard error was then 
calculated using Rubin rule. The pooled results of the 10 imputed datasets were reported 
in this article as ORs and 95% confidence intervals (CIs). A p-value ≤0.05 was considered 
as statistically significant. Statistical analyses were performed in SPSS 20.0 for Windows 
(SPSS Inc., Chicago, IL). 
RESuLTS
Subject characteristics
Maternal and child characteristics are shown in [Table 1]. Within the total group of 4420 
children, 59 children (1.3%) were TG2A positive, and of these 31 (53%) had concentrations 
>10 ULN (>70 U/ml) [Table 1, Supplementary Figure 1]. Among these latter 31, 92% carried 
the HLA-DQ2 or –DQ8 alleles [Table 1]. TG2A positivity was significantly related to higher 
socio-economic status (net household income per month), female sex and Western eth-
nicity [Table 1]. No significant differences were observed in maternal educational level, 
maternal smoking during pregnancy, mode of delivery, parity, birth weight, birth season, 
feeding habits including breastfeeding, and timing of gluten introduction,23 day-care at-
tendance in the first year, gastrointestinal and respiratory tract infections in the first year 
and antibiotic use during the first 6 years. 
Seroprevalences of herpesvirus infections 
Within the total group of 4420 children with a median age of 6.0 years, 1,672 (38%) were 
CMV infected, 2,257 (51%) were EBV infected, and 871 (20%) were HSV-1 infected. [Table 2]. 
Twenty-nine percent were seronegative for all 3 viruses, 39% was seropositive for 1 virus 
and 32% was seropositive for at least 2 viruses [Table 3]. Among children infected with CMV, 
infection with EBV and HSV-1 was more prevalent (respectively 59% and 25%) than among 
children who were not infected with CMV (respectively. 46% and 17%). [Supplementary 
Table 3].
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TG2A strongly positive children less often experienced herpesvirus infections
Children with TG2A concentrations 70 U/ml or more were less often infected with CMV 
than TG2A negative children (adjusted odds ratio [aOR] 0.38; 95% CI 0.14, 0.98; p=0.04) 
[Table 2, Figure 1]. The same tendencies were found for EBV and HSV-1 [Table 2], although 
these associations did not remain significant after adjustment for ethnicity, income and 
Table 1. Maternal and child characteristics of study population. Imputed dataset
N=4420  TG2A negative<7 IU/ml
TG2A positive
>7 U/ml
7-70 IU/ml >70 IU/ml
Characteristics n=4361 (98.7%) n=28 (0.6%) n=31 (0.7%)
Maternal characteristics
Age (years; mean, sd) 30.7 5.1 30.7 5.4 32.8* 3.4
High educational level (n;%) 3276 75% 23 82% 19 61%
Household income per month (>2200 euro) (n;%) 2349 54% 13 46% 25 81%**
Smoking during pregnancy (n;%) 1127 26% 8 29% 8 26%
Caesarean section (n;%) 572 13% 4 9% 2 6%
Multiparity (n;%) 1971 45% 16 57% 12 39%
Child characteristics
Age (years; mean, sd) 6.2 0.6 6.3 0.6 6.1 0.3
Male (n;%) 2258 52% 8 29%* 12 39%
Western ethnicity (n;%) 2901 67% 18 64% 29 94%**
HLA DQ2 DQ8 carriershipa (n;%) 1164 41% 15 88%*** 23 92%***
Missing data (n;%) 1512 35% 11 39% 6 19% 
Birth weight z-score Mean (SD) -0.07 1.00 0.18 1.19 -0.21 1.15
Birth season (autumn/winter) (n;%) 2221 51% 10 36% 14 45%
Breastfeeding (n;%)
< 6 mo 2485 57% 14 50% 20 65%
≥ 6 mo 1876 43% 14 50% 11 35%
Introduction of gluten (n;%)
< 6 mo 2413 55% 18 64% 14 45%
≥ 6 mo 1,948 45% 10 36% 17 55%
Day care attendance first year (n;%) 2925 67% 17 61% 27 87%
Gastro intestinal tract infections first year (n;%) 1960 45% 10 36% 17 55%
Respiratory tract infections first year (n;%) 2443 56% 13 46% 21 68%
Use of antibiotics / penicillin (n;%)
First year 2141 49% 12 43% 11 35% 
Ever 3371 77% 21 75% 23 74% 
*Significantly different from TG2A negative group. *P<0.05, ** p<0.01, *** P<0.001.
a Was not multiple imputed. Of 4420 children, data on HLA DQ2 or DQ8 carriership was present in n=2891 (65%) 
children. Of these, n=1202 (42%) were HLA DQ2/DQ8 positive, and 1689 (58%) children were HLA DQ2/DQ8 negative. 
Data on HLA DQ2/ DQ8 risk type was missing in n=1529 (35%)children. 
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breast-feeding (aOR EBV 0.57; 95% CI 0.27, 1.21; p=0.14) (aOR HSV-1 0.18; 95% CI 0.02, 1.29; 
p=0.10) [Table 2]. Unadjusted associations are shown in Supplementary Table 2. In ad-
dition, children with TG2A concentrations 70 U/ml or more were less often infected with 
any of the 3 viruses (aOR 0.38; 95% CI 0.18, 0.78; p<0.01). No significant differences in viral 
infection rates were observed between TG2A positive children with concentrations <70 U/
ml and TG2A negative children [Table 2].
Within the total group of 4,420 children, CMV positive children were more often infected 
with other viruses than CMV negative children [Supplementary Table 3b]. Still, the inverse 
association between CMV infection and TG2A positivity was independent of EBV and HSV-1 
infection. [Figure 1]. 
Associations between CMV infection and TG2A positivity were not significantly different 
between children with and without HLA-DQ2 or HLA-DQ8 (p>0.93). After stratifying the 
analysis on HLA-DQ2/DQ8 carriership, the same tendencies were observed for associations 
between herpesvirus infections and TG2A positivity in HLA-DQ2/DQ8 positive children. 
[Supplementary Table 4] No significant statistical interactions were found between com-
binations of viral infections, ethnicity (western/non-western, Caucasian/non-Caucasian), 
or gastrointestinal tract infection during the first year of life (p>0.18; 0.66; 0.50; and 0.33 re-
spectively). In line with this, associations between herpesvirus infections and TG2A positiv-
ity were not materially different between Caucasians and non-Caucasians [Supplementary 
Table 2. Association between herpesvirus infection and TG2A concentrations
Total 
number of 
children
TG2A 
negative
<7 U/ml
TG2A positive 
>7 U/ml
n= 4420
n= 4361 
(98.7%)
7-70 U/ml
n= 28 (0.6%)
>70 U/ml
n= 31 (0.7%)
 N (%) N (%) N (%) a OR (95% CI) N (%) a OR (95% CI)
CMV 1672 (38%) 1657 (38%) 10 (36%) 0.87 (0.39;1.92) 5 (16%) 0.38 (0.14;0.98)*
No CMV 2748 (62%) 2704 (62%) 18 (64%) Reference 26 (84%) Reference
EBV 2257 (51%) 2234 (51%) 13 (46%) 0.79 (0.37;1.68) 10 (32%) 0.57 (0.27;1.21)
No EBV 2163 (49%) 2127 (49%) 15 (54%) Reference 21 (68%) Reference
HSV-1 871(20%) 865 (20%) 5 (18%) 0.82 (0.1;2.21) 1 (3%) 0.18 (0.02;1.29)
No HSV-1 3549 (80%) 3496 (80%) 23 (82%) Reference 30 (97%) Reference
Any (EBV, CMV and/or HSV-1) 3117 (71%) 3085 (71%) 19 (68%) 0.82 (0.36;1.86) 13 (42%) 0.38 (0.18;0.78)**
None 1303 (29%) 1276 (29%) 9 (32%) Reference 18 (58%) Reference
aOR: adjusted Odds ratio; 95% CI: 95% confidence interval. ORs are from multiple imputed data and derived from 
logistic regression models.a Adjusted for ethnicity, net household income per month, breast-feeding and day-care 
attendance. Additional adjustment for maternal educational level, maternal smoking during pregnancy, parity, sex, 
birth weight z-score, caesarean section, season of birth, timing of gluten introduction, vitamin D supplementation 
age 6-12 months, gastrointestinal and respiratory tract infections in the first year (yes/no), and antibiotic use did not 
provide an alteration of ≥ 10% in OR. Unadjusted associations are shown in Supplemental Table S2. *Significantly 
different from TG2A negative group. *P<0.05, ** p<0.01
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Table 3. Association between herpesvirus infection rate and TG2A concentrations
Total number 
of children
TG2A negative 
<7 U/ml
TG2A positive 
>7 U/ml
n= 4420 n=4361 (98.7%)
7-70 U/ml
n= 28 (0.6%)
>70 U/ml
n= 31 (0.7%)
 N (%) N (%) N (%) a OR (95% CI) N (%) a OR (95% CI)
Infection frequency
0 infections 1303 (29%) 1276 (29%) 9 (32%) Reference 18 (58%) Reference
1 infection 1723 (39%) 1702 (39%) 10 (36%) 0.80 (0.32; 1.99) 11 (36%) 0.52 (0.24;1.10)
> 2 infections 1394 (32%) 1383 (32%) 9 (32%) 0.85 (0.32; 2.25) 2 (6%) 0.15 (0.03;0.65)*
aOR: adjusted Odds ratio; 95% CI: 95% confidence interval. ORs are from multiple imputed data and derived from 
logistic regression models. a Adjusted for ethnicity, net household income per month, breastfeeding and day-care 
attendance. Additional adjustment for maternal educational level, maternal smoking during pregnancy, parity, sex, 
birth weight z-score, caesarean section, season of birth, timing of gluten introduction, vitamin D supplementation 
age 6-12 months, gastrointestinal and respiratory tract infections in the first year (yes/no), and antibiotic use did not 
provide an alteration of ≥ 10% in OR. Unadjusted associations are shown in Supplemental Table S2. *Significantly 
different from TG2A negative group. *P<0.05
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Figure 1. Association between herpesvirus infections and TG2A concentrations 
A, Association between CMV infection and TG2A concentrations. Dark blue represents CMV seropositives, Light grey 
represents CMV seronegatives.
B, Association between multiple herpesvirus infections and TG2A concentrations. White represents 0 infections; 
Light blue 1 infection; Middle blue 2 infections; and dark blue 3 infections.
C, Association between multiple herpesvirus infections and TG2A concentrations according to CMV infection. Light 
blue represents 1 infection (CMV); Middle blue 2 infections (CMV+EBV+ or CMV+HSV-1+); Dark blue 3 infections 
(CMV+EBV+HSV-1+); Light grey no infections; Middle grey 1 infection (EBV+ or HSV-1+); and dark grey 2 infections 
(EBV+ and HSV-1+).
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Table 5]. However, non-Caucasians experienced more often herpesvirus infections than 
Caucasians [Supplementary Table 6].
TG2A strongly positive children were less often infected with multiple viruses
Children with TG2A concentrations 70 U/ml or more were less often infected with 2 or more 
viruses than TG2A negative children (aOR 0.15; 95 % CI 0.03, 0.65; p=0.01) [Table 3, Figure 
1]. However, associations between viral infections and TG2A positivity <70 U/ml were not 
significant. 
DISCuSSION
This population based cohort study showed an inverse association between CMV single 
infection and strongly TG2A positivity. In addition, multiple (>2) infections (EBV, CMV or 
HSV-1) were inversely related to the presence of TG2A. This could indicate an accumulated 
protective effect of multiple herpesvirus infections on the development of celiac disease 
autoimmunity in childhood.
Our results confirm and extent a case-control study that examined the association 
between CMV infection and TG2A positivity previously.31 The complex interplay between 
infections and autoimmunity has only been partly understood.32 More important, it should 
be considered that the observed associations in our study might not be causal, as herpes 
viridae can be seen as a proxy for the amount of infections early in life. CMV and EBV in-
fection are, however, known to increase effector memory CD8+ T-cell numbers,33-35 which 
influence the composition and diversity of the adaptive immune repertoire.34, 36 As a con-
sequence, the development of autoreactive antibodies, such as TG2A, may be influenced. 
Strikingly, some matched (nested) case-control studies,37, 38 suggest that serum TG2A 
could be produced during a recent or ongoing EBV or CMV infection, irrespective of celiac 
disease diagnosis.38 In these studies, data on TG2A was, however, collected retrospectively 
in patients presenting with clinical evidence of infection, such as glandular fever and hepa-
titis,37 or patients were recruited at the emergency department,38 which makes comparison 
with our study population difficult. Provocative effects of EBV and CMV have also been 
suggested in several other autoimmune diseases.1, 37 These associations, however, may 
be multidirectional and multifaceted.39 Hence, a common general pathophysiological 
mechanism to explain our results in relation to the development of TG2A may not exist. 
Our results do not support the protective effects suggested for EBV.31 A potential ex-
planation could lie in the study groups based on adult populations. Furthermore, TG2A 
concentrations were not used as a screening tool for CeD, but clinically diagnosed celiac 
disease patients were studied.31 In another study, viral seroprevalences and TG2A con-
centrations were studied in adults with diabetes mellitus type 1.40 In these patients, lower 
levels of antibodies against infection (CMV and EBV) and higher tTG-IgG antibodies were 
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observed than in the healthy control group. Therefore, they speculate that infections may 
have a protective role in development of type 1 diabetes. Their results were, however, not 
adjusted for major confounders such as ethnicity and socioeconomic status. The results of 
our univariable analysis indeed suggested an inverse association between EBV and CeD, 
but after adjusting for ethnicity, socioeconomic status, breast-feeding, and day care, the 
results for EBV did not remain significant. Thus, the earlier observed associations for EBV 
may have been indirect effects of CMV or multiple herpes virus infections. Although it could 
be hypothesized that CMV-specific and EBV-specific immune responses act synergistic 
or antagonistic in the pathogenesis of CeD because of the different T-cell responses they 
elicit,41, 42 effects on autoimmunity may also rely on the accumulating effects of infectious 
agents, irrespective of type of infection, also known as the ‘multiple hit concept’.43 Intrigu-
ingly, our results indicate a cumulative effect of CMV, EBV and HSV-1 in relation to TG2A 
concentrations, irrespective of type of viral infection. The odds of TG2A positive concentra-
tions of at least 70 U/ml were much stronger for multiple (>2) herpesvirus infections (aOR 
0.15), than for the virus-specific effects of CMV (aOR 0.38), suggesting that the effect on 
TG2A may be especially attributed to multiple herpesvirus infections, rather than to virus-
specific infections. Although accumulated viral and microbial exposure have been sug-
gested to influence CeD risk (44), this was not consistently repeated.45 In fact, provocative 
effects, rather than protective, have been observed for infections early in life. For example, 
neonatal infections (46) and repeated infectious episodes early in life44 were associated with 
increased CeD risk. Neonatal infections were, however, based on a retrospective analysis 
of the birth register, and infectious episodes early in life were based on parental reports. 
Hence, these analysis could not discriminate between various kinds of infections or 
pathogens. Potential infectious agents could be enterovirus,37 adenovirus,47 rotavirus48,and 
campylobacter,49 which affect gut microbiota or intestinal membrane permeability, rather 
than influencing adaptive immune responses. 
Methodological considerations
To our knowledge, this is the first population-based cohort study that examined associa-
tions between herpesviruses and TG2A concentrations in children. A major strength of the 
present study is the large sample, representing a typical Western multicultural community 
and information on a broad range of potential confounders, including socioeconomic sta-
tus, ethnicity, breast- bfeeding, daycare and antibiotic use. Second, we examined screening-
identified patients instead of clinically identified CeD patients. Considering the fact that 
the majority of CeD patients remain undiagnosed due to often silent or atypical forms of 
the disease,3, 11 a screening-based method will give the opportunity to study a more diverse 
and representative study population. In addition, primary infection with herpesviruses is 
often asymptomatic in childhood. Herpesviruses remain persistent after primary infection, 
even though virus particles can be undetectable. Therefore, IgG antibodies against these 
viruses provide a good correlate of viral infections in a healthy paediatric population. 
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Some limitations should, however, be taken into account. Firstly, causality remains 
uncertain, since antibodies against EBV-CA, CMV and HSV-1 were measured at the same 
time as TG2A. Therefore, reverse causation cannot be excluded: children with a more 
‘celiac disease orientated immune profile’ may be less prone to these infections. Primary 
infection is, however, related to crowding,50 rather than it is related to immune (dys)func-
tion. Hence, reverse causation is not likely. Unfortunately, we could not study the effect of 
timing of herpesvirus seroconversion on TG2A positivity, because we did not have data on 
IgM virus-specific antibodies, nor data on virus-specific antibodies at earlier ages. In addi-
tion, we only determined TG2A concentrations ate the age of 6 years, therefore it remains 
uncertain at what age children became TG2A positive. Secondly, although we adjusted for 
a broad range of confounders, the protective effect of viral infections may still be related to 
unmeasured variables. Hence, residual confounding cannot be fully excluded. Thirdly, we 
had 35% missing data on HLA-DQ2/DQ8 risk type because of missing cord blood samples. 
The presence of HLA-DQ2/DQ8 was, however, defined from cord blood samples, thus avail-
ability did not depend on CeD diagnosis. Therefore, missing data on HLA-DQ2/DQ8 are not 
likely to have influenced the results. Because previous studies have shown associations 
between TG2A positivity irrespective of CeD diagnosis,38 and because the specificity of ge-
netic risk typing is not 100%, we included the HLA-DQ2/DQ8 negative children. From a clini-
cal perspective, it may be, however, argued that children with HLA-DQ2/DQ8 negative are 
not likely to develop CeD, and therefore should not be included in the analyses. Although 
the HLA-DQ2/DQ8*CMV interaction was nonsignificant, we stratified our analysis on the 
presence of HLA-DQ2/DQ8 for clinical interpretation purposes. The same trends between 
herpesvirus infections and strongly TG2A positivity were, however, observed in the HLA-
DQ2/DQ8 positive group. Fourthly, we performed our studies in a large cohort, but because 
of the small number of patients stratified by high TG2A positivity, the limited statistical 
power may have affected the size and significance of the effect estimates. Furthermore, 
correcting for multiple confounding factors was not always possible. These factors may 
partly explain the nonsignificant results in the stratified analysis for the HLA-DQ2/DQ8 
positive children. Lastly, although the sensitivity and specificity of TG2A concentrations 
are high, we studied Celiac Disease Autoimmunity (CDA) and not CeD. CeD can merely be 
diagnosed without intestinal biopsy on condition that TG2A concentrations are increased 
10 ULN or more in accordance with both clinical symptoms and elevated endomysial 
antibody concentrations.6 Therefore, conclusions concerning final CeD diagnosis should 
be made with caution. Nevertheless, even if children with strongly TG2A positivity lack 
criteria for final CeD diagnosis, the associations between herpesvirus infections and TG2A 
positivity remain valid. 
Conclusion 
In conclusion, this population based cohort study showed an inverse association between 
CMV infection and strongly TG2A positivity. In addition, infection with 2 or more herpes-
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viruses (EBV, CMV or HSV-1) was inversely related to TG2A positivity. These 2 effects were 
independent of each other and indicate an accumulated protective effect of persistent 
viral infections on the development of celiac disease autoantibodies in childhood. 
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Supplemental Figure 1: Flowchart of the participants within the Generation R 
Study 
Visit to research center age 6 years  
(n=6690) 
	  
Serum collection  
(n=4593) 
	  
Titers of CMV/EBV/HSV1 IgG available 
(n = 4464) 
 
N=4420 included in data analysis 
Excluded children with a GFD (n=10) 
and children with diagnosed celiac 
disease but negative anti-tTG levels 
and no known GFD (n=6). 
TG2A negative 
(n=4361) 
TG2A positive 
(n=59)	  
(n=)	  
>10 times ULN 
(n=31)	  
(n=)	  
Serum TG2A concentrations available 
(n=4436) 
	  
<10 times ULN 
(n=28)	  
(n=)	  
Excluded children with no data on 
TG2A concentrations (n=8), and 
children with low IgA concentrations 
(n=20) (possible IgA deficient). 
	  
Supplemental Figure 1. Flowchart of the participants within the Generation R Study
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Supplemental Table 1. Maternal and child characteristics according to TG2A concentrations. Observed 
Dataset
N=4420 TG2A negative<7 U/ml
TG2A positive
>7 U/ml
7-70 U/ml >70 U/ml
Characteristics n= 4361 (98.7%) n= 28 (0.6%) n= 31 (0.7%)
Maternal characteristics
Age (years; mean, sd) 30.7 5.1 30.7 5.4 32.8 3.4*
High educational level (n;%) 2931 74% 18 78% 17 61%
Household income per month (>2200 euro) (n;%) 1914 58% 11 58% 21 81%*
Smoking during pregnancy (n;%) 946 25% 6 30% 6 24%
Caesarean section (n;%) 478 13% 3 12% 2 7%
Multiparity (n;%) 1890 45% 15 56% 12 39%
Child characteristics
Male (n;%) 2258 52% 8 29%* 12 39%
Western ethnicity (n;%) 2825 65% 17 61% 29 94%***
HLA DQ2 DQ8 carriership (n;%) a 1164 41% 15 88%*** 23 92%***
Missing data (n;%) 1512 35% 11 39% 6 19% 
Birth season (autumn/winter) (n;%) 2221 51% 10 36% 14 45%
Breastfeeding (n;%)
< 6 months 1829 64% 8 50% 15 65%
≥ 6 months 1023 36% 8 50% 8 35%
Age (years; mean, sd) 6.2 0.6 6.3 0.6 6.1 0.3
Introduction of gluten (n;%)
< 6 months 1260 43% 5 31% 15 58%
≥ 6 months 1644 57% 11 69% 11 42%
Day care attendance first year (n;%) 1665 88% 8 80% 21 96%
Gastro intestinal tract infections (n;%)
First year 981 59% 3 33% 13 72%
Year 4-5
Respiratory tract infections first year (n;%)
First year 1642 60% 8 50% 18 72%
Year 4-5 840 24% 3 18% 6 22%
Vitamin D supplementation age 6-12 months (n;%) 1226 45% 9 56% 13 52%
Use of antibiotics / penicillin (n;%)
First year 1203 (52%) 6 43% 7 33%
Ever 2461 61% 13 54% 19 63%
* Significantly different from TG2A negative group. *P<0.05, ** p<0.01, *** P<0.001.
a Of 4420 children, data on HLA DQ2/DQ8 carriership was present in n=2891 (65%) children. Of these, n=1202 (42%) 
were HLA DQ2/DQ8 positive, and 1689 (58%) children were HLA DQ2/DQ8 negative. Data on HLA DQ2/ DQ8 was miss-
ing in n=1529 (35%)children. 
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Supplemental Table 2. Association between herpesvirus infection and TG2A concentrations
Total 
number of 
children
TG2A 
negative 
<7 U/ml
TG2A positive 
>7 U/ml
n=4420
n=4361 
(98.7%)
7-70 U/ml
n= 28 (0.6%)
>70 U/ml
n= 31 (0.7%)
N (%) N (%) N (%) OR (95% CI) N (%) OR (95% CI)
CMV 1672 (38%) 1657 (38%) 10 (36%) 0.91 (0.42;1.96) 5 (16%) 0.31 (0.12;0.82)*
No CMV 2748 (62%) 2704 (62%) 18 (64%) Reference 26 (84%) Reference
EBV 2257 (51%) 2234 (51%) 13 (46%) 0.82 (0.39;1.74) 10 (32%) 0.45 (0.21;0.96)*
No EBV 2163 (49%) 2127 (49%) 15 (54%) Reference 21 (68%) Reference
HSV-1 871(20%) 865 (20%) 5 (18%) 0.88 (0.33;2.32) 1 (3%) 0.14 (0.02;0.98)*
No HSV-1 3549 (80%) 3496 (80%) 23 (82%) Reference 30 (97%) Reference
Any (EBV, CMV and/or HSV-1) 3117 (71%) 3085 (71%) 19 (68%) 0.87 (0.39;1.94) 13 (42%) 0.30 (0.15;0.61)***
None 1303 (29%) 1276 (29%) 9 (32%) Reference 18 (58%) Reference
Infection frequency
0 infections 1303 (29%) 1276 (29%) 9 (32%) Reference 18 (58%) Reference
1 infection 1723 (39%) 1702 (39%) 10 (36%) 0.83 (0.34;2.06) 11 (36%) 0.46 (0.21;0.97)*
> 2 infections 1394 (32%) 1383 (32%) 9 (32%) 0.92 (0.37;2.33) 2 (6%) 0.10 (0.02;0.44)**
* Significantly different from TG2A negative group. *P<0.05, ** p<0.01, *** P<0.001. OR: Odds ratio; 95% CI: 95% con-
fidence interval. ORs are from multiple imputed data and derived from logistic regression models. ORs are not ad-
justed for potential confounders. Adjusted ORs are shown in Table 2. 
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Supplemental Table 3. Frequency of co-infections in population for analysis
a. Prevalence of infections among groups 
N=4,420
Viral Infections EBV +
N=2,257
CMV +
N=1,672
HSV-1 +
N=871
Any (EBV or CMV 
or HSV1)
N=3,117 
2 or more (EBV, CMV, 
and/or HSV-1)
N=1,394
EBV + n (%) - 987 (59%) 574 (66%) 2257 (72%) 1272 (91%)
CMV + n (%) 987 (44%) - 411 (47%) 1672 (54%) 1109 (80%)
HSV-1 + n (%) 574 (25%) 411 (25%) - 871 (28%) 696 (50%)
b. Prevalence of infections within CMV+ and CMV- groups
N=4,420
Viral Infections CMV+ 
N=1,672
CMV –
N=2,748
p-value
Frequency
viral co-
Infections
CMV+ 
N=1,672
CMV –
N=2,748
p-value
0 n (%) 0 1303 (47%) <0.001
EBV + n (%) 987 (59%) 1270 (46%) <0.001 1 n (%) 563 (34%) 1160 (42%) <0.001
HSV-1 + n (%) 411 (25%) 460 (17%) <0.001 2 n (%) 820 (49%) 285 (10%) <0.001
EBV+ HSV-1+ n (%) 289 (17%) 285 (10%) <0.001 3 n (%) 289 (17%) 0 <0.001
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Supplemental Table 4. Association of herpesvirus infections and TG2A concentrations in HLA DQ2/DQ8 
positive children. 
Total number 
of HLA DQ2/ 
DQ8 positive 1
children
HLA DQ2/ DQ8 
positive 
TG2A negative
<7 U/ml
HLA DQ2/ DQ8 positive 
TG2A positive 
>7 U/ml
n=1,202 n= 1,164
7-70 U/ml
n=15 (1.2%)
>70 U/ml
n=23 (1.9%)
n (%) OR (95% CI) n (%) OR (95% CI)
CMV 453 (38%) 443 (38%) 5 (33%) 0.81 (0.28, 2.40) 5 (22%) 0.45 (0.17, 1.23)
No CMV 749 (62%) 721 (62%) 10 (66%) Reference 18 (78%) Reference
EBV 603 (50%) 586 (50%) 7 (47%) 0.86 (0.31, 2.40) 10 (43%) 0.76 (0.33, 1.74)
No EBV 599 (50%) 578 (50%) 8 (53%) Reference 13 (57%) Reference
HSV-1 224 (19%) 221 (19%) 2 (13%) 0.66 (0.15, 2.93) 1 (4%) 0.19 (0.03, 1.45)
No HSV-1 978 (81%) 943 (81%) 13 (87%) Reference 22 (96%) Reference
Any (EBV, CMV and/or HSV-1) 839 (70%) 816 (70%) 10 (66%) 0.85 (0.29, 2.51) 13 (57%) 0.55 (0.24, 1.28)
None 363 (30%) 348 (30%) 5 (33%) Reference 10 (43%) Reference
Infection frequency
0 infections 363 (30%) 348 (30%) 5 (33%) Reference 10 (43%) Reference
1 infection 473 (39%) 456 (39%) 6 (40%) 0.92 (0.28, 3.03) 11 (48%) 0.84 (0.35, 1.99)
> 2 infections 366 (30%) 360 (31%) 4 (27%) 0.77 (0.21, 2.90) 2 (9%) 0.19 (0.04, 0.89)*
* Significantly different from TG2A negative group. OR: Odds ratio; 95% CI: 95% confidence interval. ORs are from 
multiple imputed data and derived from logistic regression models. ORs are not adjusted due to limited number of 
cases in each group.
1 Of 4420 children, data on HLA DQ2 or DQ8 carriership was present in n=2891 (65%) children. Of these, n=1202 (42%) 
were HLA DQ2/DQ8 positive, and 1689 (58%) children did not carry the HLA DQ2/DQ8 risk type. Data on HLA DQ2/ 
DQ8 risk type was missing in n=1529 (35%)children.
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Supplemental Table 5. Association of herpesvirus infections and TG2A positivity in Caucasian and non-
Caucasian children. 
n=2,887
TG2A positive (n=42)
>7 U/ml
Caucasian
n=28 (1.8%)
Non-Caucasian
n=14 (1.0%)
OR (95% CI) OR (95% CI)
CMV 0.79 (0.33; 1.86) 0.43 (0.13; 1.36)
No CMV Reference Reference
EBV 0.91 (0.42; 1.96) 0.68 (0.24; 1.96)
No EBV Reference Reference
HSV-1 0.51 (0.12; 2.17) 0.25 (0.03; 1.91)
No HSV-1 Reference Reference
Any (EBV, CMV and/or HSV-1) 0.82 (0.38; 1.74) 0.35 (0.12; 1.02)
None Reference Reference
Infection frequency
0 infections Reference Reference
1 infection 0.99 (0.45; 2.18) 0.38 (0.11; 1.35)
> 2 infections 0.46 (0.13; 1.66) 0.33 (0.09; 1.19)
* Significantly different from TG2A negative group. OR: Odds ratio; 95% CI: 95% confidence interval. ORs are from 
multiple imputed data and derived from logistic regression models. ORs are not adjusted due to limited number 
of cases in each group.1 Of 4420 children, data on herpesvirus serology and ethnic background (GWAS Caucasians 
versus non-Caucasians) was present in n=2,887 (65%) children. 
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Supplemental Table 6. Characteristics in Caucasians and non-Caucasians 
n=2,887 
Caucasian Non-Caucasian
n=1,540 (53%) n=1,347 (47%)
Age (median; range) 6.0 (4.9 – 9.0)*** 6.1 (5.0 – 9.0)
Gender (male) 784 (50.9%) 682 (50.6%)
HLA DQ2 or DQ8 positive 679 (44.1%)*** 520 (38.6%)
TG2A positivity (>7 U/ml) 28 (1.8%) 14 (1.0%)
Strong positivity (>70 U/ml) 18 (1.2%) 7 (0.5%)
CMV 457 (29.7%)*** 650 (48.3%)
No CMV 1083 (70.3%) 697 (51.7%)
EBV 639 (41.5%)*** 799 (59.3%)
No EBV 901 (58.5%) 548 (40.7%)
HSV-1 200 (13%)*** 316 (23.5%)
No HSV-1 1340 (87%) 1031 (75.5%)
Any (EBV, CMV and/or HSV-1) 954 (61.9%)*** 1062 (78.8%)
None 586 (38.1%) 285 (21.2%)
Infection frequency
0 infections 586 (38.1%)*** 285 (21.2%)
1 infection 642 (41.7%)*** 498 (37.0%)
> 2 infections 312 (20.2%)*** 564 (41.8%)
* Significantly different from Non-Caucasian group, based on chi-square test for 
categorical variables, and Mann-Whitney U test for non-normally distributed variables
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ABSTRACT
Objective
The aim was to identify whether ethnic differences in celiac disease autoimmunity (CDA) in 
children at 6 years of age exist, and when present, to evaluate how these differences may 
be explained by sociodemographic and environmental factors.
Design
This study was embedded within a multi-ethnic population-based prospective cohort 
study. 
Setting and patients
4442 six-year old children born between 2002 and 2006 were included. Information on 
ethnicity, environmental and lifestyle characteristics was assessed by questionnaires. 
Ethnicity was categorised into Western (Dutch, European, Indonesian, American, Ocea-
nian) and non-Western (Turkish, Moroccan, Cape Verdean, Antillean, Surinamese). Serum 
transglutaminase type 2 antibody (TG2A) levels were measured with fluorescence enzyme 
immunoassay. Serum IgG levels against cytomegalovirus (CMV) were measured by ELISA.
Main outcome measures
TG2A positivity was defined as TG2A >7 U/ml, strong TG2A positivity as TG2A >10 upper limit 
normal (70 U/ml). 
Results
Of 4442 children, 60 (1.4%) children were TG2A positive, of whom 31 were strong positive. 
66% of children were Western, 33% non-Western. Western ethnicity, high socioeconomic 
position and daycare attendance were positively associated with strong TG2A positiv-
ity (odds ratio (OR) 6.85 (1.62-28.8) p<0.01, OR 3.70 (1.40-9.82) p<0.01, OR 3.90 (1.38-11.0) 
p=0.01 resp.), whereas CMV seropositivity was inversely related to strong TG2A positivity 
(OR 0.32 (0.12-0.84) p=0.02). Together, these factors explained up to 47% (-67 to -17; p=0.02) 
of the ethnic differences in TG2A positivity between Western and Non-Western children. 
Conclusions
Ethnic differences in children with CDA are present in childhood. Socioeconomic position, 
daycare attendance and CMV seropositivity partly explained these differences, which may 
serve as targets for prevention strategies for CDA.
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INTRODuCTION
Celiac Disease (CeD) is a common autoimmune disease with an increasing prevalence of 
1% in the general population.1 The rising prevalence of CeD cannot be merely attributed 
to increased diagnosis among physicians, nor changes in genetic factors.2-6 Hence, socio-
economic and lifestyle factors should contribute. In addition, CeD has been reported to be 
more common in Western countries among whites than in individuals from other ethnici-
ties.2-9 Intriguingly, a recent study showed that the prevalence of CeD autoimmunity (CDA) 
was four to eight times higher among non-Hispanic whites than among other ethnicities.10 
This suggests that ethnic differences are present both in CeD and in CDA. Although these 
individuals lack symptoms suggestive for CeD, antibodies against transglutaminase type 
2 (TG2A) are present, thereby possibly indicating the presence of subclinical or potential 
CeD.11 Furthermore, incidence and prevalence of CeD vary across different geographical 
areas of the world.8 Apart from differences in human leucocyte antigen (HLA)-DQ2/DQ8 
carriership among different ethnic groups,12, 13 variations in environmental factors, such 
as gluten consumption and smoking behaviour, might explain some of the geographical 
variations in prevalence of CeD.10, 14 Other studies suggested socioeconomic variation as an 
explanatory factor, as children with a higher socioeconomic position (SEP) may face differ-
ent infectious agents during early childhood.15-20 Consequently, a different programming 
of their immune system occurs.21 Furthermore, these children might seek healthcare more 
often.15, 20 However, it still remains unclear to what extent ethnic differences in childhood 
CDA are related to environmental factors. Therefore, we here aimed to identify whether 
ethnic differences in CDA in children aged 6 years exist, and when present, to evaluate how 
these differences may be explained by sociodemographic and environmental factors.
PATIENTS AND METhODS
Study design 
This study was part of the Generation R Study, a prospective multi-ethnic population-based 
cohort study from early pregnancy onward. All children were born between April 2002 and 
January 2006 in Rotterdam. The study area covers more than one-half of the city’s inhab-
itants, reflecting Rotterdam’s multi-ethnic population.22 The study was approved by the 
Medical Ethics Committee of the Erasmus Medical Center. Written informed consent was 
obtained from all of the participating parents.23
At the median age of 6 years, 6690 children visited our research centre, of whom 4593 
provided serum. After exclusion of children with no data on TG2A levels (n=131) and chil-
dren with serum IgA levels below the detection limit (n=20), a population of 4442 children 
remained eligible for analysis [Supplemental Figure 1]. 
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Ethnic background 
Ethnicity of the child was determined by country of birth of the parents.24-26 The child was 
of non-native Dutch origin if one of the parents was born in another country than the 
Netherlands.24 If both parents were born abroad, the mother’s country of birth prevailed. 
To be able to distinguish between all different ethnicities, detailed information on parental 
ethnic background based on country of birth was assessed by questionnaires at enrolment. 
Briefly, because of recent migration history, we were able to differentiate between Western 
and non-Western ethnicity. Western ethnicity included Dutch, European, American West-
ern (including North American), Asian Western (including Indonesian and Japanese) and 
Oceanian. Non-Western ethnicity included Turkish, Moroccan, Surinamese, Antillean, Cape 
Verdean, African, Asian non-Western (all Asian counties except Indonesia and Japan) and 
American non-Western (including South American and Central American).25, 27-29 [Supple-
mental Table 1].
Detection of Transglutaminase Type 2 Antibody Levels 
Serum IgA levels against TG2A were measured using a fluorescence enzyme immunoas-
say (Elia Celikey IgA, Phadia ImmunoCAP 250, Phadia AB, Uppsala, Sweden), at the child’s 
median age of 6.0 years. TG2A levels of >7 U/ml were considered to be positive as per the 
manufacturer’s instructions. In addition, TG2A-positive levels were further subdivided into 
two categories based on the >10 times upper limit normal (ULN) of the test kit (>7-70 U/ml, 
and >70 U/ml, ie, TG2A strong positives).30-32
Potential Mediating variables
SEP, parity (as indicator for siblings/family size), daycare and herpesvirus infections were 
suggested to be potential explanatory variables in the pathway between ethnic back-
ground and TG2A positivity.2-4, 7, 8, 20 Information on household income,33 and educational 
level,34 both indicators of SEP, was obtained from prenatal questionnaires. Herpesvirus 
seropositivity (IgG against Cytomegalovirus (CMV, Epstein-Barr virus (EBV), and herpes 
simplex virus type 1 (HSV-1)) was determined from plasma samples collected at 6 years 
of age.21 Data on gestational age, birth weight, parity and mode of delivery were obtained 
from obstetric records. Prenatal questionnaires included information on maternal lifestyle, 
including smoking and alcohol use during pregnancy. Data on breastfeeding was obtained 
by a combination of delivery reports and postnatal questionnaires at 2, 6 and 12 months. 
Information on the timing of gluten introduction was assessed by questionnaires at the 
age of 6 and 12 months.32 Postnatal questionnaires included information on daycare at-
tendance, respiratory and gastrointestinal tract infections. 
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Potential confounding variables 
Child’s age and gender (data obtained from obstetric records) were treated as potential 
confounders in the association between ethnicity and TG2A positivity, because they can-
not be considered indisputable explanatory variables.35, 36
Statistical analysis
First, χ2 tests, independent student’s T-tests and Mann-Whitney U tests were used to test 
whether characteristics were different between Western and Non-Western children. Logis-
tic regression analyses were performed with TG2A positivity as dependent variables (y/n). 
To study to which extent associations between ethnicity and TG2A (strong) positivity were 
explained by factors associated with SEP, crowding, breastfeeding behaviour and maternal 
lifestyle, we used Baron and Kenney’s causal step approach.35 Only those factors that were 
unequally distributed across the ethnic groups, and were significantly associated with 
TG2A (strong) positivity (independent of ethnicity, gender and age), were added separately 
to the model.35 To assess their mediating effects, the corresponding percentages of at-
tenuation of effect estimates were calculated by comparing differences of model 1 with 
the adjusted ones (100 x (OR model 1 – OR model 2 with explanatory factor)/ (OR model 
1)). Finally, a full model containing ethnicity and all the explanatory factors assessed the 
joint effects of explanatory factors. To reduce attrition bias, multiple imputation of the de-
terminant and covariates was performed (n=5 imputations). Regression coefficients were 
pooled by taking the average of the coefficients of the five imputed datasets. The pooled 
results of the five imputed datasets were reported in this paper as Odds Ratios (ORs) and 
95% confidence intervals (CI’s). A 95% CI was calculated around the percentage attenua-
tion using a bootstrap method with 1000 resamplings per imputed dataset in the statistical 
program R. All other statistical analyses were performed in SPSS 21.0 for Windows (IBM 
Corp., Armonk, NY, USA). 
RESuLTS
Of 4442 children, n=2854 (66%) were Western, and n=1472 (33%) non-Western. Western 
children were slightly younger (p<0.001), had a slightly lower body mass index (p<0.001), 
their mothers were higher educated (p<0.001), and their family household income was 
higher (p<0.001) than non-Western children. They also had a slightly higher birth weight, 
were less often breastfed (p<0.001), and more frequently introduced to gluten before 6 
months of age (p<0.001) than non-Western children. In addition, Western children had less 
often gastrointestinal and respiratory tract infections during the first year of life (p<0.001), 
and Western children were less often infected with CMV, EBV and HSV-1 than non-Western 
children (p<0.001),[Table 1]. 
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Table 1. Associations between ethnic background and potential confounders and mediators 
Ethnic background
p-valueaTotal Western Non-Western
(n=4442) (n= 2854) (n=1472)
Potential confoundersb
Age (years; mean; SD) 6.2 (0.6) 6.1 (0.47) 6.3 (0.64) <0.001
Female (n; %) 2,155 (48.5) 1,409 (49.3) 687 (46.7) 0.09
Potential mediators
Maternal educational level (n; %)
Low 863 (21.4) 366 (13.3) 497 (38.3) <0.001
Mid-low 1,230 (30.5) 741 (27.1) 489 (37.7)
Mid-high 886 (22.0) 697 (25.5) 188 (14.5)
High 1,056 (26.2) 933 (34.1) 123 (9.5)
Net household income (n; %)
≤ 2200 euro 1,386 (41.4) 633 (27.2) 732 (73.7) <0.001
> 2200 euro 1,959 (58.6) 1,696 (72.8) 260 (26.3)
Maternal smoking (n; %) 960 (24.9) 634 (24.7) 315 (24.9) 0.90
Maternal alcohol use (n; %) 1,745 (52.1) 1,138 (52.3) 559 (51.4) 0.63
Birth weight (grams; mean; SD) 3413 (569) 3460 (575) 3330 (540) <0.001
Gestational age (weeks; median; range) 40.0 (26.3-43.6) 40.1 (26.9-43.3) 39.9 (27.1-43.5) <0.001
Caesarean section (n; %) 485 (12.7) 328 (13.5) 141 (10.9) 0.03
Daycare (n; % yes) 1,543 (60.3) 1,317 (68.1) 225 (36.8) <0.001
Multiparity (n; %) 1,927 (45.0) 1,100 (40.0) 772 (53.8) <0.001
Breastfeeding (n; %)
yes 3,232 (92.5) 2,210 (91.4) 968 (95.3) <0.001
no 263 (7.5) 209 (8.6) 48 (4.7)
Gluten introduction >6 months (n; %) 1,285 (43.4) 846 (38.7) 432 (57.3) <0.001
Gastrointestinal tract infection (n; %) 1,001 (59.0) 731 (55.4) 265 (71.6) <0.001
Respiratory tract infection (n; %) 1,679 (59.8) 1,185 (56.8) 481 (68.2) <0.001
CMV seropositivity (n; %) 1,681 (37.9) 872 (30.6) 751 (51.0) <0.001
EBV seropositivity (n; %) 2265 (51.1) 1,258 (44.2) 923 (62.7) <0.001
HSV-1 seropositivity (n; %) 873 (19.7) 405 (14.2) 425 (28.9) <0.001
SDS BMI child (kg/m2) 0.28 (0.91) 0.17 (0.82) 0.48 (1.03) <0.001
Abbreviations: BMI, Body Mass index (kg/m2); CMV, cytomegalovirus; EBV Epstein-Bar virus; HSV-1 herpes simplex 
virus type 1; SDS, standard deviation score; BMI was adjusted for age. Values are percentages, means (SD) or medi-
ans (range), based on observed dataset. a p-values are calculated with the Chi-square test for categorical variables, 
Mann-Whitney U test for non- normally distributed variables and Student’s T test for continuous normal distributed 
variables, and reflects differences in characteristics between Western and Non-western groups.b Data was missing 
for maternal educational level (9.2%), net household income (24.7%), maternal smoking (13.3%), maternal alcohol 
use (24.6%), birth weight (<0.01%), gestational age (<1%), daycare (42.4%), parity (3.6%), breastfeeding (21.3%), tim-
ing of gluten introduction (33.3%), GI 61.8%, RTI (36.8%), CMV (<0.01%), EBV (0.1%), HSV-1 (<0.01%) (22.3%).
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Ethnic background and TG2A positivity
Western ethnicity was positively associated with TG2A positivity (adjusted odds ratio (aOR) 
1.94; 95% CI 1.02-3.70). The association was mainly driven by the children who were TG2A 
strong positive; (i.e. TG2A levels >70 U/ml; aOR Western ethnicity 6.85; 95% CI 1.62- 28.8),[Ta-
ble 3, model 1]. CMV seropositivity was related to both ethnicity and TG2A positivity,[Table 
1 and 2]. Therefore, CMV seropositivity was selected as explanatory variable in the associa-
tion between ethnicity and strong TG2A positivity (35). CMV seropositivity tended to explain 
9% (95% CI -18 to 0.5, P=0.059) of the differences in TG2A positivity between Western and 
Non-Western children, although the attenuation in OR was borderline significant,[Table 
3]. However, variations in SEP, daycare and CMV prevalence together explained up to 29% 
(95% CI -47 to -5, p=0.018) of the ethnic differences in TG2A positivity. EBV and HSV-1 added 
another 4% to the explanation of ethnic differences in TG2A positivity. In total, 33% (95% 
CI -50 to -13, p=0.004) of differences in TG2A positivity between Western and non-Western 
could be explained by differences in SEP, daycare, and herpesvirus seropositivity [Table 3]. 
Ethnic background and strong TG2A positivity
High SEP (high maternal educational level and high net household income), frequent 
daycare attendance and CMV seropositivity were related to ethnic background and 
strong TG2A positivity [Table 1 and Table 2]. Therefore, these variables were selected as 
explanatory variables in the association between ethnicity and strong TG2A positivity.35 
SEP tended to be the most important contributor to the association between ethnicity 
and TG2A strong positivity [Table 3]. For example, net household income tended to ex-
plain 31% (95% CI -58 to -3, p=0.07) of the differences in TG2A strong positivity between 
Western and Non-Western children, followed by maternal educational level, which tended 
to explain 22% (95% CI -37 to 5, p=0.13) [Table 3]. Daycare attendance tended to explain 
26% (95% CI -36 to 0.6, p=0.056) of the association between ethnicity and strong TG2A 
positivity. However, the alterations in effect estimates induced by the single explanatory 
variables did not reach statistical significance. In contrast, CMV seropositivity significantly 
explained 14% (95% CI -25 to -0.4; p=0.04) of the ethnic differences in strong TG2A positiv-
ity. Overall, SEP, daycare and CMV seropositivity together explained up to 47% (95% CI -67 
to -17, p=0.02) of the ethnic difference in TG2A strong positivity [Table 3]. EBV and HSV-1 
tended to explain another 4% to 51% (95% CI -68 to 21) of ethnic differences in strong TG2A 
positivity, although the alteration of the OR in the fully adjusted model no longer remained 
significant (p=0.08) [Table 3]. 
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DISCuSSION
This large multi-ethnic prospective study confirms differences in CDA between children 
from Western and non-Western ethnicity. Furthermore, SEP, daycare attendance and CMV 
seropositivity partly explained ethnic differences in TG2A positivity. 
Table 2. Associations between potential mediators and TG2A positivity (n=4442) 
TG2A positivity
TG2A pos. 
(n=60; ≥7 U/ml) p-value 
a TG2A Strong positivity 
(n=31; ≥70 U/ml) p-value 
b
Potential mediators
Maternal educational level (%)
Low Ref Ref
High 1.63 (0.95; 2.81) 0.08 3.10 (1.22; 7.93) 0.02
Net household income (%)
≤ 2200 euro Ref Ref
> 2200 euro 1.85 (0.98; 3.49) 0.056 3.70 (1.40; 9.82)  0.009
Maternal smoking (%) 1.03 (0.57; 1.88) 0.92 1.02 (0.42; 2.51) 0.96
Maternal alcohol use (%) 1.26 (0.69, 2.30) 0.45  1.09 (0.52; 2.31) 0.82
Birth weight (grams) 1.00 (1.00;1.00) 0.56 1.00 (1.00;1.00) 0.77
Gestational age (weeks) 1.03 (0.89;1.18) 0.76 1.06 (0.86; 1.31) 0.61
Caesarean Section (%) 0.75 (0.29; 1.95) 0.56 0.58 (0.12; 2.72) 0.48
Daycare (% yes) 1.70 (0.98; 2.94) 0.06 3.90 (1.38; 11.0) 0.011
Multiparity (%) 1.08 (0.64; 1.84) 0.80 (0.39; 1.66) 0.55
Breastfeeding (%)
yes Ref Ref
no 1.09 (0.46: 2.57) 0.85 2.05 (0.33; 12.65) 0.43
Timing of gluten introduction (%)
<6 months Ref Ref
>6 months 0.86 (0.36; 2.02) 0.70 0.58 (0.25; 1.35) 0.21
Gastrointestinal Tract infection (%) 1.07 (0.46; 2.50) 0.86 1.55 (0.73; 3.13) 0.26
Respiratory Tract infection (%) 1.17 (0.66; 2.09) 0.59 1.69 (0.72; 3.98) 0.22
CMV seropositivity (%) 0.53 (0.30; 0.96) 0.04 0.32 (0.12; 0.84) 0.02
EBV seropositivity (%) 0.65 (0.38; 1.09) 0.10 0.49 (0.23; 1.04) 0.06
HSV-1 seropositivity (%) 0.46 (0.20; 1.07) 0.07 0.15 (0.02; 1.09) 0.06
Abbreviations: OR, Odds Ratio; CI, confidence interval. Values are derived from multivariable logistic regression 
models (based on imputed dataset) and represent effect estimates (ORs; 95% confidence intervals), adjusted for 
child’s gender and age. 
ap-value reflects differences in characteristics between TG2A positive children (≥7 U/ml) and TG2A negative controls. 
bp-value reflects differences in characteristics between TG2A strong positive children (>70 U/ml) and TG2A negative 
controls.
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Our results confirm previous studies by the observation that CDA is more common in 
Western than in non-Western populations.2, 3, 7, 9, 10 It needs to be considered though that we 
lacked data on intestinal biopsies, thereby impeding conclusions on final CeD diagnosis. 
Still, given the high sensitivity and specificity of TG2A, even in unselected screened popula-
tions,37 these children are at increased risk to develop CeD. 
Interestingly, recent studies show an increase in CeD prevalence in non-Western, urban 
areas of the de world.38, 39 Possible explanations for this finding are more awareness of 
the disease, a wider use of serological screening tests and the worldwide shift to Western, 
gluten-rich dietary patterns. Though, the inter-country differences in CeD prevalence can-
not be convincingly explained by different predictability of HLA DQ2/DQ8 haplotypes and 
dietary patterns only. Other factors, such as SEP, environmental exposures (e.g. infections) 
and/or the presence of protective genes in non-whites,7 may also contribute to the ethnic 
and geographic variety in CeD prevalence.8, 13-18 Still, studies investigating the relative 
contribution of each factor by multivariate models in an undiagnosed population are 
scarce.9, 15-20 One study compared two Western populations with the same genetic ancestry, 
living in comparable geographical areas and equal exposures to gluten-containing cere-
als, but with markedly different lifestyle and socioeconomic circumstances. In line with 
our results, they found a significantly lower prevalence of CeD in screened children with a 
lower SEP.15 Differences in lifestyle and SEP, including the frequency of intestinal infections, 
antibiotic use and a variety of dietary factors other than gluten, may lead to differences 
in the gut microbial flora, thereby affecting the programming of the immune system.15 
This so called hygiene or ‘old friends hypothesis’ 40 has been linked to the emergence of 
atopic- and autoimmune disease. Individuals living in better hygienic conditions, that is, in 
urban environments of rich developed countries, face fewer infections during childhood.41 
Consequently, immune regulatory mechanisms become less efficient, leading to intoler-
ance to common harmless allergens.40, 41 Other environmental factors, such as delayed 
exposure to viruses or vitamin D deficiency may add to this explanation.40, 42 Disturbances 
in immunoregulatory processes might act indirectly via changes in the microbiota of the 
gut.40, 43 Still, it remains debated whether CeD patients have a different microbiome.44 An-
other explanation for the association between SEP and CeD may be that children/parents 
with a higher SEP are more likely to seek healthcare. 20 We and others 15 confirmed this 
socioeconomic gradient in a screened and asymptomatic group of children in the healthy 
population. However, children in our study were unaware of TG2A assessment, and no 
differences were observed in gastrointestinal complaints.31 Moreover, none of the TG2A 
positive children had visited a general practitioner for their complaints. Hence, the role 
of seeking healthcare may be less important. On the basis of our results, though, daycare 
attendance and herpesvirus infections may contribute. Children who attend daycare are 
likely to face various pathogens early in life. Several studies reported conflicting results on 
associations between infectious diseases in early life and CeD risk.45, 46 Although some have 
suggested a causative linkage between autoimmune disease and CMV infection, overall 
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evidence does not convincingly support this.45, 46 Still, CMV might play a role in either the 
onset, progression or amelioration of autoimmune diseases.38 In addition, other herpes-
viruses might protect against the development of CeD.46 In line with this, we found that 
EBV and HSV-1 added both to the explanation of ethnic differences in CDA. Previously, we 
observed inverse associations between combined CMV, EBV and/or HSV-1 infections and 
TG2A positivity, which may indicate a cumulative effect of herpesviruses, irrespective of 
type of viral infection.47 CMV-infected children were more often infected with other her-
pesviruses. Hence, CMV infection itself may not partly explain the ethnic variety in CDA 
prevalence, but it may reflect a diverse viral and microbial exposure in early life, which, 
together with genetic and other environmental factors, might influence the development 
of CDA. 
Methodological considerations
A major strength of this study is our large screened population-based multi-ethnic cohort. 
Mothers and children were unaware of TG2A screening at the moment of blood sampling, 
thereby minimizing the risk of selection bias. To the best of our knowledge, explaining 
ethnic differences in CDA by using mediation analysis is novel. Since environmental fac-
tors, besides genetic susceptibility, contribute to the pathogenesis of CeD, it might be of 
value that we were able to assess their relative contributions. Despite the large amount 
of immigrants in Rotterdam, the number of cases, though, was too small to divide groups 
per ethnicity. Therefore, we divided our study population into Western and non-Western 
background. Literature is scarce on ethnic differences in CeD other than Western compared 
to non-Western. This might well be explained by the low prevalence of CeD in non-Western 
groups,7, 8, 10 although recent findings have shown that the CeD prevalence is increasing 
in non-Western populations as in Asia and Africa.38, 39 SEP, daycare and CMV seropositivity 
together explained 47% of the ethnic differences in CDA. The strong correlation between 
these factors is likely to be responsible for this finding. Only CMV seropositivity explained 
a significant 14% on its own. Although reverse causation cannot be totally excluded, 
the majority (80%) of CMV positive children in our study was infected before the age of 2 
years.21 Therefore, we consider reverse causation less likely. Last, we cannot completely 
exclude the possibility of residual confounding. That is, other environmental factors, such 
as gluten intake or infectious disease in early childhood, might play a role. Hence, the pos-
sible interactions between genetics, gluten and other environmental determinants should 
be further investigated.
CONCLuSION
In this multi-ethnic population-based cohort, we found higher seroprevalence of TG2A 
positivity in Western children relative to non-Western children at 6 years of age. High so-
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cioeconomic position, daycare attendance and CMV infection partly explained the ethnic 
differences in TG2A positivity. These factors may serve as targets for primary and second-
ary prevention strategies for CDA.
What’s known about this subject: 
- Incidence and prevalence of Celiac Disease (CeD) and CeD Autoimmunity vary across 
different ethnicities and geographical areas of the world. 
- It is less clear to what extent these ethnic differences can be explained by socioeco-
nomic position and other lifestyle-related factors.
What this study adds: 
- Nearly 50% of the ethnic differences in transglutaminase type 2 antibody (TG2A) posi-
tivity between Western and non-Western children can be explained by socioeconomic 
position and lifestyle-related factors.
- High socioeconomic position, and the absence of cytomegalovirus (CMV) infection in 
Western children are associated with increased risk of CeD Autoimmunity.
- Variation in socioeconomic position was considered to be the most important explain-
ing factor, followed by cytomegalovirus (CMV) infection.
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Supplemental Figure 1. Flowchart of participants included in the study 
 
 
	  
Serum collection research center age 6 years 
(n=4,593) 
	  
Serum TG2A levels available at age 6 yr. 
(n=4,442) 
TG2A negative (<7 U/ml) 
(n=4,382) 
TG2A positive (>7 U/ml) 
(n=60) 
 
Excluded children with no data on 
TG2A levels (n=131), and children with 
low total IgA levels (n=20) (possible 
IgA deficient) 
	  
n=4,442 included in data analysis 
	  
> 10 ULN 
Strong TG2A positive (>70 U/ml) 
(n=31) 
< 10 ULN 
TG2A positive (>7 <70 U/ml) 
(n=29) 
Supplemental Figure 1. Flowchart of participants included in the study 
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Supplemental Table 1. TG2A levels per ethnic group 
Population for analysis (n=4,442)
TG2A neg. (≤7U/ml)
n=4382
TG2A pos. (7-70 U/ml)
n=60
TG2A ULN (>70U/ml)
n=31
Western ethnicity
Indonesian 25 0 0
Dutch 2450 42 26
European 326 5 3
American, western 25 0 0
Asia, western 6 0 0
Oceanie 8 0 0
Non-Western ethnicity
Turkish 307 0 0
Moroccan 247 8 1
Surinamese 314 1 0
Dutch Antilles 141 0 0
Cape Verdian 125 2 0
African 100 0 0
Asia, non-western 110 0 0
American, non-western 83 1 1
Missing 0 1 0
Total 4382 60 31
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ABSTRACT
Objective
To identify whether there are ethnic differences in cytomegalovirus (CMV), Epstein-Barr 
virus (EBV) and herpes simplex virus type 1 (HSV-1) seroprevalence rates in children at 6 
years of age, and when present, to evaluate how these differences can be explained by 
sociodemographic and environmental factors.
Study design
This study was embedded within a multi-ethnic population-based prospective cohort 
study. Serum IgG levels against CMV, EBV and HSV-1 were measured by enzyme-linked im-
munosorbent assay in 4464 children (median age 6.0 years). Information on demograph-
ics and characteristics were assessed by questionnaires. Herpesvirus seroprevalences 
between Surinamese-Creole, Surinamese-Hindustani, Turkish, Moroccan, Cape Verdean, 
Antillean and Native Dutch children were compared. 
Results
Non-western ethnicity was an independent risk factor for CMV (aOR, 2.16; 95% CI 1.81-2.57), 
EBV (1.76; 1.48-2.09) and HSV-1 seropositivity (1.52; 1.39-1.66). Among the ethnic groups, 
CMV seroprevalences ranged between 29 and 65%, EBV between 43 and 69% and HSV-1 
between 13 and 39%. Low family net household income, low maternal educational level, 
crowding and lifestyle factors explained up to 48% of the ethnic differences in HSV-1 sero-
prevalences, and up to 39% of the ethnic differences in EBV seroprevalences. These factors 
did not explain ethnic differences in CMV seroprevalences. 
Conclusion
Socioeconomic position and factors related to lifestyle only explain a part of the large 
ethnic differences in EBV and HSV-1 seroprevalences, whereas they do not explain ethnic 
differences in CMV seroprevalences in childhood. 
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INTRODuCTION
Cytomegalovirus (CMV), Epstein-Barr virus (EBV), and Herpes simplex virus 1 (HSV-1) are 
ubiquitous herpesviruses, and often are acquired in childhood. They viruses usually are 
transmitted by contact with infected saliva (all 3 viruses), breastfeeding, placental transfer 
(CMV), or through contact with infectious skin lesions or secretions (HSV-1).1, 2 The viruses 
establish a lifelong latency after primary infection, and periodically can reactivate with 
shedding of the virus. Most primary infections are mild or asymptomatic in childhood, but 
they can cause serious complications in fetuses, immunocompromised individuals, or in 
elderly.3-9 The incidence and severity of herpesvirus associated diseases vary geographi-
cally, and many studies link age at primary infection to the pathogenesis of herpesvirus 
associated diseases.10-14 
CMV seroprevalences vary between 40 and 60% in children aged 4-12 years, 8, 15, 16 with 
exclusion of African countries where almost all children seroconvert by 3 years of age. Ap-
proximately 50% of children in the US and Europe are seropositive for EBV in the first years 
of life, but seroprevalences vary from 20-80% depending on age, race/ethnicity, geographic 
location and socioeconomic development of the country.9, 12, 17, 18 HSV-1 is widespread dur-
ing the first few years of life in developing countries, whereas in some European countries 
primary infection occurs at an older age.19-22 Besides geographical differences, ethnic 
differences also have been described in population subgroups.23 Ethnic and geographical 
differences in CMV, EBV and HSV-1 seroprevalences might be explained by differences in 
behavior that facilitate transmission, such as breastfeeding, daycare, family size and socio-
economic position. 17, 22, 24, 25 Because socioeconomic position and ethnicity are strongly 
related, it remains unclear to what extent socioeconomic factors explain ethnic differences 
in herpesvirus seroprevalences.26 In addition, knowledge on other lifestyle related determi-
nants is mainly based on prevalence studies from the late 1990s,27-30 but social conditions 
and lifestyle have changed over time.31, 32 Furthermore, the relative importance of each 
risk factor needs to be assessed,26 and many studies lack the assessment of multiple risk 
factors. Previously, it has been suggested that early life exposures, in particular breastfeed-
ing, are more important for CMV infection than adulthood exposures.33 On the other hand, 
the ALADDIN birth cohort study found no strong influence of these early life risk factors.34 
Understanding transmission dynamics of herpesvirus infections within populations, and 
understanding how socioeconomic and ethnic groups are differentially exposed to these 
infections, can improve existing preventive policies and interventions, eventually includ-
ing vaccination programs.35 
The first aim of our study is to assess whether there are ethnic differences in acquisi-
tion of CMV, EBV and HSV-1 in children by 6 years of age. The second aim is to evaluate 
how possible ethnic differences in acquisition of CMV, EBV and HSV-1 can be explained by 
sociodemographic and environmental factors. 
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METhODS
Study design
This study was embedded within the Generation R Study, a prospective population-based 
cohort study from fetal life onwards.36, 37 All children were born between 2002 and 2006 in 
Rotterdam, the second largest city in The Netherlands. The study area covers more than 
one-half of the city’s inhabitants, reflecting Rotterdam’s multi-ethnic population.36 The 
largest ethnic groups are of Dutch, Surinamese, Turkish, Moroccan, Dutch Antilles and Cape 
Verdean origin.36 In total, 8305 children participated in the postnatal phase of the study, of 
whom 81% (n=6690) visited the research centre (median age 6.0 years).37 During this visit, 
blood samples were collected from 4593 children. Serologic data on EBV, CMV, HSV-1 status 
were provided on 4464 children [Supplemental Figure 1]. The study was approved by the 
Medical Ethical Committee of Erasmus MC, University Medical Centre Rotterdam. Parents 
of the children gave written informed consent. 
herpesvirus serology
Venous blood plasma samples were analysed using enzyme immunoassays for IgG antibod-
ies against CMV (purified native antigens strain “AD169”), EBV capsid antigen (EBV-CA, native 
mixture of several viral capsid antigens), HSV-1 native glycoprotein C1, (all from EUROIMMUN®, 
Lübeck, Germany).38 The assays are specific for the particular viruses and discriminate between 
HSV-1 and HSV-2. Results were evaluated semiquantitatively relative to a manufacturer-
provided reference threshold sample. Per manufacturer’s instructions, an optical density in the 
patient sample >10% above the provided threshold sample was defined as positive. 
Ethnic background 
Ethnicity of the child was determined by country of birth of the parents. The child was 
of nonnative Dutch origin if one of the parents was born in another country than The 
Netherlands.39 If both parents were born abroad, the country of birth of the mother was 
taken. To study whether ethnic background was related to herpesvirus infections, we con-
structed a dichotomous variable ‘Western/non-western’ ethnicity. Next, to study to what 
extent socioeconomic and lifestyle factors explained associations between ethnicity and 
herpesvirus infections, and to study the effect of cultural background of the mother (most 
often primary caregivers),40 a distinction was made between mothers of Dutch, Turkish, 
Moroccan, Cape Verdean, Antillean, Surinamese Creole and Surinamese Hindustani ethnic 
background. Maternal ethnic background was based on country of birth of mother’s parents 
and was assessed by questionnaires at enrollment. Mothers were considered non-native 
Dutch if one of her parents was born abroad.41 If both parents were born abroad, country 
of birth of the mother’s mother prevailed. Generational status of non-native Dutch moth-
ers was based on their own country of birth. Foreign-born mothers were classified as ‘first 
generation’ and mothers born in the Netherlands were classified as ‘second generation’. 40 
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Other determinants
Other potential determinants of herpesvirus infections were selected based on existing 
literature. 2, 12, 24, 32, 33, 42-44 These are: socioeconomic position, family size/parity, maternal 
lifestyle, breastfeeding, daycare and sex. Data on sex, gestational age, birth weight, parity 
and mode of delivery were obtained from obstetric records from hospitals and mid-wife 
practices. Data on sociodemographic and lifestyle factors were obtained by a combination of 
prenatal and postnatal questionnaires completed by both parents. Prenatal questionnaires 
included information on maternal lifestyle and maternal educational level. Information on 
family net household income was determined by questionnaires obtained at 6 years of age. 
Information on breastfeeding and daycare was obtained by postnatal questionnaires. All 
questionnaires were available in 3 languages (Dutch, English and Turkish) and further sup-
port for verbal translation of questionnaires was available in Arabic, Portuguese and French. 
Explanatory variables
Most effects of ethnicity on herpes virus infections are probably indirect ones, acting through 
more proximal determinants of CMV, EBV, and HSV-1. We considered the following factors to 
be potential explanatory variables: socioeconomic position, breastfeeding, parity as indica-
tor for siblings/family size, and day-care attendance.2, 12, 24, 32, 33, 43, 45 Information on household 
income46 and educational level,47 both indicators of socioeconomic position, were obtained 
using prenatal questionnaires. The Dutch Standard Classification of Education was used to 
categorize 4 subsequent levels of education: 1=high, 2= mid-high, 3=mid-low, and 4=low. 47 
For additional analyses, income was subdivided into three categories: 1. Below modal <2,000 
euro per month (<US $2511), 2. Between 2000 and 3200 euro per month (US $2511- $4018), 
3. >3200 euro per month (>US $4018).48, 49 Child’s age and sex were treated as potential con-
founders in the association between ethnicity and herpesvirus seroprevalences.
Statistical analysis
First, independent Student t test, and χ2 tests were used to test whether characteristics were 
different between children who were seropositive for CMV, EBV and HSV-1, and those who were 
not. To investigate which determinants were associated with CMV, EBV and HSV-1 seroposi-
tivity (yes/no), logistic regression analyses were performed with herpesvirus seropositivity at 
the age of 6 years as dependent variables (CMV yes/no, EBV yes/no, and HSV-1 yes/no). To 
study to which extent associations between ethnicity and CMV, EBV, and HSV-1 seropositivity 
were explained by factors associated with socioeconomic position, crowding, breastfeed-
ing behaviour and maternal lifestyle, we used Baron and Kenny’s causal step approach.50 
Only those factors that were unequally distributed across the ethnicity groups (determinant) 
[Supplemental Table 1], and were significantly (p<0.05) associated with CMV, EBV and HSV-1 
seropositivity (outcomes) (independent of ethnicity, sex and age) [Supplemental Table 2], 
were added separately to the model.50 To assess their mediating effects, the corresponding 
percentages of attenuation of effect estimates were calculated by comparing differences of 
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model 1 with the adjusted ones (100 x (OR model 1 – OR model 2 with explanatory factor)/ 
(OR model 1)). Finally, a full model containing ethnicity and all the explanatory factors as-
sessed the joint effects of explanatory factors. Interaction terms between ethnic background 
and the explanatory variables were tested for significance. If the test was significant (p<0.05), 
we also stratified the analysis by the variables. To reduce attrition bias, multiple imputation 
of the covariables was performed (n=5 imputations).51 Regression coefficients were pooled 
by taking the average of the coefficients of the 5 imputed datasets. The pooled results of the 
5 imputed datasets were reported in this paper as Odds Ratios (ORs) and 95% confidence 
intervals (CI’s). A 95% CI was calculated around the percentage attenuation using a bootstrap 
method with 1000 resamplings per imputed dataset in the statistical program R.52 All other 
statistical analyses were performed in SPSS 20.0 for Windows (SPSS Inc, Chicago, Illinois). 
RESuLTS
Maternal and child characteristics related to CMV, EBV and HSV-1 are shown in [Table 3]. 
Within the total group of 4464 children (median age 6.0 years), n=1692 (38%) were infected 
with CMV, n=2279 (51%) were infected with EBV, and n=877 (20%) were infected with HSV-1. 
Thirty percent (n=1319) were seronegative for CMV, EBV and HSV-1, 39% (n=1735) were in-
fected with one of these viruses, and 32% (n=1410) were infected with two or more viruses. 
Of children with available data on herpesvirus serology, a total of 2386 children were Native 
Dutch, 181 were Cape Verdean, 247 Moroccan, 109 Dutch-Antillean, 131 Suriname-Creole, 
and 136 children were of Surinamese-Hindustani origin [Supplemental Figure 1].
Determinants of CMV, EBV and hSV-1 seropositivity
CMV seropositive children were more likely of non-Western ethnicity (aOR 2.16; 95% CI 
1.81-2.57), to be girls (aOR 1.18, 95% CI 1.02-1.36), and to be breastfed for 6 months or 
longer (aOR 1.96; 95% CI 1.25-3.07) than CMV seronegative children. Multiparity was in-
versely associated with CMV seropositivity (aOR 0.76; 95% CI 0.65-0.90). In contrast, EBV 
and HSV-1 seropositive children more often had 2 or more siblings (aOR EBVparity >2 1.35; 
95% CI 1.05-1.74, aOR HSV-1parity >2 1.31; 95% CI 1.14-1.50), than EBV and HSV-1 seronegative 
children. Similar to CMV, non-Western ethnicity was an independent risk factor for EBV 
(aOR 1.76; 95% CI 1.48-2.09) and HSV-1 (aOR 1.52; 95% CI 1.39-1.66). Daycare and socio-
economic position were only associated with HSV-1 seropositivity (aOR daycare 0.89; 95% CI 
0.81-0.97). Mothers of HSV-1 seropositive children were lower educated (aOR 1.55; 95% CI 
1.35-1.79) and their family household income was lower (aOR 1.11; 95% CI 1.01-1.23), than 
mothers of HSV-1 seronegative children [Table 4; online]. Additional analyses between the 
seroprevalence of herpesvirus infections and net family household income in three groups 
strengthened the inverse associations between socioeconomic position and herpesvirus 
seroprevalences [Table 5].
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Table 3. Maternal and infant characteristics of the study population (n=4,464) 
CMV EBV HSV-1
CMV -
(n=2772)
CMV + 
(n=1692)
EBV -
(n=2185)
EBV +
(n=2279)
HSV-1 -
(n=3592)
HSV-1 + 
(n=877)
Maternal characteristics 
Age (Mean + SD; years) 31.1 (5.0) 30.1 (5.3)*** 31.4 (4.9) 30.1 (5.3)*** 31.0 (5.0) 29.5 (5.4)***
Educational level (n; %)
Low 495 (19%) 373 (25%) 333 (16%) 535 (27%) 613 (19%) 255 (35%) 
Mid low 794 (31%) 440 (29) 604 (30%) 630 (31%) 996 (30%) 238 (32%) 
Mid high 582 (23%) 312 (21%) 504 (25%) 390 (19%) 768 (23%) 126 (17%) 
Higher 689 (27%) 368 (25%) 595 (29%) 462 (23%) 936 (28%) 121 (16%) 
Net household income per month (n; %)
< € 2200 802 (28%) 591 (48%)*** 594 (35%) 799 (48%)*** 1061 (38%) 332 (57%)*** 
> € 2200 1320 (63%) 650 (52%) 1102 (65%) 864 (52%) 1718 (62%) 252 (43%) 
Smoking during pregnancy 
(n; %)
349 (16%) 187 (14%) 235 (14%) 301 (17%)** 419 (15%) 117 (18%)
Alcohol use during pregnancy (n; 
%) 
918 (44%) 519 (39%)** 782 (45%) 695 (39%)*** 1262 (44%) 215 (32%)***
BMI before pregnancy (Mean + 
SD; kg/m2)
23.7 (4.3) 23.5 (4.0) 23.3 (4.0) 23.9 (4.3)*** 23.4 (1.6) 24.3 (4.9)**
Fever in 3rd trimester of 
pregnancy (n; %)
28 (7%) 11 (6%) 22 (7%) 17 (7%) 33 (7%) 6 (8%)
Maternal atopy (n; %) 845 (35%) 453 (32%)* 670 (35%) 628 (33%) 1069 (34%) 229 (32%)
Family history of asthma atopy 
(n; %)
1263 (49%) 692 (46%)* 1018 (50%) 937 (46%)* 1611 (49%) 344 (45%)
Parity 
0 495 (19%) 373 (25%)* 1198 (55%) 1172 (54%)*** 1947 (57%) 423 (51%)* 
1 794 (31%) 440 (30%) 661 (32%) 677 (31%) 1072 (31%) 266 (32%) 
2 582 (23%) 312 (21%) 192 (9%) 257 (12%) 345 (10%) 104 (12%) 
>3 689 (27%) 368 (25%) 36 (2%) 76 (4%) 95 (2%) 51 (6%) 
Mode of delivery (n; %)
Vaginal 1746 (74%) 1066 (72%) 1342 (71%) 1468 (75%) 2240 (72%) 572 (76%) 
Forceps or vacuum assisted 305 (13%) 228 (15%) 292 (16%) 240 12%) 449 (15%) 84 (11%) 
Caesarian section  315 (13%) 190 (13%) 249 (13%) 255 (13%) 408 (13%) 97 (13%) 
Premature rupture of 
membranes (n; %)
100 (4%) 81 (5%) 96 (5%) 85 (4%) 148 (4%) 33 (4%)
Infant characteristics 
Males (n; %) 1469 (53%) 836 (49%)* 1121 (51%) 1183 (52%) 1855 (52%) 450 (51%)
Western ethnicity (n;%)¶ 1991 (73%) 877 (54%)*** 1598 (74%) 1266 (58%)*** 2426 (70%) 407 (49%)***
Gestational age ( Mean + SD; 
weeks)  
39.8 (1.8) 39.8 (1.8) 39.7 (1.9) 39.8 (1.8) 39.8 (1.8) 39.7 (1.8)*
Preterm birth (<37 weeks) (n; %) 181 (7%) 119 (7%) 159 (7%) 140 (6%) 246 (7%) 54 (6%)
Birth weight ( Mean + SD; grams) 3427 (576) 3391 (555)* 3,427 (584) 3,401 (553) 3,424 (523) 3,369(549)*
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Ethnic background and CMV seropositivity
Children of Cape Verdean, Moroccan, Turkish, Surinamese-Creole and Surinamese Hindu-
stani mothers were more often seropositive for CMV, than children of native Dutch moth-
ers. CMV seroprevalences in the non-native Dutch groups ranged between 44 and 65%, 
compared with 29% in the native Dutch group [Figure 2; online]. 
To explain the observed ethnic differences in CMV seroprevalences, the following plana-
tory variables were selected: maternal educational level, parity, daycare and breastfeed-
Table 3. Maternal and infant characteristics of the study population (n=4,464) (continued)
CMV EBV HSV-1
CMV -
(n=2772)
CMV + 
(n=1692)
EBV -
(n=2185)
EBV +
(n=2279)
HSV-1 -
(n=3592)
HSV-1 + 
(n=877)
Day-care in first year (n; %) 1069 (86%) 646 (92%)*** 940 (88%) 773 (88%) 1493 (89%) 222 (84%)*
Breastfeeding (n; %)
Never 211 (11%) 53 (5%) 140 (9%) 124 (9%) 215 (9%) 49 (10%) 
< 3 months 650 (35%) 341 (33%) 518 (34%) 472 (34%) 812 (34%) 179 (36%) 
3-6 months 395 (21%) 224 (22%) 305 (20%) 313 (23%) 524 (22%) 95 (19%) 
>6 months 626 (33%) 421 (40%) 565 (37%) 479 (35%) 870 (36%) 177 (35%) 
Infections first year (n; %)
RTI 1054 (58%) 631 (63%)** 877 (58%) 808 (61%) 1404 (60%) 281 (61%) 
LRTI 241 (14%) 131 (14%) 190 (13%) 182 (15%) 314 (14%) 58 (14%) 
URTI 975 (51%) 593 (56%)** 810 (52%) 758 (54%) 1296 (52%) 272 (55%) 
GI 623 (56%) 380 (64%)** 530 (57%) 473 (61%) 833 (58%) 170 (61%) 
Atopy first year (n; %)¶¶
Eczema 486 (26%) 305 (30%)* 440 (29%) 351 (26%) 678 (28%) 113 (24%) 
Wheezing (> 1 episode) 680 (45%) 385 (48%) 545 (44%) 520 (48%)* 884 (45%) 181 (48%) 
Asthma diagnosis at age 6 (n; %) 168 (8%) 83 (7%) 133 (7%) 118 (7%) 209 (7%) 42 (7%)
Age (Median + range; years) 6.2 (5.0-9.0) 6.2 (4.9-9.1)*** 6.1 (5.0-9.0) 6.2 (4.9-9.1)*** 6.2 (4.9-9.0)  6.2(5.0-9.1)***
BMI for age (mean; SD; SDS) 0.25 (0.90) 0.32 (0.92)** 0.21 (0.87) 0.34 (0.94)*** 0.25 (0.89) 0.41 (0.97)***
BMI, Body Mass Index; RTI, respiratory tract infections; LRTI lower respiratory tract infections; URTI upper respiratory 
tract infections; GI gastrointestinal infections.
Values are means (SD), absolute numbers (percentages) or #medians (range). Significantly different from not infect-
ed: 
*P<0.05.
 **P <0.01.
*** P <0.001. 
Table is based on observed dataset.
¶ Western ethnicity includes children from Dutch, European, American Western, and Asian Western origin. Non-
Western ethnicity included children from Turkish, 
Moroccan, Cape Verdean, Antillean, Surinamese-Creole and Surinamese-Hindustani origin.
¶¶ Atopy includes eczema, house dust mite allergy and hay-fever. Any reported autoimmune disease includes diabe-
tes mellitus, systemic lupus erythematosus, arthritis, multiple sclerosis, thyroid disorder or celiac disease.
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ing duration [Supplemental Table 1 and 2].50 However, after including all the explanatory 
factors in the model, differences in CMV seroprevalences compared with Dutch children 
increased with 55% (95% CI 24-124) for Surinamese-Hindustani children, 36% (95% CI 19-
60) for Moroccan children, 34% (95% CI 14-66) for Surinamese-Creole children, 33% (95% CI 
13-59) for Turkish children, and 23% (95% CI 5-47) for Cape Verdean children [Supplemental 
Table 6].
Ethnic background and EBV seropositivity
Children in non-native Dutch groups were more often EBV seropositive than native Dutch 
children. EBV seroprevalences in the non-native Dutch minority groups ranged between 59 
and 69%, compared with 43% in the native Dutch group [Supplemental Figure 2]. Maternal 
educational level, net household income and parity were selected to explain ethnic dif-
ferences in EBV seroprevalences [Supplemental Table 1 and 2; online].50 Socioeconomic 
position was the most important contributor to the association between ethnicity and EBV 
seroprevalence. For example, net household income explained 22% (95% CI -41 to -6) of 
the differences in EBV seroprevalences between Cape Verdean and native Dutch children, 
followed by maternal educational level, which explained 18% (95% CI -31 to -7) [Table 
Table 7. Attenuation of the OR of Epstein-Barr virus seropositivity for different ethnicities after individual 
adjustment for the explanatory variables
Surinamese-
Creolesa
OR (95% CI)
Attenuation 
a
(95% CI)
Surinamese-
Hindustani b
OR (95% CI)
Attenuation 
b
(95% CI)
Turkish c
OR (95% CI)
Attenuation 
c
(95% CI)
Moroccan d
OR (95% CI)
Attenuation 
d
(95% CI)
Cape 
Verdean e
OR (95% CI)
Attenuation 
e
(95% CI)
Antillean f
OR (95% CI)
Attenuation f
(95% CI)
EBV
Model 1 (includes child 
sex and current age)
1.77 (1.24, 2.54) 2.85 (1.96, 4.13) 2.69 (2.11, 3.44) 2.40 (1.82, 3.17) 2.18 (1.59, 2.99) 1.98 (1.33, 2.96)
Socioeconomic 
status
Model 1+ education 1.66 (1.15, 2.40) -15%
(-43 to 0.2)
2.71 (1.85, 3.95) -7%
(-17 to 3)
2.37 (1.84, 3.08) -19%
(-31 to -7)**
2.19 (1.63, 2.91) -15%
(-26 to -6)**
1.97 (1.41, 2.70) -18%
(-31 to -7)**
1.86 (1.24, 2.80) -12% 
(-32 to -0.6)*
Model 1+ income 1.63 (1.13, 2.36) -19%
(-50 to -5)*
2.60 (1.80, 3.86) -13%
(-24 to -4)*
2.36 (1.86, 3.16) -19%
(-33 to -5)*
2.11 (1.60, 2.91) -21%
(-36 to -6)*
1.92 (1.41, 2.74) -22%
(-41 to -6)*
1.77 (1.19, 2.73) -22% 
(-50 to -6)* 
Crowding
Model 1 + parity 1.80 (1.25, 2.59) +4%
(-9 to 24)
2.86 (1.96, 4.19) 1%
(-10 to 16)
2.58 (2.02, 3.31) -6% 
(-13 to 0.7)
2.21 (1.66, 2.94) -14%
(-25 to -4)*
2.03 (1.47, 2.81) -12% 
(-28 tot 1)
1.97 (1.32, 2.96) -1%
(-12 to 14)
Fully adjusted model 1.61 (1.12, 2.37) -21% 
(-56 to 3)
2.59 (1.77, 3.87) -14% 
(-30 to 5)
2.14 (1.67, 2.88) -33% 
(-48 to -17)***
1.89 (1.42, 2.61) -36%
(-55 to -19)***
1.72 (1.23, 2.44) -39% 
(-66 to -19)***
1.74 (1.17, 2.69) -25%
(-60 to -3)*
Abbreviations: CI, confidence interval; OR, Odds Ratio. Bold values represent significant differences.
a The ORs represent the attenuated effect estimate and their 95% CIs relative to model 1 after individual adjustment 
for explanatory factors.
 b Attenuations a to f represent the attenuations of effect estimates for the different ethnicities relative to model 1 
(includes confounders) after adjustment for explanatory variables (100x (OR model 1 - OR model 1 with explanatory factor) / (OR model 
1)). Dutch is the reference group. 
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07]. Overall, 39% (95% CI -66 to -19) of the difference in EBV seroprevalences prevalence 
between Cape Verdean and Dutch children was explained by differences in socioeconomic 
position and family size. These factors explained 36% (95% CI -55 to -19) of the differences 
in EBV seroprevalences between Moroccan and Dutch children, 33% (95% CI -48 to -17) of 
the differences in EBV seroprevalences between Turkish and Dutch children, and 25% (95% 
CI -60 to -3) of the differences in EBV seroprevalences between Antillean and Dutch children 
[Table 7]. 
Ethnic background and hSV-1 seropositivity
All ethnic minority groups, except for Surinamese-Creole, were more often HSV-1 sero-
positive than native Dutch children. HSV-1 seroprevalences in the non-native Dutch groups 
ranged between 22 and 39%, compared with 13% in the native Dutch group [Supplemental 
Figure 2]. To explain ethnic differences in HSV-1 seroprevalences, maternal educational 
level, net household income and breastfeeding duration were selected as explanatory 
variables [Supplemental Table 1 and 2].50 Maternal educational level and net household 
income were the most important factors to explain ethnic differences in HSV-1 seropreva-
lence. For example, 27% (95% CI -38 to -16) of this differences in HSV-1 seroprevalences 
Table 7. Attenuation of the OR of Epstein-Barr virus seropositivity for different ethnicities after individual 
adjustment for the explanatory variables
Surinamese-
Creolesa
OR (95% CI)
Attenuation 
a
(95% CI)
Surinamese-
Hindustani b
OR (95% CI)
Attenuation 
b
(95% CI)
Turkish c
OR (95% CI)
Attenuation 
c
(95% CI)
Moroccan d
OR (95% CI)
Attenuation 
d
(95% CI)
Cape 
Verdean e
OR (95% CI)
Attenuation 
e
(95% CI)
Antillean f
OR (95% CI)
Attenuation f
(95% CI)
EBV
Model 1 (includes child 
sex and current age)
1.77 (1.24, 2.54) 2.85 (1.96, 4.13) 2.69 (2.11, 3.44) 2.40 (1.82, 3.17) 2.18 (1.59, 2.99) 1.98 (1.33, 2.96)
Socioeconomic 
status
Model 1+ education 1.66 (1.15, 2.40) -15%
(-43 to 0.2)
2.71 (1.85, 3.95) -7%
(-17 to 3)
2.37 (1.84, 3.08) -19%
(-31 to -7)**
2.19 (1.63, 2.91) -15%
(-26 to -6)**
1.97 (1.41, 2.70) -18%
(-31 to -7)**
1.86 (1.24, 2.80) -12% 
(-32 to -0.6)*
Model 1+ income 1.63 (1.13, 2.36) -19%
(-50 to -5)*
2.60 (1.80, 3.86) -13%
(-24 to -4)*
2.36 (1.86, 3.16) -19%
(-33 to -5)*
2.11 (1.60, 2.91) -21%
(-36 to -6)*
1.92 (1.41, 2.74) -22%
(-41 to -6)*
1.77 (1.19, 2.73) -22% 
(-50 to -6)* 
Crowding
Model 1 + parity 1.80 (1.25, 2.59) +4%
(-9 to 24)
2.86 (1.96, 4.19) 1%
(-10 to 16)
2.58 (2.02, 3.31) -6% 
(-13 to 0.7)
2.21 (1.66, 2.94) -14%
(-25 to -4)*
2.03 (1.47, 2.81) -12% 
(-28 tot 1)
1.97 (1.32, 2.96) -1%
(-12 to 14)
Fully adjusted model 1.61 (1.12, 2.37) -21% 
(-56 to 3)
2.59 (1.77, 3.87) -14% 
(-30 to 5)
2.14 (1.67, 2.88) -33% 
(-48 to -17)***
1.89 (1.42, 2.61) -36%
(-55 to -19)***
1.72 (1.23, 2.44) -39% 
(-66 to -19)***
1.74 (1.17, 2.69) -25%
(-60 to -3)*
Abbreviations: CI, confidence interval; OR, Odds Ratio. Bold values represent significant differences.
a The ORs represent the attenuated effect estimate and their 95% CIs relative to model 1 after individual adjustment 
for explanatory factors.
 b Attenuations a to f represent the attenuations of effect estimates for the different ethnicities relative to model 1 
(includes confounders) after adjustment for explanatory variables (100x (OR model 1 - OR model 1 with explanatory factor) / (OR model 
1)). Dutch is the reference group. 
*P<0.05.
** P<0.01.
*** P<0.001.
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between Turkish and Dutch children was explained by maternal educational level [Table 
8]. Socioeconomic position and breastfeeding together explained 24% (95% CI -40 to -7) of 
the difference in HSV-1 seroprevalence between Turkish and Dutch children; they explained 
48% (95% CI -150 to -18) of the differences in HSV-1 seroprevalences between Cape Verdean 
and Dutch children; 30% (95% CI -68 to -10) of the differences in HSV-1 prevalence between 
Surinamese-Hindustani and Dutch children and 22% (95% CI -36 to -5) of the differences in 
HSV-1 seroprevalence between Moroccan and Dutch children. Maternal educational level 
was the most important explanatory factor in the association between ethnicity and HSV-1 
seroprevalence [Table 8]. 
Ethnic background and multiple herpesvirus infections
We observed that children who were seropositive for a single virus, were more likely to be 
infected with multiple herpesviruses. Specifically, EBV-infected children were 1.69 (95% CI 
1.50-1.91) times more likely to be seropositive for CMV and 2.17 (95% CI 1.86-2.53) times 
more likely to be seropositive for HSV-1 than children with EBV seronegativity. Furthermore, 
the odds ratio for both CMV and HSV-1 seropositivity was 2.95 (95% CI 2.02-3.11) times 
greater in children with seropositivity than in children with EBV seronegativity (data not 
Table 8. Attenuation of the OR of Herpes simplex virus 1 seroprevalence for different ethnicities after indi-
vidual adjustment for the explanatory variables
Surinamese-
Creolesa
OR (95% CI)
Attenuation 
a
(95% CI)
Surinamese-
Hindustani b
OR (95% CI)
Attenuation 
b
(95% CI)
Turkish c
OR (95% CI)
Attenuation 
c
(95% CI)
Moroccan d
OR (95% CI)
Attenuation 
d
(95% CI)
Cape 
Verdean e
OR (95% CI)
Attenuation
 e
(95% CI)
Antillean f
OR (95% CI)
Attenuation f
(95% CI)
CMV
Model 1 (includes child 
sex and current age)
ns NA 2.10 (1.40, 3.16) 4.08 (3.18, 5.24) 3.73 (2.80, 4.98) 1.75 (1.20, 2.54) 1.70 (1.06, 2.73)
Socioeconomic status
Model 1+ education 1.82 (1.19, 2.73) -26% 
(-61 to -10)**
3.24 (2.49, 4.26) -27% 
(-38 to -16)***
3.15 (2.28, 4.17) -21% 
(-30 to -12)***
1.45 (0.95, 2.07) -39% 
(-119 to -19)**
1.47 (0.91, 2.36) -33% 
(-160 to -7)*
Model 1+ income 1.92 (1.24, 2.87) -17%
(-41 to -0.1)*
3.58 (2.66, 4.68) -16%
(-30 to -1)*
3.29 (2.35, 4.42) -16% 
(-30 to -0.5)*
1.54 (1.01, 2.24) -28% 
(-92 to 1)
1.52 (0.91, 2.43) -26%
(-115 to 11)
Crowding
Model 1 + breastfeeding 2.04 (1.40, 3.18) -6%
(-14 to -1)*
4.29 (3.29, 5.50) +7%
(2 to 14)**
3.80 (2.89, 5.16) +2% 
(0 to 6)
1.67 (1.16, 2.47) -10% 
(-32 to -2)*
1.65 (1.02, 2.65) -8%
(-43 to 2)
Fully adjusted model 1.78 (1.17, 2.75) -30%
(-68 to -10)**
3.33 (2.43, 4.43) -24% 
(-40 to -7)**
3.14 (2.21, 4.26) -22% 
(-36 to -5)*
1.39 (0.90, 2.02) -48% 
(-150 to -18)*
1.42 (0.85, 2.30) -40% 
(-213 to 9)
Abbreviations: CI, confidence interval; ns, nonsignificant; NA, not applicable; OR, Odds Ratio. Bold values represent 
significant differences.
a The ORs represent the attenuated effect estimate and their 95% CIs relative to model 1 after individual adjustment 
for explanatory factors. 
b Attenuations b to f represent the attenuations of effect estimates for the different ethnicities relative to model 1 
(includes confounders) after adjustment for explanatory variables (100x (OR model 1 - OR model 1 with explanatory factor) / (OR model 
1)). Dutch is the reference group. 
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0shown). Finally, CMV, EBV and HSV-1 seropositive children tended to be more frequently 
born to ‘first’ generation mothers than seronegative children, although differences were 
not significant [Supplemental Figure 3]. Mothers of seronegative children were more of-
ten higher educated, and had a higher net household income, than mothers of children 
who were seropositive for 1 or 2 herpesviruses. Seronegative children were more often of 
Western origin and had fewer siblings than children who had 1 or 2 herpesvirus infections 
[Supplemental Table 9]. 
DISCuSSION
In this large and multi-ethnic population-based cohort, we found large ethnic differences 
in seroprevalences of EBV (range 43-69%), CMV (range 29-65%) and HSV-1 (range 13-39%) 
among 6 year old children, and the highest seroprevalence in non-Dutch children. Socio-
economic factors and factors related to crowding early in life partly explained ethnic differ-
ences in EBV and HSV-1 seroprevalence in childhood, but did not explain ethnic differences 
in CMV seroprevalence. 
Table 8. Attenuation of the OR of Herpes simplex virus 1 seroprevalence for different ethnicities after indi-
vidual adjustment for the explanatory variables
Surinamese-
Creolesa
OR (95% CI)
Attenuation 
a
(95% CI)
Surinamese-
Hindustani b
OR (95% CI)
Attenuation 
b
(95% CI)
Turkish c
OR (95% CI)
Attenuation 
c
(95% CI)
Moroccan d
OR (95% CI)
Attenuation 
d
(95% CI)
Cape 
Verdean e
OR (95% CI)
Attenuation
 e
(95% CI)
Antillean f
OR (95% CI)
Attenuation f
(95% CI)
CMV
Model 1 (includes child 
sex and current age)
ns NA 2.10 (1.40, 3.16) 4.08 (3.18, 5.24) 3.73 (2.80, 4.98) 1.75 (1.20, 2.54) 1.70 (1.06, 2.73)
Socioeconomic status
Model 1+ education 1.82 (1.19, 2.73) -26% 
(-61 to -10)**
3.24 (2.49, 4.26) -27% 
(-38 to -16)***
3.15 (2.28, 4.17) -21% 
(-30 to -12)***
1.45 (0.95, 2.07) -39% 
(-119 to -19)**
1.47 (0.91, 2.36) -33% 
(-160 to -7)*
Model 1+ income 1.92 (1.24, 2.87) -17%
(-41 to -0.1)*
3.58 (2.66, 4.68) -16%
(-30 to -1)*
3.29 (2.35, 4.42) -16% 
(-30 to -0.5)*
1.54 (1.01, 2.24) -28% 
(-92 to 1)
1.52 (0.91, 2.43) -26%
(-115 to 11)
Crowding
Model 1 + breastfeeding 2.04 (1.40, 3.18) -6%
(-14 to -1)*
4.29 (3.29, 5.50) +7%
(2 to 14)**
3.80 (2.89, 5.16) +2% 
(0 to 6)
1.67 (1.16, 2.47) -10% 
(-32 to -2)*
1.65 (1.02, 2.65) -8%
(-43 to 2)
Fully adjusted model 1.78 (1.17, 2.75) -30%
(-68 to -10)**
3.33 (2.43, 4.43) -24% 
(-40 to -7)**
3.14 (2.21, 4.26) -22% 
(-36 to -5)*
1.39 (0.90, 2.02) -48% 
(-150 to -18)*
1.42 (0.85, 2.30) -40% 
(-213 to 9)
Abbreviations: CI, confidence interval; ns, nonsignificant; NA, not applicable; OR, Odds Ratio. Bold values represent 
significant differences.
a The ORs represent the attenuated effect estimate and their 95% CIs relative to model 1 after individual adjustment 
for explanatory factors. 
b Attenuations b to f represent the attenuations of effect estimates for the different ethnicities relative to model 1 
(includes confounders) after adjustment for explanatory variables (100x (OR model 1 - OR model 1 with explanatory factor) / (OR model 
1)). Dutch is the reference group. 
No significant difference in HSV-1 prevalence was observed for the Surinamese-Creole group compared with the 
Dutch group, therefore attenuations in effect estimates for the Surinamese-Creole group are not presented. 
*P<0.05. 
**P <0.01. 
*** P <0.001.
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Our study design provided a unique opportunity to study determinants of these infec-
tions, the variation in seroprevalence by ethnic group, and to which extent socioeconomic 
and lifestyle factors explained these differences. Our results confirm and extend previous 
studies by observing that socioeconomic position partly explains ethnic variation in EBV 
and HSV-1 seroprevalences, but not in CMV seroprevalences.12, 35, 45 Although these 3 viruses 
are all members of the herpesvirus family, and thus share significant biological properties, 
transmission dynamics between these viruses seem to be different. Our results suggest 
that ethnic differences in CMV seroprevalences in childhood are mainly determined by 
factors that facilitate vertical transmission, which underscores that breastfeeding is the 
most important source for CMV infection in childhood.53-55 In contrast, ethnic differences in 
EBV and HSV-1 seroprevalences are partly determined by factors that facilitate horizontal 
transmission, such as family size and daycare, which are strongly related to socioeconomic 
position. In fact, we were able to explain up to 39% of the ethnic differences in EBV serop-
revalences, of which socioeconomic position was the most important contributor, which 
is in line with previous studies.42, 44 However, it has been suggested that ethnic differences 
could not be explained by crowding. Still, it could be speculated that socioeconomic posi-
tion reflects more proximal determinants (e.g. factors that facilitate horizontal transmis-
sion, such as family size, bed sharing and childcare arrangements). Indeed, the results 
from our multivariable model confirm that parity is important in estimating the risk of EBV 
infection.18 In fact, we observed a dose-response relationship between parity and the risk 
of EBV and HSV-1 seropositivity. 
In contrast with the results on EBV and HSV-1, ethnic differences in CMV seroprevalences 
could not be explained by socioeconomic position, nor by other ‘explanatory variables’ 
such as breastfeeding, daycare and parity. In fact, these factors strengthened rather than 
weakened the association between ethnicity and CMV. We expected breastfeeding to partly 
mediate this association, because breastfeeding can transmit CMV, and breastfeeding 
behavior is influenced by ethnic background.56 Vertical transmission from mother to child 
is probably more important in explaining ethnic differences in CMV seroprevalences than 
factors that facilitate horizontal transmission. Given the economic burden of CMV associ-
ated diseases, it has been suggested that vaccination in the general population would be 
the most straightforward way to control for all CMV associated diseases.3 Some opinions 
favor inclusion of 12-year old children, whereas others suggest vaccination of toddlers.33,57 
However, thus far, safe and effective vaccines have not been developed. Nevertheless, on 
the basis of our results, ethnic and socioeconomic differences should be taken into ac-
count when vaccination is contemplated. 
HSV-1 prevalence was highest in Turkish and Moroccan children according to a previous 
Dutch study in adolescents.45 Our results confirm that differences in HSV-1 seroprevalences 
between European countries could be partly explained by socioeconomic factors.22 It has 
been shown that lower socioeconomic position indeed increases the risk for HSV-1.45 All 
factors together, including socioeconomic position, breastfeeding and crowding, explained 
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up to 48% of ethnic differences in HSV-1 seroprevalence, of which socioeconomic position 
was the most important contributor, suggesting an important role for factors that facilitate 
horizontal transmission. 
An important strength of this study is that we had a large multi-ethnic cohort study 
population drawn from the general population of Rotterdam. Because immigration is 
common in Western countries, our findings may be more broadly applicable. In addition, 
our study design enabled us to assess multiple risk factors, and to study the relative im-
portance of each using multivariate models. Moreover, our use of a mediator approach 
to explain ethnic differences in herpesvirus infections is novel. Besides socioeconomic 
position, numerous other factors vary between countries, and adjustment for these factors 
might decrease ethnic/racial or geographical variation.12 Because our study was performed 
within a population-based study of a region within a single country, we were able to adjust 
for all of these variables. A limitation of this study is that we did not have data on mater-
nal CMV, EBV, HSV-1 seroprevalences in order to analyse mother-to-child transmission. A 
second limitation was lack of data on EBV, CMV and HSV-1 seroprevalences in fathers and 
siblings, precluding examination of their roles in horizontal transmission. When immuniza-
tion against these viruses is considered, ethnic and socioeconomic differences should be 
taken into account. 
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Figure 1: Flowchart of the participants within the Generation R Study 
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Supplemental Figure 1 Flowchart of the participants within the Generation R Study
A total of 4,464 children provided serological data. Of these, 2,279 children (51%) were EBV positive, 1,692 (38%) CMV 
positive, 877 (20%) HSV-1 positive, and 4,056 (91%) VZV positive. 
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Supplemental Figure 2 Seroprevalence of herpesvirus infections in childhood according to maternal eth-
nic background. Values are seroprevalences of CMV, EBV, and HSV-1 infections (%) per ethnicity category. CMV, EBV, 
and HSV-1 seroprevalences of Cape Verdean, Moroccan, Dutch Antillean, Turkish, Surinamese-Creole, and Surinam-
ese-Hindustani children are compared to Dutch children. Footnotes: ¶ p-value <0.05, #P-value <0.01, *P-value <0.001 
based on χ2 test. 
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Supplemental Figure 3 Percentages of first generation mothers according to CMV, EBV or HSV-1 seroposi-
tivity in childhood. 
Values are percentages of ‘first’ generation mothers according to CMV, EBV or HSV-1 seroprevalences in childhood. 
Generational status of non-native Dutch mothers was based on their country of birth. Foreign-born mothers were 
classified as ‘first generation’ and mothers born in the Netherlands were classified as ‘second generation’.
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Supplemental Table 1. Associations between ethnic background and potential confounders and media-
tors (n=3,528) 
Ethnic background
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P-valuea
(n=2386) (n=131) (n=136) (n=338) (n=247) (n=181) (n=109)
Potential confoundersb
Age (years) 6.1 (0.4) 6.4 (0.7) 6.3 (0.6) 6.3 (0.6) 6.4 (0.7) 6.3 (0.7) 6.6 (0.9) <0.001
Parity (%)
Nulliparous 60.3 54.3 53.8 43.7 37.9 47.7 51.9 <0.001
Potential mediators
Maternal educational level (%)
Low 12.7 32.8 31.5 53.3 45.1 50.7 36.0 <0.001
Mid-low 25.7 50.4 49.6 33.0 37.9 39.5 49.0
Mid-high 26.7 14.3 15.0 10.0 14.6 8.6 9.0
High 34.9 2.5 3.9 3.7 2.4 1.3 6.0
Net household income (%)
≤ 2200 euro 25.1 70.5 70.2 87.1 88.2 91.6 83.3 <0.001
> 2200 euro 74.9 29.5 29.8 12.9 11.8 8.4 16.7
Daycare (% yes) 89.5 83.3 70.4 57.1 65.4 92.1 82.6 <0.001
Breastfeeding duration (%)
never 10.1 8.3 4.2 1.2 3.7 11.7 13.0 <0.001
<3 months 31.8 41.7 56.9 35.5 41.1 51.9 52.2
3-6 months 22.7 18.1 20.8 18.7 18.7 18.2 8.7
>6 months 35.4 31.9 18.1 44.6 36.4 18.2 26.1
Maternal smoking (% 
continued)
14.0 27.2 15.2 32.3 4.9 17.8 20.4 <0.001
Maternal alcohol use (% 
continued)
53.4 40.4 18.6 6.8 3.0 28.5 36.3 <0.001
BMI child (kg/m2) 15.9 (1.4) 16.9 (2.7) 15.8 (2.1) 17.2 (2.3) 16.9 (2.0) 17.0 (2.3) 17.2 (2.5) <0.001
Maternal BMI (kg/m2) 23.2 (3.9) 24.9 (4.9) 23.8 (4.5) 24.9 (4.8) 25.2 (4.3) 23.7 (3.6) 25.5 (5.6) <0.001
Values are percentages or means (SD). 
a P-values are calculated with the Chi-square test for categorical variables and ANOVA for continuous variables. 
b Data was missing for maternal educational level (9.2%), net household income (24.8%), daycare (56.3%), breast-
feeding duration (34.7%), maternal smoking (13.3%), maternal alcohol use (21.0%), BMI child (0.2%) and maternal 
BMI (26.1%)
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Supplemental Table 2. Associations between potential mediators and herpesvirus seropositivity
Cytomegalovirus Epstein-Barr virus Herpes Simplex virus 1
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Potential mediators
Parity 0.89 (0.82,0.98) 0.012 1.08 (0.99,1.17) 0.096 1.07 (0.96,1.18) 0.22
Maternal educational level 
Low 0.67 (0.53,0.85) 0.001 1.34 (1.07,1.69) 0.011 1.88 (1.41,2.51) <0.001
Mid-low 0.66 (0.54,0.82) <0.001 0.99 (0.81,1.21) 0.93 1.37 (1.03,1.83) 0.03
Mid-high 0.89 (0.72,1.11) 0.31 0.92 (0.75,1.13) 0.43 1.14 (0.80,1.63) 0.46
High Ref Ref Ref
Net household income 
≤ 2200 euro 0.87 (0.72, 1.06) 0.16 1.20 (1.00, 1.44) 0.057 1.29 (1.02,1.64) 0.036
> 2200 euro Ref Ref Ref
Daycare 
No Ref Ref Ref
Yes 1.38 (1.09, 1.76) 0.009 0.97 (0.76, 1.23) 0.77 0.86 (0.68, 1.09) 0.20
Breastfeeding duration
never Ref Ref Ref
<3 months 1.34 (0.94,1.90) 0.10 0.89 (0.66,1.20) 0.44 0.74 (0.51,1.08) 0.12
3-6 months 1.48 (1.07,2.06) 0.019 1.01 (0.72,1.42) 0.95 0.67 (0.43,1.03) 0.067
>6 months 1.63 (1.13,2.36) 0.012 0.83 (0.60,1.14) 0.23 0.67 (0.44,1.02) 0.061
OR, odds ratio; CI, confidence interval. 
Table is based on imputed dataset (potential confounders and mediators are multiple imputed, determinant ob-
served).
Values are derived from logistic regression models and represent effect estimates (95% confidence intervals), ad-
justed for sex, age and ethnic background.
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Supplemental Table 4. Determinants of herpesvirus seropositivity in children at 6 years of age 
n=4,464 Cytomegalovirus Epstein-Barr Virus Herpes simplex virus 1
Determinants  (aOR 95% CI) (aOR 95% CI)  (aOR 95% CI)
Gender 
 Male 1.0 1.0 1.0 
 Female 1.18 (1.02; 1.36)* 0.99 (0.87; 1.15) 1.05 (0.97; 1.13) 
Ethnicity 
 Western 1.0 1.0 1.0 
 Non western 2.16 (1.81; 2.57)*** 1.76 (1.48; 2.09)*** 1.52 (1.39; 1.66)* 
Income
 Low (<2200) 1.18 (0.98; 1.42) 1.09 (0.91; 1.30) 1.11 (1.01; 1.23)* 
 High (>2200) 1.0 1.0 1.0 
Maternal educational level
 Low 0.95 (0.73; 1.23) 1.09 (0.85; 1.41) 1.55 (1.35; 1.79)*** 
 Mid-low 0.82 (0.66; 1.01) 0.93 (0.76; 1.15) 1.19 (1.05; 1.35)** 
 Mid-high 0.96 (0.77; 1.19) 0.94 (0.77; 1.15) 1.16 (1.03; 1.31)* 
 High 1.0 1.0 1.0 
Daycare 1.20 (1.00; 1.43) 1.06 (0.86; 1.31) 0.89 (0.81; 0.97)*
Breastfeeding duration
 Never 1.0 1.0 1.0 
 <3 months 1.53 (1.04; 2.23)* 0.98 (0.73; 1.33) 1.02 (0.89; 1.16) 
 3-6 months 1.77 (1.21; 2.60)** 1.20 (0.85; 1.69) 1.08 (0.93; 1.26) 
 >6 months 1.96 (1.25; 3.07)** 1.08 (0.78; 1.85) 1.06 (0.92; 1.22) 
Parity
 0 1.0 1.0 1.0 
 1 0.76 (0.65; 0.90)** 1.11 (0.95; 1.30) 1.18 (1.08; 1.29)*** 
 2 0.90 (0.69; 1.18) 1.35 (1.05; 1.74)* 1.31 (1.14; 1.50)*** 
 >3 0.85 (0.54; 1.33) 1.58 (1.01; 2.48)* 1.60 (1.29; 1.99)*** 
Abbreviations: aOR, adjusted Odds Ratio; CI, confidence interval. Values reflect aORs (95% CI). Table is based on 
multiple imputed dataset. *P<0.05.
** P<0.01.
*** P<0.001. Models were adjusted for age, sex, socioeconomic position (ethnicity, family net household income, 
maternal educational level), crowding (daycare, breastfeeding, parity) and maternal lifestyle (maternal age, smok-
ing and alcohol use during pregnancy, and maternal BMI).
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Supplemental Table 6. Attenuation of the OR of Cytomegalovirus seropositivity for different ethnicities 
after individual adjustment for the explanatory variables
Surinamese-
Creolesa
OR (95% CI)
Attenuation 
a
(95% CI)
Surinamese-
Hindustani b
OR (95% CI)
Attenuation 
b
(95% CI)
Turkish c
OR (95% CI)
Attenuation 
c
(95% CI)
Moroccan d
OR (95% CI)
Attenuation 
d
(95% CI)
Cape 
Verdean e
OR (95% CI)
Attenuation 
e
(95% CI)
Antillean f
OR (95% CI)
Attenuation 
f
(95% CI)
CMV
Model 1 (includes child 
sex and current age)
2.29 (1.61, 3.28) 1.92 (1.35, 
2.72)
4.41 (3.47, 5.62) 3.64 (2.77, 
4.79)
3.17 
(2.33,4.32)
n.s. NA
Socioeconomic status
Model 1+ education 2.72 (1.87, 3.88) +33%
(17 to 60)*** 
2.26 (1.56, 
3.19)
+37%
(19 to 80)*** 
5.36 (4.01, 6.76) +28%
(14 to 44)***
4.23 (3.17, 
5.61)
+22%
(11 to 36)***
3.70 (2.69, 
5.12)
+24% 
(12 to 40)***
Crowding
Model 1 + parity 2.29 (1.60, 3.28) 0% 
(-10 to 10)
1.89 (1.33, 
2.71)
-3%
(-20 to 14)
4.49 (3.51, 5.74) +2% 
(-4 to 9)
3.94 (2.97, 
5.24)
+11%
(0.5 to 24)*
3.14 (2.29, 
4.32)
-1% (-12 to 11)
Model 1 + daycare 2.37 (1.62, 3.32) +6% 
(1 to 14)**
2.14 (1.49, 
3.07)
+25%
(8 to 58)**
5.08 (3.84, 6.42) +20%
(7 to 36)**
3.90 (3.00, 
5.40)
+10% 
(3 to 19)***
3.15 (2.28, 
4.24)
-1% (-3 to 2)
Model 1 + breastfeeding 2.35 (1.63, 3.33) +5%
(0.4 to 12)*
1.99 (1.37, 
2.79)
+8%
(2 to 19)**
4.24 (3.33, 5.43) -5% 
(-8 to -2)**
3.62 (2.70, 
4.69)
-1% 
(-4 to1)
3.33 (2.45, 
4.58)
+8% 
(2 to 15)**
Fully adjusted model 2.73 (1.81, 3.83) +34%
(14 to 66)***
2.42 (1.62, 
3.42)
+55%
(24 to 124)***
5.53 (3.98, 6.97) +33% 
(13 to 59)**
4.60 (3.36, 
6.31)
+36% 
(19 to 60)***
3.68 (2.6-, 
5.07)
+23%
(5 to 47)**
Abbreviations: OR, Odds Ratio; CI, confidence interval. 
a The ORs represent the attenuated effect estimate and their 95% CIs relative to model 1 after individual adjustment 
for explanatory factors. 
b Attenuations a to e represent the attenuations of effect estimates for the different ethnicities relative to model 1 
(includes confounders) after adjustment for explanatory variables (100x (OR model 1 - OR model 1 with explanatory factor) / (OR model 
1)). Dutch is the reference group. No significant difference in CMV prevalence was observed for the Antillean group 
compared with the Dutch group, therefore attenuations in effect estimates for the Antillean group are not presented. 
* p<0.05.
 ** p<0.01. 
*** p<0.001.
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Supplemental Table 6. Attenuation of the OR of Cytomegalovirus seropositivity for different ethnicities 
after individual adjustment for the explanatory variables
Surinamese-
Creolesa
OR (95% CI)
Attenuation 
a
(95% CI)
Surinamese-
Hindustani b
OR (95% CI)
Attenuation 
b
(95% CI)
Turkish c
OR (95% CI)
Attenuation 
c
(95% CI)
Moroccan d
OR (95% CI)
Attenuation 
d
(95% CI)
Cape 
Verdean e
OR (95% CI)
Attenuation 
e
(95% CI)
Antillean f
OR (95% CI)
Attenuation 
f
(95% CI)
CMV
Model 1 (includes child 
sex and current age)
2.29 (1.61, 3.28) 1.92 (1.35, 
2.72)
4.41 (3.47, 5.62) 3.64 (2.77, 
4.79)
3.17 
(2.33,4.32)
n.s. NA
Socioeconomic status
Model 1+ education 2.72 (1.87, 3.88) +33%
(17 to 60)*** 
2.26 (1.56, 
3.19)
+37%
(19 to 80)*** 
5.36 (4.01, 6.76) +28%
(14 to 44)***
4.23 (3.17, 
5.61)
+22%
(11 to 36)***
3.70 (2.69, 
5.12)
+24% 
(12 to 40)***
Crowding
Model 1 + parity 2.29 (1.60, 3.28) 0% 
(-10 to 10)
1.89 (1.33, 
2.71)
-3%
(-20 to 14)
4.49 (3.51, 5.74) +2% 
(-4 to 9)
3.94 (2.97, 
5.24)
+11%
(0.5 to 24)*
3.14 (2.29, 
4.32)
-1% (-12 to 11)
Model 1 + daycare 2.37 (1.62, 3.32) +6% 
(1 to 14)**
2.14 (1.49, 
3.07)
+25%
(8 to 58)**
5.08 (3.84, 6.42) +20%
(7 to 36)**
3.90 (3.00, 
5.40)
+10% 
(3 to 19)***
3.15 (2.28, 
4.24)
-1% (-3 to 2)
Model 1 + breastfeeding 2.35 (1.63, 3.33) +5%
(0.4 to 12)*
1.99 (1.37, 
2.79)
+8%
(2 to 19)**
4.24 (3.33, 5.43) -5% 
(-8 to -2)**
3.62 (2.70, 
4.69)
-1% 
(-4 to1)
3.33 (2.45, 
4.58)
+8% 
(2 to 15)**
Fully adjusted model 2.73 (1.81, 3.83) +34%
(14 to 66)***
2.42 (1.62, 
3.42)
+55%
(24 to 124)***
5.53 (3.98, 6.97) +33% 
(13 to 59)**
4.60 (3.36, 
6.31)
+36% 
(19 to 60)***
3.68 (2.6-, 
5.07)
+23%
(5 to 47)**
Abbreviations: OR, Odds Ratio; CI, confidence interval. 
a The ORs represent the attenuated effect estimate and their 95% CIs relative to model 1 after individual adjustment 
for explanatory factors. 
b Attenuations a to e represent the attenuations of effect estimates for the different ethnicities relative to model 1 
(includes confounders) after adjustment for explanatory variables (100x (OR model 1 - OR model 1 with explanatory factor) / (OR model 
1)). Dutch is the reference group. No significant difference in CMV prevalence was observed for the Antillean group 
compared with the Dutch group, therefore attenuations in effect estimates for the Antillean group are not presented. 
* p<0.05.
 ** p<0.01. 
*** p<0.001.
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Supplemental Table 9. Maternal and infant characteristics of the study population
(n=4464)
Epstein Barr virus, cytomegalovirus or herpes 
simplex virus type1
0 infections 
(n=1319)
1 Infection 
(n=1735)
>2 infections 
(n=1410)
Maternal characteristics 
Age (Mean + SD; years) 31.7 (4.7) 30.8 (5.0)*** 29.7 (5.4)***
Educational level (n; %)
 Low 180 (14.4%) 322 (20.3%)*** 366 (30.1%)*** 
 Mid-Low 376 (30.0%) 476 (30.0%) 382 (31.5%) 
 Mid-High 329 (26.3%) 336 (21.2%) 229 (18.9%) 
 High 368 (29.3%) 452 (28.5%) 237 (19.5%) 
Net household income per month (n; %)
 < € 2000 177 (16%) 325 (23%) 368 (35%)*** 
 € 2000-3200 291 (22%) 370 (26%) 254 (24%) 
 > € 3200 668 (59%) 716 (51%) 443 (42%) 
Smoking continued during pregnancy (n; %) 138 (13%) 232 (17%)** 166 (15%)
Alcohol use continued during pregnancy (n; %) 487 (46%) 595 (43.4) 395 (35.7%)***
BMI before pregnancy (Mean + SD; kg/m2) 23.4 (3.9) 23.6 (1.7) 23.9 (4.3)**
Maternal atopy (n; %) 396 (33.8%) 548 (36.9%) 354 (30.2%)
Family history of asthma / atopy (n; %) 605 (48.7%) 809 (51.1%) 541 (43.7%)*
Parity 
 0 717 (57%) 917 (55%)* 736 (54%)*** 
 1 404 (32%) 533 (32%) 401 (29%) 
 2 118 (9%) 162 (10%) 169 (12%) 
 >3 23 (2%) 61 (3%) 62 (5%) 
Mode of delivery (n; %) 
 Vaginal 825 (73.4%) 1071 (72%) 914 (74.6%) 
 Forceps or vacuum assisted 166 (14.8%) 203 (13.6%) 163 (13.3%) 
 Caesarian section  133 (11.8%) 214 (14.4%) 148 (12.1%) 
Premature rupture of membranes (n; %) 51 (4.1%) 72 (4.4%) 58 (4.3%)
Infant characteristics (n=258)
Males (n; %) 683 (51.8%) 922 (53.1%) 699 (49.6%)
Western ethnicity (n;%) 1047 (80%) 1162 (69%)*** 655 (49%)***
Gestational age (Mean + SD; weeks)  39.8 (1.9) 39.8 (1.7) 39.8 (1.8)
Preterm birth (<37 weeks) (n; %) 76 (6.0%) 104 (6.0%) 79 (5.6%)
Birth weight ( Mean + SD; grams) 3442 (599) 3413 (557) 3386 (552)**
Low birth weight (<2500 gr) 75 (5.7%) 98 (5.7%) 67 (4.8%)
Day-care in first year (n; %) 567 (85%) 699 (89%)* 447 (88%)
Breastfeeding (n; %)
 Never 98 (10.2%) 114 (10.0%) 52 (6.3%)* 
 < 3 months 340 (35.5%) 364 (32.0%) 286 (34.8%) 
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Supplemental Table 9. Maternal and infant characteristics of the study population (continued)
(n=4464)
Epstein Barr virus, cytomegalovirus or herpes 
simplex virus type1
0 infections 
(n=1319)
1 Infection 
(n=1735)
>2 infections 
(n=1410)
 3-6 months 195 (20.4%) 237 (20.8%) 186 (22.7%) 
 >6 months 324 (33.9%) 423 (37.2%) 297 (36.2%) 
Infections first year (n; %)
 RTI 538 (57.2%) 652 (59.4%) 495 (63.3%)* 
 LRTI 125 (13.8%) 140 (13.5%) 107 (15.0%) 
 URTI 490 (49.8%) 607 (52.6%) 471 (56.1%)** 
 GI 329 (55.7%) 378 (58.0%) 296 (64.1%)** 
Atopy first year
 Eczema 264 (27.4%) 312 (28.2%) 215 (27.2%) 
 Wheezing (> 1 epsiode) 338 (42.8%) 412 (45.5%) 315 (49.5%)* 
Nasopharyngeal bacterial carriership 6 years (n; %)
 No pathogen 606 (47.3%) 794 (46.8%) 606 (44.2%) 
 S Aureus 338 (26.4%) 459 (27.0%) 408 (29.8%) 
 S. Pneumoniae 255 (19.9%) 296 (17.4%) 246 (17.9%) 
 H. Influenza 125 (9.8%) 197 (11.6%) 152 (11.1%) 
 M. Catarrhalis 117 (9.1%) 156 (9.2%) 156 (11.4%) 
Antibiotic use (n; %)
 YEAR 1 386 (47.6%) 504 (54.1%)** 340 (52.7%) 
 YEAR 2 413 (41.6%) 520 (44.9%) 374 (47.3%)* 
 YEAR 3 313 (32.4%) 396 (36.4%) 281 (37.5%)* 
 YEAR 4 260 (27.6%) 331 (30.1%) 247 (32.2%)* 
 YEAR 6 227 (18.9%) 339 (23.0%)* 266 (23.9%)** 
 EVER (at age 6 years) 830 (85.0%) 1059 (89.4%)** 774 (90.0%)** 
Age at focus visit 
(Median + range; years) 6.0 (5.0-8.8) 6.0 (5.0-9.0)*** 6.1 (4.9-9.1)*** 
BMI for age (mean; sd; SDS) 0.20 (0.85) 0.25 (0.92) 0.39 (0.95)***
Values are means (SD), absolute numbers (percentages) or #medians (90% range). Based on observed dataset. 
Significantly different from 0 infections*P<0.05) ** (P<0.01) *** (P<0.001) Maternal atopy: eczema, house dust mite 
allergy, hay-fever, 
any reported autoimmune disease includes diabetes mellitus, systemic lupus erythematosus, arthritis, multiple 
sclerosis, thyroid disorder or celiac disease
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ABSTRACT
Background and aims
Increased levels of anti-tissue transglutaminase (tTG) levels have been associated with 
reduced weight and bone mineral density (BMD) in symptomatic patients with celiac 
disease. Little is known about the effects of these antibodies patients with subclinical or 
other forms of celiac disease. We examined associations between anti-tTG positivity and 
growth and BMD.
Methods
In a population-based prospective cohort study, serum samples were collected from 
children (median age, 6 years, n=4442) and analysed for anti-tTG levels. All children were 
born between April 2002 and January 2006 and were not previously diagnosed with celiac 
disease. Children were categorized as anti-tTGnegative (< 7 U/ml, n=4249), or anti-tTG posi-
tive (>7 U/ml, n=57). Children’s levels of anti-tTG positive levels were further categorized 
into 2 categories on the basis of >10 times upper limit of normal (70 U/ml). Height, weight 
and body mass index (BMI) age- and sex-adjusted standard deviation scores (SDS) ((ob-
served value- mean)/SD) were obtained using Dutch reference growth charts. BMD was 
measured by dual-energy x-ray absorptiometry . Multivariable linear regression and linear 
mixed models were performed. 
Results
Children who tested positive for anti-tTG had reduced growth in weight SDS/year (reduc-
tion of 0.05; 95% CI, reductions of 0.09,0.01) and BMI SDS/year (reduction of 0.10; 95% 
CI, reductions of 0.18,0.01) from 6 months until 6 years, compared with children without 
anti-tTG; they also tended to have reduced growth in height from 6 months until 6 years 
(reduction of 0.02 SDS/year; 95% CI reductions of 0.06, 0.02). Children who tested positive 
for anti-tTG were shorter (0.29 SDS less; 95% CI reductions of 0.55, 0.04), weighed less (0.38 
SDS less; 95% CI , reductions of 0.64, 0.12), and had lower BMIs (0.26 SDS less; 95% CI, 
reductions of 0.49, 0.03) and BMDs (0.26 SDS less; 95% CI, reductions of 0.45, 0.08) at 6 years 
of age than anti-tTG negative children.
Conclusion
Anti-tTG positive children without gastrointestinal symptoms have lower BMDs and 
reduced growth trajectories until they are 6 years old. This suggests that subclinical or 
potential CD can affect BMD and growth. 
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INTRODuCTION
Celiac disease (CeD) is an autoimmune-mediated disease that is caused by ingestion 
to gluten in genetic predisposed individuals. Screening studies have shown that the 
prevalence of CeD is approximately 1%, and increases over time.1-3 However, CeD is un-
derdiagnosed, because clinical symptoms in childhood are often minor, atypical or even 
absent.4 Screening on anti-tissue transglutaminase (tTG) concentrations has the potential 
to detect these forms of otherwise undetected subclinical and potential CeD.5, 6 However, it 
remains unclear whether these forms of CeD should be treated, because the consequences 
of untreated subclinical and potential CeD in childhood remain unclear. Consequences of 
classic CeD include a decreased length, weight, body mass index (BMI), and bone mineral 
density (BMD), which completely recover by using a gluten free diet (GFD) in childhood. 
However, by the time CeD is diagnosed in adulthood, complete bone recovery is not al-
ways achieved. It is estimated that one-third of adult patients have osteoporosis, one-third 
have osteopenia, and the remaining one-third have a normal BMD.7,8 In addition, screening 
studies showed a decreased BMD even in asymptomatic adults who had positive concen-
trations of celiac antibodies,7,9 but no villous atrophy,10 indicating that merely the presence 
of positive serology in adulthood is sufficient to have adverse effects on BMD. Moreover, 
persisting osteopenia and osteoporosis in adults, despite a GFD, may be the result of sub-
clinical CeD in childhood.10,11 Because the effects on BMD in childhood are independent 
of clinical symptoms, 12 adverse effects might also be present in children with undetected 
forms of CeD. Although children with positive immunoglobulin A-endomysial antibody 
(EMA) serology are suggested to be shorter and lighter,3 effects on growth trajectories and 
bone development are not known. 
Therefore, the aim of this study was to assess whether anti-tTG positivity was associated 
with decreased height, weight, BMI and BMD in a population-based study of children from 
6 months until 6 years of age.
METhODS
Study Design
This study was embedded within a population-based prospective cohort study.13 All chil-
dren were born between 2002 and 2006. From the age of 6 years, 6690 visited the research 
center (median age, 6.0 years).13 of whom serum anti-tTG levels were available in 4442 
(66%). Of these, we excluded twins, children with a questionnaire reported CeD diagnosis 
and a GFD. The resulting population for analysis consisted of 4306 children [Supplemental 
Figure 1]. 
Chapter 11  |  TG2A antibodies, growth and bone development
256
Anti-tissue transglutaminase concentrations
Anti-tTG immunoglobulin A concentrations were measured in venous blood serum sam-
ples by using a fluorescence enzyme immunoassay (FEIA Phadia ImmunoCAP 250; EliA IgA, 
Phadia AB, Uppsala Sweden).14 Concentration of anti-tTG were categorized into 2 groups: 
group 1, anti-tTG negative (< 7 U/ml) and group 2, anti-tTG positive (>7 U/ml) [Supplemental 
Figure 1]. In addition, anti-tTG positive concentrations were categorized into 2 categories 
on the basis of below or above the > 10 times upper limit of normal concentrations of the 
test kit (>70 U/ml). 5 
hLA DQ2 DQ8
A genome-wide association scan (Illumia 610K) of child DNA was taken from 5908 cord-
blood samples. A tag single nucleotide polymorphisms approach was used to capture 
whether children carried the HLA-DQ risk type DQ2 or DQ8.15,16 Children were genotyped for 
HLA-DQ2 (rs2187668, rs2395182, rs4713586 and rs7775228) and DQ8 (rs7454108) by using 
genome wide Illumina 610 Quad Array (San Diego, CA, USA). Genotype and allele frequen-
cies were in Hardy Weinberg equilibrium (rs2187668, p=0.88; rs2395182, p=0.78; rs4713586, 
p=0.95; rs7775228, p=0.86; rs7454108, p=0.90). 
Growth measurements
Child anthropometrics were obtained by measurements at 6, 14, 24, 36 and 48 months and 
at 6 years of age.17 We obtained age-adjusted standard deviation scores (SDS) by using 
Dutch reference growth curves (Growth Analyzer 3.0; Dutch Growth Research Foundation, 
Rotterdam, Netherlands). Definitions of overweight (>1.1 to 2.3 SDS) and obesity (BMI > 2.3 
SDS) were based on internationally established age- and sex-adjusted BMI distributions.17,18 
Gastrointestinal symptoms
Gastrointestinal symptoms were assessed by parental reported questionnaires (median 
age, 6 years). Functional constipation was defined if at least the following symptoms of 
Rome III 19 were reported in the past year: (1) defecation frequency <3 times a week, (2) 
predominantly hard faeces for the majority of stools, (3) ≥1 episode of fecal incontinence 
per week. The stool pattern of the child was assessed using questionnaires at the age of 
6 years. Mothers were asked whether their child had abdominal complaints during the 
last 3 months (y/n), if their child was feeling sick or nauseous while or after having eaten 
(y/n), and how their child’s faeces usually looked over the past 3 months (answer options 
included: ‘very hard’ to ‘very soft/slushy’ or ‘watery’). Diarrhea was defined when ‘very soft/ 
slushy’ or ‘watery’ faeces was indicated. 
Bone Mineral Density, Bone Mineral Content and Bone Area
BMD (g/cm2), bone mineral content (BMC) (g), and bone area (BA (cm2) were measured 
by a dual-energy X-ray absorptiometry (DXA) scan (iDXA, General Electrics-Lunar, 2008, 
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Madison, WI) (median age, 6 years).20 All scans were performed by well-trained research 
assistants and by using the same device and software (enCORE, version 13; GE Healthcare, 
Little Chalfont, Buckinghalshire, United Kingdom). Total body less head BMD, BMC, and BA 
were used to analyze total body bone mass. 21
Covariates
Maternal anti-tTG concentrations were measured during pregnancy and maternal height 
and weight were measured at enrollment. Fetal gender, gestational age and birth weight 
were obtained from obstetric records.13 Ethnicity was determined according to the clas-
sification of Statistics Netherlands.22 Data on other sociodemographic and lifestyle factors, 
including educational level23 and household income,24 were obtained by a combination of 
pre- and postnatal questionnaires completed by both parents. Postnatal questionnaires 
also included information on feeding behavioure, physical activity, and family history of 
CeD. 
Statistical methods
First, independent T test and Chi-square tests were used to test for differences in char-
acteristics between the anti-tTG negative and positive groups. Then, to assess whether 
growth characteristics were different between these groups, 2 different types of analyses 
were performed. First, to longitudinally assess associations between anti-tTG and growth, 
repeated-measurement analyses were performed by using linear mixed models with an 
unstructured symmetry covariance structure (the Statistical Analysis System). These mod-
els take the correlations between repeated measurements within the same subject into 
account. The between-measurement correlations for height and weight decreased with 
increasing age, from 0.81 to 0.58 for height, and 0.84 to 0.52 for weight. Goodness-of-fit 
indices (AIC’s) of models with a CS, UN and AR1 symmetry covariance structure were com-
pared. The UN model provided the smallest AIC and was therefore applied. Second, we 
performed cross-sectional analyses to examine associations between anti-tTG positivity 
with height, weight, BMI and BMD at 6 years of age in 2 linear regression models: (1) a 
basic model and (2) a confounder model, which also adjusted for covariates that showed a 
change in effect estimate of >10%.25 We constructed age-adjusted standard SDS ([observed 
value- mean]/SD) for childhood outcomes to enable comparison of effect estimates. In 
addition, we assessed whether HLA DQ2-DQ8 status, ethnicity, gender, breastfeeding and 
timing of gluten introduction modified the association, but no significant interactions were 
observed. Binary logistic regression models were performed to assess the associations 
between anti-tTG and gastrointestinal complaints. To reduce bias associated with missing 
data, multiple imputation (n=10) of the covariates was performed.26 Regression coefficients 
were pooled by taking the average of the 10 imputed data sets. The pooled standard error 
was calculated by using the rules of Rubin and Schenker.27 Last, sensitivity analyses were 
performed to test whether the associations between anti-tTG and height, weight, BMI and 
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BMD were different before and after excluding HLA DQ2/DQ8 negative children. Longitudi-
nal mixed model analyses were performed in Statistical Analysis System 9.3 (SAS Institute 
Inc., Cary, NC). Imputation procedures and cross-sectional analyses were performed in 
SPSS 20.0 for Windows (SPSS Inc., Chicago, Il), 
RESuLTS
Subject characteristics
Mean child’s age was 6.2 (range 4.9, 9.1) years. Out of 4306 children, 57 (1.3%) had anti-tTG 
positive levels at 6 years of age, and 4249 (98.7%) had anti-tTG negative concentrations 
[Table 1, Supplemental Figure 1, Supplementary Table 1]. Of children with anti-tTG posi-
tive concentrations, 91% carried the HLA-DQ2 or -DQ8 molecule [Table 1]. Higher income, 
female gender and Western Ethnicity were related to positive anti-tTG concentrations. 
Breastfeeding duration and timing of gluten introduction were not different between anti-
tTG positive and negative children.14
Gastrointestinal symptoms
No significant differences were observed in doctor’s diagnosis of (functional) constipation 
according to the ROME III criteria (adjusted odds ratio 0.57; 95% CI 0.22,1.46), abdominal 
pain (aOR 1.50; 95% CI 0.82, 2.72), a soft/watery stool pattern (aOR 1.32; 95% CI 0.55, 3.18), 
or a sick or nauseous feeling while/after having eaten (aOR 0.61; 95% CI 0.18,2.06) [Table 2].
Longitudinal growth outcomes
Longitudinal analysis on height, weight and BMI from 6 months until 6 years of age derived 
from linear mixed models are illustrated in Figure 1. Children who tested positive for anti-
tTG tended to be shorter (0.12 SDS less; 95% CI reductions of 0.39, 0.14 SDS) and to weigh 
less (0.14 SDS less; 95% CI reductions of 0.41, 0.14) at 6 months than anti-tTG negative 
children, although these effects were not significant. However, anti-tTG positive children 
had reduced growth in weight SDS/year (reductions of 0.05; 95% CI reductions of 0.09, 
0.01, p=0.01), and BMI SDS/year (reductions of 0.10; 95% reductions of 0.18, 0.01, p=0.03) 
from 6 months until 6 years, compared with children without ant-tTG; they also tended 
to have reduced growth in height (reduction of 0.02 SDS/year; 95% CI reductions of 0.06, 
0.02) although this effect was non-significant. The differences in height, weight and BMI 
between children with and without anti-tTG positive levels became stronger with increas-
ing age and were mostly noticeable at 6 years of age. Anti-tTG positive children tended to 
be shorter(0.24 SDS shorter; 95% CI reductions of 0.52, 0.04, p=0.09) and weighed less (0.41 
SDS less; 95% CI reductions of 0.69, 0.14, p=0.003) at 6 years of age than anti-tTG negative 
children [Figure 1].
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Figure 1.  Longitudinal growth differences (SDS) between positive tTG levels (>7 U/ml) relative to negative tTG levels (reference).
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Estimated regression lines derived from longitudinal linear mixed model analysis reflect difference in Height (A), Weight (B) and BMI (C) standard deviation scores (SDS) over time in children with positive
anti-tTG levels relative to children with negative anti-tTG levels.
Á. No significant differences in Height over time (p=0.27). Borderline difference in height at 6 years of age (-0.24 SDS, p=0.09).
B. Significant difference in Weight over time (p=0.013). Most prominent difference at 6 years of age (-0.41 SDS, p=0.003)
C. Significant difference in BMI over time (p=0.029). Most prominent difference  at 6 years of age (-0.55 SDS, p=0.021)
Adjusted for timing of introduction of gluten (<6months), gender, ethnicity, income, breastfeeding, birth weight and maternal tTG level during pregnancy.
 
A. B. C.
p=0.029p = 0.27 p = 0.013
Figure 1. Longitudinal growth differences between tTG levels positive children relative to tTG negative 
children. 
Estimated regression lines derived from longitudinal linear mixed model analysis reflect difference in height (A), 
weight (B) and BMI (C) SDS fr m 6 months until 6 y ars in in anti-tTG positive anti-tTG levels relative to anti-tTG 
negative children.
Á. No significant difference in height over time (p=0.27). Borderline difference (-0.24 SDS) in height at 6 years of age 
(p=0.09).
B. Significant difference in weight over time (p=0.013). Significant difference (-0.41 SDS) at 6 years of age (p=0.003)
C. Significant difference in BMI over time (p=0.029). Significant difference (-0.60 SDS) at 6 years of age (p=0.021)
Adjusted for timing of introduction of gluten, gender, ethnicity, income, breastfeeding, birth weight and maternal 
tTG level during pregnancy.
Growth outcomes at 6 years of age
Cross-sectional analysis on height, weight, and BMI are shown in Table 3 and Supplemen-
tal Table 2. Anti-tTG positive children were shorter (0.29 SDS shorter; 95% CI reductions 
of 0.55, 0.04), weighed less (0.38 SDS less; 95% CI reductions of 0.64, 0.12) and had lower 
BMI (0.26 SDS less; 95% CI reductions of 0.49, 0.03) at 6 years of age than anti-tTG nega-
tive children. Results were most eminent in children with high concentrations (> 70 U/ml). 
Children who tested positive for anti-tTG concentrations > 70 U/ml weighed less (0.45 SDS 
less; 95% CI reductions of 0.80, 0.10) and had lower BMI (0.33 SDS less; 95% CI, reductions 
of 0.65, 0.02) at 6 years if age than anti-tTG negative children, but no differences in weight 
and BMI were observed in those with positive concentrations below 10 times upper limit of 
normal (7-70 U/ml), (respectively 0.28 SDS less; 95% CI reductions of 0.65, 0.09), (0.19 SDS 
less; 95% CI reductions of 0.53, 0.14). Associations were independent of gastrointestinal 
symptoms, including constipation, abdominal pain, soft, slushy or watery faeces and a sick 
or nauseous feeling while or after having eaten.
Bone Mineral Density outcome at 6 years of age
Anti-tTG positive children had lower BMDs of total body and spine (respectively, 0.26 SDS 
less; 95% CI reductions 0.47, 0.05) (0.35 SDS less; 95% CI reductions of 0.56, 0.13) at 6 years 
of age than anti-tTG negative children [Table 4]. In addition, inverse linear associations 
were observed between anti-tTG concentrations, weight, BMI, and BMD of total body 
and spine [Supplemental Table 3]. Results were most eminent in children with anti-tTG 
concentrations > 10 times upper limit of normal [Table 4]. Children who teste positive for 
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anti-tTG concentrations > 70 U/ml had lower total BMDs and spinal BMDs (respectively, 
0.40 SDS less; 95% CI reductions of 0.70, 0.11) (0.55 SDS less; 95% CI reducetions of 0.85, 
0.25) at 6 years of age than anti-tTG negative children, but no differences in total BMDs 
and spinal BMDs were observed in those with positive concentrations below the 10 times 
upper limit of normal (7-70 U/ml), (respectively, 0.11 SDS less; 95% CI reductions of 0.41, 
0.20), (0.13 SDS less; 95% CI reductions of 0.44, 0.18). Associations were independent of 
gastrointestinal symptoms.
Sensitivity analyses
After excluding children who were HLA DQ2/DQ8 negative, sensitivity analysis confirmed 
the associations between anti-tTG positivity and decreased height, weight, BMI and BMD 
SDS. In fact, effect sizes were stronger in the HLA DQ2/DQ8 positive children. Within the 
population of HLA DQ2/DQ8 carriers, anti-tTG positive children were shorter (0.45 SDS 
shorter; 95% CI reductions of 0.77, 0.14), weighed less (0.51 SDS less; 95% CI reductions 
of 0.83, 0.20), had lower BMIs (0.31 SDS lower; 95% CI reductions of 0.60, 0.02), lower total 
body BMDs (0.29 SDS less; 95% CI reductions of 0.55, 0.003) and lower BMDs of the spine 
(0.46 SDS less; 95% CI reductions of 0.72, 0.20) than anti-tTG negative children. Differences 
in height weight, total BMDs, and spinal BMDs were more prominent in children who tested 
positive for anti-tTG > 70 U/ml [Supplemental Table 4].
DISCuSSION
Interpretation of main findings
This prospective observational study showed that anti-tTG positivity was associated with a 
deviation in height, weight, BMI, and BMD in young children. The effects of positive anti-tTG 
were mostly present in children with anti-tTG levels >10 times upper limit normal (> 70 U/
ml). 
This is a population-based study that assessed associations between anti-tTG levels and 
growth longitudinally and BMD in anti-tTG positive children without gastrointestinal symp-
toms. Previous studies did not assess BMD3 or growth longitudinally,3 but they reported 
decreased weight and BMD at the time of CeD diagnosis in symptomatic children.28-33 Our 
results indicate that reduced weight and BMD even occurred in screening identified anti-
tTG positive children. All anti-tTG positive children did not receive a previous CeD diagnosis, 
because we excluded children with a GFD or CeD diagnosis. Interestingly, children carrying 
anti-tTG antibodies in our study did not report more often abdominal pain, functional con-
stipation, a soft/watery stool pattern or a sick/nauseous feeling while or after having eaten. 
Apart from diarrhea, this is in line with Bingley et al,3 who found that in antibody positive 
children, who were detected by active anti-EMA screening, gastro-intestinal symptoms 
such as vomiting, abdominal pain and constipation, were not prominent. Comparable to 
261
Chapter 11  |  TG2A antibodies, growth and bone development
Ch
ap
te
r 1
1
our results they found that these antibody positive children were 0.76 SDS shorter and 0.54 
SDS lighter than antibody negative children at 7 years of age. We found that children with 
anti-tTG concentrations > 10 times upper limit of normal were 0.31 SDS shorter and 0.45 
SDS lighter. This equates to about 6-9 months growth (approximately 2 kg weight gain) in 
an average child around this age. These associations were independent of gastrointestinal 
symptoms, which are in line with Bingley et al, who presumed that the effects on height 
and weight are unrelated to malabsorption. Our results can be explained by 2 mechanisms: 
First, anti-tTG positive concentrations might lead to villous atrophy and nutrient deficiency, 
such as calcium, and vitamin D deficiency, which consequently may have adverse effects 
on BMD and growth. Second, anti-tTG positive concentrations might induce inflammation, 
which influences bone development and growth.32 A deviation of -0.55 SDS in BMD (total 
body less head) equates to about 1 year developmental delay in bone mass density at the 
age of 6 years.33 A decreased BMD in childhood is a strong predictor of low peak bone mass 
in young adulthood, which influences the risk of osteoporosis in later life.34 
 In adult CeD patients, BMD has been shown to be independent of clinical symptoms at 
diagnosis.9 Although a GFD improves the BMD in clinical CeD, it does not always restore os-
teopenia or osteoporosis completely. However, a GFD started in early childhood in patients 
with proven CeD reaches complete recovery of BMD within 1 year. 6,12 Once the GFD starts, 
most children catch up their height-weight growth and bone mineralization rate.10 The 
younger the children start with a GFD, especially before puberty 31, the better the BMD.12 
Therefore, persisting osteopenia and osteoporosis in adults, despite a GFD, might reflect 
subclinical and asymptomatic CeD in childhood, which underlies failure to reach peak 
bone mass during bone-building years.11 This highlights the importance of diagnosing CeD 
as early as possible, and it suggests that these patients would benefit from screening to 
start early with treatment. However, the effects of a GFD on growth and BMD in children 
with subclinical or potential CeD remain unclear. Until the effectiveness of a GFD in these 
children has been shown, it would be premature to recommend screening. In addition, 
follow-up is necessary to determine to what extent children with anti-tTG positivity will 
develop CeD later in life. 
Methodological considerations
Detailed information on height, weight and BMI from birth until 6 years was collected 
prospectively, which enabled us to assess childhood growth longitudinally. In addition, 
information on a broad range of potential confounders was available. 
However, some limitations should be taken into account. First, although the sensitivity 
and specificity of anti-tTG is high,5 we did not have biopsy specimens and anti-EMA levels, 
thus final conclusions concerning CeD diagnosis should be made with caution. According 
to the ESPGHAN criteria5, only when anti-tTG levels are increased >10 times upper limit of 
normal in accordance with clinical symptoms and EMA positive concentrations, CeD can be 
diagnosed without duodenal biopsy. However, even if childrenwith positive anti-tTG con-
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centrations lack criteria for final CeD diagnosis, the association between anti-tTG positivity 
and decreased BMD remains valid. Another point of consideration is that HLA DQ2/DQ8 
negative children were included which might have diluted the effect estimates. However, 
sensitivity analysis confirmed the observed associations between height, weight, BMI and 
BMD. In fact, effect estimates were stronger in the HLA DQ2/DQ8 positive population, and 
most pronounced in children with anti-tTG concentrations > 70U/ml, suggesting that the 
results are driven by children who are likely to have CeD. Second, symptom assessment 
was performed by parental reported questionnaires, thus underreporting of symptoms 
cannot be totally excluded. However, questionnaires were filled in before anti-tTG mea-
surement, which makes recall bias less likely. Third, we had 33% missing data on HLA DQ2 
DQ8 status. Nevertheless, because the genetic risk types were defined from cordblood 
samples, availability did not depend on CeD diagnosis, and missing data on HLA are not 
likely to have influenced the observed associations. Fourth, we only determined anti-tTG 
concentrations at the age of 6 years. Therefore, it remains uncertain at what age children 
became positive. Last, missing blood samples at the 6-year visit were mainly due to non-
consent of the parents or child. However, non-response would only lead to biased effect 
estimated if the association between anti-tTG concentration and height, weight and BMD 
was different between those included and those not included in the analysis. This seems 
unlikely, but cannot be excluded. 
Conclusion
Screeningdetected anti-tTG positive children have lower BMDs and reduced growth trajec-
tories until they are 6 years old. This suggests that subclinical or potential CeD can affect 
BMD and growth. 
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Table 1. Maternal, Paternal and Child characteristics according to anti-tTG levels multiple
imputed data set (n=4306)
Negative anti-tTG (<7 U/ml)
N=4249 (99%)
Positive anti-tTG (> 7 U/ml)
N=57 (1%)
N (%) N (%)
Maternal
Age (mean +SD; years) 30.7 (5.1) 31.7 (4.6)
Height (mean +SD; cm) 167.7 (7.4) 168.1 (7.5)
Weight (mean +SD; kg) 69.7 (13.0) 66.3 (11.0)
BMI before pregnancy (mean; SD: kg/m2) 23.7(4.2) 23.0 (3.1)
Educational level (n;%) 
Low 2003 (47%) 22 (39%) 
High 2246 (53%) 35 (61%) 
Household income (n;%)
< 2000 Euro 1114 (26%) 11 (19%)* 
> 2000 Euro 3135 (74%) 46 (81%) 
Gastrointestinal disease (n;%)
None or no reported 3208 (99%) 36 (97%) 
Celiac disease 1 (0.0%) 1 (3%) 
Lactose intolerance 1 (0.0%) 0 (0%) 
Inflammatory Bowel disease 4 (0.1%) 0 (0%) 
Bowel complaints without known organic cause 13 (0.4%) 0 (0%) 
Any questionnaire reported autoimmune disease 
(diabetes mellitus, SLE, arthritis, MS or thyroid disorder) 
(n; %)
122 (3%) 2 (4%)
Smoking during pregnancy (n;%) 1102 (26%) 14 (25%)
Alcohol during pregnancy (n;%) 2313 (54%) 36 (63%)
Nulliparous (n;%) 2325 (55%) 31 (54%)
Paternal
Age (mean +SD; years) 33.3 (5.6) 33.4 (4.6)
Height (mean +SD; cm) 182.3 (8.0) 181.9 (7.8)
Weight (mean +SD; kg) 83.9 (13.0) 82.5 (13.6)
BMI (mean +SD: kg/ m2) 25.2 (3.4) 24.8 (3.8)
Child
Male gender (n;%) 2201 (52%) 19 ((33%)**
Western ethnicity (n; %) 2738 (64%) 44 (77%)*
CeD in family (n; %) 626 (15%) 9 (16%)
Estimated fetal growth (mean + SD: grams)
Second trimester 384 + 98 385 + 82 
Third trimester 1630 + 264 1627 + 250 
Birth weight (mean + SD: grams) 3436 + 601 3466 + 601
Gestational age (mean + SD: weeks) 39.8 + 1.4 39.9 + 1.4
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imputed data set (n=4306) (continued)
Negative anti-tTG (<7 U/ml)
N=4249 (99%)
Positive anti-tTG (> 7 U/ml)
N=57 (1%)
Ever Breastfeeding (n;%) 3885 (91%) 55 (96%)
Timing of introduction of gluten <6 mo (n;%) 1819 (43%) 28 (49%)
HLA DQ2 or DQ8 present (n; %) 1147 (40%) 38 (91%)***
Television watching > 2 hours a day (n;%) 1002 (24%) 14 (25%)
Playing outside > 2 hours a day (n;%) 1404 (33%) 15 (26%)
Suppletion of vitamin D, AD or multivitamin (n;%) 2118 (50%) 29 (51%)
Age child at 6 year visit (median + range; years) 6.02 (4.9; 9.1) 6.04 (5.6; 8.2)
Weight child at 6 year visit (median + range; kg) 22.6 (13.0; 56.0) 21.0 (16.0; 35.6)**
Height child at 6 year visit (median + range; cm) 119.3 (99.0; 148.3) 117.6 (1.06; 135.3)
BMI (body mass index (median + range; kg/ m2) 15.9 (11.9; 29.2) 15.4 (13.0; 19.4)**
Overweight BMI >1.1-2.3 SDS (n;%) 307 (7.2%) 4 (7%) 
Obesity BMI >2.3 SDS (n;%) 142 (3.3%) 0 (0%) 
* P<0.05
** P<0.01
***P<0.001
Table 2. No significant association between tTG-IgA levels and constipation (A), abdominal pain (B), soft 
faeces (C) and feeling nauseous (D)
A. Functional constipation according ROME III
OR (95% CI)
N=3120
B. Abdominal pain 
OR (95% CI)
N=3093
N (%) OR (95% CI) aOR (95% CI)a N (%) OR (95% CI) aOR (95% CI)a
Negative 572/3074 
(19%)
Ref (1.0) Ref (1.0) 1227/ 3048 
(40%)
Ref (1.0) Ref (1.0)
Positive 6/46 (13%) 0.66 (0.28,1.56) 0.57 (0.22,1.46) 24/45 (53%) 1.69 (0.94,3.06) 1.50 (0.82,2.72)
 7-70 4/21 (19%) 1.03 (0.35, 3.07) 0.72 (0.21, 2.49) 11/20 (55%) 1.81 (0.75, 4.39) 1.48 (0.60, 3.68)
 ≥70 2/25 (8%) 0.62 (0.30, 1.27) 0.66 (0.32, 1.36) 13/25 (52%) 1.27(0.86, 1.88) 1.23  (0.83,1.82)
C. Soft/slushy/watery faeces 
OR (95% CI)
N=3015
D. Feeling sick /nauseous while/after eating 
OR (95% CI)
 N=1562
N (%) OR (95% CI) aOR (95% CI)a N (%) OR (95% CI) aOR (95% CI)a
Negative 90/2971 (3%) Ref (1.0) Ref (1.0) 283/1535 (18%) Ref (1.0) Ref (1.0)
Positive 2/44 (5%) 2.26 (0.52, 3.03) 1.32 (0.55, 3.18) 4/27 (15%) 0.77 (0.26, 2.24) 0.61 (0.18, 2.06)
 7-70 1/20 (5%) 1.69 (0.22, 12.7) 2.28 (0.29, 17.4) 2/13 (15%) 0.80 (0.18, 3.65) 0.39 (0.05, 3.06)
 ≥70 1/24 (4%) 1.18 (0.43, 3.23) 1.21 (0.44, 3.32) 2/14 (14%) 0.86 (0.41, 1.82) 0.91 (0.43, 1.94)
OR: Odds Ratio, aOR: adjusted Odds Ratio, 95% CI: 95% confidence Interval. a Adjusted for: ethnicity, income, sex
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Table 3. Association between TG2A A level and Height (SDS), Weight (SDS) and BMI (SDS) 
TG2A (U/ml) Crude Model (β; 95% CI) Multivariate Model (aβ; 95% CI)
height (SDS) adjusted height
Negative (N=4249) Ref ref
Positive (> 7)
 7-70 U/ml (N=27)
 ≥70 U/ml (N=30)
-0.19 (-0.46,0.07)
-0.14 (-0.52,0.25)
-0.25 (-0.61,0.12)
-0.29 (-0.55,-0.04)*
-0.22 (-0.59,0.14)
-0.31 (-0.65,0.04)
weight (SDS) Adjusted weight (SDS)
Negative (N=4249) Ref Ref
Positive (> 7)
 7-70 U/ml (N=27)
 ≥70 U/ml (N=30)
-0.35 (-0.62,-0.08)*
-0.17 (-0.56,0.22)
-0.51 (-0.88,-0.14)**
-0.38 (-0.64,-0.12)**
-0.28 (-0.65,0.09)
-0.45 (-0.80,-0.10)*
BMI adjusted BMI
Negative (N=4249) Ref Ref
Positive (> 7)
 7-70 U/ml (N=27)
 ≥70 U/ml (N=30)
-0.30 (-0.54,-0.06)*
-0.13 (-0.47,0.22)
-0.46 (-0.78,-0.13)**
-0.26 (-0.49,-0.03)*
-0.19 (-0.53, 0.14)
-0.33 (-0.65,-0.02)*
Values (β’s) are based on linear regression models and reflect between group differences in mean height, weight and 
BMI SDS relative to reference group; 95% CI: 95% confidence interval. aβ; adjusted beta. 
Multivariate Model: adjusted for child’s age, sex, ethnicity, household income, birth weight, breastfeeding, timing 
of gluten introduction, and tv-watching. Models with weight as an outcome were additionally adjusted for height 
(SDS). 
*P<0.05. 
** P<0.01.
Table 4. Association between TG2A level and Bone Mass Density (SDS)
Anti-tTG (U/ml) Crude Model (β; 95% CI) Multivariate Model (aβ; 95% CI)
Total BMD (SDS) Total BMD (SDS)
Negative (N=4249) Ref Ref
Positive (> 7)
 7-70 U/ml (N=27)
 ≥70 U/ml (N=30)
-0.36 (-0.61,-0.11)**
-0.14 (-0.49,0.22)
-0.56 (-0.91,-0.22)***
-0.26 (-0.47, -0.05)*
-0.11 (-0.41, 0.20)
-0.40 (-0.70,-0.11)**
BMD Spine (SDS) a BMD Spine (SDS)
Negative (N=4249) Ref Ref
Positive (> 7)
 7-70 U/ml (N=27)
 ≥70 U/ml (N=30)
-0.41 (-0.66,-0.17)***
-0.11 (-0.45,0.24)
-0.70 (-1.04,-0.37)***
-0.35 (-0.56,-0.13)**
-0.13 (-0.44, 0.18)
-0.55 (-0.85,-0.25)***
Values (β’s) are based on linear regression models and reflect between group differences in mean height, weight 
and BMI Standard Deviation Scores relative to reference group; 95% CI: 95% confidence interval. aβ; adjusted beta. 
Multivariate Model: adjusted for child’s age, sex, ethnicity (western/non-western), height (SDS), total body lean mass, 
total body fat mass, household income, breastfeeding, timing of gluten introduction, tv-watching, playing outside 
and vitamin D suppletion. 
*P<0.05. 
** P<0.01.
*** P<0.001.
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Supplemental Figure 1. Flowchart of participants included in the analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 year visit research centre  
n=6,690 (81%) 
Serum collection 
n=4,593 (69%) 
Excluded:  
- Twins (n=120) 
- Children with known celiac disease      
(n=8) of whom n=2 with gluten free 
diet) 
- Children with gluten free diet / 
gluten low diet (n=10)  
	  
tTG-IgA 6 year 
n=4,442 (97%) 
	  
Negative tTG-IgA 
< 7 U/ml 
n = 4,249 (98,7%) 
 
Positive tTG-IgA level 
> 7 U/ml  
n = 57 (1,3%) 
 
Population for analysis 
(n=4,306) 
Participation Phase 3 
n=8,305 (85%) 
Excluded, due to not visiting the 
research center at age 6 (n=1,615) 
tTG-IgA 6 year 
n=4,306 
	  
Excluded, due to no consent / 
technical/logistic failure (n=2097) 
Excluded, IgA too low to detect 
(n=20), not enough serum/ 
technical/logistic failure, (total n=151) 
Supplemental Figure 1. Flowchart of participants included in the analysis 
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Supplemental Table 1. Maternal, paternal and child characteristics according to anti-tTG levels observed 
data set (n=4306)
Negative
anti-tTG (<7 U/ml)
n=4249 (99%)
Positive
anti-tTG (> 7 U/ml)
n=57 (1%)
Maternal
Age (mean +SD; years) 30.7 (5.1) 31.7 (4.6)
Missing (n; %) 0 (0%) 0 (0%) 
Height (mean +SD; cm) 167.7 (7.4) 168.1 (7.5)
Missing (n; %) 417 (10%) 11 (19%) 
Weight (mean +SD; kg) 69.7 (13.0) 66.2 (11.0)
Missing (n; %) 417 (10%) 12 (21%) 
BMI before pregnancy (mean; SD: kg/m2) 23.6 (4.2) 22.3 (3.0)
Missing (n; %) 1093 (26%) 23 (40%) 
Educational level (n;%) 
Low 1580 (43%) 17 (33%) 
High 2094 (57%) 34 (67%) 
Missing (n; %) 575 (14%) 6 (11%) 
Household income (n;%)
< 2000 Euro 828 (23%) 8 (16%) 
> 2000 Euro 2836 (77%) 43 (84%) 
Missing (n; %) 575 (14%) 6 (11%) 
Gastrointestinal disease (n;%)
None or no reported 3208 (99%) 36 (97%)* 
Celiac disease 1 (0%) 1 (3%) 
Lactose intolerance 1 (0%) 0 (0%) 
Inflammatory Bowel disease 4 (0.1%) 0 (0%) 
Bowel complaints without known organic cause 13 (0.4%) 0 (0%) 
Missing (n; %) 1011 (24%) 20 (35%) 
Any reported autoimmune disease (diabetes mellitus, SLE, arthritis, MS or 
thyroid disorder) (n; %)
122 (3.0%) 2 (4.0%)
Unknown (n;%) 375 (9%) 8 (14%) 
Smoking during pregnancy (n;%) 921 (25%) 11 (26%)
Missing (n; %) 559 (13%) 14 (25%) 
Alcohol during pregnancy (n;%) 1871 (56%) 27 (69%)
Missing (n; %) 879 (21%) 21 (37%) 
Nulliparous (n;%) 2253 (55%) 31 (55%)
Missing (n; %) 156 (4%) 1 (2%) 
Paternal
Age (mean +SD; years) 33.3 (5.6) 33.4 (4.6)
Missing (n; %) 1336 (31%) 18 (32%) 
Height (mean +SD; cm) 182.2 (8.0) 181.9 (7.8)
Chapter 11  |  TG2A antibodies, growth and bone development
270
Supplemental Table 1. Maternal, paternal and child characteristics according to anti-tTG levels observed 
data set (n=4306) (continued)
Negative
anti-tTG (<7 U/ml)
n=4249 (99%)
Positive
anti-tTG (> 7 U/ml)
n=57 (1%)
Missing (n; %) 1341 (32%) 18 (32%) 
Weight (mean +SD; kg) 83.9 (13.0) 82.6 (13.6)
Missing (n; %) 1341 (32%) 19 (33%) 
BMI before pregnancy (mean; SD: kg/m2) 25.2 (3.4) 24.8 (3.8)
Missing (n; %) 1344 (32%) 19 (33%) 
Child
Male gender (n;%) 2201 (52%) 19 (33%)**
Missing (n; %) 0 (0%) 0 (0%) 
Western ethnicity (n; %) 2738 (64%) 44 (77%)*
missing (n; %) 0 (0%) 0 (0%) 
Celiac disease in family(n; %) 23 (0.8%) 2 (4.5%)*
Missing (n;%) 1221 (29%) 13 (23%) 
Estimated fetal growth (means + SD: grams)
Second trimester 383 + 94 385 + 95 
missing 639 (15%) 12 (21%) 
Third trimester 1631 + 265 1627 + 250 
Missing (n; %) 519 (12%) 13 (23%) 
Birth weight (mean + SD: grams) 3437 + 549 3466 + 601.5
Missing (n; %) 8 (0.1%) 0 (0%) 
Gestational age (mean + SD: weeks) 39.84 + 1.74 39.88 + 1.41
Missing (n; %) 30 (0.7%) 1 (2%) 
Ever Breastfeeding (n;%) 3091 (92%) 43 (98%)
Missing (n; %) 905 21%) 13 (23%) 
Breastfeeding duration (median; range: months) 3.5 (0.1;30.0) 5.0 (0.5-12.0) 
Missing (n; %) 188 (44%) 22 (39%) 
Timing of introduction of gluten <6 months (n;%) 1240 (44%) 19 (48%)
Missing (n; %) 1412 (33%) 17 (30%) 
HLA DQ2 or DQ8 present (n; %) 1147 (41%) 38 (91%)***
Missing (n; %) 1435 (34%) 15 (26.%) 
Television watching > 2 hours a day (n; %) 662 (20%) 11 (23%)
Missing 929 (22%) 10 (18%) 
Playing outside > 2 hours a day (n;%) 893 (29%) 10 (24%)
Missing 1208 (28%) 15 (26%) 
Suppletion of vitamin D, AD or multivitamin (n;%) 928 (48%) 15 (58%)
Missing 2315 (54%) 31 (54%) 
Age child at 6 year visit (median + range; years) 6.02 (4.9; 9.1) 6.04 (5.6; 8.2)
missing (n; %) 0 (0%) 0 (0%) 
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Supplemental Table 1. Maternal, paternal and child characteristics according to anti-tTG levels observed 
data set (n=4306) (continued)
Negative
anti-tTG (<7 U/ml)
n=4249 (99%)
Positive
anti-tTG (> 7 U/ml)
n=57 (1%)
Weight child at 6 year visit (median + range; kg) 22.6 (13.0; 56.0) 21.0 (16.0; 35.6)**
missing (n; %) 6 (<1%) 0 (0%) 
Height child at 6 year visit (median + range; cm) 119.3 (99.0; 148.3) 117.6 (1.06; 135.3)
missing (n; %) 6 (<1%) 0 (0%) 
BMI (body mass index; median + range; kg/ m2) 15.9 (11.9; 29.2) 15.4 (13.0; 19.4)**
missing (n; %) 6 (<1%) 0 (0%) 
Overweight BMI >1.1-2.3 SDS (n;%) 307 (7.2%) 4 (7%) 
missing (n; %) 6 (<1%) 0 (0%) 
Obesity BMI >2.3 SDS (n;%) 142 (3.3%) 0 (0%) 
missing (n; %) 6 (<1%) 0 (0%) 
MS, multiple sclerosis; SLE systemic lupus erythematosus. *Significantly different from anti-tTG negative levels *p 
<0.05, **P <0.01, ***p<0.001
Supplemental Table 2. Linear association between tTG level and height, weight, BMI
All tTG-IgA levels (SDS)
0.1 – 125 U/ml 
(n=4306)
Positive tTG levels (SDS)
> 7 U/ml (SDS) 
(n=57)
(β; 95% CI) (β; 95% CI)
Height
Crude model
Adjusted Model
-0.02 (-0.06;0.01)
-0.04 (-0.07;-0.00)*
-0.02 (-0.07;0.04)
-0.04 (-0.09;0.02)
Weight
Crude model
Adjusted Model
-0.05 (-0.08;-0.02)**
-0.05 (-0.08;-0.02)**
-0.05 (-0.10;0.01)
-0.05 (-0.09;-0.00)*
BMI
Crude model
Adjusted Model
-0.04 (-0.07;-0.01)**
-0.04 (-0.07;-0.01)*
-0.04 (-0.09;0.00)*
-0.04 (-0.09;0.02)
Note. Values are based on linear regression models and reflect differences and 95% CI in Height, weight and BMI 
(Standard Deviation Scores), for an increase in tTG-level (Standard Deviation Score). Models were adjusted for child’s 
age, gender, ethnicity, Net household income, birth weight, breastfeeding, and tv-watching. Models with weight as 
an outcome were additionally adjusted for height (SDS). *p <0.05, **P <0.01
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Supplemental Table 3. Linear association between tTG level and BMD, BMC, adjusted BMC and BA. 
All tTG-IgA levels (SDS) 0.1 – 125 U/ml 
(n=4306)
Model 1 (β; 95% CI) Model 2 (β; 95% CI)
Total Body
BMD
BMC
Adjusted BMC
 BA
-.05 (-.08; -.03)***
-.04 (-.07; -.02)***
-.02 (-.03;-.00)*
-.03 (-.05;-.01)*
-.04 (-.06;-.02)**
-0.02 (-0.03;-0.01)**
-0.02(-0.03;-0.00)**
-0.01 (-0.02;0.00)
Spine 
BMD
BMC
Adjusted BMC
BA
-.06 (-.09; -0.04)***
-.03 (-.05;-.00)*
-.03 (-.05;-.02)***
.00 (-.02;.03)
-0.05 (-0.07;-0.02)***
-0.01 (-0.03;0.01)
-0.01 (-0.02;-0.01)
0.02 (-0.01; 0.04)
Note. BMD = BMC (g/cm)/=BA (g/cm2) Values are based on linear regression models and reflect differences and 95% 
CI in Bone Mass Density, BMC and BA (SDS), for 1 SDS increase in tTG-level. 
Model 1: adjusted for Height (SDS), models with aBMC as an outcome were additionally adjusted for BA (SDS).
Model 2: adjusted for child’s age, gender, ethnicity, income, height at focus visit, total body lean mass, total body fat 
mass, birth weight, breastfeeding, timing of gluten introduction, vitamin D suppletion, tv-watching, playing outside. 
Models with adjusted BMC as an outcome were also adjusted for BA (SDS). *p <0.05, **P <0.01, ***p<0.001
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Supplemental Table 4. Sensitivity analysis: Association between tTG-Immunloglobulin A level and height, 
weight, BMI and BMD in total population and in HLA DQ2/DQ8 population.
Total population (n=4306) HLA DQ2/DQ8+ population (n=1185)
Anti-tTG (U/ml)
Multivariate Model
(aβ; 95% CI) Anti-tTG (U/ml)
Multivariate Model
(aβ; 95% CI)
a Height a Height
Negative (N=4249) Ref Negative (N=1147) Ref
Positive (> 7)
 7-70 U/ml (N=27)
 >70 U/ml (N=30)
-0.29 (-0.55,-0.04)*
-0.22 (-0.59,0.14)
-0.31 (-0.65,0.04)
Positive (> 7)
 7-70 U/ml (N=15)
 >70 U/ml (N=23)
-0.45 (-0.77,-0.14)**
-0.27 (-0.77, 0.22)
-0.57 (-0.98,-0.17)**
a Weight (SDS) a Weight (SDS)
Negative (N=4249) Ref Negative (N=1147) Ref
Positive (> 7)
 7-70 U/ml (N=27)
 >70 U/ml (N=30)
-0.38 (-0.64,-0.12)**
-0.28 (-0.65,0.09)
-0.45 (-0.80,-0.10)*
Positive (> 7)
 7-70 U/ml (N=15)
 >70 U/ml (N=23)
-0.51 (-0.83,-0.20)**
-0.33 (-0.82,0.17)
-0.64 (-1.04, -0.23)**
a BMI a BMI
Negative (N=4249) Ref Negative (N=1147) Ref
Positive (> 7)
 7-70 U/ml (N=27)
 >70 U/ml (N=30)
-0.26 (-0.49,-0.03)*
-0.19 (-0.53, 0.14)
-0.33 (-0.65,-0.02)*
Positive (> 7)
 7-70 U/ml (N=15)
 >70 U/ml (N=23)
-0.31 (-0.60,-0.02)*
-0.22 (-0.68,0.23)
-0.36 (-0.73,0.01)
BMD Total BMD Total
Negative (N=4249) Ref Negative (N=1147) Ref
Positive (> 7)
 7-70 U/ml (N=27)
 >70 U/ml (N=30)
-0.26 (-0.47, -0.05)*
-0.11 (-0.41, 0.20)
-0.40 (-0.70,-0.11)**
Positive (> 7)
 7-70 U/ml (N=15)
 >70 U/ml (N=23)
-0.29 (-0.55,-0.03)*
-0.15 (-0.55, 0.26)
-0.39 (-0.73, -0.06)*
BMD Spine BMD Spine
Negative (N=4249) Ref Negative (N=1147) Ref
Positive (> 7)
 7-70 U/ml (N=27)
 >70 U/ml (N=30)
-0.35 (-0.56,-0.13)**
-0.13 (-0.44, 0.18)
-0.55 (-0.85,-0.25)***
Positive (> 7)
 7-70 U/ml (N=15)
 >70 U/ml (N=23)
-0.46 (-0.72,-0.20)***
-0.34 (-0.74, 0.06)
-0.55 (-0.88, -0.21)***
Note. Values (β’s) are based on linear regression models and reflect between group differences in mean height, 
weight, BMI and BMD Standard Deviation Scores relative to reference group; 95% CI: 95% confidence interval. aβ; 
adjusted beta. 
Multivariate Models for height weight and BMI were adjusted for child’s age, gender, ethnicity, household income, 
birth weight, breastfeeding, timing of gluten introduction, and tv-watching. Models with weight as an outcome were 
also adjusted for height (SDS). Multivariate Models for BMD were adjusted for child’s age, gender, ethnicity, income, 
height at focus visit, total body lean mass, total body fat mass, birth weight, breastfeeding, timing of gluten introduc-
tion, vitamin D suppletion, tv-watching, playing outside. *P<0.05, ** p<0.01, ***p<0.001
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ABSTRACT
Background
The objective of our study was to assess whether TG2A levels in the healthy childhood 
population can be predictive for subclinical CeD.
Methods
A total of 4442 children (median age 6.0 yrs) participating in a population-based prospec-
tive cohort study were screened on serum TG2A. Those with positive TG2A (>7 U/ml; n=60, 
1.4%) were invited for clinical evaluation (median age 9.0 yrs). Medical history, physical 
examination, serum TG2A and IgA-endomysium (EMA) were assessed, as well as HLA 
DQ 2.2/2.5/8 typing. Patients with positive serologies and genetic risk types underwent 
duodenal biopsies. TG2A levels at the time of biopsy were compared with the degree of 
enteropathy. 
Results
Fifty-one TG2A-positive children were included in follow-up: 31 (60.8%) children had 
CeD, ten (19.6%) did not have CeD, and 10 (19.6%) were considered potential CeD cases 
because of inconclusive serologies. Duodenal biopsies were performed in 26/31 children. 
CeD with Marsh 3a/b enteropathy was observed in 75% (15/20) of children having TG2A 
levels >10ULN at 6 years of age, as well as in 75% (6/8) of children having a positive TG2A 
<10 ULN (OR 1.00; 95% CI 0.15-6.64). CeD cases had a lower BMI SDS (mean -0.49, SD 0.92) 
than children without CeD (mean 0.47, SD 1.37; p=0.02). No differences were observed in 
gastrointestinal symptoms.
Conclusions
Serum TG2A screening at 6 years of age in the healthy childhood population has a positive 
predictive value of 61% to detect subclinical CeD. We did not find a positive correlation 
between serum TG2A levels and the degree of enteropathy. 
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INTRODuCTION
Celiac Disease (CeD) is one of the most common, but largely underdiagnosed chronic dis-
eases in childhood, and associated with excess morbidity and mortality.1 The prevalence of 
CeD is 0.5-3% and increasing over time.2-5 Despite increased awareness among physicians, 
active case-finding and screening strategies,6-9 the majority of CeD patients still remain 
unrecognized in childhood. Diagnosis is difficult as recent insights have shown CeD can be 
present in asymptomatic children that do have a positive serology as well as enteropathy.10 
CeD can be characterized by the presence of serum IgA against transglutaminase type 2 
(TG2A), IgA against endomysium (EMA), genetic carriership for HLA DQ2.2, DQ2.5 and/or DQ8, 
and a gluten induced enteropathy, 11 which is graded according to the Marsh-Oberhuber 
criteria.12-14 Serum TG2A and EMA positivities have sensitivities and specificities of >90% for 
detection of small intestinal enteropathy.15 Screening of healthy populations frequently 
detects seropositive subjects without symptoms and with mild enteropathy (i.e., subclini-
cal CeD), or seropositive subjects with normal small bowel mucosa (i.e., potential CeD). 
Thus, serology testing is only the first step in the diagnosis.6 Nevertheless, several studies 
have shown that high TG2A levels (>10 times upper limit normal of the test; ULN) have a 
high specificity for severe enteropathy (Marsh 3) in symptomatic patients.16-18 Therefore, the 
ESPGHAN guideline recommends that biopsies may be omitted when TG2A levels >10 ULN 
in symptomatic patients. It is still recommended to evaluate biopsies in asymptomatic or 
screening-identified individuals, irrespective of TG2A levels,19 although some studies argue 
the need in subclinical and screening-detected patients with TG2A levels >10 ULN values.20 
Recently, one study found that TG2A levels correlate with the severity of mucosal lesions 
in both asymptomatic and symptomatic children.21 Still, studies validating the correlation 
between TG2A levels and the degree of enteropathy in subclinical CeD are scarce. 
Therefore, the primary aim of this study was to study the positive predictive value of 
TG2A screening to detect subclinical CeD in the healthy childhood population. A second 
aim was to study whether serum TG2A levels in subclinical CeD correlate with the degree 
of enteropathy.
MATERIALS AND METhODS
Design and screening strategy
This study was embedded within the Generation R study, a prospective population based 
cohort study from fetal life until young adulthood, described in detail previously. 22, 23 
Children were born between April 2002 and January 2006 in Rotterdam, The Netherlands. 
At the age of 6 years, 6690 children visited the research center. During this visit, serum 
samples were collected from 4593 (69%) children and subsequently stored over a time 
period of 2.5 years from.22 In 2013, after the inclusion of the whole cohort was completed 
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and children were 9 years old, these samples were thawed and analyzed for TG2A levels. 
Children and parents were not aware of TG2A determination. We excluded 20 children in 
whom total IgA concentrations were below the detection limit, possibly indicating IgA de-
ficiency. Finally, 4442 children provided data on TG2A levels at 6 years of age.24, 25 Between 
November and December 2013, when children were 9 years old, parents of 60 children 
were informed about a positive TG2A screening result at 6 years of age, and invited for 
diagnostic follow-up. Of these, eight children were lost to follow-up and one child was 
diagnosed with CeD prior to the initial serology screening at 5 years of age, and therefore 
excluded. Of the remaining 51 children, two children were on a gluten free diet (GFD), and 
had been diagnosed with CeD prior to the follow up (between 6 and 9 years of age). There-
fore, these children were excluded from clinical retesting (but not from the final analyses). 
In total, 49 children received diagnostic follow-up within 3 months after initial notification 
of the elevated TG2A level at 9 years of age (January-April 2014). None of them consumed 
a low- or gluten free diet (GFD). 
Written informed consent was obtained from all participants. Approval for the study was 
obtained from the Medical Ethical Committee of Erasmus MC, University Medical Centre 
Rotterdam, the Netherlands. 
Screening on serum TG2A 
TG2A serum levels were measured using a fluorescence enzyme immunoassay (EliA Celikey 
IgA, Phadia ImmunoCAP 250, Phadia AB, Uppsala, Sweden). The intra- and interassay coef-
ficient of variation (CV) was below 10% and 15% respectively. Sera with a TG2A level of 7 
U/ml or higher were considered to be positive per manufacturer’s instructions. We further 
subdivided positive TG2A levels into two categories on the basis of below or above the 10 
upper limit normal (ULN) of the test kit (>70 U/ml). 19, 24, 25
Diagnostic Follow-up 
Of 51 children included, two were diagnosed with CeD between 6 and 9 years of age, and 
one child received follow-up elsewhere [Figure 1]. To assess whether clinical symptoms 
were different between the CeD groups [Table 1], these three children were excluded 
from analyses (but not from the final analyses). From the remaining 48 children visiting 
the Sophia Children’s Hospital at the median age of 9.9 years, a standardized medical and 
family history was taken by a pediatric gastroenterologist. The presence of gastrointestinal 
complaints was assessed systematically after parents were informed about the TG2A 
positivity at 6 years of age. Information on gluten intake was assessed by diet questions 
recorded at 6 years of age prior to TG2A screening, and at the moment of follow-up at 9 
years of age, by asking whether their child had been on a low- or GFD. If not, the child 
was considered to be exposed to a normal amount of gluten. Height and weight were 
measured without shoes and heavy clothing, and body mass index (BMI; kg/m2) was calcu-
lated. Age- and sex-adjusted standard deviation scores (SDS) were obtained using Dutch 
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reference growth curves.26 Prior data on height and weight as recorded in the community 
health centers were included. A delay in linear growth over time was defined as decrease 
of >0.5 SD height-for-age relative to the normal SD line. The second TG2A test at 9 years of 
age was performed using the same fluorescence enzyme immunoassay (exact same kit). 
In addition, anti-endomysial antibody (anti-EMA) levels were measured, and children were 
genotyped for HLA DQ2.2, DQ2.5 and/or DQ8. Serological criteria for recommending an 
upper gastrointestinal (GI) endoscopy are summarized in Figure 1. All GI endoscopies were 
performed by two experienced pediatric gastroenterologists (MG or JCE) between March 
and December 2014. Mucosal biopsies were taken from both the proximal (including the 
bulb) and distal (2nd or 3rd) part of the duodenum as recommended.27-29 Enteropathy was 
graded according to the Marsh-Oberhuber criteria,12, 13 which can vary from intraepithelial 
lymphocytosis (IEL; >30 lymphocytes/100 enterocytes; Grade 1) to more extensive lesions 
including crypt hyperplasia (Grade 2), and various degrees of villous atrophy (Grade 3a 
partial; Grade 3b subtotal, Grade 3c total). Enteropathy was defined as having Marsh II or 
greater.19
 
HLA DQ2/DQ8– TG2A - EMA- (n=3) 
HLA DQ2/DQ8+ TG2A - (0 U/ml) EMA- (n=6)  
HLA DQ2/DQ8- TG2A  <3ULN EMA- (n=1) 
(n=10) 
 
HLA DQ2 DQ8 + TG2A >10 ULN EMA+ (n= 20) 
HLA DQ2 DQ8 + TG2A >10 ULN EMA- (n= 0) 
(n=20)  
 
Retesting serology 9-yr (n=49) 
 
Intestinal biopsy performed (n=26/31) 
Follow-up 
n=10 
Marsh grade 1 
n=3  
(of whom TG2A > 10 ULN n=3) 
 
Marsh grade 2-3 
n=23 
(of whom TG2A > 10 ULN n=16) 
 
TG2A and HLA DQ2/DQ8 positive children (n=60, TG2A >7 U/ml)  
Follow-up elsewhere  
(1 diagnosis, based on 2x TG2A >10 ULN) and clinical symptoms 
Exclusion: n=1 CD diagnosis at 5 yrs of age (biopsy confirmed marsh 3a/b) 
Lost (n=8) (4 no contact, 4 no consent FU)  
HLA DQ2/DQ8+ TG2A - EMA+ (n=2) 
HLA DQ2/DQ8+ TG2A - (>5<7 U/ml) EMA- (n=2) 
HLA DQ2/DQ8 + TG2A <3 ULN EMA+ (n=2) 
HLA DQ2/DQ8 + TG2A <3 ULN EMA- (n=1) 
(n=7) 
No celiac disease 
n=10 
Subclinical celiac disease 
n=31  
Erasmus MC Sophia Children’s Hospital (n=48) 
HLA DQ2/DQ8 + TG2A (>3<10 ULN) EMA+(n=11)  
HLA DQ2/DQ8+ TG2A (>3<10 ULN) EMA- (n=0)  
(n=11) 
 
no consent  
GI endoscopy (n=5) 
of whom TG2A >10 ULN 
(n=3) 
   
n=7 
10/51 = 19.6% 
10/51 = 19.6% 
31/51 = 60.8% 
Screening on TG2A levels in cohort  (n=4,442 children; median age 6.0 years) 
Inclusion: n=2 CD diagnosis at 6 and 9 yrs of age (1 biopsy confirmed, marsh 3a/b)     
No symptoms, no GFD (n=8) 
Abdominal bloating, low gluten containing diet, (n=1) 
Lost n=1 
Figure 1. Outcome of screening for anti-tissue transglutaminase antibodies (TG2A) in a population based 
prospective cohort study. 
Sixty children had a positive TG2A test result at 6 years of age. 31/51 (60.8%) children were considered to have CeD, 
10/51 (19.6%) children needed follow-up, and 10/51 (19.6%) children did not have CeD. 
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Table 1. Characteristics according to Celiac Disease diagnosis (in tekst invoegen)
Characteristics
Diagnosis 
p-valuebNo CeD
(n=10)
Potential CeD
(n=10)
Definitive CeD 
 (n=28)
Age at outpatient center (median; range; yrs) 10.6 (9.9-11.4) 9.1 (8.4-10.3) 9.8 (8.6-11.2) <0.01
Female gender (n;%) 8 (80%) 7 (70%) 19 (68%) 0.48
Medical History
Asymptomatic* 1 (10%) 3 (30%) 9 (32%) 0.17
No GI symptoms 1 (10%) 3 (30%) 10 (36%) 0.12
Abdominal pain (n;%) 7 (70%) 5 (50%) 16 (57%) 0.88
Constipation (n;%) 4 (40%) 1 (10%) 12 (43%) 0.88
Diarrhea (n; %) 4 (40%) 0 (0%) 6 (21%) 0.25
Nausea (n; %) 3 (30%) 1 (10%) 8 (29%) 0.93
Vomiting (n;%) 2 (20%) 0 (0%) 1 (4%) 0.10
>2 gastrointestinal symptoms (n;%) 6 (60%) 1 (10%) 11 (39%) 0.26
>3 gastrointestinal symptoms (n;%) 3 (30%) 0 (0%) 9 (32%) 0.90
Fatigue (n;%) 4 (40%) 1 (10%) 3 (11%) 0.04
GP visit for abdominal complaints (n;%) 2 (20%) 1 (10%) 0 (0%) 0.02
Family with CD (n;%)
1st degree 0 (0%) 2 (20%) 1 (4%) 0.48 
2nd degree 0 (0%) 1 (10%) 4 (14%) 
3rd degree 1 (10%) 0 (0%) 1 (4%) 
Physical examination
Delayed linear growth curve 0-9 yrs (n;%) 1 (10%) 1 (10%) 3 (11%) 0.47
Missing data (n;%) 1 (10%) 2 (20%) 8 (29%) 
Height 9 years (median; range; cm) 147.2 (132.2-158.2) 135.0 (131.0- 153.5) 138.6 (105.0-164.2) 0.32
Weight 9 years (median; range; kg) 36.8 (25.9-69.8) 28.6 (27.1-50.4) 29.3 (19.2-61.6) 0.04
BMI (median; range; kg/m2) 17.5 (14.4-27.9) 15.5 (15.1-21.4) 15.4 (12.8-22.8) 0.04
Height for age SDS (mean; SD) -0.45 (1.30) -0.09 (0.78) -0.24 (1.05) 0.61
Weight for age SDS (mean; SD) 0.06 (1.68) -0.20 (0.78) -0.45 (0.99) 0.26
BMI for age SDS (mean; SD) 0.47 (1.37) -0.11 (0.66) -0.49 (0.92) 0.02
Abbreviations; CeD celiac disease; GI gastrointestinal; GP general practitioner; BMI Body Mass index; SDS standard 
deviation score adjusted for sex and age; TG2A Tissue transglutaminase type 2 antibody (IgA); ULN upper limit nor-
mal. Values represent means (SD’s), medians (range), or numbers (percentages). 
a Delayed linear growth was defined as: > -0.75-1.5 SDS decrease over time from 0-9 years of age. 
b p-value reflects differences between biopsy proven (definitive CeD) and potential CeD group versus ‘No CeD = ref-
erence’ group (Mann–Whitney U test-tests were used for non-normally distributed variables, and χ2 tests were used 
to test for differences in proportions between groups). 
*‘Asymptomatic’ refers to no GI symptoms, nor anorexia, fatigue, or irritability. None of the children was diagnosed 
with an autoimmune disease, including diabetes mellitus 1, or autoimmune thyroid disease. Thirty-one children 
were classified as definitive CeD cases, but only 28 were included in the analyses, because two children were di-
agnosed at an earlier age because of symptoms, and one child was diagnosed in another hospital (diagnosis was 
based on 2x TG2A >10 ULN in accordance with clinical symptoms), thus assessment of medical histories and physical 
examination may be different from the 28 asymptomatic children included in the analyses. 
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Endomysial antibodies 
Endomysial antibodies (EmA) of IgA isotype were determined by indirect immunofluo-
rescence using commercial monkey oesophagus slides, according to the manufacturer’s 
instructions (Inova Diagnostics, San Diego, CA) [S1].
Genotyping of hLA DQ2.2, 2.5 and DQ8
Presence of CeD-associated HLA-DQ haplotypes DQ2.2 (DQA1*02/DQB1*02), DQ2.5 
(DQA1*05/DQB1*02) and DQ8 (DQA1*0301/DQB1*0302) was determined by EUROArray, 
according to the manufacturer’s instructions (Euroimmun AG, Lübeck, Germany) [Supple-
mental 1].30 
Statistical analysis
Chi-square tests were used to test whether gastro-intestinal complaints were different 
between the children with and without final CeD diagnosis. The variables ‘more than 
two gastrointestinal complaints’ and ‘more than three gastrointestinal complaints’ were 
calculated by taking the sum of the following complaints: abdominal pain (y/n), constipa-
tion (y/n), diarrhoea (y/n), nausea (y/n) and vomiting (y/n), resulting in two dichotomous 
variables. Non-parametric Mann-Whitney U tests were used to test for differences in non-
normally distributed variables, including median age, height, weight and BMI between 
children with and without CeD diagnosis. Chi-square tests were used to test whether clini-
cal complaints and the degree of enteropathy were related to the TG2A categories. Binary 
logistic regression analyses were performed to test whether TG2A levels were related to 
CeD diagnosis (CeD versus no CeD, and potential CeD versus no CeD) and enteropathy 
(Marsh 3 versus Marsh 0, 1, or 2). 
RESuLTS
Subject characteristics
Of 4442 screened children (median age 6.0 years), 60 children (1.4%) had increased TG2A 
levels (>7 U/ml), of whom 31 children had TG2A levels above 10 ULN (>70 U/ml). Of 60 
children, eight children were lost to follow-up, and one child was diagnosed with CeD at 5 
years of age (prior to the initial serology screening) and therefore excluded from analyses. 
Two children (4%) had received a CeD diagnosis in the period preceding retesting (between 
6 and 9 years of age) and consumed a gluten free diet (GFD). Here, CeD was detected based 
on gastrointestinal symptoms by routine clinical care in the Netherlands, of whom one 
diagnosis was confirmed by biopsy (Marsh 3a/3b) [Figure 1]. 
Chapter 12  |  Subclinical celiac disease in childhood
282
Outcome of Follow-up 
Of 48 children who were retested in the Sophia Children’s Hospital, 31 (65%) were posi-
tive for TG2A and EMA, carried HLA DQ2.2, DQ2.5 or DQ8, and were advised to undergo 
gastrointestinal endoscopy. Of these, 20 had TG2A levels >10 ULN [Figure 1]. Of 26 children 
who underwent GI endoscopy, 20 children had Marsh grade 3 ((3a n=13), 3b (n=7)); three 
children had Marsh grade 2; and three children had Marsh grade 1. Of 23 children with 
Marsh grade 2-3 lesions, 16 children (70%) had TG2A levels >10 ULN. All three children with 
Marsh grade 1 lesions had TG2A levels >10 ULN and were advised to continue on a gluten 
containing diet, and to consider a second serology and/or intestinal biopsy when clinical 
complaints compatible with CeD occur. A total of 10 children were HLA DQ2.2, DQ2.5 and 
DQ8 negative, or carried the genetic risk type but lacked EMA and TG2A positivity, and were 
therefore considered not to have CeD. The second serology was not conclusive in seven 
children: they carried the genetic risk type, but had TG2A concentrations <3 ULN, or TG2A 
levels were negative in accordance with a positive EMA, whereas the initial screening TG2A 
test result at 6 years of age was positive. Furthermore, these children mentioned gastro-
intestinal complaints (abdominal pain), and had a first-degree family history of CeD (in 
contrast to the 10 children who were considered not to have CeD). Hence, these children 
were advised to be serologically retested in 6-12 months. During the period of follow-up 
(January 2014 - April 2017), none of the ten children received a CeD diagnosis; only one 
child occasionally mentioned complaints of abdominal bloating, and was on a low gluten 
containing diet (but not gluten free). The remaining children did not mention CeD associ-
ated symptoms while consuming a gluten containing diet. 
In total, 31 of 51 (60.8%) children were considered to have CeD, of whom two children 
had developed symptomatic CeD within 3 years after the screening test was performed; 
10/51 (19.6%) needed follow-up because of inconclusive serology (n=7) or negative intes-
tinal biopsies (n=3, of whom all three had levels exceeding 10 ULN); and 10/51 (19.6%) 
children were considered to not have CeD [Figure 1]. Thus, the positive predictive value of 
TG2A screening was 61%, (95% CI 49-75), to detect subclinical CeD and 81%, (95% CI 70-91) 
to detect both potential and subclinical CeD.
Clinical symptoms
All 48 children consumed a normal gluten containing diet at 6 years of age, as well as at the 
visit to the pediatric gastroenterologist at 9-10 years. Of 28 CeD cases who provided data 
on medical history and physical examination at 9 years of age, nine (32%) children were 
truly asymptomatic relative to one (10%) of the children without CeD diagnosis (p=0.17). 
Abdominal pain was reported most frequently (57%), followed by constipation (43%), nau-
sea (29%) and diarrhea (21%), but no significant differences in gastrointestinal symptoms 
were observed between children with and without CeD diagnosis (p=0.12) [Table 1]. In 
addition, no significant differences were observed in the presence of anorexia, irritability, 
food allergy, lactose intolerance, eczema, and absenteeism from school between children 
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with and without CeD diagnosis (data not shown), nor in family history of CeD [Table 1]. 
However, CeD cases weighed less (median 29.3 kg; range 19.2-61.6, p=0.04) than children 
who did not have CeD (median 36.8 kg; range 25.9-69.8). In addition, their BMI was lower 
(mean BMI SDS -0.49, SD 0.92, p=0.04) compared to children without CeD (mean BMI SDS 
0.47, SD 1.37) No significant differences in height were observed between children with and 
without CeD diagnosis (p>0.32) [Table 1]. Associations were not substantially different in 
children without gastrointestinal symptoms [Supplemental Table 2]. 
In addition, no significant differences in gastrointestinal symptoms were observed 
between children who were TG2A negative (<7 U/ml) and strongly positive (>10 ULN), but 
children having TG2A levels exceeding 10 ULN weighed less (median 29.1 kg, range 19.2-
44.0) and had a lower BMI (mean BMI SDS -0.51, SD 0.85), than children who were TG2A 
negative (median 35.3 kg, range 25.9-69.8 and SDS BMI 0.21, SD 1.16 resp.) [Supplemental 
Table 3]. 
Development of CeD over time according to CeD diagnosis
We observed a high variability in serum TG2A levels at 6 and 9 years of age [Figure 2]. Of 
29 CeD cases, 20 children (69%) had high TG2A levels (>10 ULN) at 6 years of age, which 
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Figure 2. Serum TG2A concentrations at 6 and 9 years of age according to celiac disease diagnosis. 
Thin dotted line indicates clinical cutoff for IgA-TG2A positivity (>7 U/ml). 
a, TG2A concentrations between 6-9 years in CeD group, bold line reflects n=14 CeD cases who had strong positive 
IgA-TG2A concentrations (>125 U/ml at 6 years of age, and >128 U/ml at 9 years of age). 
b, TG2A concentrations between 6-9 years in potential CeD group.
c, TG2A concentrations between 6-9 years in children lackes criteria for CeD diagnosis.
Four children were excluded because of negative genetic risk type. In addition, three children who received a CeD 
diagnosis between 6 and 9 years of age were excluded from this figure. 
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increased to a higher level in the majority (16/20) of cases at 9 years of age. Of ten children 
who needed follow-up at 9 years of age because of negative serologies, four children (40%) 
had TG2A concentrations exceeding 10 ULN levels at 6 years of age. Of 6 children who car-
ried the genetic risk type, but did not have CeD, one child had TG2A levels exceeding 10 
ULN at 6 years of age [Figure 2].
Association between level of TG2A concentration, CeD diagnosis and degree of 
enteropathy
A positive linear tendency was observed for TG2A levels in predicting CeD diagnosis: 
children having high TG2A levels (>10 ULN) at 6 and 9 years of age were more frequently 
diagnosed with CeD than children having TG2A positive concentrations below <10 ULN 
((OR 7.7; 95% CI 2.2-27.4) and (OR 10.0 (1.07-93.4) resp.) [Supplemental Table 4]. Second, 
we observed that TG2A levels at 6 or 9 years of age were not related to the presence of 
severe intestinal enteropathy (Marsh 3) [Supplemental Table 5; Figure 3]. 
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Figure 3. Association between serum IgA-TG2A concentrations and the degree of enteropathy in children 
with undiagnosed celiac disease. 
a, TG2A concentrations at 6 years of age according to Marsh-Oberhuber classification. 
b, TG2A concentrations at 9 years of age to Marsh-Oberhuber classification. 
The three children who received a CeD diagnosis between 6 and 9 years of age were excluded from this figure. 
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Incidence of Celiac Disease in TG2A negative cohort
At the child’s age of 9 years, parents were asked by questionnaire whether their child had 
ever received a doctors diagnosis of CeD. Of 4382 TG2A negative children at 6 years of age, 
nine (0.2%) received a doctors diagnosis of CeD between 6 and 9 years of age. 
DISCuSSION
This population based prospective cohort study shows that: 1) Serum TG2A screening at 6 
years of age in the healthy childhood population has a positive predictive value of 61% to 
detect subclinical CeD. 2) The level of serum TG2A in subclinical CeD is not predictive for 
the severity of enteropathy. 
Although we followed the ESPGHAN guideline for CeD diagnosis in the majority of 
asymptomatic children, the PPV of TG2A screening may still have been influenced by 
misclassification of the outcome. According to the Oslo definitions,10 potential CeD refers 
to children who are at increased risk of developing CeD as indicated by positive serology, 
but with a normal small intestinal bowel mucosa. In our study, 23 children were considered 
to have subclinical CeD on the basis of the combination of positive TG2A and the presence 
of enteropathy. However, five CeD cases did not consent for GI endoscopy, thus we lacked 
formal proof for diagnosis of CeD. Still, three of them had elevated levels >10 ULN, and 
they were all EmA and HLA DQ2 or 8 positive, suggesting that enteropathy is highly likely. 
Therefore, excluding these children would likely result in underdiagnosis. Second, loss to 
follow-up might have affected the precision of the PPV of TG2A screening. If children who 
were lost to follow-up (n=8) would not have CeD, then the initial PPV of screening on TG2A 
would have been 31/59 (53%). In contrast, if all children who were lost would be CeD cases, 
then the PPV would have been 39/59 (66%). Thus, the positive predictive value of serum 
TG2A screening to detect subclinical CeD in the general childhood population would be 
maximally 66%. 
In contrast with several other studies, we did not find a positive association between 
serum TG2A levels and the degree of enteropathy.[16, 21, 31-33] However, these previous 
studies concerned children with gastrointestinal symptoms that triggered CeD testing, and 
contrast our cases of subclinical CeD, complicating a direct comparison between studies. 
In fact, it has been shown that TG2A levels are more strongly correlated with the severity 
of intestinal lesions in symptomatic patients, than in asymptomatic children.21 Hence, the 
association between TG2A levels and the degree of enteropathy might be differentially 
influenced by the presence -or lack- of symptoms. In our study, the majority of children 
with high TG2A levels mentioned gastrointestinal symptoms. According to the ESPGHAN 
guideline, biopsies could have been omitted in this group. However, on the basis of the 
present study, it needs to be considered that children with TG2A >10 ULN in most cases 
needed a biopsy to confirm CeD. Moreover, our results confirm that the presence and 
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severity of gastrointestinal symptoms, such as abdominal pain, are insufficient to discrimi-
nate subclinical CeD cases from healthy children.34 The majority (90%) of children who 
did not develop CeD mentioned gastrointestinal symptoms as well, such as abdominal 
pain, constipation, diarrhea, nausea or fatigue. Gastrointestinal symptoms were also 
not related to the degree of enteropathy, nor TG2A levels. Nonetheless, consistent with 
our previous findings,25 subclinical children weighed less than healthy children. Interest-
ingly, the TEDDY study demonstrated that the majority of subclinical children had normal 
weight and height growth at age 4,21 which may suggest that the deviation in height and 
weight growth becomes more prominent between 4-6 years of age, and appears before 
gastrointestinal symptoms occur. Hence, increased clinical vigilance focusing on weight 
growth parameters, especially BMI,35 or systematic growth monitoring in the general 
pediatric population, might improve early detection of CeD.36 Nevertheless, the effects of 
early diagnosis, and the benefit of treatment with a gluten free diet of subclinical patients, 
needs to be further studied. In the short run, symptoms that may -or may not- have been 
recognized upon the start of a GFD may disappear, serving as a proof to parents,37 but 
evidence in children is lacking. In addition, the benefits and cost-effectiveness of screening 
in asymptomatic individuals remains controversial.38-40 Introducing a screening test in the 
general pediatric population with a positive predictive value of 61% to diagnose a disease 
with lifelong consequences (such as a gluten free diet, regular health care visits, screening 
for other diseases, screening and investigating family members, fear of complications, and 
economic burden from the gluten free diet) may not be reasonable. Therefore, it would be 
too premature to recommend screening in the general pediatric population.
Methodological considerations
The premise of the study was the identification of CeD in asymptomatic children. Three 
children in our study developed symptoms following screening, thereby triggering CeD 
diagnosis in routine clinical practice. One of the strengths of our study is that we used a 
prospective study design, with a similar protocol for the diagnostic process for all screened 
TG2A positive children. Furthermore, all screened TG2A positive children were of the same 
age, and analyzed 3 years later by the same laboratory and same test kit. Because all par-
ticipants were unaware of TG2A determination, we were able to study the development of 
TG2A levels over 3 years of time. Ten children with negative TG2A did not have CeD, despite 
TG2A positivity at 6 years of age. Explanations for the contradictory test results at 6 and 9 
years may be that TG2A levels were transiently high at 6 years, test results at 6 years were 
false positive (i.e. 1-specificity), or gluten intake decreased over time. Intriguingly, on top 
of the 1.4% of children with positive TG2A levels at 6 years of age (of whom 61% received a 
subclinical CeD diagnosis), 0.2% of TG2A negative children developed CeD within 3 years 
after the negative TG2A screening result at 6 years of age. The median age of retesting was 
9.9 years, with a range between 8.4 and 11.4 years. This large age range is related to the 
inclusion period of 2.5 years. Another strength of our study is that TG2A measurements 
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were performed in combination with assessment of EMA, genetic risk types and biopsy 
specimens at the same time of second serology assessment. Last, all biopsies were evalu-
ated by expert pathologists by using the Marsh-Oberhuber criteria to classify the degree of 
enteropathy. Nevertheless, several limitations should be taken into account as well. First of 
all, five children in the CeD group were considered to have subclinical CeD without biopsy 
results. Therefore, we did not fully meet the ESPGHAN criteria for CeD diagnosis. However, 
three of them had levels exceeding 10 ULN, they were all EMA positive and carried the 
genetic risk type. Hence, CeD diagnosis is highly likely. Second, symptoms were assessed 
only among those with TG2A positivity at 9 years of age, after parents were informed about 
the initial screening TG2A status which might have induced bias. However, the presence of 
gastrointestinal symptoms was evaluated systematically during routine clinical evaluation, 
preceding second serological (TG2A) assessment, additional EMA assessment, genetic risk 
typing, and gastrointestinal endoscopies at 9 years of age. Hence, symptom assessment 
was independent of the outcome, making bias less likely. Furthermore, symptoms were 
assessed by one experienced gastroenterologist minimizing inter-observer bias. We did 
not specifically ask for the presence of joint pains or neurological symptoms, but these 
complains were not reported on the general question “ any complaints”. Hence, the occur-
rence of joint pains and neurological symptoms seems unlikely. 
Conclusion 
Our results indicate that the majority of asymptomatic 6-year-old TG2A positive children 
developed subclinical CeD within 3 years following screening. We did not find a positive 
association between serum TG2A concentrations and the degree of enteropathy. Thus, 
TG2A screening at 6 years of age could substantially advance CeD diagnosis as children 
with subclinical CeD in our study only showed a small deviation in height and weight, and 
lacked gastrointestinal symptoms.
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SuPPLEMENTAL METhODS 
Endomysial antibodies 
Endomysial antibodies (EmA) of IgA isotype were determined by indirect immunofluores-
cence using commercial monkey oesophagus slides, according to the manufacturer’s in-
structions (Inova Diagnostics, San Diego, CA). Briefly, slides were incubated with 1:2 diluted 
human serum for 30 minutes at room temperature, followed by PBS wash and incubation 
with anti-human IgA-FITC (Inova Diagnostics) for 30 minutes at room temperature. Washed 
slides were embedded in glass cover slips and evaluated by fluorescence microscopy by 
two independent observers.
Genotyping of hLA DQ2.2, 2.5 and DQ8
Presence of CeD-associated HLA-DQ haplotypes DQ2.2 (DQA1*02/DQB1*02), DQ2.5 
(DQA1*05/DQB1*02) and DQ8 (DQA1*0301/DQB1*0302) was determined by EUROArray, 
according to the manufacturer’s instructions (Euroimmun AG, Lübeck, Germany).30 Briefly, 
HLA-DQA1 and HLA-DQB1 gene fragments were PCR amplified in parallel from genomic 
DNA, isolated from whole blood using standard procedure. Fluorescent PCR products 
were subsequently hybridized on a microarray containing probe spots specific for different 
HLA-DQ variants (HLA-DQA1: *02, *02/*0301, *03, *0302/03 and *05; HLA-DQB1: *02 and 
*02/*0302). Detection of specifically hybridized PCR products was analyzed by the Euro-
immun microarray scanner, and genotypes and diagnostic findings were automatically 
deduced by the EUROArrayScan software.
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Supplemental Table 2. Growth characteristics according to diagnosis stratified on the presence of symp-
toms
Diagnosis
No CeD (n=10) Potential CeD 
(n=10)
CeD (n=28) p-valueb
Characteristics No GI symptoms 
(n=10)
GI symptoms 
 (n=18)
Delayed linear growth 0-9 yrs 
(n;%)a
1 (10%) 1 (10%) 1 (10%) 2 (11%) 0.66
Missing data (n;%) 1 (10%) 2 (20%) 1 (10%) 7 (39%)  
Height 9 years (median; range; 
cm)
147.2 (132.2-
158.2)
135.0 (131.0- 
153.5)
140.0 (128.0-
152.2)
137.8 (105.0-
164.2)
0.31
Weight 9 years (median; range; 
kg)
36.8 (25.9-69.8) 28.6 (27.1-50.4) 31.4 (25.0-36.8) 28.9 (19.2-
61.6)*
0.04
BMI (median; range; kg/m2) 17.5 (14.4-27.9) 15.5 (15.1-21.4) 15.5 (14.4-18.5) 15.4 (12.8-22.8) 0.08
Height for age and sex SDS (mean; 
SD)
-0.45 (1.30) -0.09 (0.78) -0.47 (1.05) -0.11 (1.05) 0.46
Weight for age and sex SDS 
(mean; SD)
0.06 (1.68) -0.20 (0.78) -0.58 (0.94) -0.39 (1.05) 0.38
BMI for age and sex SDS (mean; 
SD)
0.47 (1.37) -0.11 (0.66) -0.51 (0.80) -0.48 (1.01)* 0.04
Abbreviations; CeD celiac disease; GI gastrointestinal; BMI Body Mass index; SDS standard deviation score adjusted 
for sex and age. 
a Delayed linear growth was defined as: ≥ -0.75-1.5 SDS decrease over time from 0-9 years of age. Values represent 
means (SD’s), medians (range), or numbers (percentages).
b p-value reflects differences between symptomatic CeD group versus no CeD group (MW-test were used for non-
normally distributed variables, and χ2 tests were used to test for differences in proportions between groups) ‘No GI 
symptoms’ includes: No abdominal pain, constipation, diarrhea, nausea or vomiting. None of the children was di-
agnosed with an autoimmune disease, including diabetes mellitus 1, or autoimmune thyroid disease. n=32 children 
were classified as CeD cases, but only 28 were included in the analyses, because 4 children were diagnosed at an 
earlier age, or in other hospital, thus assessment of medical histories and physical examination might be different 
from the 28 children included in the analyses.
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Supplemental Table 3. Characteristics according to TG2A levels
n=48
Characteristics
TG2A levels at 9 years of age
p-valueb
TG2A 
negative
(<7 U/ml)
(n=13)
TG2A 
<10 ULN
(7<70 U/ml)
(n=15)
TG2A
 >10 ULN
(>70 U/ml)
(n=20)
Age at outpatient center (median; range; 
yrs)
10.3 (8.4-11.4) 9.7 (8.8-10.9) 9.9 (8.6-11.2) 0.30
Female gender (n;%) 10 (77%) 10 (67%) 14 (70%) 0.82
Medical History
Asymptomatic* 2 (15%) 4 (27%) 7 (35%) 0.38
No GI symptoms 2 (15%) 4 (22%) 8 (38%) 0.49
Abdominal pain (n;%) 8 (62%) 10 (67%) 10 (50%) 0.59
Constipation (n;%) 3 (23%) 7 (47%) 7 (35%) 0.43
Diarrhea (n; %) 4 (31%) 3 (20%) 3 (15%) 0.55
Nausea (n; %) 3 (23%) 3 (20%) 6 (30%) 0.78
Vomiting (n;%) 2 (15%) 0 (0%) 1 (5%) 0.23
>2 gastrointestinal symptoms (n;%) 5 (39%) 6 (40%) 7 (35%) 0.95
>3 gastrointestinal symptoms (n;%) 3 (23%) 4 (27%) 5 (25%) 0.98
Food allergy (n;%) 0 (0%) 1 (7%) 1 (5%) 0.66
Anorexia (n;%) 1 (8%) 1 (7%) 2 (20%) 0.93
Fatigue (n;%) 4 (31%) 3 (20%) 1 (5%) 0.28
Irritability (n;%) 0 (0%) 0 (0%) 0 (0%) NA
Lactose intolerance (n;%) 0 (0%) 0 (0%) 1 (5%) 0.49
Eczema (n;%) 1 (8%) 3 (20%) 1 (5%) 0.33
GP visit for abdominal complaints (n;%) 3 (23%) 0 (0%) 0 (0%) 0.01
Absenteeism from school (n;%) 1 (8%) 0 (0%) 1 (5%) 0.55
Family with CeD (n;%)
1st degree 2 (15%) 1 (7%) 0 (0%)  
2nd degree 1 (8%) 1 (7%) 3 (15%) 0.61 
3rd degree 1 (8%) 0 (0%) 1 (5%)  
Physical examination
Delayed height growth curve 0-9 yrs (n;%)
Missing data 
1 (8%)
2 (15%)
3 (20%)
3 (20%)
1 (5%)
6 (30%)
0.54
Height 9 years (median; range; cm) 144.9 (132.2-158.2) 137.8 (131.0-164.2) 138.2 (105.0-162.8) 0.32
Weight 9 years (median; range; kg) 35.3 (25.9-69.8) 29.6 (27.1-61.6) 29.1 (19.2-44.0) 0.05
BMI (median range; kg/m2) 16.6 (14.4-27.9) 15.5 (13.3-24.2) 15.4 (12.8-17.5) 0.08
Height for age SDS (mean; SD) -0.24 (1.26) -0.03 (0.85) -0.43 (1.03) 0.63
Weight for age SDS (mean; SD) 0.00 (1.46) -0.16 (1.03) -0.59 (0.92) 0.17
BMI for age SDS (mean; SD) 0.21 (1.16) -0.18 (1.10) -0.51 (0.85) 0.047
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Abbreviations; CeD celiac disease; GI gastrointestinal; GP general practitioner; BMI Body Mass index; SDS standard 
deviation score adjusted for sex and age; TG2A Tissue transglutaminase type 2 antibody (IgA); ULN upper limit nor-
mal. Values represent means (SD’s), medians (range), or numbers (percentages).
a Delayed linear growth was defined as: > -0.75-1.5 SDS decrease over time from 0-9 years of age. 
b p-value reflects differences between TG2A >10 ULN group versus TG2A negative group (reference-group). Mann–
Whitney U tests were used for non-normally distributed variables, and χ2 tests were used to test for differences in 
proportions between the 2 groups. None of the children was diagnosed with an autoimmune disease, including 
diabetes mellitus 1, or autoimmune thyroid disease. 
*‘Asymptomatic’ refers to no GI symptoms, nor anorexia, fatigue, or irritability.
Supplemental Table 4. Association between TG2A levels and celiac disease diagnosis.
n=32 Number of children per TG2A group
CeD diagnosis
n (%)
OR for CeD 
diagnosis
(95% CI)
p-value
TG2A at 6 years of age 
<10 ULN (<70 U/ml) 29 9/24 (38%) reference
>10 ULN (>70 U/ml) 31 23/28 82%) 7.7 (2.2; 27.4) 0.002
Per Unit/ml increase 60 32 1.03 (1.01; 1.04) <0.001
TG2A at 9 years of age 
Negative (TG2A <7U/ml) 13 - -
<10 ULN (<70 U/ml) 18 12/18 (67%) reference
>10 ULN (>70 U/ml) 21 20/21 (95%) 10.0 (1.07; 93.4) 0.04
Per Unit/ml increase 48 32/52 (62%) 1.05 (1.02; 1.08) <0.001
Abbreviations; CeD celiac disease; TG2A Tissue transglutaminase type 2 antibody (IgA); ULN upper limit normal. 
OR: Odds ratio; 95% CI: 95% confidence interval. OR’s are derived from binary logistic regression models, with CeD 
diagnosis as dependent variable (y/n), and TG2A levels as (dichotomous and continuous) independent variable. 
Supplemental Table 5. Association between TG2A levels and Marsh 3 enteropathy.
n=28
Number of biopsies per 
TG2A group
n (%)
Marsh 3 biopsies
n (%)
OR for Marsh 3 
enteropathy 
(95% CI)
p-value
TG2A at 6 years of age 
<10 ULN (<70 U/ml) 8/29 6/8 (75%) reference
>10 ULN (>70 U/ml) 20/31 15/20 (75%) 1.00 (0.15; 6.64) 0.99
Per Unit/ml increase 28/60 21/28 1.00 (0.98; 1.02) 0.98
TG2A at 9 years of age 
<10 ULN (<70 U/ml) 9/18 6/9 (67%) reference
>10 ULN (>70 U/ml) 19/20 15/19 (79%) 3.33 (0.56, 19.59) 0.18
Per Unit/ml increase 28/48 21/28 1.02 (1.00; 1.04) 0.09
Abbreviations; TG2A Tissue transglutaminase type 2 antibody (IgA); ULN upper limit normal. OR: Odds ratio; 95% CI: 
95% confidence interval. ORs are derived from binary logistic regression models, with Marsh 3 enteropathy relative 
to Marsh 2, 1 or 0) as dependent variable, and TG2A levels as (dichotomous and continuous) independent variable. 
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GENERAL DISCuSSION 
A.  RATIONALE FOR STuDYING ACQuISITION OF IMMuNE COMPETENCE FROM A 
CLINICAL PERSPECTIVE
Celiac disease (CeD) is a multisystem immune-mediated disorder, characterized by an 
excessive inflammatory “Th1” response against dietary gluten in genetically susceptible 
individuals (i.e. HLA-DQ2/ HLA-DQ8 carriers).1-3 The prevalence of CeD is 1-3% in the general 
population, while the HLA-DQ2/ HLA-DQ8 haplotypes are present in >25% of the general 
population, suggesting that, besides genetic predisposition, additional factors must con-
tribute to disease initiation.1, 2, 4-6 Still, it remains unclear why exposure to dietary gluten 
in one genetically susceptible person results in an excessive immune reaction, yet not in 
another exposed genetically susceptible person. Apart from gluten and the role of dietary 
factors early in life, such as the duration and exclusiveness of breastfeeding, the search 
for environmental determinants of CeD has reached limited success.1, 7 Furthermore, the 
search has been complicated by the broad heterogeneity of the disease, including subclini-
cal and potential forms,8, 9 raising further questions, such as: What is the clinical course of 
these undiagnosed forms? Are these clinically relevant? Do these forms cause detrimental 
health effects, and should these forms be treated to avoid deleterious effects? 
Understanding normal acquisition of immune competence in childhood, and its main 
driving forces, may help to better understand disorders such as CeD, as well as other forms 
of immune dysfunction (either unwanted responses (i.e. autoimmunity, atopic diseases) or 
insufficient responses, i.e. immunodeficiencies or premature immunosenescence). Many 
research focuses on how and when aberration results in disease, and on the mechanisms 
that operate to prevent these unenviable aberrations.10 Therefore, it may be helpful to 
better understand normal processes of immune maturation. This vision captures the prin-
ciples of the Barker’s hypothesis, or Developmental Origin of Health and Disease (DOHad)11 
that posits that environmental exposures in early life (pregnancy, neonatal period, and 
early childhood) may present a “window of immune vulnerability” for dysregulation and 
development of immune-mediated diseases later in life. During early childhood, exposure 
to infectious and non-infectious particles induces immune responses that shape immune 
homeostasis and induce the formation of long-term immunity. However, which determi-
nants define this early childhood immune homeostasis? And to which extent do these early 
life exposures leave a lasting “fingerprint” on the immune system? And is this “fingerprint” 
associated with beneficial or potentially detrimental effects later in life?
This thesis is composed of research conducted in a population-based prospective cohort 
study with two main aims: 1. Identification of determinants of the maturing immune sys-
tem in childhood, focusing predominantly on adaptive immunity; 2. To study determinants 
and consequences of celiac disease autoimmunity. In this General Discussion chapter, the 
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main findings of the research are placed in a broader context, and methodological aspects 
are discussed. In the following paragraphs, the effects of various pre-, peri- and postnatal 
determinants on immune maturation will be discussed, with a predominant focus on 
breastfeeding and herpesvirus seropositivity. Based on the results presented in this thesis, 
the crucial role of timing of these external determinants will be discussed; i.e. whether a 
window of “immune vulnerability” exists, whether immune effects are dynamic, temporary 
or persistent, and which factors are associated with immune-mediated diseases, such as 
celiac disease autoimmunity (CDA). 
B. WhAT IS “NORMAL” IMMuNE MATuRATION DuRING EARLY ChILDhOOD?
B.1 “Normal” immune maturation is a broad concept influenced by age, sex and 
various external factors
Which factors drive immune homeostasis? This question remains difficult to explain as 
blood and tissue cell numbers are affected by many factors that are connected, and still 
not entirely elucidated.12, 13 For example, the numbers of circulating leukocytes depend on 
their production from primary lymphoid tissue (bone marrow, thymus), the in- and efflux 
from circulation to lymphoid and peripheral tissues, such as intestines, lungs and skin, 
proliferation in immune responses and cell death (Figure 1).13-15 Therefore, direct trans-
lation to biological functions such as immune homeostasis, production, recirculation, 
(Bone marrow, Thymus)
Homing
to Tissues
Apoptosis
Tissue
Residency
Release 
in the 
Blood cell
count
Processes inﬂuencing numbers of 
FIG 1. Schematic representation of the dierent mechanisms that influence peripheral blood immune cell
counts.  Adapted from van Lier et al., J allergy Clin Immunol  2017;139:1793-4. 
Figure 1. Sche atic representation of the different mechanims that influence blood immune cell counts. 
Adapted from van Lier et al., J Allergy Clin Immunol 2017; 139:1793-4
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extravascular homing, persistence and cell death remains difficult.13 These functional and 
connecting immunological processes may in part be delineated by using mouse models. 
However, mouse models have limitations as well, therefore some have advocated convinc-
ingly that we should return to concentrate on human studies.15-17 We performed our studies 
within the framework of a large-scale cohort of healthy children, which provided us with 
the unique opportunity to observe populations prospectively, and the ability to delineate 
the factors that drive immune maturation over a large period of time. The studies described 
in Part I were performed during early childhood (birth to 6 years) when the immune cell 
composition is most dynamic.18-21 This unique approach enabled assessment of the rela-
tive contributions of various pre-, peri and postnatal determinants (Chapter 2). Our results 
were in line with previous studies estimating that non-genetic factors account for ~50-75% 
of inter-individual immunological variation,16, 22-24 of which the most profound effect can 
be attributed to aging.16, 25 In early childhood, the strongest fluctuation in cell numbers is 
observed shortly after birth, in the first 6 months of life, followed by a relative stabilization 
after 5-6 years of age (Chapter 2). Which factors drive these robust age-associated changes 
in immune equilibrium?
First, transient immunological fluctuations shortly after birth reflect the newborns 
sudden, and robust adjustment from the relatively protective uterus to the extra-uterine 
environment, a period of quickly changing exposures and colonization by various harmful 
and non-harmful pathogens. Newborns are more vulnerable to infections than adults; this 
is not entirely understood, but suspected to be in part explained by the lack of acquired 
immunity, as well as by the prolonged “feto-maternal tolerance”26 that may persist after 
delivery.10, 27-29 However, this immunological priming may not be detrimental, it may also 
challenge the neonate’s immature immune system to ‘learn’ to balance between tolerating 
non-harmful antigens and minimizing potential harmful inflammation.10 Furthermore, in 
the first months of life, maternal derived antibodies (esp. sIgA from breastmilk) are likely 
to provide passive humoral protection, thereby supporting the child’s innate immunity to 
provide protection from invading pathogens (Chapter 3, Supplemental figure 1). Breast-
feeding induces a transient skewing towards cellular immunity, whilst the formation of 
memory B cells is reduced (Chapter 3), possibly in part through the passive protection of 
maternal immunoglobulins. Hence, a longer breastfeeding duration may not only affect lo-
cal B cell, but also systemic B-cell responses. Furthermore, breastfeeding may prime the T 
cell compartment (Chapter 3), which may further explain why breastfed children respond 
better to vaccinations than non-breastfed children.30 Furthermore, T cell maturation, at 
the expense of B cell maturation, may prove beneficial for infections with persistent cyto-
megalovirus (CMV) that require memory T cell responses to achieve long-term suppression 
(Chapters 2, 3 and 4).
A second determinant that drives age-related changes in immune cell composition is 
postnatal infections. Various pathogens profoundly determine the number and differen-
tiation state of memory cells.13, 31-34 Of all pre-, peri- and postnatal determinants, chronic 
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infections with cytomegalovirus (CMV) and Epstein Barr virus (EBV) were the strongest 
determinants for CD4+ and CD8+ T-cell maturation (Chapters 2 and 4). Our observations 
are in line with previous thoughts that variation in immune cell composition between 
individuals is largely driven by non-heritable factors, of which the most profound effect 
has been attributed to aging and CMV.23 It remains unclear though, why CMV infection in 
children was predominantly associated with enlargement of late CD45RA+ memory T cells, 
whereas EBV was predominantly associated with enlargement of early CD45RO+ effector 
memory T cells. Explanations may include that these distinct viruses need different antiviral 
responses to clear and suppress each virus,33 and functional properties of phenotypically 
distinct memory CD8+ T cells are different with respect to proliferative potential, cytotoxic-
ity, polyfunctionality, avidity, and molecule production upon stimulation.15, 33-39 It may also 
be that the dosage and timing of the initial anti-viral response defines the phenotype and 
functional characteristics of the CD8+ T cells. In Chapter 4 we observed higher CMV than 
EBV seroprevalence in 2-year-old children, which may suggest that CMV infection occurs 
at a relatively younger age than EBV infection due to vertical transmission. Hence, differ-
ences in the inflammatory environment at the timing of infection, and route of primary 
herpesvirus transmission may further explain our findings.15, 40 For example, growth factors 
and cytokines (for example IL-15) in breastmilk may stimulate CD8+ T cell functions, reduce 
intestinal permeability, or activate the local intestinal epithelial immune response against 
infectious pathogens.41-43 Intriguingly, the major factor that explains age-dependent inter-
individual immunological variation (and convergence) in adults was recently attributed to 
“parenting”: Parents raising a child together seemingly have more similar immune profiles 
than randomized couples; a robust effect that even extended the effect of acute and 
untreated gastroenteritis.16 Various explanations were provided, including the process of 
“spousal concordance”, which relates to shared lifestyle behaviors, such as diet, smoking, 
alcohol intake, exercise, sleep deprivation, chronic diseases and convergent microbiomes 
in couples.16, 44 Furthermore, explanations may be sought in shared transmission of child-
hood viral pathogens, including EBV and CMV.16, 23 Hence, childhood herpesvirus infection 
may also shift the immunological landscape of their parents towards a longstanding, 
closer equilibrium. 
Third, age-related differences may in part be explained by sex, with girls showing a mild 
skewing of humoral and early differentiated CD4+ T-cell responses over cellular cytotoxic 
responses in contrast to boys (Chapters 2 and 5). Our observations are consistent with 
previous reports showing subtle effects of sex on CD4+ T cells.16, 45 Furthermore, sex may 
interact with CMV infection, as CMV-infected pre-elderly men had lower numbers of naive 
and central memory T cells within the CD4 and CD8 lineages, as well as memory B cells 
than CMV-infected females.46 Notably, this interaction only holds in adults, not in children 
(Chapter 5). The potential difference between these populations could be age-related, 
and affected by differences in hormone balances, as well as by genetic differences.47 If this 
hypothesis holds, then interactions between sex and CMV become noticeable in teenagers 
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and in young adults. These insights may be valuable considering that autoimmune dis-
eases are more prevalent in premenopausal females than males.47, 48 Furthermore, sex may 
differentially affect vaccine responses, as responses may be more pronounced in women,49 
although inconsistent results have been reported.49-51 
Last, age-related changes may be explained by (epi)genetics. It has been estimated that 
80% of the age-related changes in the immune system can be attributed to age and genet-
ics, and the remaining variability by age-genetic interactions.16 However, the influences of 
(epi)genetics are beyond the scope of this thesis and will therefore not be discussed. In 
conclusion, age and CMV may be considered the most profound non-genetic determinants 
explaining age-dependent inter-individual variability in the immunological profile in child-
hood. These observations are important considering that immune function in elderly, such 
as susceptibility to infections, vaccination responses and cancer immunosurveillance, 
declines with age.16
B.2. Prenatal determinants: a critical window of immune-vulnerability? 
The strongest prenatal effect on innate leukocyte development was observed for mater-
nal educational level, (Chapter 2) which was specifically associated with a reduction in 
patterns of eosinophils and classical monocytes over time. Importantly, the magnitude 
of this “lifestyle” effect was comparable to the substantial positive effect size of postnatal 
CMV and EBV infection on CD8+ TemRO and TemRA lymphocyte dynamics over time, 
which suggests that prenatal maternal lifestyle may shape innate immunity as much as 
postnatal determinants such as CMV and EBV shape adaptive immunity. In line, maternal 
educational level was found to be the strongest confounder in the association between 
breastfeeding and immune cell subsets at six months of age (Chapter 3). How can these 
lifestyle effects be explained? As we included cord blood immune cells in the longitudinal 
analyses, prenatal maternal lifestyle or maternal physiology may affect fetal immune 
maturation. The effect of maternal educational level could not be explained by prenatal 
maternal autoimmune measures, such as maternal atopy, maternal TG2A and anti-TPO 
levels, nor by measures related to prenatal maternal lifestyle such as maternal Body Mass 
index, smoking, and alcohol consumption (Chapters 2 and 3). Hence, the mediator(s) 
of maternal educational level still need to be elucidated, but might be related to other 
(unmeasured) environmental factors that may be linked to maternal lifestyle and socio-
economic position, such as nutritional status, vitamin D exposures, or other infectious 
agents.52, 53 Fetal regulatory T cells have been shown to respond to non-genetic maternal 
antigens such as infectious agents and food antigens,29, 54 and this effect seems to persist 
at least until early adulthood.29, 55 Hence, early development of the immune system may 
relate to significant biological consequences, such as development of peripheral tolerance 
and responses against pathogens that cross the placenta. These functions may develop 
specifically during a phase of rapidly changing peripheral environments,55 which may 
link to Barker’s principles11. In conclusion, considering the longitudinal effect of maternal 
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prenatal lifestyle on immune cell dynamics during early childhood, prenatal factors seem 
as much as important as postnatal viral exposures (Chapter 2). 
B.3. Temporary or persistent effects on adaptive immunity 
Various pre-, peri and postnatal factors influence the longitudinal kinetics of quantitative 
adaptive lymphocyte cells from birth until 6 years of age (chapter 2), and maybe longer, 
which suggests that most external factors have persistent, or longer-lasting priming effects 
on adaptive immunity in childhood, rather than transient or temporary effects. However, 
our analyses were limited up to the age of 6 years, and lacked information thereafter. A 
limitation might be that the strong longitudinal effects of bacterial and viral exposure, 
such as of herpesvirus infections were mainly driven by the moment IgG serology against 
these viruses was determined (in the majority of children only measured at 6 years of 
age). Most of CMV-seropositive children were infected before the age of 2 years (chapter 
4), suggesting a longer virus-induced persistence of immune kinetics over time. Still, to 
enable conclusions on the persistence of these kinetics in childhood and adolescence, 
detailed longitudinal follow-up is necessary. On the other hand, the combined results from 
Chapters 2 and 3 may provide evidence for temporary effects. Based on these chapters it 
could be speculated that breastfeeding transiently reduces the induction of systemic B cell 
responses during the period of breastfeeding and not thereafter, whereas breastfeeding 
may have a long-lasting reducing effect on the local CD27-IgA+ cells after a longer period 
of breastfeeding, or effects appear in children older than 6 months of age.56 In line, the 
effects on CD8+ TCM cells are likely to be transient, as effects were no longer detectable at 
older ages. Though speculative, these transient effects may explain the beneficial effects 
of breastfeeding on the reduction of gastro-intestinal and respiratory tract infections. One 
of the major postnatal factors that drive immune maturation are herpesviruses (Chapter 
2 and 4). The results in Chapter 4 suggest that EBV infection within the first 2 years of life 
induces a transient decline of memory B-cells around 2 years of age that normalizes before 
6 years of age, whereas vaccination responses against measles and tetanus seemed nor-
mal. Together, our results imply that the majority of environmental determinants induce 
temporary responses, but we also found evidence for persistent effects on the develop-
ment of lymphocyte kinetics from birth until 6 years of age. Longitudinal follow-up may 
determine to what extent the effects on the longitudinal kinetics in early childhood remain 
present during adolescence. 
B.4. Age at primary herpesvirus infection, immune plasticity and associations 
with clinical disease
We observed that CMV and EBV infection before 2 years of age induced smaller T cell-
expansions than infection between 2-6 years of age (Chapter 4). These observations may 
be important considering the age-dependent associations between timing of herpesvirus 
acquisition and the prevalence of atopic and allergic diseases. EBV infection before 2 years 
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of age has been associated with beneficial effects in relation to atopic and allergic disease; 
whereas infection after 2 years of age was associated with opposite effects.57 Although ef-
fector memory T cell populations did not increase in early CMV and EBV infected children 
between 2-6 years of life, long-term follow-up of these children is needed to assess whether 
the observed mild changes prevail, or eventually result in detrimental immunological 
effects. In contrast to early childhood, CMV infection in elderly has been associated with 
accumulation of CD8+ late effector memory T cells, and a subsequent profound shrinkage 
of the T-cell receptor (TCR) diversity and loss of naive cells.56, 58 Furthermore, CMV-specific 
T cells in children were mainly CD45RA- (Chapter 4) rather than CD45RA+, which is in line 
with previous reports in children,38 but opposes observations in elderly showing that CMV 
specific T cells are mainly CD45RA+ (TemRA).56 These CD45RA+ cells in elderly may have 
more effector cell properties, are likely to increase with age, and thus may be a conse-
quence of repeated antigenic stimulation.33, 56, 59 Notably, accumulations of TemRA may 
also be associated with loss of immunity, as these cells show signs of replicative senes-
cence.56, 60, 61 Hence, differences in timing of herpesvirus acquisition may in part explain 
whether the immune response is mild or symptomatic, and to what extent the immune 
system is able to return to its steady state. For example, most primary EBV infections in 
children are completely asymptomatic, whereas primary EBV infection in adolescence may 
manifest as acute infectious mononucleosis (AIM).62 These symptoms in AIM have been 
suggested to be caused by CD8 overexpression,63 whereas carriership of EBV infection in 
young children is associated with an accumulation, rather than over-expansion, of virus 
specific CD8+ T cells (Chapter 4).63 Additionally, delayed EBV and CMV acquisition, esp. in 
high socioeconomic groups, (Chapter 10) has been associated with a 2-3 times increased 
risk of malignancies,62 cardiovascular disease risk and mortality.64, 65 The onset and course 
of these clinical outcomes may depend on interactions between environmental factors, 
genetics and CMV that together may determine the speed of immunosenescence.58 This hy-
pothesis is in line with the observation in Chapter 6, showing that CMV infection modifies 
associations between CeD and CD57+ exhausted T cells, which may suggest that replica-
tive senescence may be involved in disease onset or deterioration.61 Notably, alterations 
in blood Vδ1 and CD57+ expressing T-cell numbers were already present in children with 
subclinical CeD (Chapter 6), suggesting that early recruitment of Vδ1+ T cells from blood 
to the intestinal mucosa potentially occurs prior to the onset of intestinal inflammation 
and appearance of symptoms. Although we need to be careful with conclusions on causal 
mechanisms (Chapter 8), future studies assessing blood lymphocyte markers in (subclini-
cal) CeD patients should adjust for confounding elicited by herpesviruses. In conclusion, 
age at primary herpesvirus acquisition may contribute to explain the onset and course 
of CMV and EBV associated disease epidemiology. Altogether, the studies in Part I of this 
thesis illustrate the dynamics of childhood immune maturation, the factors that drive im-
mune maturation, and the plasticity of the childhood immune system upon exposure to 
various external immunogenic factors.
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C. hERPESVIRuS INFECTIONS IN ChILDhOOD
C.1. The changing epidemiology of primary herpesvirus infections in childhood
Infections with CMV, EBV, HSV-1 and VZV are common, and reach 30-100% seropositivity 
in adults.66-74 Though, a large variation in seroprevalence between various ethnic and geo-
graphical groups exists worldwide, with substantial differences in timing of seroconversion. 
We hypothesized that age at primary infection of herpesviruses is dependent on behavior 
that facilitates transmission, which may differ according to ethnic background. Chapter 10 
describes the basic epidemiology of three herpesviruses among children living in modern 
multi-ethnic urban societies. We observed substantial racial/ethnic differences in antibody 
prevalence, with native-Dutch 6-year old children having lower seroprevalences than five 
distinct non-native Dutch ethnic groups living in Rotterdam. These observations are in line 
with previous literature showing that primary infection occurs early in non-industrialized 
countries and in low socioeconomic groups, whereas in wealthy countries primary infec-
tion is often delayed until adolescence.62 Socioeconomic position and factors related to 
lifestyle explained up to 39% of the ethnic differences in EBV seroprevalences, of which 
socioeconomic position was the most important contributor. In contrast, these factors did 
not explain differences in CMV antibody prevalence, suggesting important roles for vertical 
transmission such as breastfeeding. Hence, despite the occurrence of substantial environ-
mental changes in Western societies during the last half-decade, the routes of childhood 
HSV-1 and EBV transmission still seem comparable (Chapter 10).75 Nowadays, low family 
net household income is still one of the most predominant risk factors for transmission of 
both HSV-1 and EBV (Chapter 10). Similarly, in the 1960s and 1970s, childhood herpesvirus 
infections were prevalent among lower income families with children living under crowded 
conditions.75 Between 1950-1970 transmission of herpesviruses decreased in higher in-
come households with only 1 or 2 children sleeping in separate bedrooms.76 Concurrently, 
breastfeeding and contact with saliva (pre-chewing baby’s food, or kissing) became less 
common in these families. Therefore, primary EBV acquisition moved from early childhood 
to late adolescence resulting in symptomatic acute infectious mononucleosis (AIM).75, 77 
HSV-1 infection showed a similar pattern of early acquisition in children in poor families. 
Nowadays, the trend of delayed primary herpesvirus acquisition seems to persist: only 
13% of native Dutch 6-year old children were seropositive for HSV-1, whereas seroposi-
tivities reach 69% in Dutch pregnant women.78 Notably, delayed primary HSV-1 acquisition 
during pregnancy may increase the prevalence of maternal genital herpes and congenital 
herpes; similar to what was observed for delayed EBV acquisition resulting in AIM.75 This is 
in line with observations of increasing genital herpes incidence in the Netherlands, the UK, 
Ireland and the USA between 2002-2014.79-83 Explanations could be an increase in unsafe 
sexual behavior, better and faster diagnosis, but also a delay in HSV-1 acquisition. If the rise 
in primary genital HSV-1 infection in young women continues, it may be hypothesized that 
neonatal herpes infections will occur more frequently and severely in the next decade.81 
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C.2. herpesvirus infections and autoimmunity 
Herpesviruses are ubiquitous and highly contagious, but the age at primary infection is 
delayed in high Western countries compared to non-western countries,84, 85 concurrent 
with an increase in autoimmune diseases such as CeD.86-89 Together with the observations 
that herpesviruses are less common among higher socioeconomic groups with higher 
incidence of CeD (Chapters 9 and 10), it is tempting to speculate that the herpesvirus 
epidemiology explains some of the ethnic/geographic variation in incidence of autoim-
mune diseases, such as CeD. In Chapter 8, we observed inverse associations between 
CMV seropositivity and CDA. Similar protective effects of herpesviruses have previously 
been described for allergic diseases.56, 57, 90 Importantly, the protective effect was limited 
to infection before the second year of life.56, 57 In line with these observations, we observed 
smaller T-cell expansions in children who were infected with CMV and EBV before 2 years 
of age (Chapter 4). Additionally, the protective role may not be limited to CMV single infec-
tion, but may also include infection with multiple herpesviruses, as children with single 
herpesvirus infections were more often seropositive for other herpesviruses (Chapter 10). 
Moreover, the association with CDA was stronger for multiple herpesvirus infections than 
for single CMV infection. Potential causal mechanisms have been described in Chapter 8. 
Alternatively, herpesvirus seropositivity may be a proxy for the amount of other infections 
in early life, which is in line with the hygiene hypothesis, or old friend’s theory.40 Increasing 
hygienic living conditions, smaller family sizes with fewer siblings, and decreasing rates of 
breastfeeding, in combination with fewer early life pathogen exposures and concomitant 
changes in the diversity of the microbiota may contribute to the increasing incidence of 
allergic and autoimmune diseases.40, 56 Hence, these environmental changes may also 
contribute to explain ethnic differences in autoimmunity, such as CeD. In Chapter 9 we 
confirmed the presence of substantial ethnic variation in CeD incidence,86, 88, 89, 91-95 and 
observed that up to 47% of ethnic differences in CDA could be explained by differences 
in daycare attendance, socioeconomic position and CMV acquisition in childhood. The 
nature of early life herpesvirus infection is often asymptomatic, and combined with the 
observations that these viruses induce only small T cell expansions when acquired <2 years 
of age, in contrast to infections later in life, suggests that it may be favorable to acquire 
these viruses early in life. Early life infection has been shown to protect against the devel-
opment of CDA and allergies, particularly if children are infected prior to 2 years of age.57 
Therefore, it may be questioned whether immunization against these viruses may prove 
beneficial in children that were not infected during the first few years in life.56 Considering 
the broad adverse effects of herpesvirus infections in pregnant women and newborns, as 
well as complications of primary herpesvirus infections in elderly or immunocompromised 
or -suppressed individuals, one may argue for primary prevention in the form of universal 
vaccination. Although some argue in favor of universal vaccination,73, 96, 97 the effectiveness 
and safety of current vaccines are still discussed. Nevertheless, future vaccination pro-
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grammes in typical Western multiethnic urbanizations such as Rotterdam, should at least 
include geographic and socioeconomic information.
D. CELIAC DISEASE: DEFINITIONS, DIAGNOSIS AND TREATMENT
Celiac disease (CeD) is a common chronic immune-mediated disorder, but largely unrecog-
nized by clinicians due to the heterogeneity of disease presentation.98 Patients with silent 
CeD (the patient meets the diagnostic criteria for CeD, but lacks symptoms), subclinical 
CeD (symptoms are below the CeD testing threshold and biopsies showing villous atro-
phy) or potential CeD (positive serology without histologic confirmation) may experience 
health effects, however this has been extensively debated.99 Primary prevention is defined 
as preventing the development of CeD, and secondary prevention as diagnosing CeD in 
its earliest stage through active case finding, targeted screening in at risk populations, or 
population mass-screening. However, should we search for CeD, diagnose and treat pa-
tients with minimal or no symptoms associated with CeD? The general discussion focuses 
on improvement of early diagnosis, and reduction of the high underdiagnosis rate of CeD, 
taking long-term consequences of delayed diagnosis, complications, and early treatment 
with a gluten free diet (GFD) into account. 
D.1. PRIMARY PREVENTION OF CELIAC DISEASE: ENVIRONMENTAL 
DETERMINANTS
D.1.1. A focus on early nutrition
Until 2014-2015, a special emphasis was placed on the timing and mode of gluten 
introduction to prevent the development of CeD. Results from previous retrospective 
observational studies suggested that the introduction of gluten between 4 and 6 months 
of age represents ‘a window of opportunity’ to influence the risk of developing CeD.100, 101 
Therefore, in 2012, Dutch and European guidelines recommended to introduce gluten 
gradually between 4-6 months of age (not earlier or later), preferably while the infant is still 
being breastfed.102 However, we showed that the risk of CDA is not influenced by introduc-
ing gluten after the age of 6 months, nor by breastfeeding (Chapter 7). Our results are in 
line with results from other prospective studies.103-105 The final answer was given by the 
PREVENT CD Study,1 a randomized, double-blinded placebo controlled trial comparing 
infants from high risk families, whose children were randomized in either placebo or gluten 
intervention at the age of 3 months and underwent repeated CeD screening up to 3 years of 
age: Introducing gluten in small quantities between 4-6 months of age while breastfeeding 
was not associated with CeD risk.1, 104 Recently, neither high amounts of gluten, nor gluten 
consumption patterns were associated with altered CeD risk.106 Furthermore, maintenance 
of breastfeeding at the time of gluten introduction, and breastfeeding in general did not 
reduce the risk of CeD. In line, a systematic review107 concluded that breastfeeding and 
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timing of gluten introduction did not ameliorate CeD risk, obligating for an update of the 
European guidelines in 2016.108 These adjusted guidelines recommend introducing dietary 
gluten between 4 and 12 months of age, and state that breastfeeding and the timing of 
gluten introduction do not influence the risk of developing CeD in childhood.108 
D.1.2. Geographical and ethnic differences in CeD 
Genetic variation in the HLA DQ2.2, 2.5 and DQ8 haplotypes, and exposure to dietary gluten 
are the two undeniable factors required to develop CeD. However, most of the individuals 
carrying HLA-DQ2 and/or HLA-DQ8 who are exposed to gluten do not develop the disease. 
40% of the European population carries these predisposing haplotypes, while CeD occurs 
in only a small fraction (1%).1, 109 Hence, besides gluten, it is conceivable that additional 
genetic and environmental factors play a role in disease initiation.
Epidemiological studies observed substantial differences in CeD prevalence according 
to geographic location and ethnic background: CeD is common in Europe, US, North Africa, 
the middle east, sub-Saharan Africa and east-Asia, and more common among whites than 
among individuals from other ethnicities.110-112 Also across different European countries, 
CeD prevalence varies remarkably (8-fold).112 Furthermore, the occurrence of CeD seems to 
follow a north-south gradient in the US population, which was found to be independent 
of race/ethnicity, socioeconomic status, or body mass index.110 Notably, this north-south 
gradient was also observed in occurrence of several other auto-immune diseases, which 
may suggest a role for vitamin D, sunlight, or ultraviolet B radiation in disease pathogen-
esis.110, 113
Intriguingly, not only CeD, but also the prevalence of CDA varies according to ethnicity: 
we found CDA to be more common among Western vs non-Western children living in urban 
Rotterdam (Chapter 9). Our results are in line with previous observations in the USA, where 
CDA is estimated to be 4-8 times greater among non-Hispanic whites than among other 
ethnic minorities.114 Aside from differences in HLA-DQ2/DQ8 carriership among different 
ethnic groups, and differences in gluten consumption, variations in other environmental 
factors may explain some of the ethnic and geographic variations in CeD prevalence. Some 
studies suggested socioeconomic variation as an explanatory factor, as children with a 
higher socioeconomic position (SEP) may face different infectious agents during early 
childhood, consequently affecting the gut microbiota and immune programming (Part I). 
Indeed, of environmental factors, SEP contributed mostly to explain the ethnic variation in 
CDA prevalence, followed by daycare and CMV seropositivity. Furthermore, we found that 
CMV seropositivity is inversely related to the development of CDA (Chapter 8). This may 
reflect a causal association; however, as effects on CDA were stronger for the combination 
of EBV, HSV-1 and CMV (Chapter 8), it is much more likely that herpesvirus seropositivity 
may serve as a proxy for other, undefined, determinants, of which the combination of these 
different types of environmental factors may eventually induce villous atrophy. Children 
who acquire CMV early in life come from a lower socioeconomic environmental back-
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ground (e.g. they are longer breastfed, attend daycare more often, and experience more 
often respiratory and gastrointestinal tract infections in their first year of life, than children 
primarily infected at a relatively later age (Chapter 10). Hence, numerous factors may 
contribute. For example, reovirus infections have recently been found to trigger develop-
ment of TH1 immunity to gluten.115 Still, it is likely that additional events are necessary for 
induction of TG2A antibodies and villous atrophy, and it may be reasonable to assume that 
the combination of various types of other, in part still undefined environmental stimuli, 
such as members of the microbiota and intestinal dysbiosis may eventually cause villous 
atrophy.115 An obvious counter-argument against the partial explanations by SEP, daycare 
and CMV (Chapter 9) may be that early infant feeding practices differ between Western and 
non-Western children. Nonetheless, as we adjusted for breastfeeding duration and timing 
of gluten introduction (Chapter 9), these factors are less likely to contribute. Besides, early 
feeding practices have been shown that they cannot prevent the onset of CeD.1, 104 A second 
counter-argument may be that genetic predisposition may vary among different ethnic 
groups, as we did not adjust for HLA DQ2/DQ8 carriership. Still, associations between 
ethnic background and CDA remain valid even in individuals who lack carriership for these 
associated haplotypes, and thus lack a final CeD diagnosis. Furthermore, the presence of 
other (protective) genes may contribute to prevent disease onset. To date, it has been es-
timated that up to ~50% of CeD heritability can be explained by genetic variation.116 These 
are promising findings that leave a role for other CeD associated loci and environmental 
factors that may serve as novel disease biomarkers in future. 
In conclusion, primary prevention of CeD (prevention of the development of CeD) is not 
possible at this moment. Therefore, secondary prevention strategies represent the only 
way to improve the high underdiagnosis rate. 
D.2. SECONDARY PREVENTION: IS IT TIME TO SCREEN FOR CELIAC DISEASE? 
D.2.1. Active-case finding, and targeted screening in populations at risk: when and how?
To diagnose CeD in its earliest stage, “active-case finding” is recommended,102 which means 
an active approach by clinicians to seek for CeD-associated symptoms and related diseases. 
However, due to the wide variety of disease presentation (often subtle, atypical, or absence 
of symptoms), the majority of screening-detected CeD cases cannot be diagnosed by case-
finding.117 Therefore, current European102 and American guidelines 118, 119 recommend to 
screen asymptomatic children and adolescents with an increased risk for CeD, provided 
that they have consumed an adequate, gluten-containing diet for at least 1 year prior to 
testing. At risk populations include first- or second- degree relatives, or patients with other 
autoimmune diseases, such as type 1 diabetes mellitus (T1DM). First-degree relatives have 
a 5-20% higher risk of developing CeD. However, the risk is differentially affected by sex 
(F/M= 2-3:1 at age 3 yrs.) and HLA-genotype. Homozygous HLA-DQ2 increases the risk to 
14.9%, followed by heterozygous HLA-DQ2 (3.9%) and HLA DQ8 hetero- and homozygous 
(0.9%).1 HLA-testing, followed by IgA-TG2A determination, is recommended to start around 
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3 years of age.119 Approximately 50% of children with a CeD diagnosis and a family history 
of CeD have been shown to develop CeD antibodies by 3 years of age,1 suggesting that 
the potential forms start early in life, and testing may start prior to 3 years of age. Even in 
very young children, TG2A testing shows good sensitivities and specificities.1 If IgA-TG2A is 
negative and IgA deficiency is excluded, then CeD is unlikely. However, as the disease may 
still develop later in life, serological testing should be repeated at regular intervals; i.e. 
every 2 to 3 years. Notably, targeted screening in the Generation R cohort would not have 
led to early identification of CeD, as only a few children with positive TG2A levels had a first 
or second-degree relative with CeD (Chapters 10 and 11). 
D.2.2. Population mass screening: yes or no? If yes, when and how?
Mass-screening in the general population may be another approach to improve early diag-
nosis of CeD, which means that all individuals regardless of symptoms undergo serological 
testing, followed by esophagogastroduodenoscopy (EGD) with duodenal biopsy in those 
with positive TG2A levels.102 Currently, biopsies can only be avoided in symptomatic chil-
dren presenting with 1 symptom, TG2A levels exceeding 10 ULN, and positive EmA twice.120 
These criteria have recently been validated by a large, multinational, prospective study,120 
showing that burden, risks and costs of endoscopy can be prevented for >50% of CeD 
patients worldwide. Moreover, HLA testing seems not to improve accuracy of CeD diag-
nosis in symptomatic patients, and may therefore be omitted.120 Notably, the guideline 
is currently discussed, as the diagnostic ESPGHAN criteria for symptomatic children may 
also be applied to asymptomatic screening identified children. Swedish observations121 
and previous observations from the Prevent CD study1 indicate that TG2A levels >10 ULN 
show good diagnostic accuracy in screened children. In line, all children with TG2A levels 
>10 ULN in the Generation R cohort and in the Prevent CD Study1 had severe enteropathy, 
and the positive predictive value of TG2A did not depend on symptoms (Chapters 10 and 
11),1 necessitating for an update of the diagnostic ESPGHAN criteria. Hence, as burden, 
risks and costs of endoscopy may be avoided, the screening debate would be placed in 
a totally different context. To assess the harms and benefits of mass-screening for CeD, 
the criteria according to Wilson and Jungner122 can be applied (Table 1). Several recent 
epidemiological studies, including ours (Chapters 10 and 11), made efforts to reopen 
the screening debate. For example, 3 US studies focusing on the natural course of CeD 
found that 0% to 15% of patients with positive serology (without histologic abnormalities) 
developed symptoms after 10 to 45 years.86, 87, 123 Still, some questions remain unanswered. 
In the following paragraphs, we aimed to describe recent considerations to assess the net 
harm and benefits of mass-screening. 
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Table 1. Wilson and Jungner criteria for mass-screening applied to CeD
Criterium CeD situation References
1.  Important health problem 1% of general population:33.600 children in The Netherlands 124-126
2.  Accepted treatment GFD, good adherence in screening detected cases in prospective 
studies
127, 128
3.  Facilities diagnosis Presence of CeD specific antibodies 8, 102
4.  Recognizable latent/ early 
symptomatic stage 
Presence of CeD specific antibodies 8, 102
5.  Suitable test detection Presence of CeD specific antibodies 8, 102
6.  Test acceptable for the 
population
Depends, data from prospective studies, PPV’s in subclinical disease 
discussed
86, 87, 123, 129
7.  Natural history understood Data from prospective studies showing potential and subclinical 
forms
86, 87, 123, 127, 130, 131
8.  Agreed policy of whom to 
treat
Depends, data from prospective studies showing adverse health 
effects in subclinical disease, and recovery upon treatment
125, 132-136
127, 131, 137, 138
9.  Cost-case finding 
economically balanced
Limited data 139, 140
10.  Case finding continuous 
process
No data available
D.2.3. Potential benefits of screening in asymptomatic populations
Symptomatic CeD is associated with a wide variety of symptoms of malabsorption (which 
may appear several years prior to diagnosis), excess mortality, intestinal adenocarcinoma, 
and lymphoma.86 Screening may enable early diagnosis and treatment before overt symp-
toms develop, relief mild but unacknowledged symptoms, and prevent malabsorption 
and associated nutritional deficiencies.99 However, it remains unclear whether subclinical 
CeD is associated with the same risks as reported for symptomatic CeD. Screening identi-
fied children with subclinical CeD in the Generation R cohort had reduced bone mineral 
densities and growth trajectories from 6 months onwards (Chapter 10). Our observations 
are in line with others,132-134 showing that growth falters in most children with CeD, even in 
anti-EMA positive children without biopsies.134 Recent Norwegian observations132 showed 
that growth retardation in children commonly starts at 12 months of age, and precedes 
clinical symptoms that usually bring the suspicion of CeD. Notably, the average age of CeD 
diagnosis is between 40-60 years of age;99, 141, 142 often too late to reverse detrimental effects 
on bone health, such as reduced mineral density, osteopenia/osteoporosis. Hence, if con-
sidering mass-screening, screening should start early in life. Importantly, screening studies 
showed a decreased BMD even in asymptomatic adults who had positive concentrations 
of celiac antibodies,135, 136 but no villous atrophy,143 indicating that the presence of positive 
serology may induce adverse effects on BMD. 
In contrast to the relatively high PPV of 61% in our study (Chapter 11), studies among 
US adults reported rather lower PPV values, i.e. from 0% to 15%,86, 87, 123 suggesting that 
the PPV of TG2A to detect (subclinical) CeD may be substantially different among children 
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and adults. Varying results may be in part explained by differences in disease prevalence 
among children and adults,144 differences in time of follow-up, the absence or presence 
of histologic confirmation, 99, 145 and the spectrum of CeD. For example, in untreated CeD, 
high sensitivities (TG2A IgA 85-95%; EMA IgA 80-90%) and specificities (TG2A- IgA 95-99% 
; EMA IgA 95-100%) have been reported, whereas in refractory CeD patients, sensitivities 
reach barely 50%.146 These patients had normal levels of TG2A while mucosal atrophy was 
not recovered upon a GFD. Hence, sensitivities and specificities of CeD specific antibody 
tests may be different for screening-identified ‘subclinical’ CeD than for symptomatic CeD. 
D2.4. Effectiveness of early treatment in asymptomatic populations
Several studies have shown that screening and early treatment with a GFD among screen 
detected CeD children and adults results in significant health improvements.127, 131, 137, 138 On 
the short run, a GFD has been shown to improve symptoms of diarrhea, abdominal pain, 
constipation, fatigue, malabsorption, irritability, oral aphthous ulcers and growth retarda-
tion in Dutch screened children.127 In adult Finish CeD patients, a GFD improved chronic 
health problems as gastroesophageal reflux, indigestion and anxiety.131 Furthermore, 
dietary adherence seems excellent after screening; CeD-related QOL was not different 
between screen-detected and symptom-detected patients.127, 131, 137 Of screening identified 
children with CeD in the Generation R cohort (Chapter 11), treatment with a GFD in the 
~first 6-9 months following diagnosis resulted in the majority of children in improvement 
of abdominal pain and fatigue (which were present in 11/18 children). CeD associated 
symptoms were subtle and only recognized after initiation of a GFD, suggesting that mass-
screening enables identification of patients who are symptomatic in retrospect. Nonethe-
less, these ‘subtle’ symptoms did not result in visitation of the general practitioner (Chap-
ters 10 and 11). Hence, a GFD seems to alleviate even mild, but otherwise unrecognized 
symptoms that are below the awareness of the patient as a clinical symptom. Furthermore, 
a GFD resulted in improvement of growth parameters at 13 years of age. On the long run, 
screening may prevent complications such as osteoporosis, reduced height, subfertility 
and perinatal problems. Osteopenia affects 26-72% of all untreated CeD patients, resulting 
in increased fracture risk.147, 148 Furthermore, we showed that screening identified children 
with CeD experience growth retardation (Chapter 10), which is in line with others.132, 134 
Generally, osteopenia/osteoporosis and growth failure recover completely within 1-2 years 
upon start of the GFD in childhood, in contrast to diagnosis after 25 years of age, underscor-
ing the need for early diagnosis and treatment.149-151
D.2.5. Potential harms of screening in asymptomatic populations
False-positive, or inconclusive serology and biopsy results are potential harms of screen-
ing, resulting in unnecessary burden or complications. In high risk individuals, the diagnos-
tic accuracy of screening tests is considered to be good with sensitivities and specificities 
reaching >90%, (Chapter 1) and PPV’s of approx. 40-80%.99 However, evidence in asymp-
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tomatic pediatric populations is scarce. Only one study reported that TG2A levels >10 times 
ULN has, concurrent with a positive EMA IgA test result, a sensitivity and specificity of 83% 
and 67% to detect enteropathy (i.e. Marsh stage 2 or 3).129 We found the PPV of IgA-TG2A 
testing for CeD in 6-year old children to be relatively high with 61% (Chapter 11). These 
observations are in line with observations in the general European adult population.112 
Of 29,000 screened individuals, 147 individuals had both positive TG2A as well as positive 
EMA, of whom 100 had enteropathy, suggesting a combined PPV for CeD of 68%. Assuming 
a PPV of 61%, still, more than 1/3 of children should currently undergo biopsies, whereas 
they do not have CeD. On the other hand, a PPV of 60-70% may be appreciable, consider-
ing that colorectal cancer in the general population (age >50 years) is accepted in most 
countries of the world, based on a PPV of guaiac fecal occult blood (gFOC) of 9%, and 
together with detection of adenoma’s, a PPV of 30%.152 
Second, it remains unclear how many asymptomatic individuals who screen positive, 
will undergo invasive gastrointestinal endoscopies. Though speculative, because of the 
absence of symptoms, these individuals may be more likely to refuse biopsies, thereby 
complicating diagnosis. In our study, 16% (5/31) of parents of children who were suspected 
to have CeD, refused duodenal biopsies, of whom 3 had levels exceeding 10 ULN (Chapter 
11). Considering that CeD diagnosis in screening identified children can be made without 
biopsies, the screening debate would be placed in a totally different view, as complica-
tions, patient burden, anxiety and costs of time-consuming endoscopies may be avoided. 
Third, the natural course of asymptomatic and subclinical CeD/CDA is understudied in the 
general population. Only 5 long-term follow-up studies in children and adults,86, 87, 123, 127, 130 
have shown that some screening identified CeD cases never develop symptoms. Together, 
these observations suggest that over-diagnosis may be an important concern. On the 
other hand, adverse effects on health seem to be present irrespective of the presence of 
clinical symptoms (Chapter 10).117, 132 However, most individuals are probably not truly 
asymptomatic, and only become aware of the presence of (subtle) symptoms after they 
have been placed on a GFD.131 
Fourth, dietary adherence may be questionable, as the GFD may have a major impact 
on daily life, is expensive, and difficult to maintain, especially in screening identified, 
asymptomatic, or minimally symptomatic individuals who do not expect to gain health as 
much as symptomatic patients. However, dietary adherence has been found excellent in 
Dutch and 12-year old Swedish children screened positive.127, 128 Second, in screened Dutch 
children and Finnish adults, a GFD has been shown effective in terms of alleviating early 
and chronic CeD associated symptoms (including symptoms of diarrhea, abdominal pain, 
constipation, fatigue, irritability, oral aphthous ulcers, growth failure, indigestion, gastro-
esophageal reflux and anxiety).127, 131 Furthermore, a GFD has been shown to improve serol-
ogy and mucosal atrophy in adults.131
Last, the impact of CeD diagnosis and treatment of GFD on quality of life probably varies 
between countries, as changes in perceived health must be balanced against logistical, 
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economic and social burden.153, 154 Despite these concerns, Swedish observations suggest 
that mass-screening is acceptable for most of CeD patients and their parents.155 In fact, 
parents suggested it to be more beneficial if performed early in life.155 In line, quality of 
life among Finnish, US, and Dutch patients seems high, and not materially different 
between screening detected patients and patients who are diagnosed based on symp-
toms.127, 131, 137, 156 
To conclude is it time to screen for CeD instead of targeted screening? Considering 
the important detrimental health effects of unrecognized CeD, mass-screening may be 
justified. However, the benefits of screening (prevention or reduction of complications 
of undiagnosed CeD by early diagnosis and treatment) should outweigh the harms (false 
negative test results, anxiety, costs and burden of gastrointestinal biopsies and GFD). To 
assess this balance more adequately, some questions remain unanswered. Furthermore, 
cost-effectiveness analyses are missing in a large childhood population. 
METhODOLOGICAL CONSIDERATIONS
The studies described in this thesis were performed within the Generation R Study; a popu-
lation based prospective cohort study.157 Cohort studies provide the unique opportunity to 
observe populations prospectively, thereby identifying factors associated with an outcome 
of interest. The studies presented in this thesis combine a unique combination of detailed 
immunological analyses on the origin, maturation and responsiveness of specific lympho-
cyte populations, and large-scale epidemiological analyses that include associations with 
herpesvirus acquisition and CDA. However, several methodological considerations need to 
be taken into account. 
E. Outcome definitions / Information bias 
E.1. Immune cell analyses
The mainly cross-sectional studies described in Part I include detailed assessment of im-
munological flowcytometric analyses at multiple time points. Flow cytometry has proven 
highly successful in characterizing blood immune cells in health and disease.158 Population 
numbers included (n=230-377 from birth until 24m; and n=~1,100 at 6 years), are consid-
ered extremely large in the field of immunology, however, –from an epidemiological point 
of view- these groups comprise relative small numbers, thereby limiting statistical power 
(and the possibility to adjust for a wide range of potential confounders). 
E.2. Misclassification of determinants 
We gathered the majority of data on pre-, peri and postnatal determinants (such as 
maternal lifestyle, infant feeding practices (breastfeeding duration, gluten introduction)) 
retrospectively by questionnaires, which may be prone to misclassification.159 However, 
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because any misclassification would be independent of our outcomes (as participants 
were not aware of determining laboratory findings such as immune cell numbers, CDA, 
and herpesvirus persistence), it is unlikely that these have affected our outcomes.
E.3. Selection bias, missing data and data imputation
Cohort studies may be prone to selection bias do to either loss of study participants, or loss 
to follow-up. Initially, this may occur if a proportion of the target study population does not 
participate, and is systematically different from the original study population with regard to 
exposure and outcomes. Participating mothers in the Generation R Study more often come 
from a higher socioeconomic background than non-participating mothers, which may 
have affected the external validity. However, only if associations between determinants 
and outcomes are different for participants and non-participants, selection bias could have 
influenced our findings. In non-immunological chapters, we dealt with missing data by us-
ing multiple imputation techniques. In the field of epidemiology, multiple imputations are 
recommended to adjust for potential attrition bias and loss of information that may occur 
when performing complete-case analyses. Notably, results of multiple imputations are 
valid under the assumption that data are missing at random (MAR).160, 161 However, in this 
thesis it was not possible to distinguish between data being MAR or missing not at random 
(MNAR). When data was MNAR this could have affected the prediction of the missing values 
and therefore the uncertainty of the effect estimates observed.
E.4. Confounding and reverse causation
Prospective cohort studies do not conclusively prove causal association, because first, 
associations between exposure and outcome may be distorted by confounders (i.e. factors 
that are related to both determinant and outcome, and are not intermediates in the path-
way from exposure to outcome). We tended to adjusted our studies for multiple potentially 
confounding variables. Still, residual confounding cannot be fully excluded. This may be 
due to the fact that some potential confounders were not (sufficiently) measured during 
the process of data gathering (e.g. timing, duration and dose of infections, or because 
measurement of variables contained errors. Second, reverse causality cannot be fully 
excluded, for example in the association between herpesvirus seropositivity and CDA, as 
both herpesvirus seropositivity and TG2A were determined cross-sectional at 6 years of 
age. 
CONSIDERATIONS FOR FuTuRE RESEARCh
Non-genetic determinants that shape immunity 
The results presented in Part I may be essential to begin to understand the gradual and 
ordered acquisition of immune competence in childhood.13 However, our observations 
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raise further questions, such as: “Which mechanisms operate to regulate circulating, (and 
lymphoid tissue) resident immune cells?” How do circulating immune cell numbers relate 
to functions such as production, homeostasis and inflammation.12, 13 Furthermore, future 
studies should include information on the diversity of antigen receptor repertoires to de-
termine the immunologic flexibility to respond adequately to pathogens.13 Many postnatal 
determinants have been studied in cross-sectional studies including only a small numbers 
of participants, but the crucial role of timing of these environmental factors, i.e. whether a 
critical or vulnerable time period exists, needs to be further studied in longitudinal studies. 
For example, future studies should evaluate the timing of herpesvirus infection on immune 
plasticity/ TCR diversity. These studies should include not only postnatal, but also pre- 
and perinatal factors in a multivariable model to assess their relative contributions. The 
Generation R Study provides a unique opportunity to longitudinally assess immunological 
patterns, and to provide information on the quantification and maturation of, for example, 
IgE producing B cells that are strongly linked to atopic diseases. Questions include: “Which 
pre- peri- and postnatal determinants are associated with IgE-producing B cells at 9 years 
of age? What is the role for CD27-IgA+ cells in gut homeostasis, and to what extent are 
CD27-IgG+ cells related to CD(A)?” Furthermore, the intestinal microbiome should be 
linked to immune maturation. 
Determinants and consequences of Celiac Disease Autoimmunity
The overall feasibility of mass-screening needs to be assessed by studying the acceptance-
rate of mass-screening in the general population, among parents and clinicians, the psy-
chological impact, compliance to diagnostic procedures and treatment in those screened 
positive, cost-benefit analyses, and the ethical aspects involved. Furthermore, the optimal 
age-range to screen asymptomatic children should be assessed, as well as the need for 
repeated testing.144 Furthermore, a cost-effectiveness analysis of screening and treatment 
(compared with the total healthcare costs) should be performed in the general pediatric 
population that includes all of the aforementioned aspects of screening, and also the 
long-term CeD associated complications. In the young adult general population, mass-
screening for CeD was found to be cost-effective if the time delay to diagnosis was longer 
than 6 years,140 with a cost-effectiveness ratio of 48.960 USD per QALY. One of the aims is to 
further explore the cost-effectiveness balance in Dutch children participating in the Genera-
tion R Study. Furthermore, the course of CDA in the general population remains unknown. 
The Generation R cohort provides the unique opportunity to longitudinally evaluate the 
course of TG2A seropositivity/subclinical CeD at 6 and 9 years of age. This would provide 
information on the number of new onset CeD or CDA cases if screening is repeated. 
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CONCLuDING REMARKS
To conclude,
1. “Healthy” or “normal” maturation of the immune system in childhood is characterized 
by a wide range of distinct innate and adaptive immune cell patterns, which differ 
greatly between children, and depend highly on age. This immunological variation 
between individuals is largely driven by non-heritable (environmental) factors, of which 
postnatal herpesvirus acquisition has been considered one of the most profound de-
terminants. Furthermore, the results presented in this thesis imply that the “window of 
immune vulnerability” starts in utero, of which pre- and perinatal determinants may 
be just as important as postnatal determinants that leave a longer-lasting fingerprint 
on the maturing immune system. Furthermore, our results imply that early herpesvi-
rus acquisition does not adversely affect the plasticity of the immune system, which, 
together with observations from others, may prove beneficial in terms of modifying 
“clinical disease risk”. 
2. Currently, primary prevention strategies cannot prevent the onset of CeD. Other en-
vironmental determinants, such as infections, may play a role in disease onset, but 
are relatively understudied, and poorly understood. Therefore, the only method to 
optimize early diagnosis of CeD is secondary prevention. Because active-case finding 
and targeted screening cannot resolve the high underdiagnosis rate, mass-screening 
may be a reasonable and realistic alternative. 
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SuMMARY 
The early childhood period may reflect a vulnerable time period, during which various de-
terminants ‘shape’ the immune system, and possibly affect the development of immune-
mediated diseases. A competent immune system provides long-lasting protection against 
harmful antigens, without losing control, which requires a delicate balance between ‘too 
little and too much’ tolerance. Aberrant immune protection, however, results in clinical 
disease, such as autoimmune diseases with an immune response directed against self-
antigens, or allergies/hypersensitivities with an excessive reaction to harmless foreign 
particles. The development of celiac disease autoimmunity (CDA) is an example of such an 
excessive reaction against dietary gluten. Although considerable knowledge on the etiology 
of celiac disease (CeD) has been gained with studies focusing on early childhood nutrition, 
the etiology of CeD is still not fully understood. 40% of the general European population 
carries the HLA DQ2/DQ8 risk alleles, but only 1% develops CeD, suggesting that additional 
factors must contribute to pathogenesis. However, besides dietary gluten and the role of 
breastfeeding, other environmental determinants are relatively understudied. 
The first aim of this thesis was to identify determinants of the developing immune 
system in childhood, focusing predominantly on the adaptive immune compartment. The 
second aim was to study determinants and the consequences of celiac disease autoimmu-
nity within a population based prospective cohort. These aims were explored within the 
framework of The Generation R Study, a population-based prospective cohort study from 
fetal life onwards. The studies in this thesis particularly referred to the childhood period 
from birth until 6 years of age. 
Part I is devoted to determinants that affect the shaping of adaptive immunity in 
childhood. In Chapter 2 we studied the dynamics of leukocyte subsets within the innate, 
naive and memory T- and B-cell lineages in childhood from birth until the age of 6 years, 
and we studied which environmental determinants affect these dynamics over time. We 
identified that patterns of leukocyte subsets could be divided in 4 major groups, with 
functionally similar leukocyte populations following similar kinetics over time. Various 
non-genetic determinants were identified that influence these patterns, including factors 
that are related to prenatal maternal lifestyle, maternal immune-mediated diseases, birth 
characteristics, and postnatal bacterial and viral exposures. Persistent viral infections, esp. 
cytomegalovirus (CMV) and Epstein Barr Virus (EBV), contributed mostly to the kinetics of 
memory B and T cells over time. Our data confirms previously described effects of these vi-
ral infections on the memory T and B cell compartments, and identified new determinants, 
including inverse associations between herpes simplex virus 1 (HSV-1) seropositivity and 
B cell numbers. Our large-scale analyses of all leukocyte subsets and various non-genetic 
determinants shed new light on the shaping of the adaptive immune system in the first 6 
years of life, and enabled identification of various pre- and postnatal determinants that 
contribute to this shaping. 
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The effects of breastfeeding on the immune compartments were studied in more de-
tail in Chapter 3. Breastfed versus bottle-fed children showed increased cytotoxic CD8+ 
central memory T(cm) cells at 6 months of age, which was irrespective of the duration 
of breastfeeding, whereas the numbers of T-cell dependent CD27- IgG+, CD27+ IgM+ and 
CD27+ IgA+ memory B cell subsets at 6 months of age were inversely related to the duration 
of breastfeeding. Nevertheless, these effects disappeared after discontinuation of breast-
feeding. The transient increase in cytotoxic T cell numbers may suggest a lasting priming of 
CD8+ T-cell immunity via breastfeeding. Furthermore, breastfeeding may enable stepwise 
immune maturation, by reducing the need for humoral immune responses, while priming 
cellular immune responses. 
Chapter 4 reveals how CMV and EBV infections affect the memory B and T cell compart-
ments in 6-year-old children. Infected adults were previously reported to have expansions 
of memory T and B cells, at the expense of naive and Tcm cells. We observed similar 
virus-associated memory T-cell expansions in children. However, these expansions did not 
result in loss of naive or Tcm cells, nor in loss of responses to the non-related Measles 
or Tetanus vaccines. Moreover, children infected before 2 years of age showed a stable 
control of these persistent viruses with only moderate expansions of effector memory T 
cells, which is suggestive of better viral suppression with less effector memory T cells upon 
childhood infection with CMV or EBV. Timing of CMV or EBV infection may be crucial to 
determine to what extent these herpesviruses have immunomodulatory properties. This is 
important for our understanding of herpesvirus-associated immunosenescence in elderly. 
Furthermore, previous literature suggests that persistent infections with CMV differentially 
affects the host immune phenotype in middle-aged males and females, however whether 
these differential effects also exist in children remains unclear. 
In Chapter 5 we studied whether sex modifies associations between CMV and multiple 
B and T cell subsets in 6-year-old children. We observed that sex and CMV independently 
impacted on multiple B and T cell subsets, however there was no interaction between the 
two. Importantly, the effects of sex and CMV were in part explained by age and infections 
with other herpes viruses. Thus, immune aging is likely to be more complex, with involve-
ment of hormonal changes, socioeconomic status, birth characteristics and pathogen 
exposure. 
The associations between specific peripheral T cells, persistent viral infections and 
the development of subclinical celiac disease (CeD) are discussed in Chapter 6. CeD is 
a digestive and autoimmune disorder driven by an immune response to modified gluten 
peptides. Affected intestines show infiltrates of various T-cell and NK-cell subsets, but it 
remains unclear if systemic abnormalities in immune cells are already present in children 
with subclinical CeD, and when present, whether CMV infection modifies this association. 
We observed abnormalities in CD57+ cytotoxic T cells and Vδ1+γδ T cells in 6-year old chil-
dren with subclinical CeD, which were affected by cytomegalovirus seropositivity. Children 
with subclinical CeD had fewer peripheral Vδ1+ T cells which was predominantly observed 
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in CMV seronegative children, and more CD57+ T cells than healthy genetic susceptible 
controls. Hence, children with subclinical CeD have alterations in specific blood T cell 
subsets that are linked to viral pathology. 
In Part II we identified determinants that are associated with CDA and persistent herpes 
virus seropositivity. The timing of gluten introduction and breastfeeding duration in rela-
tion to the development of CDA at the age of 6 years is discussed in Chapter 7. A delayed 
introduction of gluten was not associated with an increased risk of CDA. In addition, 
breastfeeding did not decrease the risk of CDA. Hence, other environmental factors are 
likely to contribute to the increasing incidence and geographic variability of celiac disease 
incidence worldwide. Persistent viral infections have been implicated in the etiology of 
autoimmune diseases in adulthood, but it is not known whether persistent viral infections 
in childhood are associated with CeD. In Chapter 8 we described inverse associations 
between herpesvirus infections and the presence of Transglutaminase type 2 Antibodies. 
CMV single infection, and combined CMV, EBV and HSV-1 infections were inversely associ-
ated with transglutaminase type 2 antibody positivity in children at 6 years of age. Hence, 
persistent viral infections may have a protective effect in the pathogenesis of CDA. 
Ethnic differences in CDA in childhood were described in Chapter 9. Within our cohort, 
we observed a higher incidence of CDA in Western than in non-Western children, and we 
examined how these differences may be explained by sociodemographic and environmen-
tal factors. Following correction for potential differences in the timing of gluten introduc-
tion and duration of breastfeeding, we observed that socioeconomic position, daycare 
attendance and CMV seropositivity in part explained these differences, which may serve as 
targets for future prevention strategies. 
Large differences in infection seroprevalences for CMV, EBV and HSV-1 in children with 
different ethnic origins were described in Chapter 10. The ethnic differences in EBV and 
HSV-1 could in part (up to 39%) be ascribed to differences in socioeconomic position, and 
other factors related to lifestyle, which suggests an important role for horizontal transmis-
sion for EBV and HSV-1. In contrast, these factors did not explain ethnic differences in 
CMV seroprevalences in childhood. Together with the observation that breastfeeding was 
a strong determinant for CMV seropositivity, this suggests an important role for vertical 
transmission from mother to child. 
The consequences of CDA (TG2A has only been measured on one occasion and was posi-
tive) are described in Part III. Screening identified TG2A positive children without gastro-
intestinal symptoms have lower bone mineral densities, and reduced growth trajectories 
until they are 6 years old (Chapter 11). This suggests that CDA is associated with reduced 
bone development and growth retardation. Hence, there is a need for early identification 
of children at risk, which could be made possible through implementation of a screening 
program for TG2A in young children between 6-10 years of age.
Furthermore, in Chapter 12 we aimed to describe to what extent CDA in the healthy 
childhood population can be predictive for the identification of (potential or subclinical) 
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CeD. We observed that serum TG2A screening at 6 years of age in the healthy pediatric 
population has a positive predictive value of 61% to detect subclinical CeD. We did not find 
a positive correlation between serum TG2A levels and the degree of enteropathy. 
Finally, in Chapter 13, a general discussion on the results of this thesis has been 
described related to recent published studies. In addition, recommendations for future 
research are provided. 
Combined, the studies described in Part I of this thesis illustrate the complex, and large 
age-dependent inter-individual variability of immune maturation during childhood. This 
variability is largely driven by non-heritable (environmental) factors, of which postnatal 
herpesvirus acquisition may be considered one of the most profound determinants. Our 
results stress the ability of the immune system in childhood to suppress a persistent virus, 
such as herpesviruses, without the negative effects that have been observed in elderly. 
Follow-up of this cohort in young adults is recommended to observe whether immune 
modulatory effects are persistent. These studies should include comprehensive analyses 
on the role of the intestinal microbiome to further unravel the complex interconnecting 
pathways involved in immune maturation. Furthermore, we provide evidence that the 
epidemiology of herpesvirus infections has not changed substantially during the last 
half-decade, and we identified several high risk groups that may serve as targets for future 
prevention strategies of herpesvirus associated diseases. 
The studies described in Part II of this thesis underscore that current primary prevention 
strategies cannot prevent the onset of CeD. Other environmental determinants, such as 
infections, may play a role in disease onset, but are relatively understudied, and poorly 
understood. Therefore, the only method to optimize early diagnosis of CeD is secondary 
prevention. Because active-case finding and targeted screening cannot resolve the high 
underdiagnosis rate, mass-screening may be a reasonable and realistic alternative. Future 
follow-up of the Generation R cohort is recommended to identify new onset CeD cases, 
and to analyze cost-benefit ratios taking short- and long term complications into account. 
Furthermore, the overall feasibility of mass-screening should be assessed, by studying the 
acceptance-rate of mass-screening in the general population, among parents and clini-
cians, the psychological impact, compliance to diagnostic procedures and treatment in 
those screened positive with inclusion of ethical aspects involved.
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SAMENVATTING 
De vroege kinderleeftijd reflecteert een gevoelige periode waarin diverse determinanten 
het immuunsysteem beïnvloeden, en mogelijk ook de ontwikkeling van immuun-geme-
dieerde aandoeningen later in het leven. Een gezond immuunsysteem biedt langdurige 
bescherming tegen schadelijke antigenen, zonder dat het immuunsysteem de controle 
verliest. Dit vereist een gezonde balans tussen “te weinig” en “te veel” tolerantie. Afwijkende 
immuunreacties daarentegen kunnen resulteren in verschillende klinische ziektebeelden, 
zoals auto-immuunziektes waarbij de afweer is gericht tegen antigenen van het eigen 
lichaam, of allergieën/ hypersensitiviteiten waarbij de afweer is gericht tegen niet-eigen 
onschadelijke allergenen. De ontwikkeling van coeliakie auto-immuniteit is een voorbeeld 
van een multifactoriële aandoening, waarbij een excessieve reactie bestaat tegen gluten 
uit het dieet. Hoewel aanzienlijke kennis over de etiologie van coeliakie is bewerkstelligd 
met onderzoek dat zich richt op de rol van voeding op de vroege leeftijd, is de etiologie van 
coeliakie nog steeds niet helemaal opgehelderd. 40% van de algemene Europese populatie 
draagt een van de HLA DQ2/ DQ8 allelen, maar slechts 1% ontwikkelt coeliakie. Deze be-
vindingen suggereren dat aanvullende factoren een rol moeten spelen in de pathogenese 
van coeliakie. Echter, naast voeding in het vroege leven, zoals de introductie van gluten en 
borstvoeding, zijn andere mogelijke omgevingsdeterminanten relatief weinig bestudeerd. 
Het eerste doel van dit proefschrift was het in kaart brengen van determinanten van het 
ontwikkelende immuunsysteem op de kinderleeftijd. We waren hoofdzakelijk gericht op 
het beschrijven van de normale ontwikkeling van het immuunsysteem, waarbij onze aan-
dacht uitging naar het adaptieve, ofwel verworven, immuunsysteem. Ons doel was om te 
beschrijven hoe de normale immuun-ontwikkeling op de kinderleeftijd verloopt als reactie 
op diverse antigenen die het immuunsysteem na de geboorte tegenkomt, met specifieke 
aandacht voor het effect van borstvoeding en persisterende herpesvirus infecties. Deze 
herpesvirussen blijven na infectie latent in het lichaam aanwezig, en oefenen grote druk 
uit op het immuunsysteem. Het tweede doel was om de determinanten van coeliakie auto-
immuniteit te bestuderen, met specifieke aandacht voor de rol van voeding in het eerste 
levensjaar, en het doormaken van persisterende herpesvirus infecties. Daarnaast was ons 
doel om de consequenties van ongediagnosticeerde coeliakie auto-immuniteit op de kin-
derleeftijd te bestuderen. De doelstellingen van dit proefschrift werden onderzocht binnen 
de Generation R Studie, een populatie-gebaseerd prospectief bevolkingsonderzoek in Rot-
terdam waarin kinderen gevolgd worden vanaf het foetale leven. De studies beschreven in 
dit proefschrift richten zich voornamelijk op de vroege kinderleeftijd; de periode vanaf de 
geboorte tot op 6-jarige leeftijd. 
Deel I is toegewijd aan determinanten die het adaptieve immuunsysteem vorm geven. 
In Hoofdstuk 2 hebben we bestudeerd hoe de aantallen van diverse leukocyten subtypes 
in het bloed binnen de aangeboren, naïeve en geheugen B- en T cellijnen veranderen vanaf 
de geboorte tot op 6-jarige leeftijd. Daarnaast hebben we bestudeerd hoe omgevingsfac-
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toren deze dynamische patronen over de tijd beïnvloeden. Op basis van de dynamiek in 
cel aantallen over de tijd hebben we 4 verschillende patronen geïdentificeerd, waarbij 
functioneel gelijke leukocyten populaties dezelfde kinetiek volgden. We toonden aan dat 
diverse niet-genetische determinanten deze patronen beïnvloeden, inclusief factoren 
die gerelateerd zijn aan de levensstijl van moeder tijdens de zwangerschap, maternale 
immuun-gemedieerde ziektebeelden, perinatale factoren, en postnatale blootstelling aan 
bacteriële en virale ziekteverwekkers. Persisterende virale infecties, met name cytomega-
lovirus (CMV) en Epstein Barr Virus (EBV), waren de voornaamste factoren die de kinetiek 
van geheugen B en T cellen op de kinderleeftijd beïnvloeden. Onze data bevestigen voor-
gaande onderzoeken die de effecten van deze virale infecties beschrijven op de geheugen 
B en T cellen. Daarnaast toonden we nieuwe associaties aan, zoals (inverse) relaties tussen 
herpes simplex virus 1 (HSV-1) seropositiviteit en naïeve B cel aantallen. Onze grootschalige 
analyse van alle leukocyten populaties, waarbij we de invloed onderzochten van vele non-
genetische determinanten, biedt inzicht in hoe de normale ontwikkeling van het adaptieve 
immuunsysteem verloopt onder invloed van vele omgevingsfactoren, en brengt in kaart 
welke omgevingsfactoren de meeste invloed hebben op een gezonde immunologische 
ontwikkeling. 
Het effect van borstvoeding op het immuunsysteem werd in meer detail onderzocht in 
Hoofdstuk 3. Borst-gevoede kinderen hadden ten opzicht van kinderen die kunstvoeding 
kregen een vergrote populatie van cytotoxische CD8+ centrale memory cellen T(cm) op de 
leeftijd van 6 maanden. Dit effect was onafhankelijk van de duur van borstvoeding. Daar-
entegen werden T-cel afhankelijke B-geheugencel populaties (CD27- IgG+, CD27+ IgM+ and 
CD27+ IgA+), kleiner naarmate de duur van borstvoeding toenam. Desondanks verdwenen 
deze effecten na het stoppen van borstvoeding. De tijdelijke vergroting in cytotoxische T cel 
populaties suggereert een langdurige ”priming” van CD8+ T cellen via borstvoeding. Daar-
naast, suggereren deze bevindingen dat borstvoeding een stapsgewijze immunologische 
ontwikkeling mogelijk maakt doordat er tijdelijk minder humorale immuniteit gevormd 
hoeft te worden, waardoor de vorming van cellulaire immuniteit wordt gestimuleerd. 
Hoofdstuk 4 onthult in meer detail hoe CMV en EBV infectie aantallen van T en B geheu-
gencellen beïnvloedt in 6-jarige kinderen. In voorgaande studies is aangetoond dat in een se-
lectie van CMV- en EBV geïnfecteerde ouderen een expansie optreedt van infectie specifieke T 
en B geheugencellen, ten koste van naïeve en Tcm cellen, en ten koste van de afweerrespons 
tegen vaccinaties. We hebben aangetoond dat CMV en EBV infectie werden geassocieerd met 
een toename van verschillende typen geheugen T-cellen op 6-jarige leeftijd. Echter, in tegen-
stelling tot in ouderen, resulteerden deze expansies in kinderen niet in verlies van naïeve of 
Tcm cellen, of in verlies van vaccinatie responsen tegen de niet-gerelateerde ziekteverwekkers 
mazelen of tetanus. Bovendien lieten kinderen die voor het 2e levensjaar waren geïnfecteerd 
met CMV of EBV een kleinere expansie zien van geheugen effector T cellen, dan kinderen die 
na het 2e levensjaar waren geïnfecteerd. Deze bevindingen suggereren dat vroege infectie er 
voor kan zorgen dat er minder effector geheugen T cellen nodig zijn, en er daardoor alleen 
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een milde verschuiving in het T cel repertoire ontstaat. Het tijdstip van CMV en EBV infectie 
kan daarom cruciaal zijn voor de mate waarin deze herpesvirussen immuunmodulatoire ef-
fecten bewerkstelligen. Deze bevindingen zijn belangrijk voor het begrijpen van herpesvirus 
geassocieerde immuunveroudering in ouderen. 
In de literatuur is beschreven dat persisterende infecties met CMV het immunologische 
fenotype verschillend beïnvloeden in mannen en vrouwen op middelbare leeftijd. Het is 
echter niet bekend of dit verschil ook aanwezig is op de kinderleeftijd. In Hoofdstuk 5 
hebben we daarom bestudeerd of geslacht de associaties tussen CMV en aantallen van 
meerdere typen T en B cellen modificeert in 6-jarige kinderen. We vonden dat geslacht en 
CMV onafhankelijk van elkaar de T en B cel aantallen beïnvloedden, maar dat er geen inter-
actief effect aanwezig was tussen CMV en geslacht. De onafhankelijke effecten van geslacht 
en CMV werden gedeeltelijk verklaard door leeftijd en infecties met andere herpesvirussen. 
Het is dus aannemelijk dat immuunveroudering complexer verloopt dan gedacht. Ook 
hormonale factoren, socio-economische status, perinatale factoren en postnatale bloot-
stelling aan verscheidene pathogenen zijn hoogstwaarschijnlijk van invloed op dit proces. 
De associaties tussen specifieke perifere T cellen, persisterende virale infecties en 
de ontwikkeling van subklinische coeliakie auto-immuniteit worden bediscussieerd in 
Hoofdstuk 6. Coeliakie, ofwel glutenenteropathie, is een auto-immuun gemedieerd ziek-
tebeeld met inflammatoire kenmerken ter hoogte van de mucosa van het duodenum. Dit 
geeft in typische gevallen aanleiding tot het ontstaan van de kenmerkende villeuze atrofie 
en hyperplasie van de crypten. Deze worden gedreven door een immuunrespons tegen 
gemodificeerde glutenpeptides. De aangedane mucosa bevat infiltraten van vele typen 
T- en NK-cellen, maar het is onbekend of deze aantallen ook afwijkend zijn in het bloed van 
kinderen met subklinische coeliakie. Daarnaast is het onbekend in hoeverre CMV infectie 
deze associaties beïnvloeden. We vonden afwijkende aantallen van CD57+ cytotoxische T 
cellen en Vδ1+γδ T cellen in 6-jarige kinderen met subklinische coeliakie, welke beïnvloed 
werden door cytomegalovirus seropositiviteit. Kinderen met subklinische coeliakie had-
den minder Vδ1+ T cellen in het bloed, en dit effect was voornamelijk zichtbaar in CMV 
seronegatieve kinderen. Daarentegen waren er meer CD57+ T cellen aanwezig in het bloed 
in vergelijking met gezonde kinderen die de genetische predispositie voor coeliakie heb-
ben. Deze bevindingen suggereren dat kinderen met subklinische coeliakie verschuivingen 
in specifieke aantallen T cellen in het bloed laten zien die geassocieerd kunnen worden 
met virale pathologie. 
In Deel II hebben we determinanten geïdentificeerd die geassocieerd zijn met coeliakie 
auto-immuniteit en herpesvirus seropositiviteit. Het tijdstip van gluten introductie en de 
duur van borstvoeding in relatie tot de ontwikkeling van coeliakie auto-immuniteit wor-
den bediscussieerd in Hoofdstuk 7. We toonden aan dat een late introductie van gluten 
(>6 maanden) niet geassocieerd was met een hoger risico op coeliakie auto-immuniteit. 
Daarnaast toonden we aan dat borstvoeding het risico op de ontwikkeling van coeliakie 
auto-immuniteit niet verlaagt. Het is daarom aannemelijk dat andere omgevingsfactoren 
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bijdragen aan de stijgende incidentie en geografische variabiliteit in de incidentie van 
coeliakie wereldwijd. 
Persisterende virale infecties spelen mogelijk een rol in de etiologie van verschillende 
auto-immuunziekten in volwassenen, maar het is onduidelijk of persisterende virale in-
fecties op de kinderleeftijd zijn geassocieerd met coeliakie. In Hoofdstuk 8 beschrijven 
we een omgekeerde associatie tussen herpesvirus seropositiviteit en de aanwezigheid van 
antistoffen tegen transglutaminase type 2. CMV infectie, en de combinatie van CMV met 
EBV en HSV-1, waren omgekeerd geassocieerd met de aanwezigheid van antistoffen tegen 
transglutaminase type 2 in kinderen op 6-jarige leeftijd. Dit suggereert dat persisterende 
virale infecties een beschermende rol kunnen spelen in de pathogenese van coeliakie 
auto-immuniteit. 
Etnische verschillen in coeliakie auto-immuniteit zijn beschreven in Hoofdstuk 9. We 
observeerden een hogere incidentie van coeliakie auto-immuniteit in Westerse dan in niet-
Westerse kinderen in ons cohort, en we onderzochten hoe deze verschillen konden worden 
verklaard door socio-demografische en omgevingsfactoren. Na correctie voor potentiele 
verschillen in het tijdstip van gluten introductie en de duur van borstvoeding, vonden we 
dat etnische verschillen gedeeltelijk werden verklaard door sociaal economische verschil-
len, verschillen in bezoek aan kinderdagverblijf, en CMV seropositiviteit. Deze factoren 
kunnen mogelijk dienen als aangrijpingspunten in toekomstige preventiestrategieën. 
In Hoofdstuk 10 toonden we grote verschillen aan in seroprevalenties voor CMV, EBV 
en HSV-1 tussen kinderen van verschillende etnische achtergronden. De etnische verschil-
len in EBV en HSV-1 konden gedeeltelijk (tot en met 39%) toegeschreven worden aan 
verschillen in socio-economische positie, en andere factoren die gerelateerd zijn aan de 
levensstijl. Deze bevinden suggereren dat er een belangrijke rol is weggelegd voor hori-
zontale transmission van EBV en HSV-1, terwijl deze factoren de etnische verschillen in 
CMV seroprevalentie op de kinderleeftijd niet verklaarden. Dit suggereert, gezamenlijk met 
de bevinding dat borstvoeding een sterke determinant was voor CMV seropositiviteit, een 
belangrijke rol voor verticale transmissie van moeder op kind. 
De consequenties van coeliakie auto-immuniteit (gedefinieerd als eenmaal TG2A 
positiviteit) zijn beschreven in Deel III. TG2A positieve kinderen zonder gastro-intestinale 
symptomen die door middel van screening werden geïdentificeerd, hadden een vermind-
erde botdichtheid, en lieten retrospectief een vertraagde groei zien tot op de leeftijd van 6 
jaar (Hoofdstuk 11). Deze bevindingen suggereren dat CDA is geassocieerd met groeiretar-
datie en een verminderde botontwikkeling, en laten zien dat er een noodzaak bestaat voor 
vroege identificatie van kinderen die een verhoogd risico hebben op het ontwikkelen van 
coeliakie. Dit kan mogelijk gemaakt worden door implementatie van een screeningspro-
gramma in kinderen van 6-10 jaar oud. 
Daarnaast was ons doel om te beschrijven in hoeverre coeliakie auto-immuniteit in de 
algemene kinderpopulatie voorspellend kan zijn voor het identificeren van kinderen met 
(potentiele of subklinische) coeliakie (Hoofdstuk 12). We toonden aan dat serum TG2A 
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screening een positief voorspellende waarde heeft van 61% voor het detecteren van sub-
klinische coeliakie in een gezonde populatie van 6-jarige kinderen. We vonden echter geen 
positieve correlatie tussen serum TG2A waarden en de ernst van de enteropathie. 
Tenslotte beschrijven we in Hoofdstuk 13 een algemene discussie over de resultaten 
in dit proefschrift in relatie tot andere studies die recent gepubliceerd zijn. Ook worden 
aanbevelingen gegeven voor vervolgonderzoek.
Gezamenlijk illustreren de studies in Deel I van dit proefschrift de complexe, en leef-
tijdsafhankelijke –interindividuele variabiliteit van het ontwikkelende immuunsysteem op 
de jonge kinderleeftijd. Deze variabiliteit wordt met name gedreven door niet-genetische 
(omgevings-) factoren, in het bijzonder door postnatale herpesvirus infecties. Onze resul-
taten benadrukken het vermogen van het immuunsysteem van kinderen om een infectie 
met een persisterende virus, zoals de herpesvirussen onder controle te houden, zonder 
dat dit gepaard gaat met negatieve effecten zoals die beschreven worden in ouderen. 
We adviseren vervolgonderzoek in adolescenten om te bestuderen of de geobserveerde 
immuunmodulatoire effecten persisteren. Deze studies moeten idealiter uitgebreide 
analyses bevatten die ook de effecten van het intestinale microbioom omvatten, zodat 
de samenhangende compartimenten van het ontwikkelende immuunsysteem beter in 
kaart gebracht kunnen worden. Daarnaast suggereert onze data dat de epidemiologie 
van herpesvirusinfecties niet wezenlijk veranderd is gedurende de afgelopen 50 jaar, en 
we identificeren risicogroepen voor primaire preventie van herpesvirus geassocieerde 
aandoeningen. 
De studies in Deel II van dit proefschrift benadrukken dat de huidige primaire preven-
tieve strategieën niet toereikend zijn om de ontwikkeling van coeliakie te voorkomen. 
Andere omgevingsdeterminanten, zoals infecties, kunnen een rol spelen in het ontstaan 
van coeliakie, maar deze zijn onduidelijk en relatief onder bestudeerd. De enige manier om 
vroege diagnose van coeliakie te optimaliseren is daarom secundaire preventie. Omdat 
actieve opsporing van coeliakie, en gerichte screening van risicogroepen, de hoge onder 
diagnose cijfers niet kan terugdringen, is algehele populatiescreening wellicht een redelijk 
en realistisch alternatief. Vervolgonderzoek van het Generation R cohort wordt aanbe-
volen om het aantal nieuwe coeliakie diagnoses in kaart te brengen, en om een kosten-
effectiviteitsanalyse uit te voeren, met inachtneming van gevolgen op zowel de korte als 
lange termijn. Daarnaast moet de algemene haalbaarheid van populatiescreening worden 
onderzocht, door te inventariseren hoe acceptabel screening is onder ouders en clinici, 
de psychologische impact van screening, de acceptatie om diagnostische procedures te 
ondergaan, de compliance van het glutenvrije dieet in positief gescreende kinderen, en de 
ethische aspecten hiervan. 
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I LIST OF ABBREVIATIONS
AAP American Association of Pediatrics
Anti-TPO Anti-thyroid peroxidase IgG
aOR Adjusted odds ratio
APC Antigen presenting cell
AD Atopic dermatitis
β Beta; regression coefficient
BCR B-cell receptor
BMC Bone mineral content
BMD Bone mineral density
BMI Body Mass Index
CCR Chemokine receptor
CI Confidence Interval
CeD Celiac disease 
CDA Celiac disease autoimmunity
CMV Cytomegalovirus
CR Complement receptor
CSR Class switch recombination
CV Coefficient of variation
DC Dendritic cell
DGPA Deamidated gliadin peptide antibody
DNA Desoxyribonucleic acid
DXA Dual-energy x-ray absorptiometry
EAACI European Society of Allergy and Clinical Immunology
EBV Epstein Barr Virus
EmA Endomysial antibody 
ESPGHAN European Society for Pediatric Gastroenterology, Hepatology and Nutrition
FSC Forward scatter
FFQ Food frequency questionnaire
g Gram
GA Gestational age
GEE Generalized Estimating Equations
GI Gastrointestinal tract infections
GLMM Generalized linear mixed model
H. Influenzae Haemophilus Influenzae
HLA Human leukocyte antigen
HSV-1 Herpes simplex virus -1
Ig Immunoglobulin
IgA Immunoglobulin A
IgG Immunoglobulin G
IgM Immunoglobulin M
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IL Interleukin
INF interferon
IQR Interquartile range
ISAAC International Study of Asthma and Allergy in Childhood
kg Kilogram
L Liter
LRTI Lower respiratory tract infections
m Meter
MAR Missing at random
MCAR Missing completely at random
MCMC Markov Chain Monte Carlo
MHC Major histocompatibility complex
MNAR Missing not at random 
M. cattarhalis Moraxella catarrhalis
MEC Medical Ethical Committee
mg Milligram
ml Milliliter
mm millimeter
MRI Magnetic resonance imaging
n Number (sample size)
NK cell Natural killer cell
nmol Nanomol
OR Odds ratio 
PCA Principal component analyses
RR Relative risk 
RTI Respiratory tract infections
S. aureus Staphyococcus Aureus
SD Standard deviation
SDS Standard deviation score
SES Socioeconomic status
SEP Socioeconomic position
SGA Small for gestational age
SHM Somatic hypermutation
S. pneumoniae Streptococcus pneumoniae
SPSS Statistical package social sciences
SSC Side scatter
Tc Cytotoxic T cell; CD8+ T cell
Tcm Central memory T cell
TCR T-cell receptor
TD T cell-dependent
Tem Effector memory T cell
TemRA CD45RO- effector memory T cells
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TemRO CD45RO+ effector memory T cells
TG2A Tissue transglutaminase type 2 antibody (IgA)
Th Helper T cell; CD4+ T cell
TI T cell-independent
TNF Tumour necrosis factor
Treg Regulatory T cell
TV Television
URTI Upper respiratory tract infections
VCA Viral capsid antigen
VZV Varicella Zoster Virus
WFH Weight for height
WHO World Health Organization

345
Ch
ap
te
r 1
5
Chapter 15  |  Author’s Affiliations
II AuThOR’S AFFILIATIONS
The Generation R Study Group, Erasmus Medical Center, Rotterdam, the Netherlands.
Ilse I.M. Tromp, Vincent W.V. Jaddoe, Albert Hofman, Hein Raat, Selma H. Bouthoorn, Jessica C. Kiefte-de Jong, Sytske A. 
Beth, Romy Gaillard, Johan C. de Jongste, Henriëtte A. Moll. 
Department of General Pediatrics, Erasmus Medical Center, Rotterdam, the Netherlands.
Vincent W.V. Jaddoe, Henriëtte A. Moll
Department of Immunology, Erasmus Medical Center, Rotterdam, the Netherlands
Menno C. van Zelm, Diana van den Heuvel, Herbert Hooijkaas, Jacques J.M.van Dongen, Wim A. Dik, Marco W.J. Schreurs, 
Halima Bouallouch-Charif, E.G. van Lochem, L.E. Bakker-Jonges.
Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, Victoria, 
Australia
Menno C. van Zelm
Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands.
Vincent W.V. Jaddoe, Albert Hofman, Jessica C. Kiefte-de Jong, Romy Gaillard
Department of Pediatric Gastroenterology, Erasmus Medical Center, Rotterdam, the Netherlands.
Johanna C. Escher
Department of Pediatric Gastroenterology, Maasstad Hospital, Rotterdam, the Netherlands.
Michael Groeneweg
Department of Pediatric Pulmonology, Erasmus Medical Center, Rotterdam, the Netherlands.
Johan C. de Jongste
Department of Public Health, Erasmus Medical Center, Rotterdam, the Netherlands. 
Hein Raat, Selma H. Bouthoorn
Department of Biostatistics, Erasmus Medical Center, Rotterdam, the Netherlands. 
Kazem Nasserinejad

347
Ch
ap
te
r 1
5
Chapter 15  |  List of Publications
III LIST OF PuBLICATIONS 
1)  Jansen MAE, Tromp IIM, Kiefte-de Jong JC, Jaddoe VWV, Hofman A, Escher JC, Hooijkaas H, Moll H.A. Infant 
feeding and anti-tissue transglutaminase antibody concentrations in the Generation R Study. Am J Clin Nutr 2014 
Oct;100(4):1095-101. 
2)  Jansen MAE, Kiefte-de Jong JC, Gaillard R, Escher JC, Hofman A, Jaddoe VWV, Hooijkaas H, Moll HA. Growth 
Trajectories and Bone Mineral Density in Anti-Tissue Transglutaminase Antibody-positive Children: The Generation R 
Study. Clin Gastroenterol Hepatol 2015 May;13(5):913-20.e5.
3)  Jansen MAE, van den Heuvel D, van Zelm MC, Jaddoe VWV, Hofman A, de Jongste JC, Hooijkaas H, Moll HA. 
Decreased memory B cells and increased CD8 memory T cells in blood of breastfed children: The Generation R Study. 
PLoS One 2015; May 18;10(5):e0126019.
4)  Van den Heuvel D, Jansen MAE, Dik WA, Bouallouch-Charif H, Zhao D, van Kester K, Smits-te Nijenhuis MAW, Kolijn-
Couwenberg MJ, Jaddoe VWV, Arens R, van Dongen JJM, Moll HA, van Zelm MC. Cytomegalovirus- and Epstein-Barr 
Virus-Induced T-cell Expansions in Young Children Do Not Impair Naive T-cell Populations or Vaccination Responses: 
The Generation R Study. J Infect Dis. 2016 Jan 15;213(2):233-42.
5)  Jansen MAE, van den Heuvel D, Bouthoorn SH, Jaddoe VWV, Hooijkaas H, Raat H, Fraaij PLA, van Zelm MC, Moll 
HA. Determinants of Ethnic differences in Cytomegalovirus, Epstein-Barr Virus, and Herpes Simplex Virus Type 1 
Seroprevalence in Childhood. J Pediatr. 2016 Mar;170:126-34.e1-6.
6)  Jansen MAE, van den Heuvel D, van der Zwet KVM, Jaddoe VWV, Hofman A, Escher JC, Fraaij PLA, Hooijkaas H, 
van Zelm MC, Moll HA. Herpesvirus infections and Transglutaminase Type 2 Antibody Positivity in Childhood. The 
Generation R Study. J Pediatr Gastroenterol Nutr. 2016 Oct;63(4):423-30.
7)  Beth SA, Jansen MAE, Elfrink MEC, Kiefte-de Jong JC, Wolvius EB, Jaddoe VWV, van Zelm MC, Moll HA. Generation R 
birth cohort study shows that specific enamel defects were not associated with elevated serum transglutaminase 
type 2 antibodies. Acta Paediatr. 2016 Oct;105(10):e485-91.
8)  Gervin K, Page CM, Aass HCD, Jansen MAE, Fjeldstad HE, Andreassen BK, Duijts L, van Meurs JB, van Zelm MC, Jaddoe 
VWV, Nordeng H, Knudsen GP, Magnus P, Nystad W, Staff AC, Felix JF, Lyle R. Cell-type specific DNA methylation in cord 
blood: A 450K reference data set and cell count-based validation of estimated cell-type composition. Epigenetics. 
2016 Sep;11(9):690-698.
9)  Van den Heuvel D, Jansen MAE, Bell A, Rickinson AB, Jaddoe VWV, van Dongen JJM, Moll HA, van Zelm MC. Transient 
reduction in IgA+ and IgG+ memory B-cell numbers in young EBV-Seropositive children. The Generation R study. J 
Leukoc Biol. 2017 Apr;101(4):949-956. 
10)  Van den Heuvel D, Jansen MAE, K Nasserinejad, Dik WA, van Lochem EG, Bakker-Jonges LE, Bouallouch-Charif H, 
Jaddoe VWV, Hooijkaas H, van Dongen JJM, Moll HA, van Zelm MC. Effects of nongenetic factors on immune cell 
dynamincs in early childhood: The Generation R Study. J Allergy Clin Immunol. 2017;139(6): 1923-1934.e17.
11)  Jansen MAE, Beth SA, Kiefte-de Jong JC, Raat H, Jaddoe VWV, van Zelm MC, Moll HA. Ethnic differences in coeliac 
disease autoimmunity in childhood. The Generation R Study. Arch Dis Child. 2017 Jun; 102(6):529-534
12)  Jansen MAE, van den Heuvel D, Jaddoe VWV, Moll HA, van Zelm MC. No Interactive Effects of Sex and Persistent 
Cytomegalovirus on Immune Phenotypes in Young Children. The Generation R Study. J Infect Dis. 2017 Mar 
15;215(6):883-888.
13)  Jansen MAE, van den Heuvel D, Jaddoe VWV, van Zelm MC, Moll HA. Abnormalities in CD57+ cytotoxic T cells and 
Vδ1+γδ T cells in subclinical Celiac Disease in Childhood are affected by Cytomegalovirus. Clin Immunol. 2017 Apr 26. 
pii: S1521-6616(17)30278-4. 
Chapter 15  |  List of Publications
348
14.  Jansen MAE, van Zelm MC, Groeneweg M, Jaddoe VWV, Dik WA, Schreurs MWJ, Hooijkaas H, Moll HA, Escher JC. The 
Identification of Celiac Disease in Asymptomatic Children. J. Gastroenterol. 2016 June 6. [Epub ahead of print].
15.  Looman KIM, Jansen MAE, Voortman T, van den Heuvel D, Jaddoe VWV, Franco OH, van Zelm MC, Moll HA. The 
Role of Vitamin D on circulating Memory T cells in Children: The Generation R Study. Pediatr Allergy Immunol. 2017 
Sep;28(6):579-587
16.  Looman KIM, Jansen MAE, Voortman T, van den Heuvel D, Jaddoe VWV, Franco OH, van Zelm MC, Moll HA. Fatty acids 
and the Maturation of Memory T cells in Children: The Generation R Study. In progress
349
Ch
ap
te
r 1
5
Chapter 15  |  About the Author
IV ABOuT ThE AuThOR
Michelle Anne Elisa Jansen was born on april 14th 1985 in 
Deventer, the Netherlands. In 2003 she completed secondary 
school at the Carmel College Salland in Raalte, Overijssel. In 
the same year, she started her study Biomedical Sciences at 
the University of Utrech, and in 2004, she started her Medicine 
Study at the Erasmus University of Rotterdam. During her study, 
she participated in several research projects in the Sophia Chil-
dren’s Hospital. In 2008, she received, as one of two selected 
students of her year, a 6 months research scholarship at Johns 
Hopkins Medical Hospital, in Baltimore, USA. Under supervision 
of prof. Dr. Marilee C. Allen, she worked on her MSc research topic ‘preterm brain injury in 
neonates’. During her internships (2009-2011) she spent 7 weeks at the neonatology and 
pediatric intensive care unit (NICU, PICU) in the Auckland City Hospital in New Zealand 
(supervisor Dr. Jane Alsweiler). In april 2011 she obtained her medical docter (MD) degree 
(cum laude) at the Erasmus University Rotterdam. From april 2011 she started working as 
a medical doctor (MD) and PhD student at the Generation R Study, department of general 
pediatrics, Immunology and Epidemiology (supervisor Prof. Dr. Henriëtte A. Moll and Dr. 
Menno C. van Zelm). Her research was focused on early determinants shaping adaptive im-
munity and celiac disease autoimmunity in childhood, of which the results are presented in 
this dissertation. In 2013 she obtained a MSc degree in Clinical Epidemiology (Netherlands 
Institute for Health Sciences, Erasmus University Rotterdam) and she worked as clinical 
epidemiologist and MD onwards. In 2013 and 2014, she was awarded a fellowship from 
the Dutch society of gastroenterology and hepatology for attendance of the international 
conference in Jerusalam, she received the first price of the European Pediatric young in-
vestigator award from the European Society for Pediatrics in Barcelona, and she obtained 
a research funding from the Dutch Organization NutsOhra. From April-September 2015 she 
worked as a pediatric resident (ANIOS) at the Maasstad Hospital in Rotterdam (Supervi-
sor Dr. M. Groeneweg), and from September 2015 she returned back to her PhD project to 
complete her research while focusing fulltime on the project. In 2016 and 2017 she worked 
as a resident (ANIOS) at the department of pediatric psychiatry, Lucertis, Rotterdam, and 
at the outdoor department eating disorders of Rintveld, Altrecht, Zeist). From March 2018 
onwards she hopes to start with the general practitioner training at the University Medical 
Center Utrecht (UMCU). 
In her spare time, Michelle likes to sport, travel, read, golf- and kitesurf, and spend time 
with family and friends. Michelle is married to Paul Didden (1981), a gastroenterologist 
working at the University Medical Center Utrecht (UMCU). They have one daughter Velize 
Mila (October 2016). 

351
Ch
ap
te
r 1
5
Chapter 15  |  PhD Portfolio
V PhD PORTFOLIO 
Name PhD student: Michelle Anne Elisa Jansen
Erasmus MC Department: Pediatrics, Immunology, Generation R
Research School: Netherlands Institute for Health Sciences
Promotor: Prof. dr. H.A. Moll 
Copromotor: Dr. Menno C van Zelm
PhD period: April 2011 - December 2017
1.PhD training Year Workload
(ECTS)
Master’s degree Health Sciences, specialization 
Clinical Epidemiology, NIHES, Erasmus University 2011-2013 120
General courses
Principles of Research in Medicine and Epidemiology 2011 0.7 
Clinical Decision Analysis 2011 0.7 
Methods of Public Health Research 2011 0.7 
Topics in Meta-analysis 2012 0.7 
Pharmaco-epidemiology 2011 0.7 
Markers and Prognostic Research 2011 0.7 
The Practice of Epidemiologic Analysis 2011 0.7 
Conceptual Foundation of Epidemiologic Study Design 2012 0.7 
Cohort Studies 2012 0.7 
Case-control studies 2012 0.7 
Introduction to Global Public Health 2012 0.7 
Social Epidemiology 2012 0.7 
Core courses
Biostatistical Methods: Basic Principles 2011 5.7 
Biostatistical Methods II: Popular Regression Models 2011 4.3
Study Design 2012 4.3
Clinical Epidemiology 2012 5.7 
Methodologic Topics in Epidemiologic Research 2012 1.4 
Advanced courses
Epidemiology of Infectious Diseases 2012 1.4
Repeated Measurements in Clinical Studies 2012 1.4 
Courses for the Quantitative Researcher 2012 1.4 
Women’s Health 2013 0.9 
Chapter 15  |  PhD Portfolio
352
General academic skills 
English Language 2011 1.4 
Introduction to Medical Writing 2011 1.1
In depth courses
Biomedical English Writing and communication 2012 4.0
Advanced Molecular Immunology, Postgrad course, 2013 1.4
Molmed Erasmus MC  
Seminars, workshops and symposia
Generation R research meetings 2011-2015 2.6
Seminars department of Epidemiology 2011-2015 1.0
TULIPS Grant writing and presenting weekend, NVK 2013 0.6
(Inter)national presentations at conferences and congresses
-General pediatrics research meeting - poster presentation 2012 0.4
-Sophia Children’s hospital research day - poster presentation 2012 0.4
-Developmental Origins of Health and Disease (DOHaD), 2012 0.4
Rotterdam, poster presentation
-European Society for pediatrics and infectious diseases (ESPID), 2012 0.4
Thessaloniki, Greece, poster presentation
-European Academy of Pediatrics (EAP), Lyon, France, 2013 2.8
2 oral presentations
-European Society for Pediatric Gastroenterology, Hepatology 2014 1.4
and Nutrition (ESPGHAN) Jerusalem, Israel, oral presentation 
-European Academy of Pediatric Society (EAPS) Barcelona, 2014 2.8
2 oral presentations
-Pediatric Gastroenterology Meeting (SMDL-NVK), Utrecht 2014 1.4
oral presentation 
-European Society for Pediatric Gastroenterology, Hepatology 2015 0.4
and Nutrition (ESPGHAN), poster presentation
-Dutch society for pediatrics - oral presentation 2015 1.4
Obtained fundings
Fonds NutsOhra ‘Celiac Disease; the tip of the iceberg’ 2013 1.4
Mrace Doelmatigheid ‘Coeliakie, een gemiste diagnose?’ 2014 0.4
Other (o.a. Stichting Coolsingel, Nederlandse coeliakie vereniging) 2014-2015 1.4
Other
Peer review of articles for scientific journals (JAMA pediatrics, Journal of Pediatric 
Gastroenterology and Nutrition)
2014-2016 1.0
353
Ch
ap
te
r 1
5
Chapter 15  |  PhD Portfolio
2.Teaching activities Year Workload 
(ECTS)
Supervising Master’s theses medical students:
-‘Herpes virusinfections and childhood celiac disease’ 2013 2.0 
Mw. Kirsten van der Zwet, MSc.
-“Herpes virusinfections and childhood asthma symptoms’ 2013 2.0
Mw. Noortje Haenen, MSc.
- ‘Vitamin D and childhood immune phenotypes’ and 2016- 4.0
Maternal prenatal fatty acids and childhood immune phenotypes 2017
Mw. Kirsten I.M. Looman, MSc. 

355
Ch
ap
te
r 1
5
Chapter 15  |  Dankwoord
VI DANKWOORD
Tot slot wil ik graag de belangrijkste personen bedanken zonder wie dit proefschrift nooit 
tot stand gekomen zou zijn. Allereerst, alle kleine deelnemers en ouders: zonder jullie zou 
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heb je het onderzoek klinische betekenis gegeven. Ook kijk ik met veel plezier terug naar 
onze gezellige tijd in Israël. Daarnaast wil ik ook graag prof. dr. Harry de Koning, Dr. Anton 
Langerak en Dr. Pieter Fraaij bedanken voor het zitting nemen in de commissie. Pieter, 
dank voor je laagdrempelige contact en je nuttige feedback op de manuscripten. 
Ten vijfde, mijn cruciale schakel naar de immunologie: Diana van den Heuvel. Lieve, 
Diana, inmidels ook doctor, wat waren het bewogen jaren, met af en toe wat downs, maar 
bovenal veel ups! Zonder jou was dit proefschrift er nooit geweest. Dankzij jouw enorme 
hoeveelheid werk hebben we beiden ons proefschrift kunnen afmaken. Bedankt voor onze 
vele gezellige klets- en koffie momentjes. Inmiddels ben je postdoc in Leiden, volgens mij 
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zit je goed op je plek! Met jouw enorme doorzettingsvermogen weet ik zeker dat je een 
mooie toekomst tegemoet gaat! Ten zesde, wil ik graag een speciaal woord richten aan 
Prof. Dr. Hooijkaas: Beste Herbert, veel dank dat ik, ook dankzij jouw vertrouwen in mij, 
aan dit project kon starten. Ik heb met veel plezier met je samengewerkt. De immunologie 
was soms lastig, maar door jouw uitleg werd het toch enigszins behapbaar, en dat is een 
kunst. Door een noodlottige gebeurtenis, ik was ontdaan bij het horen van dit bericht, kon 
je je werkzaamheden helaas niet voortzetten, een gemis voor de afdeling. Ik wens je heel 
veel sterkte toe, en hoop dat je met een goed gevoel terugkijkt op de mooie dingen die 
we hebben bereikt. Ook wil ik graag alle co-auteurs van de manuscripten bedanken: Prof. 
dr. Vincent Jaddoe, beste Vincent, dank voor je snelle blik op de manuscripten. Je leverde 
altijd nuttige en helder commentaar waar ik van kon leren, dank voor de fijne en gezellige 
samenwerking. Prof. dr. A. Hofman, prof. dr. H. Raat, Prof. dr. O. Franco, en prof. dr. J.C. de 
Jongste: bedankt voor het kritisch beoordelen van mijn manuscripten.
Een speciaal woord van dank wil ik richten richten aan mijn dierbare vriendin Sanne 
Beth. Lieve Sanne, bedankt dat je mijn lieve vriendin bent. Je bent een bijzonder warm, 
sterk en lief persoon. Dat je daarnaast ook nog eens mijn collega’tje werd, was natuurlijk 
een extra fijne en leuke bijkomstigheid. Maar bovenal wil ik je graag laten weten dat jouw 
vriendschap heel veel voor me betekent. Je hebt het niet altijd makkelijk: weet dat ik veel 
bewondering voor je heb en veel waarde hecht aan onze vriendschap. Je bent een fantasti-
sche moeder van een lief, klein ventje: jouw grootste en liefste wens. Zo bijzonder dat onze 
kleintjes samen opgroeien, en dat we ook deze periode in ons leven kunnen delen met 
elkaar. Ik hoop op nog heel veel jaren samen! 
Daarnaast de vele collega’s van Generation R. Het gaat te ver om alle mensen op te 
noemen die afgelopen jaren voor mij tot een feestje maakten, maar ik wil graag enkele 
personen noemen die me in het bijzonder hebben geraakt. Lieve Sel en An; wat was het 
gezellig met jullie, we waren al snel vriendinnen, door jullie voelde GenR als thuis. Marjo-
lein en Zoe; fijn om op maandag eerst een lekkere doppio met jullie te doen! Dank voor de 
gezelligheid! Ankie, door jou werd ik nieuwsgierig naar een plekje bij Henriette, dankjewel 
voor je tip, en de vele gezellige borrels tijdens onze coschappen inmiddels heel wat jaren 
geleden. Volgens mij worden we nu echt oud..!;) Lieve Jes, wat een geluk dat ik als groentje 
bij jou op de kamer kwam. Je bent de meest slimme analyticus ever! Dankjewel dat ik 
zoveel van je mocht leren. Lieve Zoe, heerlijke positieveling, jij maakte me altijd aan het 
lachen! Inmiddels ben je in opleiding tot gynaecoloog, wat ben je een goede dokter, en 
niet op de laatste plaats ook moeder van een lief meisje met een - net zo - vrolijke lach: zo 
moeder, zo dochter!:) Lieve Ilse, inmiddels ook doctor! Wat fijn dat je samen met mij een 
stuk wilde schrijven, dat ging van een “leien dakje”, dankjewel voor de gezellige moment-
jes! Marjolein en Claudia, de immuno datasets waren soms “verschrikkelijk” maar altijd 
reageerden jullie razendsnel op mijn verzoeken; het leek nooit te veel waar ik om vroeg; 
veel dank hiervoor! Zonder jullie hulp zou ik nergens zijn! Mijn studenten Kirsten, Noortje 
en Kirsten: we hebben een aantal mooie manuscripten kunnen schrijven: bedankt voor 
357
Ch
ap
te
r 1
5
Chapter 15  |  Dankwoord
jullie inzet! Kirsten, je gaat nu zelf ook aan de slag: veel succes, je bent een enorm attente 
en supersnelle leerling! Was fijn om met je te werken! Ook wil ik graag de vele personen 
bedanken die me hebben geholpen om de flowcytometrie data in het lab te verzamelen: 
Marja, Marion, Nicole, Halima en Kevin, en ongewtijfeld vergeet ik nog een heleboel meer 
personen: Sorry dat alles -maar dan ook echt alles- overnieuw moest. Ik heb bewondering 
voor de enorme hoeveelheid werk die jullie verzet hebben om dag- in- dag uit- weer aan de 
slag te gaan met die complexe analyses, net zo lang tot onze ogen vierkant werden van het 
scherm. Bedankt voor jullie onuitputtelijke energie, zonder jullie hulp waren die analyses 
nog steeds niet af! Diana Dufour, bedankt dat je alle TG2A levels zo snel hebt bepaald! 
Marco Schreurs en Wim Dik: bedankt voor jullie immuno-methodologische bijdrage aan 
onze manuscripten. Tevens gaat mijn dank uit naar de collega’s in het Maasstad ziekenhuis 
die mijn tijd op de kindergeneeskunde bijzonder hebben gemaakt. Carsten, dankjewel dat 
je me in contact bracht met Henriette. Michael, dankjewel voor je betrokkenheid, en uiter-
aard voor al je werk om alle scopieën uit te voeren. “The intuitive mind is a sacred gift, and 
the rational mind a faithful servant.” Dat had je goed aangevoeld! Dank ook aan Jennifer 
voor je adviezen, verhalen en luisterend oor! Tevens dank voor alle gezellige (afdelings-) 
uitjes met onze focusdames, medepromovendi uit het Sophia, Epidemiologie en Immu-
nologie: helaas te veel om bij naam te noemen. Astrid, dank dat je altijd alle afspraken en 
documenten tot in de puntjes voor me hebt geregeld. Rosa, Pety en Naomi; jullie hebben 
gezorgd voor een fijne plek bij Lucertis! Dank voor jullie betrokkenheid, ook tijdens mijn 
zwangerschap. Mijn nieuwe collega’s Linne, Oriana en Maaike: Ik werk nog maar kort bij 
jullie, maar dankzij jullie met veel plezier! 
Ten slotte, mijn lieve vriendinnen Anna, Jorie, Sanne, Margaux, Wendy, Wendelien, Lalini 
en Margreeth: jullie maakten mijn tijd in Rotterdam, en de vele jaren erna, extra warm. Het 
blijft altijd een gevoel van ‘thuiskomen’ als ik weer samen met jullie ben. Lieve Margaux, 
wat fijn dat je terugkomt uit Curaçao: aftellen geblazen; ik heb je gemist! En je kleine 
knappe hartendief( jes) ook! Lieve Melis, wat hebben we een gezellige tijd samen gehad 
(Baltimore, en iets met een emmer..;)) ons contact is me nog steeds heel dierbaar! Lieve 
Manon, wat straalde je onlangs: prachtige bruid! Al op de peuterspeelzaal en basisschool 
deden we volgens mij lippenstift op die we kregen van..?;) Lieve Loet, bijzonder dat we alle 
ontwikkelingen in ons leven samen delen. Je bent een prachtige, sterke vrouw, fantasti-
sche moeder, crea bea, optimist, en altijd lieve, oprechte en geïntereseerde vriendin: aan 
een half woord hebben we genoeg. Ik zie onze meisjes volgend jaar al samen zandtorentjes 
bouwen in het zand bij Rapa Nui..J 
Lieve (schoon)familie The-Didden; bedankt voor jullie zorg en betrokkenheid, en de vele 
lekkere indische verassingen die jullie altijd meebrengen. Lieve Im en “brabo G”: heerlijke 
wereldreizigers! Gelukkig was ik, dankzij jullie verhalen, ook weer een beetje op ontdek-
kingsreis. Maar nog veel fijner dat jullie weer thuis zijn! Bedankt dat jullie op Vtje hebben 
gepast, voor de momenten dat jullie hebben getimmerd en gezaagd in ons huis en voor de 
nodige likjes verf her en der!;) Lieve sis, ik weet niet wat ik zonder jou had gemoeten. Be-
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dankt voor je adviezen, gezelligheid, luisterend oor, en warme kaartjes de afgelopen jaren. 
Ik kan me geen liever zusje wensen. Lieve pap en mam, jullie zijn van onschatbare waarde, 
Vtje is zo ontzettend op jullie gesteld, klusjes oppakken zonder dat we er om vragen; niets 
is jullie te veel. Maar nog meer ben ik jullie dankbaar voor alle mogelijkheden die jullie me 
hebben aangereikt. Jullie onvoorwaardelijke en onuitputtelijke steun en liefde draag ik 
altijd bij me, ik kan me geen fijnere ouders wensen. 
Als laatste gaat mijn dank uit naar mijn man Paul. Lieve Paul, met jou naast me is het 
zoveel leuker! Je bent mijn ‘rock’, je hebt ons een prachtige dochter geschonken, we zijn 
inmiddels 3 huizen verder, een paar steden verder, een paar banen verder; we did it! Ik 
hoop op nog veel meer mooie avonturen met jou samen! Lieve Velize, ik heb het laatste 
gedeelte van dit proefschrift geschreven in de uurtjes dat je lag te slapen. Stiekem hoop ik 
dat je niet te snel groeit, want ik geniet zo van jouw kleine en vrolijke aanwezigheid. Ik hoop 
dat je altijd zult voelen dat je het meest prachtige geschenk bent dat ik me kan wensen! 
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